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Abstract of the PhD 
Background: The prevalence of respiratory disorders in children has steadily increased over the 
past decades to such an extent that asthma is now the most common chronic disease of 
childhood. Childhood asthma resembles a complex syndrome rather than a single disease, and 
includes many wheeze phenotypes, making its diagnosis challenging. Most likely, it is not a 
single risk factor that determines whether a child develops asthma, but several risk factors (e.g. 
environmental, immunological, genetic, onset of respiratory symptoms) that each make small 
contributions to the development of the disease. Already infancy, lung function tests are 
available to assess airway disease. These tests are predominantly used in patients with Cystic 
Fibrosis (CF), for whom preservation of normal lung function is crucial. Despite recent advances 
in lung function testing, several methodological issues remain unanswered. Higher quality tests 
are required in order to effectively study the various risk factors involved in the development of 
complex airway diseases 
Aim: The first aim was to describe methodological issues during infant lung function testing in 
order to improve their quality. The second aim was to study different risk factors for asthma 
development, and to investigate their association with respiratory diseases during childhood. 
Methods: The study was conducted within the prospective Basel-Bern infant lung development 
(BILD) cohort, a population-based cohort of unselected infants of Central-European origin. The 
survey collects prenatal data via standardized interviews and cord blood samples for the 
assessment of immunological and genetic information. During the first year of life, research 
nurses call the parents weekly to assess the occurrence of respiratory symptoms. Pulmonary 
function tests, as well as measurement of fractional exhaled nitric oxide (FeNO) to assess airway 
inflammation, are completed at 5 weeks of age, and again at 6 years of age during follow-up. 
Results: We provided specific recommendations on how to improve outcomes from infant lung 
measurements. Furthermore, we measured airway obstruction using the interrupter technique 
(Rint) in unsedated infants shortly after birth, and were able to show that measurements were 
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feasible but had a high variability. We compared Rint between term and preterm infants, and 
found that Rint was higher, and variability of Rint lower, in term-born infants. We assessed 
FeNO in healthy newborn infants, and in infants with CF. FeNO at birth had no predictive value 
for asthma development at school age. In CF patients, FeNO at birth was lower compared to 
matched healthy controls. 
We could also show that polymorphisms in the chitinase 3-like 1 (CHI3L1) gene encoding YKl-
40 were associated with asthma at 6 years. There was some indication that increased YKL-40 
levels at birth may also be involved in the development of airway disease. We also developed a 
novel method to characterize the time series of prospectively assessed respiratory symptom 
scores during infancy. This method assesses symptom dynamics in an observer-independent 
manner. Using this method, we were able to identify a high-risk phenotype, which was 
predominantly male, and contained more infants exposed to maternal asthma, and environmental 
tobacco smoke. This phenotype was also at increased risk for asthma and atopy at school age.  
Conclusions: Infant lung function is useful to study airway disease at an early age, and 
outcomes can be improved by applying minimal changes in analyses algorithms. Assessment of 
airway obstruction in infants is feasible, but measurements require careful interpretation due to 
the high variability. We found some indication that FeNO levels early in life are determined by 
environmental factors and the child’s genetic profile. In CF patients, FeNO after birth was 
associated with the severity of the genetic mutation. In healthy infants, FeNO levels early in life 
seem to be influenced by environmental exposures.  
Our findings contribute additional, relevant knowledge on asthma risk factors and their 
association with respiratory symptoms from birth through school age. We found associations 
between genetics and the immunological status at birth with asthma at school age. The 
development of asthma may also depend on respiratory symptoms early in life. We could show 
that the pattern of symptom deterioration and recovery during the first year of life determines 
whether or not a child has persistent wheezing until school age.  
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1 Introduction 
The prevalence of respiratory disorders in children has steadily risen over the last several years 
[1]. Asthma is currently the most common chronic respiratory disease in childhood, and because 
of its high prevalence, it is a major health issue. Asthma is an inflammatory disease of the small 
airways with the most common symptom in children being cough and wheeze. In more severe 
cases, breathlessness, chest tightness or pressure and even chest pain, are reported [2].  
Asthma is a complex syndrome with many different wheezing phenotypes. The classic 
phenotypes of transient, persistent and late-onset wheeze in childhood were initially described in 
the Tucson Children’s Respiratory Study [2], and were found to be associated with distinct 
patterns of lung function changes [3]. While these phenotypes were frequently used in 
epidemiological research, recent studies have attempted to further characterize phenotypes of 
preschool wheeze using modern mathematical techniques and found similar phenotypes [4-7]. 
Furthermore, the distribution of risk factors has been shown to differ for the various wheeze 
phenotypes [5, 8], which underlies the complexity of the interaction between risk factors and 
respiratory diseases.  
The varying presentation and disease courses of these phenotypes often make it difficult to 
distinguish health from disease in early childhood. Lung function tests are currently available to 
assess airway function in young children, and even infants [9, 10]. These tests can help improve 
our understanding of the multiple determinants influencing lung development during the critical 
time window of early childhood.  
1.1 Complexity of respiratory disease in childhood  
Many factors are likely to contribute to the development of respiratory diseases. There are host 
factors (e.g. maternal atopy, sex) [8, 11], which may predispose children to respiratory 
symptoms, and environmental factors (tobacco smoke exposure, air pollution), which may 
further influence the severity and recovery patterns of respiratory symptoms [8, 12]. Prospective 
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studies have shown that life style factors, such as overweight during early childhood, preceded of 
the later development of asthma symptoms [13]. Although some risk factors maybe more 
relevant for later respiratory disease than others [14], it is most likely a complex interplay 
between various factors that determine whether or not a child will develop persistent symptoms. 
Furthermore, given that there are many risk factors known to increase the risk for asthma, it can 
be speculated that each risk factor has only a small impact on asthma development. Several 
studies support this hypothesis. For example, several prospective studies repeatedly found that 
air pollution exposure early in life was associated with reduced lung function at school age [15-
18] and adolescence [19]. However, effect sizes of increased air pollution levels were small: e.g. 
a decrease of 4.8% in forced expiratory volume in 1 second (FEV1) per 10-µg/m
3
 increase in 
traffic-particulate matter with aerodynamic diameter <10 µm (PM10) was reported [15], and a 
decrease of 3.2% in peak expiratory flow (PEF) per µg/m
3
 increase in nitrogen dioxide (NO2) 
[16], respectively.  
It is difficult to assess the small effects of different risk factors on lung development, which can 
only be achieved by high quality lung function tests. Especially in infants, achieving this goal is 
extremely challenging, since some outcomes have high variability [9, 20, 21]. In other words, 
infant lung function tests have an unfavorable signal-to-noise ratio, as the power of the signal 
(the outcome of interest) is limited by the background noise (e.i. variability of the outcome). 
Improving the quality of infant lung function outcomes is therefore needed to better characterize 
airway disease and understand the impact of risk factors early in life.  
1.2 Assessing lung function in childhood  
Lung function measurements provide objective information on airway function, and are a 
fundamental measure in the diagnosis and management of respiratory diseases. They are widely 
applied in epidemiological studies to investigate the impact of risk factors, as well as 
interventional studies to assess treatment response. Classic lung function tests, such as 
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spirometry, measure expiratory flow in the large airways [22]. The breathing maneuvers during 
spirometry, however, require cooperation, making this technique inapplicable in younger 
children.  
There are lung function tests available that require only minimal cooperation, making them more 
attractive in the pediatric setting. For example, airway obstruction can be measured during tidal 
breathing using the interrupter technique (Rint) [23]. Multiple breath washout (MBW) is also a 
tidal breathing lung function test. MBW allows for the detection of early lung disease, even 
before pathologies can be detected by spirometry [24]. While these tests are attractive, as they 
can be performed in infants during natural sleep, several methodological aspects of these lung 
function tests require careful interpretation.   
This PhD thesis used results from all of the aforementioned lung function tests. A description of 
the applied tests is provided in the general methods section.   
1.3 Methodological challenges of lung function tests in childhood  
Methodological challenges to assess airway function in young children and infants relate, e.g. to 
complex analyses algorithms, and to the high variability of results. For example, studies 
systematically assessing Rint in infants and children reported poor repeatability [21, 25] and high 
variability of measurements [26-28]. Often discussed is the impact of dead space on test results. 
The total apparatus dead space is the volume through which the infants must breathe while 
attached to the equipment. The ERS/ATS task force recommended a maximum of 2 ml/Kg in 
newborn infants [29], but many studies do not achieve this recommendation [21]. An 
unfavorably large dead space may have a physiological effect, and contribute to variability of 
measurements. 
MBW tests allow for the assessment of the functional residual capacity (FRC), as well as, 
ventilation homogeneity of the small airways. However, relevant methodological aspects should 
be noted. For example, studies have shown that ventilation homogeneity, as assessed by MBW, 
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depends on software settings and device setups [30, 31]. Several studies have assessed FRC in 
newborn infants and reported large differences. Our research group previously published 
reference values for FRC from an European population [27]. A recent birth cohort study in 
Africa [32] performed lung function tests at the same time point at infancy, but reported 
significantly different FRC values. Differences in software settings between studies may be one 
reason for the observed differences in FRC. Furthermore, differences in population 
characteristics may have also contributed to differing FRC values, as numerous reports 
documented differences in lung function between ethnic groups [33]. Besides ethnic differences, 
different exposures between study populations might also have contributed to differences in lung 
volumes. While it is not easy to discern whether the differences in FRC are due to ethnicity, 
environmental factors, or a combination of both, this complex interaction should be considered 
when interpreting study results or determining associations with environmental factors. 
1.4 Methodological challenges to assess airway inflammation in childhood  
The varying presentation of asthma symptoms and airway obstruction, especially in young 
children, makes it difficult to distinguish health from disease. Methods to assess airway 
inflammation are already applicable in infancy. The fraction of exhaled nitric oxide (FeNO) is a 
non-invasive biomarker used to assess airway inflammation, and can be measured already in 
infancy [34-36]. The biomarker is routinely used in asthmatic children to monitor treatment 
response. Recent studies assessed whether or not an early assessment of FeNO might be 
predictive for later asthma development. There was some indication that increased FeNO levels 
during early childhood were associated with a later diagnosis of asthma [36, 37]. While elevated 
FeNO seems to be a sensitive biomarker in the early march of asthma development [38], it is 
important to remember that airway inflammation and FeNO levels fluctuate in asthma [39, 40]. 
The dynamic nature of FeNO may, therefore, limit its application for later disease prediction.  
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1.5 Impact of immune regulation and the environment on respiratory disease 
Immune regulation during the prenatal period and early infancy is known to be important for 
later lung development [41]. The direct and detailed assessment of immune function is routinely 
performed by obtaining blood samples. However, especially in children, it is better to assess 
inflammatory processes non-invasively. Assessment of airway inflammation is already feasible 
in infants, by way of FeNO measurements [27, 35, 42]. FeNO is one of the few biomarkers 
which made it from bench to bedside, and is now in routine clinical use in order to detect 
eosinophilic airway inflammation and to monitor corticosteroid treatment response in asthmatic 
patients [43]. FeNO measured during early childhood is useful to predict subsequent respiratory 
morbidity [36, 37]. This association should, however, be interpreted within the context of 
environmental factors since e.g. air pollution [44] and maternal smoking [45, 46] impact upon 
FeNO levels. Furthermore, some studies reported a direct induction of the inducible nitric oxide 
synthase (iNOS) after environmental exposure to viruses [47] and allergens [48], underlining the 
relevance of the environmental impact on FeNO levels.  
Recent studies have suggested new methods to non-invasively assess airway inflammation 
within the lungs, by collecting exhaled breath condensate [49-51]. This method has great 
potential, since it enables measurements of a variety of cytokines (e.g. interferon-gamma, 
interleukins) [50]. However, this technique is still in development and not yet available for 
clinical use. Aside from studies needed to investigate methodological issues of this novel 
technique, the impact of environmental factors e.g. tobacco smoke exposure, and air pollution, 
remain largely unknown [52, 53].  
There are a variety of other immune markers to assess the risk for the development of respiratory 
diseases [41]. For example, the assessment of eosinophilia is useful to identify specific asthma 
phenotypes [54]. Further, assessment of eosinophilia in blood is part of the asthma predictive 
index (API), a well validated tool to assess the risk of a child to develop asthma [55]. With the 
assumption that asthma has several phenotypes, and that there are potentially several 
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immunological processes involved in their development, recent studies searched for new 
biomarkers to describe these phenotypes. These novel biomarkers may present the opportunity to 
improve the diagnosis of asthma sub-phenotypes, and may assist in the prediction of outcomes 
and optimal treatment options [41].  
Much attention has recently been given to chitinase-like proteins (C-CLP), which have been 
found to cross talk with the innate and adaptive immune system. The prototype of C-CLP in the 
human body is YKL-40, which has been found to be elevated in a variety of inflammatory 
diseases including asthma [56]. YKL-40 was shown to be increased in adult asthmatics [57, 58] 
and in children with severe asthma [59]. A specific pathophysiological importance of YKL-40 
for lung diseases has been discussed, since YKL-40 may be involved in the development of 
fibrosis and remodeling of the lung [60]. YKL-40 was shown to be increased in adult asthmatics 
[57, 58] and in children with severe asthma [59]. Genetic studies revealed that variation in the 
gene encoding YKL-40, chitinase 3-like (CHI3L1), contributes to the pathogenesis of asthma 
[61]. Genetic variation in CHI3L1 was associated with pathological lung function values in 
adults [61], and correlated with poor asthma control and inflammatory markers in severe 
asthmatic children [59]. Whether or not genetic variation of CHI3L1 or YKL-40 levels can serve 
as predictors for asthma development in unselected, healthy infants is unknown.   
Early immune regulation is modified by exposure to environmental factors. Depending on the 
exposure, they can increase- or reduce the risk for respiratory diseases. Exposure to outdoor air 
pollutants, such as PM10, NO2, ozone (O3), diesel, and tobacco smoke are known to impact upon 
immune regulation [62, 63], and are associated with subsequent respiratory diseases and reduced 
lung function [64, 65]. On the other hand, some factors are described as protective against 
asthma. An inverse association between living on a farm with the development of IgE-mediated 
allergic diseases is well described [66]. Further, greater microbial diversity was protective for 
asthma development [66-68], and specific species, e.g. S. pneumoniae, H. influenzae, seem to 
increase the risk [69]. Further understanding on the interaction between environmental factors 
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and genetics, as well as their impact on early immune development, may help to identify infants 
at risk for childhood asthma.  
1.6 Impact of genes and the environment on respiratory disease 
Twin studies demonstrated the high heritability of asthma, and further analyses have suggested 
that this heritability might be due to few genes with moderate effects [70]. This was suggested 
from findings in which data were derived from studies using the positional cloning approach and 
candidate gene studies. These two approaches, however, were limited by the a priori selection of 
candidate genes. The completion of the human genome sequence project offered the possibility 
to identify novel genetic effects or pathways relevant for subsequent respiratory disease [70]. 
Already a decade ago, over 100 genes were studied with about 25 of those genes found to have 
the potential of being true susceptibility genes. These genes were replicated in several 
populations [71] and further genes were added to the list of susceptibility genes reported for 
asthma and associated traits [71].  
Nowadays, there are affordable toolkits available to study the genetic basis of complex diseases. 
Sequencing the entire human genome together with technological development has opened up 
the possibility to perform genome wide association studies (GWAS) in large populations [70, 
71]. The first GWAS in childhood asthma discovered a major signal from chromosome 17q21, 
harboring the Orosomucoid like 3 (ORMDL3) gene [72]. ORMDL3 is a member of a novel class 
of genes that encodes transmembrane proteins anchored in the endoplasmic reticulum. Although 
this gene has been extensively studied, its function in asthma is still only poorly understood [72, 
73]. While the GWAS approach led to the discovery of novel disease loci, it is interesting to note 
that a number of candidate genes previously described could not be replicated in genome-wide 
significance levels [74], possibly due to the fact that previous associations were false positive. 
On the other hand, it could also be that chips used for GWAS did not sufficiently cover many 
asthma candidate genes [74]. Nevertheless, the numerous studies on genetics in asthma so far 
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have provided a well validated list of susceptibility genes, helping to define important biologic 
pathways [75].  
Recently, there has been increased interest in epigenetic-regulation, i.e. heritable changes in gene 
expression without any change in the DNA. Epigenetic mechanisms may be influenced by 
external, environmental factors, and recent studies suggest that complex gene-environment 
interactions may lead to the development of pediatric airway diseases [76]. This underlies the 
significance of the environment for respiratory morbidity in childhood. While the risk for asthma 
maybe partly inherited, environmental factors act together with susceptibility genes during 
special windows of opportunity in time. The effect of this interaction may result in impaired lung 
development, tissue remodeling and persistent dysregulation of the airway tone [77]. Genetic and 
environmental factors may negatively affect lung growth independently, or by an interplay. Early 
lung development, in particular, is suggested to be a very sensitive time period for these stimuli 
[64, 78] with long term effects. Traffic related air pollution is considered a relevant 
environmental factor resulting in increased frequency of asthma exacerbations and impaired lung 
development in infants [79], children [17], and adults [19]. For younger children and infants, 
there is evidence that environmental tobacco smoke impact upon lung development during 
pregnancy and early life [80].  
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1.7  Aims of the PhD 
The first aim of this thesis was to strengthen the quality of infant lung function tests. The second 
aim was to study different asthma risk factors (biomarkers, genetics, respiratory symptoms early 
in life), and to investigate their association with respiratory disease during childhood. These aims 
were investigated mainly within the context of the ongoing BILD cohort study, for which I 
organized and collected data. Furthermore, I worked in the affiliated wet lab of the University 
Children’s Hospital Basel under the supervision of Prof. Philipp Latzin (former group leader of 
the Pediatric Pneumology research group, funded by the Fondation Botnar), and Dr. Loretta 
Müller.  
The following specific aims will be addressed in this work: 
1) To address the complex mechanistic interaction of factors influencing the development of 
airway disease in children.  
2) To comprehensively describe the currently available lung function tests which serve to 
diagnose airway disease and function at an early age. Next, the aim was to provide 
recommendations of how to improve quality of the outcomes. 
3) To further understand airway function in infancy, the aim was to compare airway resistance 
measurements by Rint assessed at 42 weeks’ postmenstrual age between term and preterm 
infants. In addition to this, we assessed variability of Rint in both study groups. We 
hypothesized that: i) preterm infants have increased airway resistance compared to term 
infants in infancy and ii) measurements have high variability in both study groups.  
4) To study the association between FeNO measured within a white, Central European 
population shortly after birth [78], and diagnoses of asthma and atopy at school age. Further, 
we compared FeNO levels after birth between healthy infants of the BILD cohort and FeNO 
levels from patients with CF enrolled in the Swiss Cystic Fibrosis Infant Lung Development 
birth cohort [81]. 
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5) To analyze the effect of polymorphisms in genes known to be relevant for asthma 
development. We focused on a biomarker suggested to be useful in the diagnosis of asthma 
[56], called YKL-40. Genetic studies in adults and infants at an increased risk for asthma 
development revealed that variation in the gene encoding YKL-40, CHI3L1, contributes to 
the pathogenesis of asthma. However, if CHI3L1 polymorphisms are associated with 
respiratory morbidity in unselected, healthy infants is unknown.  
6) To characterize the symptom dynamics of respiratory symptoms during infancy. For this, we 
used weekly assessed respiratory symptom scores during infancy to develop a method which 
characterizes this time series. Next, we tested whether specific dynamic symptom patters 
predicted wheezing and atopy at school age. Lastly, we investigated whether different 
environmental factors were associated with specific dynamic symptom patterns. 
7) Several epidemiological studies indicate that exposure to air pollution is associated with 
respiratory disease [64, 82, 83]. Well studied are the effects of short-term exposure to high 
levels of air pollution on an individual level [84], and some epidemiological studies have 
investigated long-term effects [17, 85]. However, the effects of short-term exposure on 
immune cell function have not been studied in detail. Therefore, our aim was to assess the 
influence of short-term gasoline exhaust exposure (freshly emitted from and passenger car) 
on immune cells within an experimental in vitro setting.  
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2 Methods 
2.1 The Basel-Bern infant lung development cohort   
In 1999, the Basel-Bern infant lung development (BILD) cohort was established in Bern, and 
later in Basel (2011), to study and better understand early lung development. The study aims to 
investigate physiological properties of the respiratory system, and environmental and genetic risk 
factors, affecting lung development in healthy individuals from infancy through childhood in 
relation to wheeze and asthma.  
Infants were recruited before birth and standardized interviews and questionnaires were used to 
assess risk factors for respiratory morbidity during childhood. At birth, cord blood samples for 
the assessment of immune cells and genetic information were collected. Additionally, the 
infant’s urine was collected at several time points during infancy for analyses of metabolic 
markers. During infancy, the respiratory health of the infants was monitored in detail. This 
includes conducting a non-invasive lung function test at 42 weeks’ postmenstrual age, as well as 
weekly calls during the first year of life by study nurses to assess the child’s health and 
occurrence of respiratory symptoms. At six years of age, the study participants are invited for a 
follow-up, including lung function tests and assessment of asthma and allergic diseases. An 
overview of the study outline is given in Figure 1. The study has been previously described in 
greater detail [78]. The Ethics Committees of Bern and Basel, Switzerland approved the study. 
Written informed consent was obtained from parents before enrolment. 
2.2 Respiratory symptoms during infancy  
Respiratory symptoms during the first year were assessed by weekly telephone interviews done 
by research nurses using a standardized symptom score that groups symptoms into four levels 
according to severity, with a high sensitivity for lower respiratory tract symptoms [86, 87].
  
 
Figure The BILD cohort: time-flow of recorded data, as well as of tests and procedures performed during the follow-up. Vt: tidal volume; FeNO: 
fraction of exhaled nitric oxide; MBW: multiple breath washout; FRC: functional residual capacity; LCI: lung clearance index; PCR: polymerase 
chain reaction; Rint: airway resistance by interrupter; Reff: effective airway resistance (measured by bodyplethysmography); FEV1: forced 
expiratory volume during the first second of expiration; MEF25-75: mid-expiratory flow [78]. 
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2.3 Cord blood sampling 
Shortly after birth, cord blood was sampled and stored at -80°C for the assessment of genetic 
information and immunological markers. Genome-wide single nucleotide polymorphism 
genotyping was conducted in collaboration with asthmagene.de (University of Regensburg, 
Germany). Cord blood YKL-40 was measured in duplicates by an enzyme-linked 
immunosorbent assay (ELISA) (R&D Systems, USA).  
2.4 Lung function 
Interrupter technique 
At 5 weeks of age, Rint was measured according to ATS/ERS guidelines for preschool children 
[10] and recommendations for infants [29, 88] during behaviorally defined, unsedated non-REM 
sleep in supine position using a rigid face mask (Teleflex medical AG, Ruesch, Silicone, size 2, 
Belp Switzerland) lined with putty to ensure a leak-free seal and to reduce dead space. 
Interruptions were manually triggered (Exhalyzer D, Eco Medics AG, Duernten Switzerland) 
every 3-6 breaths. Rint was calculated using the linear back-extrapolation method, applied to the 
trace of pressure at airway opening between 30 and 70 ms post-interruption [26]. Rint was 
recorded and processed [26, 89] using WBreath (Version 3.28.0.0, ndd Medizintechnik AG, 
Zurich, Switzerland). Before data analysis, values were corrected to body temperature pressure 
saturation (BTPS) and zero-offset of flow baseline was performed, as described previously [90]. 
Multiple breath washout 
MBW measurements were performed in infants at 5 weeks of age according to current ERS/ATS 
standards [9], as previously reported [91]. In brief, unsedated infants were measured while 
breathing through an infant facemask (Homedica AG, Baar, Switzerland), during natural sleep, 
in a supine position with the head midline through an ultrasonic flowmeter (Exhalyzer D, Eco 
Medics AG, Duernten, Switzerland) using 4% SF6, as previously described [91, 92]. 
  
Methods 
24 
Spirometry 
During follow up at six years of age, spirometry was performed to measure forced expiratory 
volume in 1 second (FEV1), forced vital capacity (FVC), and forced expiratory flow at 25-75% 
of FVC (FEF25-75%), according to ATS standards [22]. Data were expressed as z-scores using 
normative data from the Global Lung Function Initiative [33]. Spirometry was done using the 
MasterLab setup (Jaeger, Wuerzburg, Germany). 
2.5 Exhaled nitric oxide 
FeNO measurements in newborns  
FeNO measurements were performed at 5 weeks of age from multiple breaths during natural 
sleep, as previously described [29, 35], with a rapid response chemiluminescence analyser (CLD 
77; EcoMedics, Duernten, Switzerland; Analysis software: WBreath Version 3.28.0.0, ndd 
Medizintechnik AG, Zurich, Switzerland. Measurements were done in unsedated infants during 
natural sleep. 
FeNO measurements in school aged children  
During follow up at six years of age, FeNO was measured by the single-breath method with a 
rapid-response chemoluminescence analyzer (CLD 88 sp; EcoMedics, Duernten, Switzerland). 
Flow was recorded using an ultrasonic flow meter (Spiroson; EcoMedics) according to current 
guidelines [93]. 
2.6 Clinical outcomes at school age  
Respiratory health was assessed using questions from the International Study of Asthma and 
Allergies in Childhood (ISAAC) [94]. Asthma was diagnosed if one on the following was 
present in the previous year: (1) physician diagnosis of asthma or (2) episodic wheeze. Atopy 
was defined by allergic rhinitis, allergic asthma, or atopic dermatitis. A skin-prick test was done 
for the following allergens: (Dog dander, cat dander, Dermatophagoides pteronyssinus, mixed 
tree pollens, mixed grass pollens, Alternaria tenuis, positive control (histamine), negative control 
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(NaCl), Allergomed, Switzerland) positive in case of hives bigger than histamine in any of the 
tested allergens. 
2.7 Assessment of air pollution in vitro 
A coculture model composed of bronchial epithelial cells (ECs) and natural killer cells (NKs) 
mimicking the human airways was used to compare toxic effects between pure gasoline and 
ethanol-gasoline-blend exhaust emitted from a flexfuel gasoline car. The effects of exhaust on 
the cells were assessed by quantitative real-time-polymerase chain reaction, flow cytometry 
analysis, and oxidative stress assay. 
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3 Results 
3.1 Complexity of airway disease  
Asthma and obesity in children: current evidence and potential systems biology 
approaches 
Frey U, Latzin P, Usemann J, Maccora J, Zumsteg U, Kriemler S 
Published in Allergy. 2015 Jan;70(1):26-40. 
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3.2 Methodological challenges of lung function tests 
3.2.1 Application of multiple breath wash out  
 
Inert gas washout: background and application in different lung diseases 
Usemann J, Yammine S, Singer F, Latzin P 
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obstructive pulmonary disease DLCO: diffusion capacity for carbon monoxide CO2: carbon 
dioxide FEV1: forced expiratory volume in one second FVC: forced vital capacity FRC: 
functional residual capacity He: helium HCT: haematopoietic stem cell transplantation ICS: 
inhaled corticosteroids ILD: interstitial lung disease LCI: lung clearance index MBW: multiple 
breath-washout MR: moment ratio MRI: magnet resonance imaging N2: nitrogen N2O: nitrogen 
dioxide O2: oxygen PCD: primary ciliary dyskinesia RMS: respiratory mass spectrometer Sacin: 
slope of acinar airways Scond: slope of conducting airways SF6: sulfur hexafluoride 
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Abstract  
Multiple breath inert gas washout (MBW) is a lung function technique to measure ventilation 
inhomogeneity in the lungs. The technique was developed more than 60 years ago, but not much 
used for many decades. Technical improvements, easy protocols, and higher sensitivity 
compared to standard lung function tests in some disease groups have led to a recent renaissance 
of MBW.  
The lung clearance index (LCI) is a common measure derived from MBW tests, and offers 
complementary information on lung pathology compared to conventional lung function, such as 
spirometry. The LCI measures the overall degree of pulmonary ventilation inhomogeneity. Other 
MBW outcomes, such as slope III derived parameters describe more regional airway ventilation 
and enable specific information on conductive or acinar ventilation inhomogeneity. How this 
specific ventilation distribution is exactly related to different disease processes has not entirely 
been examined yet.  
MBW measurements are performed during tidal breathing, making this technique attractive for 
even young children and infants. These benefits and the additional physiological information on 
ventilation inhomogeneity early in the course of lung diseases have led to increasing research 
activities and clinical application of MBW especially in pediatric lung diseases, such as Cystic 
Fibrosis (CF). In these patients, LCI detects early airway damage and enables the monitoring of 
disease progression and treatment response. Guidelines for the standardization of the MBW 
technique were recently published. These guidelines will, hopefully, increase comparability of 
LCI data obtained in different centers or intervention trials in children and adults.  
In this non-systematic review article, we provide an overview of recent developments in MBW. 
Literature was searched in Pubmed, and in the North American and European clinical trial 
registries. Search terms were: CF, lung clearance index, lung function test, lung disease, and 
washout. We specifically focused on literature in children. We first explain the physiological and 
technical background of this technique with a short explanation of several methodological 
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aspects. These are important to understand the principle behind the technique and to enable high 
quality measurements. We then provide examples of MBW application in different lung diseases 
of children and adults, both with regards to clinical application and research activities. Lastly, we 
report on ongoing clinical trials using MBW as outcome and give an outlook on possible future 
developments 
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1. Introduction 
For decades, conventional spirometry has been the standard technique to assess the degree of 
airway obstruction in most chronic lung diseases, including Cystic Fibrosis (CF), asthma, and 
chronic lung disease of prematurity (CLD). However, there is mounting evidence that based on 
its underlying physiological principle, spirometry is insensitive for the assessment of peripheral 
airway involvement and for the assessment of ventilation distribution. This resulted in an 
increased interest in gas dilution techniques, in particular multiple breath-washout (MBW), for 
the assessment of small airway function, i.e. efficient, homogeneous ventilation  distribution [1, 
2].   
MBW was first described more than 60 years ago by Ward S. Fowler [3]. In his pioneering work 
of 1952, he compared nitrogen (N2) clearance from single breath washouts between healthy 
subjects and patients with cardiopulmonary disease, to assess the degree of uneven alveolar gas 
dilution [3]. However, the technique was little appreciated until gas analyzers and computers 
were further developed to improve automated analysis of gas and volume signals during 
measurements [4, 5]. Today, the technique is returning to “prime time”, especially in the 
pediatric pulmonology community. Recently, an international workshop reviewed current 
literature on the monitoring of preschool lung disease. Besides detailed recommendations for 
technical standards and measurement procedures, this report suggested MBW as a promising tool 
in preschool children with CF, highlighting its importance [6].    
2. Physiological background, mechanisms of ventilation inhomogeneity 
The main function of the human lung is to homogeneously ventilate the lungs, enabling efficient 
gas exchange. During fetal lung development, the lungs grow from proximal to distal by a 
continuous division of the airways, which later form the unique structure of the bronchial tree. 
The bronchial tree consists on average of 23 bronchial generations, but gas exchange only occurs 
in approximately the last 9 generations. The bronchial tree resembles a self-similar, so-called 
fractal structure, enabling efficient gas transport. Normal ventilation distribution occurs by 
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convection and diffusion. Three main mechanisms of ventilation inhomogeneity are currently 
known: i) convection-dependent inhomogeneity (CDI) in the conducting airway zone (more 
proximal located airways); ii) diffusion-limitation related inhomogeneity in the diffusion-
dependent airway zone (distal airways, acini); iii) interaction between convection and diffusion 
in an intermediate zone at the level of the diffusion-convection front, which is thought to arise at 
the acinar entrance [7]. The acinar compartment, i.e. the alveoli, is separated by a thin tissue 
layer from a capillary meshwork and forms a large surface for efficient oxygen (O2) and carbon 
dioxide (CO2) gas exchange. 
3. Technical background 
3.1 MBW testing  
Besides analysis devices, MBW tests require only a tight facemask or mouthpiece and quiet tidal 
breathing for 2-10 minutes per test, making this technique applicable across all age groups, even 
during infancy. Measurements in infants are done in a supine position during quiet non-rapid 
eye-movement sleep (or with sedation), using a face mask. In older children and adults, 
measurements are usually performed in a sitting position with a mouth-piece and nose clip. 
Differences between sitting and supine position have been described [8] and need to be taken 
into account when comparing data or in longitudinal studies. To support regular breathing 
patterns, distraction with videos is recommended in children [9], while visual breathing pattern 
feedback may be useful in adolescents and adults [10]. Because time for triplicate testing can be 
demanding in busy outpatient clinics or patients with advanced lung disease, promising, 
abbreviated protocols were proposed [11, 12]. 
Each MBW test consists of a wash-in and a wash-out phase. Depending on the gas for the MBW 
test employed, there are in principle two different ways to perform MBW: 1) When using an 
inert extrinsic gas (i.e. 4% sulfur hexafluoride (SF6); 20% helium (He)), the gas mixture is 
inspired until an equilibrium is reached. Then, the washout phase starts from this point of 
equilibrium by again breathing room air. 2) For inert intrinsic gas (i.e. N2), no formal wash-in 
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phase is required for the first of three tests. For N2 washout of the airways, 100% oxygen (O2) is 
usually used. Regardless of the gas used, the washout is stopped when the test gas reaches 1/40
th
 
(or 2.5% from the initial starting concentration set to 100%) of the initial gas concentration [7]. 
This cut-off was recently challenged to improve comparability between different techniques as 
the role of N2 is not fully understood yet [13]. Figure 1 shows a typical washout trace of an 
MBW test using N2 washout.  
3.2 MBW outcomes 
There are three main parameters reported from MBW tests: the functional residual capacity 
(FRC), the lung clearance index (LCI), and moment ratios (MR). The FRC is the volume of air 
present in the lung after tidal expiration in those open lung regions that are in communication 
with the mouth. LCI and MR are both measures for global ventilation inhomogeneity. Besides 
LCI and MR, other parameters assessing specifically peripheral airway ventilation can be 
calculated, as detailed below.  
Given that MBW setups measure inert gas concentrations and the cumulative volume required to 
washout the resting lung volume (FRC), the latter can be calculated. The FRC is derived from a 
ratio, i.e. the cumulative expired volume (CEV) of the inert gas over the difference of the end-
tidal concentration of the inert gas (Cet) measured at the start (Cetstart) and end (Cetend) of the 
washout. The LCI is a volume ratio, net CEV (including all gas fractions) over FRC: 
LCI=CEV/FRC. An increased ventilation inhomogeneity would thus result in more tidal breaths 
(greater net CEV) needed to wash out the inert gas, and in a subsequently increased LCI. To 
adjust for lung size, net CEV is divided by FRC to obtain LCI. 
MR also quantifies ventilation inhomogeneity, but is   less commonly used. They have been 
described in detail elsewhere [4, 14-23]. The advantage of MR over LCI is that they can be 
weighted to specific parts of the washout curve.  
Specific markers for peripheral lung ventilation are the slopes of alveolar phase III (SIII) of the 
inert gas expirogram. The first SIII value is thought to reflect ventilation inhomogeneity within 
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diffusion–convection-dependent acinar airways (Sacin), while the subsequent evolution of SIII 
values from lung turnover 1.5 to 6.0 is thought to reflect ventilation inhomogeneity within 
convection-dependent conducting airways (Scond) [7, 24]. While these indices were derived 
from numerical lung models [24], recent comparative data from ventilation imaging techniques 
are reassuring [25, 26]. 
3.3 MBW equipment and analysis procedures  
One of the earliest and most recognized systems for MBW is based on a respiratory mass 
spectrometer (RMS), allowing the simultaneous measurement of multiple gases at 33 Hz or 
higher. Drawbacks of the AMIS 2000 (Innovision, Denmark) relate to the custom design, 
sophisticated maintenance and costs [27]. Other customized systems have been described in 
detail elsewhere [7, 28]. Currently, there are at least three commercially available devices which 
strongly differ i.e. in regards to the inert gas used, the gas analyzer, analysis algorithms, and the 
age group to which application is recommended (Table 1).  
3.4 Gases for MBW testing  
Depending on the choice of gas and setup, derived MBW indices significantly differ [29]. For 
example, He is much lighter than SF6
 
and generates systematically higher LCI values [7]. 
Furthermore, in subjects with emphysematous diseases, the diffusion equilibrium in the enlarged 
peripheral airways differs across gases. Other aspects regarding the use of SF6 are its costs and 
limited availability since it belongs to the most potent greenhouse gases. Applications using 
lower SF6 fractions may be more suitable for routine use. 
The choice for intrinsic gases (i.e. N2) for MBW has the advantage that the required O2 for 
washout is widely available and affordable. Another strength is that N2 is resident in all lung 
units and this gas, therefore, has great sensitivity to detect abnormality compared to extrinsic 
gases. Further, the wash-in is done using room air and without the need for a tight mouthpiece, 
making it much easier to apply. 
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There is clear evidence that breathing patterns may change during MBW. While in adults fixed 1 
litre breathing protocols may have some advantages with regards to slope III standardisation and 
analysis [30], most studies nowadays use free tidal breathing in order to take advantage of 
natural breathing pattern. This is especially important in children, as fixed breathing protocols 
have been shown to influence MBW outcome parameters substantially [31]. Application of 
100% O2 in MBW was shown to alter breathing patterns in infants [22], and SF6 induced 
transient hypopnea in preterm and healthy infants [32, 33]. However, in school-aged children, 
MBW indices were not influenced by inhalation of 100% O2 [34]. In addition, the effect of N2 
back-diffusion from tissue N2 requires further studies. 
3.5 Sample flow and gas analysis  
Tidal flow and gases are usually measured within the main path of the respiratory flow 
(mainstream), or a continuous sample is taken from a capillary (sidestream). Yet sidestream 
sample flow (suction) may impact upon the analyzer response and add noise to “small” signals 
i.e. from infants. Flows and integrated volumes have to be further corrected for BTPS (body 
temperature, pressure, saturated with water) [7]. The gas concentrations can then be measured 
directly (RMS, infrared, etc.) or indirectly (molar mass, cumulative gas fractions, etc.) [35]. Of 
note, usually the flow and gas signals are not sampled at the same sensor point. Signals, 
therefore, need to be aligned in time. Poor BTPS correction or signal misalignment can be a 
source of error in MBW outcomes [7, 36].  
3.6 Impact of dead space on LCI 
Dead space roughly consists of two compartments. Technical dead space consists of the volume 
of MBW hardware (mask, mouthpiece, and tubes) required to transport gases to the sensors. 
Anatomical and physiological dead spaces refer to the volume of upper and lower airways, 
respectively, which transport gases but do not participate in gas exchange. Technical dead space 
is hardware specific and impacts upon LCI [37, 38]. The impact seems larger in younger children 
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compared to adults, and is apparently independent of lung disease. Thus, a small technical dead 
space ≤2 ml/kg is recommended [39]. 
3.7 Software for MBW analysis  
For analyses of MBW indices, commercially available online and offline software is available, 
and several custom-made software applications exist. While offline data analysis was frequently 
used in the past, it has the disadvantage that analysis is time consuming, and therefore limits its 
application in clinical settings. Several studies reported an impact on MBW indices due to 
different software and settings [36, 40, 41]. Current commercial setups usually provide recording 
and analysis software on-board. Yet these applications undergo constant development and 
software updates need to be validated in clinical settings for reliability [42-44]. 
3.8 Normative data for MBW  
Depending on the age of subjects and the factors mentioned above (gas, equipment, dead space, 
software) LCI is usually below 8.5 lung turnovers (LCI units) in healthy subjects. However, 
normative data for MBW measurements across different age groups are scant [45]. Some data 
stem from customized setups [46], limiting generalizability. Furthermore, data is not only 
system, but also gas-specific, and may even be influenced by the analysis approach. The latter 
has been shown for both, healthy, and CF patients [40, 41]. Two previous studies reported MBW 
reference values for infants using common available equipment from a large Swiss [45] and 
African population [47], with measurements conducted at 5 weeks postnatal age. Since LCI is 
thought to decrease throughout infancy and early childhood, then remains constant and increases 
in the elderly [46], these reference data cannot be applied to other age groups. There are other 
relevant factors which impact upon MBW measures including the posture during tests (supine 
versus seated) [8], the gas choice (SF6 versus N2) [37], dead space [38, 48, 49], as well as 
sedation, which may play a significant role for LCI variability across age.   
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3.9 Limitations of MBW testing, knowledge gaps  
Limitations to MBW application relate to technical and physiological aspects. Much effort has 
been done to improve standardization of MBW protocols and analysis, but there are still several 
unanswered questions as mentioned above. Overcoming these knowledge gaps seems difficult, 
considering the, at times, poor software transparency [43]. Besides software, there are other 
aspects which may change MBW indices. There is evidence that interventions prior to MBW 
testing, such as raised volume rapid thoracoabdominal compression [50] or physiotherapy [51-
53], subsequently effect MBW outcomes. Other important aspects have been outlined previously 
[7].  
The impact of repeat LCI measurements for the assessment of respiratory disease outcomes is 
largely unknown. While data suggest a clear association with infection burden, structural airway 
pathology or later pulmonary exacerbation in CF, it remains unclear what change in LCI should 
prompt clinicians to intervene. As true for most lung function outcome parameters, the beneficial 
effect of regularly measurement of LCI in clinics on disease outcome has not been assessed yet. 
Recent data may help to establish what would constitute a clinically important change in LCI, at 
least in preschool children [54]. 
3.10 Single-breath washout  
There are techniques other than MBW to assess ventilation inhomogeneity, i.e. single-breath 
washout (SBW) tests, using a single or double inert tracer gas mixture. Several studies have used 
this technique, also in younger children. SBW has been used in CF patients to detect early lung 
disease [55], assess response to airway clearance [56], and to study the involvement of small 
airways in patients with mild asthma [57], COPD [58-61], PCD [62, 63] and bronchiolitis 
obliterans (BO) [64-66]. SBW may be attractive for clinical settings, since measurements can be 
completed more quickly than for MBW, and SBW is applicable during normal tidal breathing or 
forced maneuvers. While acceptable reproducibility of this test has been reported in adults [60] 
and children [55], reproducibility is lower compared to MBW. Several unanswered technical 
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aspects also remain (i.e. impact of breathing pattern) [7, 67, 68], precluding its use for clinical 
decision making.  
4 Application of MBW in lung diseases  
4.1 Cystic Fibrosis 
CF is an inherited life-limiting disease with a mean prevalence of approximately 0.8/10.000 in 
Europe and the United States [69]. In Switzerland, CF newborn screening, introduced in 2011, 
enables early CF diagnosis and follow-up of lung function [44]. CF lung disease is characterized 
by mucus plugging, chronic infection and inflammation resulting in irreversible lung damage. 
Treatment advances have resulted in the preservation of normal forced expiratory volume in one 
second (FEV1) (>-1.64 z-scores) into young adulthood, but progression of bronchiectasis may be 
undetected by spirometry [70]. This led to more research to detect early airway abnormalities in 
CF patients by MBW, and several observational studies and clinical trials support its usefulness, 
as detailed below.  
4.1.1 Observational studies  
The majority of longitudinal data from infants and children with CF are currently obtained from 
two large prospective cohorts, the Australian Respiratory Early Surveillance Team for Cystic 
Fibrosis (AREST-CF), and the London Cystic Fibrosis Collaboration (LCFC), (reviewed in 
[71]). There is mounting evidence that compared to healthy controls, LCI is already abnormal 
shortly after birth in patients with CF [1, 72, 73]. In infancy, LCI is normal in approximately half 
of the infants. Interestingly, there are infants with normal LCI values in the presence of abnormal 
forced volume values (as assessed by raised volume rapid thoracoabdominal compression 
technique) [74]. Several observational studies “tracked” LCI from preschool age to school age 
[75, 76].  A multi-center study assessed LCI at several time points and was able to identify 
significant deterioration of LCI in CF over time, which was not detected by spirometry [54]. 
Another study found that LCI during preschool years was more likely to be abnormal than 
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spirometry, and an abnormal LCI in preschool children predicted both, abnormal LCI, and 
abnormal spirometry at school age [75].  
Studies in infants [77], children [74, 78], and adults [79] could show that patients with evidence 
of a bacterial infection were more likely to have abnormal LCI values. Findings from the 
longitudinal study AREST-CF, suggested that LCI has a more pronounced increase in infants 
with airway infections compared to those without, and that this increase was long lasting [80]. 
Several studies used MBW to monitor treatment response to antibiotic therapy in infants and 
adult patients with CF [81-83]. A systematic review included data from 176 exacerbations and 
observed an overall decrease, albeit small (~ -3%), in LCI after antibiotic treatment. However, 
the LCI response to therapy was very heterogeneous in CF patients, and is not fully understood 
[81]. 
4.1.2 Clinical trials  
There is an ongoing debate about whether or not MBW can be used in multicenter trials. The 
Cystic Fibrosis Foundation Workshop Report from 2015 concluded that, for example, lack of 
knowledge on MBW equipment hampers routine application of MBW in clinical trials [6]. On 
the other hand, the European CF Society Clinical Trial Network Standardization Committee [84] 
suggested LCI as an outcome measure, especially in young children and those with mild CF 
disease.  
To date, several single- and multicenter trials with CF patients using LCI as outcome have been 
published. Two multicenter interventional studies investigated the treatment effect of drugs 
modifying the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) defect in CF 
patients. One study enrolled patients >6 years, with at least one copy of the rare G551D mutation 
and normal FEV1, and assessed the ability of LCI to detect a treatment effect of ivacaftor. 
Treatment with ivacaftor resulted in significant improvement of LCI compared to placebo [85]. 
Another study enrolled patients 6-11 years, homozygous for F508del-CFTR, to assess the 
treatment effect of combined therapy with ivacaftor and lumacaftor on LCI. While no changes in 
Results - Application of multiple breath wash out 
60 
FEV1 were observed after 24 weeks of intervention, there was significant improvement in LCI 
[86].  
Two trials examined the usefulness of LCI in infants and preschool children to assess treatment 
response to hypertonic saline inhalation [87, 88]. One study performed MBW measurements 
before and after treatment with hypertonic saline (twice daily for 48 weeks) in 25 children <6 
years. LCI decreased (improved) significantly more in the hypertonic saline group, compared to 
controls [87]. Of note, the pattern of LCI change with treatment was age-dependent: when 
specifically analyzing a subgroup of subjects <1 year of age, LCI was in the normal range at 
baseline and did not change after treatment [87]. A recent study in 18 older children (mean age 
14.0 years) investigated the short term effect of hypertonic saline inhalation [88], and found that 
LCI did not change after 24 hours treatment [88].  
Responsiveness of LCI was assessed in two randomized, double-blind, placebo-controlled trials 
in older children. While FEV1 was not systematically affected, LCI improved over a 1-month 
period after treatment with hypertonic saline [89], and with dornase alfa (Pulmozyme
®
), an 
enzymatic agent improving mucus clearance in CF [90].  
A cross-sectional study assessed the effect of antibiotic therapy on LCI abnormalities and 
magnet resonance imaging (MRI) in clinically stable patients, aged 1-20 years. LCI and MRI 
were sensitive to detect an effect of antibiotic treatment for pulmonary exacerbations [82], 
indicating that these tools are useful endpoints in intervention trials.  
4.1.3 MBW indices and lung imaging  
Several recent studies in children and infants compared the association of LCI with structural 
airway damage or functional correlates using lung imaging techniques, including computer 
tomography (CT) and MRI. While studies in infants reported poor association between LCI and 
i.e. bronchiectasis as assessed by CT [91, 92], a closer correlation was found in preschool- and 
school-aged children [92]. This is not the case for spirometry indices. A strong correlation 
between LCI and MRI imaging was reported in clinically stable CF patients (age range 2-20 
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years) [82]. This study could further show that LCI and MRI are sensitive to detect disease 
severity levels, supporting the application of these tools for diagnostic and therapeutic 
monitoring. Taken together, these data support the concept of LCI as a sensitive measure of 
structural airway pathology. However, LCI cannot replace lung imaging yet, as negative 
predictive values to exclude bronchiectasis appear too low, especially in younger children. An 
overview of MBW application in CF lung disease is given in table 2. 
4.2 Wheezing 
Lower respiratory tract infections, or other triggers, such as allergen exposure leading to 
wheezing episodes in preschool children, are highly prevalent. Some, but not all wheezers 
experience worsening lung function [93] and involvement of the small airways, as assessed by 
MBW and lung biopsy [94]. Functional data using MBW are conflicting. One study measured 
LCI in 110 preterm infants who required respiratory support during the first days of life. 
Measurements were performed with sedation, at approximately 42 weeks postmenstrual age. The 
authors found a higher LCI in infants with less (≤3%), compared to infants with more (>3%) 
expiratory wheezing [95]. These results were supported in a subsequent study reporting a higher 
LCI in 40 non-wheezing infants, compared to 41 infants with wheezing [38]. These findings 
contradict a study in preschool children, which reported an increased LCI in wheezers compared 
to healthy controls [94], but mean LCI differences were small (6.8 versus 6.6.), and within the 
normal range. Apparently, the effect of bronchodilator inhalation on LCI is somewhat 
paradoxical. LCI may increase (worsen) after inhaling salbutamol in controls, but not in 
wheezing subjects [96]. High variability between MBW tests at baseline, and heterogeneous 
response to bronchodilatators questions the use of MBW to distinguish preschool wheezers from 
healthy controls [96]. To summarize, current data does not support application of MBW 
measurements in infants and children to characterize wheezing or to monitor treatment response.  
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4.3 Asthma  
Asthma is the most common chronic respiratory disease in children, typically characterized by 
eosinophilic airway inflammation, airway hyperresponsiveness (AHR), and reversible airway 
obstruction. AHR is the ability of airways to narrow excessively due to provoking stimuli. While 
current guidelines recommend symptom assessment and spirometry for the diagnosis of asthma 
[97], the value for monitoring asthma is not clear [98]. Spirometry was rather insensitive for 
peripheral airways, unless severe obstruction was present [99]. LCI in asthmatic subjects was 
slightly elevated compared to healthy controls, but often within normal range, and therefore not 
helpful to diagnose asthma at the individual level [100-102]. Few studies assessed the 
association between MBW measures and AHR. A study in older asthmatic subjects (age range 
59-80) found that AHR was predicted by higher Sacin [103], and a study in asthmatic adults (age 
range 18-66 years) found that AHR was associated with LCI, and that treatment with inhaled 
corticosteroids (ICS) decreased the LCI [104]. In adults with severe asthma, ICS uptitration 
resulted in a decrease in Scond with no effect on Sacin [105]. The study further reported that 
those patients with increased ventilation inhomogeneity at baseline had the greatest improvement 
following ICS dose uptitration [105]. An effect of bronchodilator response on LCI is still poorly 
understood. While two studies in children found no effect [100, 102], another study reported that 
the LCI was elevated in adolescents with asthma, and decreased after treatment with nebulized 
bronchodilatator [106]. To summarize, while MBW can be useful to explore the exact degree of 
airway damage and physiological impairment in asthma, until now, the technique is not 
established for diagnosis or monitoring treatment response in asthma. 
4.4 Chronic lung diseases of prematurity 
Disruption of normal lung development due to preterm birth results in complex structural 
changes of airways, lung parenchyma, and vasculature. This may result in smaller airway 
calibres, and impaired alveolarization, along with a reduced number of alveoli and enlarged 
airspaces [107].  
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The functional relevance of disrupted airway development during infancy and thereafter is not 
fully understood. This can be partly explained since the degree of airway obstruction is 
underestimated by spirometry. Recent studies in former preterm infants used other outcomes 
including the LCI [108-113], FRC [110, 113, 114], and parameters specifically assessing 
peripheral airway damage (Scond, Sacin) [109]. Results are inconsistent, probably reflecting the 
heterogeneity of the disease and different measurement techniques. Abnormal values for LCI 
have been reported in preterm infants during infancy [110], and for former preterm infants at 
school age [112]. Other studies reported no difference in LCI values in former preterm infants 
compared to healthy subjects during early infancy [113], at 1 year [114], between 9-11 [115], 
and 7-13 years [109] of age. The latter study further investigated parameters specifically 
assessing peripheral airway ventilation. In that study, FEV1 and Scond were often abnormal at 
school age, while Sacin was comparable between former preterm and healthy subjects. A 
functionally normal alveolar compartment at school age, together with functionally abnormal 
central conducting airways suggests a disynaptic growth pattern of the lungs in former 
prematurely born children [109]. Using MBW measurements, studies assessed the development 
of lung volume. Prematurity was associated with a reduced FRC during early infancy [110] and 
at 1 year of age [114].  
4.5 Primary ciliary dyskinesia 
Primary ciliary dyskinesia (PCD) is a rare congenital disease characterized by defective ciliary 
function, leading to impaired mucociliary clearance and recurrent chronic upper and lower 
airway infections [116]. The diagnosis of PCD is challenging due to the heterogeneous nature of 
the disease and poorly standardized algorithms [116]. Patients with PCD may already have 
reduced lung function (i.e. FEV1, and forced vital capacity (FVC)) at preschool age [117]. 
Similar to CF, spirometry may underestimate the full degree of functional impairment in early 
PCD lung disease [118, 119]. Recent studies reported marked peripheral airway dysfunction, 
assessed by MBW, in almost all patients with PCD [62, 63, 120]. Another study compared the 
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association between LCI and FEV1 with structural abnormalities, as assessed by CT, in 38 
patients. The authors reported a higher concordance between LCI and structural abnormalities 
compared to FEV1 (83% versus 53%), suggesting that LCI measurements may be of clinical 
relevance in PCD patients [119]. Interestingly, studies using SF6 MBW did not find this 
association [121]. Taken together, PCD lung disease is characterized by marked peripheral 
airway dysfunction, and MBW may be a promising tool for early detection of airway damage. 
Compared to CF, MBW data in PCD are scarce. Whether MBW has utility in the management 
and/or treatment of PCD still needs to be determined in longitudinal studies.  
4.6 Chronic obstructive pulmonary disease  
Chronic obstructive pulmonary disease (COPD) is characterized by a variable combination of 
airway and parenchymal abnormalities. COPD may partly develop irrespective of tobacco 
smoking, and much earlier in life than previously assumed [122, 123]. The hallmark of COPD is 
mainly irreversible airﬂow obstruction resulting from the narrowing of small conducting 
airways, loss of lung elastic recoil, or both. In the diagnosis of airﬂow obstruction in COPD, 
simple spirometry is the main diagnostic tool, although it is recognized that none of the derived 
parameters are sensitive to peripheral airway narrowing [124, 125].  
Within a prospective study of subjects who smoked ≥10-pack years, an increase in ventilation 
inhomogeneity in both, the conductive and acinar airways was detected, indicated by increased 
Scond and Sacin values. Moreover, Scond and Sacin were associated with FEV1/FVC values, but 
Scond was associated with FEV1 and Sacin to diffusion capacity for carbon monoxide (DLCO) 
[126]. Similar results were reported from a cross-sectional study of 57 COPD patients with ≥15-
pack years. COPD patients had increased Sacin but not Scond values compared to healthy 
controls [127], and an association between Sacin and DLCO was also reported [60]. Taken 
together, these studies suggest that MBW measurements have the potential to diagnose 
subclinical disease at an earlier state, separate airway from parenchymal abnormalities, and to 
further characterize clinical features of advanced COPD. While good feasibility and 
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reproducibility of washout measurements in COPD patients were shown [60], there is still 
further need to validate this method for non-invasive detection of early abnormalities or 
peripheral or parenchymal sites [128].  
4.7 Other disease groups   
In addition to the application of MBW in patients with CF and other common lung diseases, 
recent studies have applied this technique in less frequent lung disease, of which some studies 
will be reported.  
BO is a small airway disease in which chronic inflammation results in fibrotic remodeling of the 
peripheral airways. It can occur e.g. after exposure to toxic substances, or following allogeneic 
haematopoietic stem cell transplantation (HCT). Early detection of BO is important to prevent 
later lung damage. One study reported abnormal washout indices before a decrease in FEV1 was 
observed [129], and measurements may even be used to detect different severity grades of BO, 
as recently reported [130]. In patients undergoing HCT, a study of 33 clinically stable recipients 
provided some evidence that measures of MBW were more sensitive than spirometry to detect 
BO at an early stage [131].  
Alpha-1-antitrypsin deficiency (AATD) is a genetically inherited disorder resulting in 
emphysematous lung changes. Within a heterogeneous group of 193 patients with AATD (age 
range 4-79 years), LCI was higher in patients compared to controls. Furthermore, LCI was found 
to be abnormal in patients with normal spirometry measures, indicating that LCI identifies 
AATD related lung disease earlier than spirometry, comparable to the chronic lung diseases 
discussed earlier in this article [132]. 
Bronchiolitis is a common respiratory tract infection during early childhood. A recent study 
included 29 infants (mean age 3.7 months) with bronchiolitis and reported an increased LCI 
compared to controls [133]. Another prospective study enrolled infants hospitalized with 
bronchiolitis due to respiratory syncytial virus (RSV) infection below <1 year of age, and 
reported no difference in LCI, but FEV1, between patients and controls at the age of 18 [134].  
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4.8 MBW in ongoing clinical trials  
Currently, there are more than 50 ongoing studies using MBW indices as outcome measures 
listed in the North American [135] and European [136] clinical trials registries. While most of 
these trials are performed in patients with CF and asthma, some are performed in less common 
lung diseases. We present a selection of trials we consider interesting, though it is not a 
comprehensive overview.  
The first trial using LCI as primary outcome in CF patients (aged 6-11 years) homozygous for 
the F508del mutation after treatment with combined therapy of lumacaftor/ivacaftor (Orkambi
®
) 
twice daily over 24 weeks is still ongoing [137]. The study assesses efficacy and safety of the 
drug, as well as treatment effects on LCI. Two further trials in children are investigating the 
treatment effect of 8 weeks ivacaftor. One trial is already ongoing, aiming to recruit 50 children 
3-5 years with different CFTR mutations to assess changes in LCI[138], and another trial will 
study the efficacy of ivacaftor in subjects >6 years old, focusing on a specific CFTR mutation 
[139]. 
One trial is being conducted in PCD patients within the BESTCILIA (Better Experimental 
Screening and Treatment for primary CILIAry dyskinesia) study. This is a European multicenter, 
double-blind, randomized, placebo-controlled trial with the aim to determine the efficacy of 
azithromycin maintenance therapy for 6 months on respiratory exacerbations in patients with 
PCD. This interventional trial is currently ongoing and aims to recruit 125 PCD patients, aged 7-
50 years old. Besides the quality of life assessment, one of the main outcomes is the LCI [140]. 
This trial will hopefully help elucidate whether or not maintenance therapy with azithromycin 
has beneficial effects in patients with PCD.  
Several trials assess treatment response to inhaled glucocorticoids, betamimetics or hypertonic 
saline in adult [141] and pediatric patients with asthma [142] and CF [143]. For example, in 
patients with CF aged 6-18 years of age, a randomized-controlled trial is assessing the short term 
effects (within 24 hours post-dose) of hypertonic saline inhalation on LCI [143]. 
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There is an observational, prospective study recruiting children with CF and asthma, but 
interestingly, also children with BO and sickle cell anemia [144]. This trial will validate the 
MBW device for different lung diseases in Canada, where it is not currently licensed yet. This 
study may also provide insights for the application of MBW in pulmonary complications in 
children with sickle cell disease, which has not yet been investigated.  
Little is currently known of the involvement of small airways in patients with interstitial lung 
disease (ILD). One trial currently underway will perform MBW in adult patients with different 
manifestations of ILD (i.e. Wegner’s Disease, idiopathic pulmonary fibrosis, sarcoidosis), to 
further understand the complex pathology and heterogeneous presentation of these diseases 
[145]. 
5 Conclusion  
MBW has regained interest in recent years. Reasons for this renaissance relate to technical and 
physiological considerations. The technique is sensitive for early detection of lung function 
impairment often arising in small peripheral airways. MBW provides information that cannot 
currently be obtained by other lung function tests or chest imaging. MBW is especially attractive 
for young patients, as measurements require minimal cooperation. There is mounting evidence 
that the LCI is useful for assessing the extent and progression of lung disease as well as 
treatment response in patients with CF. LCI is already broadly applied in clinical care for CF 
patients, yet a number of unresolved questions remain. For example, there are currently poorly 
defined upper limits of normal for LCI values and its natural variability over time. Further, 
different software settings and device-setups may impact upon LCI values. Application of MBW 
tests in other chronic lung diseases may be attractive for research while the impact on clinical 
management and respiratory disease outcomes require further studies. 
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Figure 
 
Figure 1 Example of a typical multiple-breath washout (MBW) trace. A) Black line represents 
volume; red line represents flow signal. B) Nitrogen (N2) and C) O2 signal from an N2 MBW 
test. Stable breathing pattern can be observed before washout is started (black, continues arrow), 
and during the time series display of MBW (black, dotted arrow). 
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Tables  
Table 1 Current available multiple-breath washout devices 
 Eco Medics infants Eco Medics 
preschool and 
older 
ndd 
EasyOne Pro 
LAB
*
 
Innovision Innocor 
Method 
Flow / Volume 
measurement 
 
Tracer gas 
measurement 
SF6  
Ultrasonic 
flowmeter 
 
Indirect via molar 
mass mainstream 
N2  
Ultrasonic 
flowmeter 
 
Indirect via O2 and 
CO2 measurement 
N2  
Ultrasonic 
flowmeter 
 
Indirect via 
molar mass, 
O2 and CO2 
measurement 
SF6  
Pneumotachometer 
 
 
Direct via 
photoacoustic 
spectroscopy, gas 
reservoir bag 
Gas 
concentration 
4% SF6 100% O2  100% O2  SF6 mixture (0.1% 
or 0.2% SF6 (27.6% 
O2, 0.35% N2O)) 
Validation 
studies 
 
Lung model 
Schmidt [146], 
Gustafsson [147]
 
Lung model and in 
vivo Singer [35] 
 
- In vivo Horsley [10] 
Lung model  
and in vivo Gonem 
[148] 
Methodological 
studies 
 
Anagnostopoulou 
[40],  Latzin [48] 
Jensen [37], 
Summermatter [36] 
- Horsley [149], 
Downing, [150], 
Grønbæk [151], 
Gonem [25], Gonem 
[148], Nielsen 
[152], Shawcross 
[153] 
Application in 
healthy 
Fuchs [45], 
Anagnostopoulou 
[40], Gray [47] 
Gray [114] 
  Downing [150] 
Studies in CF Belessis [77], 
Simpson [80], Hall 
[91]. 
Stanojevic [54], 
Stahl [82], Amin 
[88], Ramsey [92] 
 Davies [85] 
CF and controls  Singer [78], Poncin 
[29] 
Poncin [29] Downing [150] 
Other disease 
groups 
 
Hulskamp [110], 
Latzin [113] 
Yammine [109], 
Boon [119], Nyilas 
[118], Madsen [62], 
Jarenback [127] 
Fuchs [132] Macleod [100] 
This table is meant to provide a current overview on available setups and does not necessarily 
represent the full body of existing literature. Please refer to the respective manufacturer for an update 
on current studies and recent developments. Manufacture of AMIS 2000 (Innovision) has been 
discontinued (http://www.innovision.dk/Products/AMIS_2000.aspx, accessed on 1.3.2017). 
*
 Before 
2012, ndd EasyOne Pro was in use for multiple-breath washout measurement using 4% SF6 (MM 
sidestream) (Fuchs [154], Fuchs [155], Ellemunter [156], Fuchs [132]). CF: Cystic Fibrosis: CO2: 
carbon dioxide N2: nitrogen N2O: nitrogen dioxide O2: oxygen SF6: sulfur hexafluoride.  
  
  
Table 2 Overview of studies in pediatric patients with Cystic Fibrosis using multiple-breath washout measurements 
Study description   Patient 
number  
Age at 
study 
Study type Main findings Reference
*
 
CF versus controls      
Infants 71 3 months cross-sectional Higher LCI and FRC in infants with CF compared to 71 
controls.  
Hoo [74] 
Preschool/School age/Adults  40 2.5-5 years cross-sectional Higher LCI in patients with CF compared to 37 controls. Aurora [1] 
 48 4.09 (0.7) 
and 7.83 
(1.3) years 
prospective Higher LCI in CF patients at preschool age compared to 
45 controls. Preschool LCI predicted abnormal LCI in 
CF patients at school age. 
Aurora 
[75] 
 78 2.5-6 years prospective LCI measurements in CF patients and 70 controls at 1, 
3, 6 and 12 months detected lung function deterioration 
over time in CF patients. 
Stanojevic 
[54] 
 60 7.8 (1.3) 
years 
cross-sectional  Higher LCI in CF patients versus 60 controls.  Owens 
[73] 
 43 3-18 years cross-sectional  Higher LCI and MR in CF patients versus 28 controls.  Gustafsso
n [72] 
 47 9.5-16.1 
years  
cross-sectional LCI was higher in CF patients compared to 50 controls. 
Comparison of LCI measured by two different MBW 
devices revealed poor agreement between different 
setups.  
Poncin 
[29] 
CF with versus without bacterial infection 
 47 0.32-3.24 
years 
cross-sectional  LCI of 25 healthy subjects was lower compared to CF 
patients without, and with bacterial infection. In CF 
patients, inflammatory markers from BAL correlated 
with LCI.  
Belessis 
[77] 
 78 4-16 years prospective LCI was higher in CF patients compared to 53 controls. 
LCI strongly correlated with Pseudomonas aeruginosa 
infection.  
Singer 
[78] 
 108 0.1-2.5 
years 
prospective LCI measurements at three time points during 2 years 
revealed a long-lasting increase in LCI after pulmonary 
infections. Haemophilus influenzae infections had in 
particularly detrimental effects on lung function.  
Simpson 
[80] 
  
 41 8-67 years cross-sectional LCI was higher in CF patients compared to 6 controls. 
A lower colony count of aerobic/anaerobic bacteria was 
associated with a higher LCI in CF patients. 
O`Neill 
[79] 
Assessment of treatment  
Antibiotic treatment for 
pulmonary exacerbations 
  systematic 
review of 
studies 
published until 
March 2014 
Overall, LCI decreased after antibiotic treatment but 
individual response was heterogeneous in CF patients.  
Sonneveld 
[81] 
 26 1.8-19.9 
years 
prospective LCI was sensitive to detect response to antibiotic 
therapy for pulmonary exacerbations. 
Stahl [82] 
Hypertonic saline (7%) 25 1-5 years observational Hypertonic saline twice daily for 48 weeks improved 
LCI. 
Subbarao 
[87] 
 18 7-56 years observational Hypertonic saline 5 times over 24 hours did not improve 
LCI. 
Amin [88] 
 19 10.5 (3.1) 
years 
observational Hypertonic saline twice daily over 4 weeks improved 
LCI. 
Amin [89] 
CFTR  regulator Ivacaftor 21 8-43 years clinical trial Ivacaftor 150 mg twice daily for 28 days improved LCI.  Davies 
[85] 
CFTR  regulators 
Lumacaftor/ivacaftor 
combinded 
58 6-11 years clinical trial Lumacaftor 200 mg/ ivacaftor 250 mg twice daily for 24 
weeks improved LCI, sweat chloride and nutritional 
status.   
Milla [86] 
Dornase alpha 
(Pulmozyme
®
) 
17 6-18 years clinical trial For weeks 2.5 ml daily Pulmozyme
®
 inhalation 
improved LCI. 
Amin [90] 
Lung imaging and MBW  
Magnet resonance imaging 97 0.2-21.1 
years 
prospective, 
cross-sectional 
LCI correlated with abnormalities in MRI in infants, 
toddlers and children with CF.  
Stahl [82] 
Computer tomography 60 7.8 (1.3) 
years 
cross-sectional  Abnormal findings on lung CT correlated strongly with 
increased LCI in CF patients. 
Owens 
[73] 
 49 8.7-112.1 
weeks 
cross-sectional  Air trapping and bronchiectasis assessed by CT were 
associated with MR, but not LCI. 
Hall [91] 
 
 
     
  
 42, 38, 
and 39 
0-2, 3-6, 
and 7-16 
years 
cross-sectional  Agreement between LCI and bronchiectasis in preschool 
and school age children, but not infants. Air trapping 
and LCI was only associated in infants.  
Ramsey 
[92] 
This table is meant to provide a current overview on studies in pediatric patients with CF and does not necessarily represent the full body of 
existing literature. 
*
At the time of publication. BAL: bronchoalveolar lavage CF: Cystic Fibrosis. CFTR: Cystic Fibrosis Transmembrane 
Conductance Regulator LCI: lung clearance index MR: moment ratio. Age at study is given in range or means (standard deviation).  
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3.2.2 Quality assessment of multiple breath washout 
 
Multiple breath washout analysis in infants: quality assessment and 
recommendations for improvement 
Anagnostopoulou P, Egger B, Lura M, Usemann J, Schmidt A, Gorlanova O, Korten I, 
Roos M, Frey U, Latzin P. Multiple breath washout analysis in infants: quality 
assessment and recommendations for improvement. 
Published in Physiol Meas. 2016 Mar;37(3):L1-L15. doi: 10.1088/0967-3334/37/3/L1 
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Multiple breath washout analysis in infants: quality assessment 
and recommendations for improvement  
 
Pinelopi Anagnostopoulou, Barbara Egger, Marco Lurà, Jakob Usemann, Anne Schmidt, Olga 
Gorlanova, Insa Korten, Markus Roos, Urs Frey and Philipp Latzin 
 
SUPPLEMENTARY DATA 
 
METHODS 
1. Standard analysis specifications 
As recommended by the manufacturer and the most recent guidelines (Frey et al. 2000), the raw 
signal was corrected as follows: body temperature pressure saturation (BTPS), and flow baseline 
corrections were applied to the volume signal, and MM temperature simulation and MM step 
response correction to the MM signal (Latzin et al. 2007). After that, the end-inspiratory MM-
step (EIMM-step) was used to determine the 100% step of SF6 (Anagnostopoulou et al. 2015).  
 
2. Details to alternative analysis settings 
2.1 Analysis by changing the ‘FRC-analysis’ parameters 
We challenged results by repeating the analysis changing each time only one of the parameters, 
mentioned in details below. 
2.1.1 Analysis without MM temperature simulation (figure S1(a)). Temperature simulation aims 
to correct the MM signal for the influence of temperature and humidity using the temperature 
model (Latzin et al. 2007) (figure S2(a)). 
2.1.2 Analysis without MM step response correction. The uncorrected signal leads to different 
end-inspiratory MM (EIMM) values. We performed the analysis using those values (figure 
S1(a)). 
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2.1.3 Analysis with expiratory MMfit. The software uses the MM expirogram instead of the MM 
curve for FRC computations (figure S1(a)). 
2.1.4 Analysis by changing the EE start and stop percentile. These numbers define the part of the 
inspiration/expiration in proportion used to calculate the EIMM and end-expiratory MM 
(EEMM) values respectively. We set the EE start and stop percentile at 60-90%, 55-85%, and 
50-80%, respectively (figure S1(b)). 
2.2 Temperature recordings in the software 
Temperature is one of the main factors that influence MM calculation using the ultrasonic 
flowmeter (Schibler and Henning 2001) and is measured in different compartments of the device 
(figure S2(a)): the ‘body-temperature’ is set as being stable at 37 °C, the ‘case-temperature’ is 
measured in the side-chamber of the ultrasonic flowmeter, and the ‘room-temperature’ should 
represent the temperature of the inspired gas, but in fact is measured inside the device. This 
means that the device while running leads unavoidably to a non-realistic increase of ‘room-
temperature’. 
2.3 MM step response parameters 
MM step response aims to correct the signal for the inhomogeneous gas mixing inside the 
flowmeter caused by the side-chambers during the measurement (Schmalisch et al. 2015). The 
correction is based on two physical constants included in the temperature model, as shown in 
figure S2(a), that depend on the set-up of the device and on the tracer gas used (Latzin et al. 
2007): the MMDifuTau is the time the air needs to diffuse into the side-chamber and the 
SPLCham accounts for the length of the side-chamber.  
 
3. Description of WBreath software version 3.39.4  
Amongst other changes, version 3.39.4 uses the median of data points between 65-95% of 
inspiration or expiration for EIMM and EEMM calculation respectively, instead of the mean 
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value. The rest of the analysis was performed as described above, using the refined ‘room-’ and 
‘case-temperature’ values. 
 
4. Description of the LungSim software (version 2.1.0) 
4.1. FRC calculation in the LungSim 2.1.0 software 
In order to calculate FRC, the expired tracer gas volume is determined. In WBreath, this quantity 
is evaluated with help of prototype expirograms based on first few appropriately normalized 
washout breaths. With the EEMM value of any breath, this prototype is then scaled and 
integrated to provide its contribution to the expired tracer gas. 
In LungSim, the expired tracer gas volume is calculated as follows: 
 The volume flow  and MM signal  are used to calculate the mean molar mass 
defined by  for each breath (Figure S3). ts and te 
signify the start and end time of the expiration and  is the expired 
volume. 
 During normal breathing, this value represents the mean MM signal due to the expiration 
of CO2, N2 and O2. Typically, the  values of the last three breaths of a washout 
(normal breathing again) are averaged to provide . 
  approximates the expired tracer gas 
volume, as the contributions from the normal air gas species in  are subtracted.  
 
4.2. Other advantages of the LungSim software 
LungSim uses automatically the EIMM-step to define the completion of the measurement. 
Further, it provides for the user the opportunity to choose either the washin or the washout part 
of a measurement for analysis, without prior manual cutting. 
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RESULTS 
 
1. Analysis by changing the ‘FRC-analysis’ parameters 
1. Analysis without MM temperature simulation. By deactivating the temperature simulation 
correction we found significantly higher FRC/body weight values compared with the standard 
analysis (table S2, paired t-test, p < 0.0001). LCI was lowered to 4.1 ± 5.6 (mean ± SD, table S2, 
paired t-test,      p < 0.0001). In 45 out of 72 measurements (62.5%) the LCI was zero, because 
the software considered them as incomplete (end tracer gas concentration higher than 2.5%). 
2. Analysis without MM step response correction. The analysis without using the MM step 
response correction changed the EIMM-step significantly, as expected (paired t-test, p < 0.0001). 
This changed further FRC/body weight values from 26.9 ± 5.8 to 23.0 ± 3.6 ml/kg (mean ± SD, 
table S2, paired      t-test, p < 0.0001) and LCI from 7.1 ± 1.2 to 5.7 ± 0.5 (mean ± SD, table S2, 
paired t-test, p < 0.0001). Apart from that, the software considered several measurements as 
invalid, due to a high variability in EIMM values in successive breaths. 
3. Analysis with expiratory MMfit. When the expiratory MMfit was activated, FRC/body weight 
(table S2) and LCI values (table S2) differed significantly from the ones derived from the 
standard analysis in both centres (paired t-test, p < 0.0001). An extreme example shows a 
decrease of 8.4 ml/kg in FRC/body weight (from 31.6 to 23.2), followed by an increase of 3.3 
LCI units (from 9.3 to 12.6). 
4. Analysis by changing the EE start and stop percentile. The reduction in EE start and stop 
percentile led to progressively lower values for FRC and higher values for LCI, which differed 
significantly between them and systematically in comparison with the standard analysis (table 
S2, ANOVA-test,     p < 0.0001).  
 
2. ‘Room-’ and ‘case-temperature’ refinement 
The temperature refinement changed significantly the mean EIMM-step (from -5.618 ± 0.1 to              
-5.601 ± 0.09 (mean ± SD, g/mol), t-test, p < 0.0001). Consequently, it changed the breath 
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number where the 2.5% LCI is determined. This explains why the decrease in FRC/body weight 
seems rather systematic and smaller (figure 3(e)), while at the same time the change in LCI 
values was very heterogeneous and larger (figure 3(f), t-test, p < 0.0001).  
 
3. Analysis with alternative MM step response corrections 
The analysis using alternative MM step response corrections resulted in significantly different 
EIMM-step values, and subsequently different end tracer gas concentrations. Further, FRC and 
LCI values were significantly changed. Interestingly, the more distant MMDifuTau and 
SPLCham values were from the original ones, the more washouts were detected as incomplete 
(end tracer gas concentration > 2.5%) (table S3). 
 
4. Analysis with a different software version of the same software package 
The more recent WBreath software version (3.39.4) decreased FRC and FRC/body weight values 
in a rather systematic way (figure S4(a), table S4, t-test, p < 0.0001)) and increased LCI (figure 
S4(b), table S4, t-test, p < 0.0001)), compared with the old version (WBreath 3.28.0.0). 
However, the variability of the results remained high, as shown by differences in FRC and LCI 
between washin and washout ranging from -14% to +26% (figures S4(c), S4(d) and table S4).  
 
5. Analysis with a new software package (LungSim) 
In terms of the absolute values, we found a rather systematic decrease in FRC (figure S5(a), table S5, t-
test, p < 0.0001)) when using the new analysis software compared with the WBreath software (version 
3.28.0.0). LCI changes were more heterogeneous (figure S5(b), table S5, t-test, p = 0.0016), attributable 
probably to the EIMM changes (mean ± SD (g/mol): -5.648 ± 0.1, t-test, p < 0.0001, compared with 
WBreath version 3.28.0.0 with corrected temperature). The comparison with FRC and LCI values 
obtained with the 3.39.4 WBreath version gave similar results (figure S6). 
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Table S1: Demographic characteristics and MBW outcomes of study subjects in children’s 
hospitals from Basel and Bern.  
  
 
 
Basel 
 
Bern 
Between-centre 
comparison 
(unpaired t-test) 
Number 
(male/female) 
12 (6/6) 12 (6/6)  
 
Age, wks 
 
5.1 (0.8)
a
 
 
4.9 (0.4)
a
 
p = 0.51 
Gestational age, wks 44.6 (1.2)
a
 45.1 (0.9)
a
 p = 0.3 
Weight, kg 4.3 (0.6)
a
 4.6 (0.6)
a
 p = 0.19 
Length, cm 54 (2.6)
a
 55 (2.5)
a
 p = 0.47 
FRC, ml 126 (24)
b
 111 (22)
 b
 p = 0.0097 
FRC/body weight in 
ml/kg 
29.6 (5.8)
 b
 24.2 (4.4)
 b
 p < 0.0001 
FRC/length in ml/cm 2.3 (0.4)
 b
 2.0 (0.4)
 b
 p = 0.0019 
LCI 7.1 (1.5)
 b
 7.1 (0.7)
 b
 p = 0.88 
 
a
 at the time of the measurement, data are given in mean (SD) 
 
b 
analysed with WBreath version 3.28.0.0 using the original temperature and the standard analysis method,
 
data 
are given in mean (SD)
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Table S2: Impact of changing ‘FRC-analysis’ parameters on FRC/body weight and LCI in 24 
healthy infants (n = 72 measurements). Values are reported as mean (SD).  
 Analysis methods
a
 
 Standard 
no 
TempSi
m 
no step-
response 
with 
MMfit 
MM calculation at (%) of 
inspiration/expiration 
EE start 
and stop 
percentile
b
 
Standard (65-95%) 60-90% 55-85% 50-80% 
FRC/bod
y weight   
in ml 
26.9(5.8) 31.3(7.1)
c
 
23.0(3.6)
c
 
24.5(4.9)
c
 
26.4(5.6)
d
 
25.7(5.4)
d
 
25.0(5.2)
d
 
LCI  7.1 (1.2) 4.1 (5.6)
c, e
 5.7 (0.5)
c
 7.8 (1.4)
c
 7.2 (1.2)
d
 7.4 (1.2)
d
 7.4 (1.3)
d
 
a 
results obtained with the standard analysis, and when using the following changes in analysis parameters: 
inactive temperature simulation (no TempSim), inactive step response (no step-response), active MMfit (with 
MMfit), and percentage of inspiration/expiration used for MM calculations set at 60-90%, 55-85% and 50-80% 
respectively
 
b 
End Expiratory (EE) start and stop percentile 
c
 in comparison with the standard analysis, paired t-test, p < 0.0001
 
d 
one-way ANOVA, p < 0.0001 
e 
n = 27 measurements (42 measurements considered as incomplete with LCI = 0)
 
  
 
Table S3: Impact of different SPLCham and MMDifuTau values on MBW outcomes from Basel and Bern (n = 36 measurements per centre, if nothing else is 
reported), data are given in mean (SD). EIMM-step: end inspiratory molar mass step, End conc.: Tracer gas concentration at the end of washout. 
SPLCham [1/100 mm] 
 
1620
a
 
 
1770 
 
1920 
 
1920
b
 
 
1920 
 
2070 
MMDifuTau [ms]  4500
a
   6000   6000   7500
b
   9000   9000 
 
Basel 
EIMM-step 
[g/mol] 
 
-5.687 
(0.031) 
 
-5.738 
(0.031) 
 
-5.754 
(0.032) 
 
-5.794 
(0.034) 
 
-5.833 
(0.038) 
 
-5.853 
(0.040) 
Bern 
EIMM-step 
[g/mol] 
 
-5.418 
(0.048) 
 
-5.465 
(0.044) 
 
-5.479 
(0.043) 
 
-5.515 
(0.040) 
 
-5.552 
(0.038) 
 
-5.569 
(0.038) 
 Basel End conc.[%] 
 
0.20 (0.4) 
 
0.76 (0.65) 
 
1.10 (0.68) 
 
1.72 (0.73) 
 
2.34 (0.76) 
 
2.75 (0.79) 
Bern End conc.[%] 
 
0(0) 
 
0.01 (0.06) 
 
0.03 (0.12) 
 
0.14 (0.27) 
 
0.48 (0.45) 
 
0.84 (0.52) 
 
Basel 
FRC/body 
weight [ml/kg] 
 
27.9 (5.1) 
 
28.4 (5.2)
d
 
 
29.4 (5.6)
d
 
 
29.3 (5.7)
d
 
 
29.1 (5.6)
d
 
 
30.2 (5.7)
d
 
Bern 
FRC/body 
weight [ml/kg] 
 
24.3 (3.7)
d
 
 
23.7 (3.8)
e
 
 
24.2 (4.0)
d
 
 
23.6 (4.0) 
 
23.2 (4.0)
d
 
 
24.1  (4.2)
d
 
  
n 
 
n 
 
n 
 
n 
 
n 
 
n 
 
Basel LCI 36 6.7 (0.6) 36 7.6 (1.0)
d
 35
c
 7.9 ((1.0)
d
 30
c
 9.0 (1.5)
d
 27
c
 10.5 (2.2)
d
 19
c
 11.7 (2.7)
d
 
Bern LCI 36 6.0 (0.4)
d
 36 6.4 (0.5)
d
 36 6.5 (0.5)
d
 36 6.9 (0.6)
d
 36 7.3 (0.8)
d
 36 7.5 (0.9)
d
 
 
a
 configuration values for Basel 
b
 configuration values for Bern 
c
 number of measurements reaching the 2.5% end tracer gas concentration at the washout   
d 
p < 0.0001, paired t-test, compared with the analysis using the original configuration values for each centre
 
e 
p = 0.3, paired t-test, compared with the analysis using the original configuration values for Bern
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Table S4: MBW outcomes in Basel and Bern (n = 36 measurements per centre) analysed with 
different WBreath software versions (WBreath 3.28.0.0 and WBreath 3.39.4). Data are reported as 
mean (SD). We used the refined ‘room-’ and ‘case-temperature’ for both analyses. 
 WBreath 3.28.0.0 WBreath 3.39.4 
 Basel Bern Basel Bern 
FRC (ml) 119 (21) 108 (20) 109 (17)
c
 101 (16)
c
 
FRC/body weight 
(ml/kg) 
28 (5) 24 (4) 26 (4)
c
 22 (3)
c
 
Diff-FRC(wo-wi) (ml/kg) 1.2 (3) 0.6 (2.7) 1.4 (2.3)
a
 0.6 (1.8)
a
 
CV of FRC (%) 9 (6) 6 (3) 7 (6)
b
 4 (3)
b
 
LCI 6.7 (0.6) 6.9 (0.5) 7.3 (0.7)
c
 7.5 (0.6)
c
 
Diff-LCI(wo-wi) 0.3 (0.6) 0.2 (0.6) 0.3 (0.6)
a
 0.2 (0.5)
a
 
CV of LCI (%) 7 (4) 4 (3) 6 (3)
a
 4 (3)
a
 
a
 comparison with WBreath 3.28.0.0, t-test, non-significant 
b
 comparison with WBreath 3.28.0.0, t-test, p < 0.05
 
c
 comparison with WBreath 3.28.0.0, t-test, p < 0.0001
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Table S5: MBW outcomes in Basel (n = 35 measurements, N = 11 infants, one measurement did not 
reach the 2.5% of SF6 in the washout) and Bern (n = 36 measurements, N = 12 infants) analysed with a 
custom-made software package (LungSim 2.1.0). FRC (ml), FRC/body weight (ml/kg), FRC/length 
(ml/cm), CV% of FRC, Diff-FRC (wo – wi) (% of wo), LCI, CV% of LCI and Diff-LCI (wo – wi) (% of wo) are 
reported as mean (SD). 
 LungSim 2.1.0 
 Basel 
Comparison with 
WBreath 3.28.0 
(t-test) 
Bern 
Comparison with 
WBreath 3.28.0 
(t-test) 
FRC (ml) 106 (10) p < 0.0001 99 (14) p < 0.0001 
FRC/body weight 
(ml/kg) 
25 (4) p < 0.0001 22 (3) p < 0.0001 
FRC/length (ml/cm) 2.0 (0.2) p < 0.0001 1.8 (0.2) p < 0.0001 
CV% FRC 5 (3) p = 0.042 5 (3) p = 0.044 
Difference FRC(wo – wi)       
(% of wo) 
-3.5 (6.6) p = 0.0002 -4.0 (6.2) p = 0.004 
LCI 6.5 (0.7) p = 0.2 6.6 (0.7) p = 0.0014 
CV% LCI 6 (4) p = 0.6 6 (4) p = 0.2 
Difference LCI(wo – wi)       
(% of wo) 
3.6 (7.6) p = 0.7 0.4 (7.5) p = 0.4 
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Figure S1: Schematic illustration of the ‘FRC analysis’ parameters as shown in the software 
during the standard analysis (WBreath, ndd Medizintechnik AG, Zuerich, Switzerland). The 
parameters included in boxes were changed manually for the alternative ways of analysis, as 
described in methods, parts 2.1.1-2.1.4. 
 
 
Figure S2: Schematic illustration of (a) the ‘room-’ and ‘case-temperature’ settings and (b) the 
temperature model as shown in the software (WBreath, ndd Medizintechnik AG, Zuerich, 
Switzerland). The values in white background are user-changeable. The values included in a box 
were manually changed as described in the part 2.3 in methods for panel (a) and in the part 2.2 in 
methods for panel (b), respectively. 
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Figure S3: Original SF6-MBW tracing from a healthy infant analysed with the LungSim 2.1.0 
software. The algorithm for the calculation of the mean molar mass during expiration is shown. 
This quantity is used to evaluate the expired tracer gas volume.  
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Figure S4: MBW outcomes using the newer version of the WBreath analysis software (3.39.4). 
(a-b) Comparison of (a) FRC/body weight in ml/kg and (b) LCI analysed with WBreath version 
3.28.0.0 and 3.39.4 (t-test, n = 72 measurements). (c-d) Modified Bland Altman plot for (c) Diff-
FRC(wo-wi)      (% of FRCwo) and (d) Diff-LCI(wo-wi)(% of LCIwo) analysed with WBreath version 
3.28.0.0 (closed circles) and 3.39.4 (open circles) (t-test, n = 62 measurements, 10 excluded as 
incomplete in washin when analysed with version 3.39.4). Dotted lines (version 3.28.0.0) and 
solid lines (version 3.39.4) indicate mean ± 1.96 SD limits. 
 
 
Figure S5: Comparison of MBW outcomes analysed with two different softwares (WBreath 
version 3.28.0.0 and LungSim 2.1.0) in healthy infants from Basel and Bern. (a) FRC (ml) and 
Results - Quality assessment of multiple breath washout 
110 
(b) LCI values in 71 measurements (one measurement excluded because it did not reach the 
2.5% of SF6 concentration when analysed with LungSim) analysed with WBreath and LungSim, 
p values for paired t-test for the comparison between the two softwares. 
 
 
Figure S6: Comparison of MBW outcomes analysed with two different softwares (WBreath 
version 3.39.4 and LungSim) in healthy infants from Basel and Bern. (a) FRC (ml), (b) LCI 
values in 71 measurements and (c) Diff-FRC(wo-wi) (% of FRCwo) and (d) Diff-LCI(wo-wi) (% of 
LCIwo) in 58 measurements (1 washout and 13 washin measurements excluded as incomplete 
when analysed with the one or the other software) analysed with WBreath 3.39.4 and LungSim, 
p values for t-test for the comparison between the two softwares. 
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3.2.3 Interrupter technique in newborn infants  
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ABSTRACT 
Background: In preschool children, measurement of airway resistance using interrupter 
technique (Rint) is feasible to assess the degree of bronchial obstruction. Although some studies 
measured Rint in infancy, values of Rint and its variability in preterm infants are unknown. In 
this study, Rint and its variability was measured at infancy and compared between healthy term 
and preterm infants.  
Methods: High quality Rint measurements in term (n=50) and preterm (n=48) infants were 
obtained at postmenstrual age of 42-50 weeks in two study centers in Switzerland. Intra-
measurement variability of Rint in one measurement and inter-measurement variability between 
two subsequent measurements was assessed by coefficient of variation (CV). 
Results: Mean Rint in term infants was 4.2 ± (SD; 1.9) kPa·s·L⁻ ¹ and in preterm infants was 5.6 
± (2.8) kPa·s·L⁻ ¹. Mean CV in term infants was 29.6 ± (14.9) % and in preterm infants was 20.2 
± (8.4) %. Rint was significantly lower (95% CI -2.31 to -0.38; P=0.007) and CV significantly 
higher (95% CI 4.53 to 14.3; P<0.001) in term compared to preterm infants. There were no 
differences in mean Rint and mean CV between the first and the second measurement obtained 
in a subgroup of term (n=24, 48%) and preterm (n=22, 45%) infants. 
Conclusions: Our results suggest that differences in airway mechanics between term and 
preterm infants can be assessed with the interrupter technique during early infancy. Before 
clinical application of Rint measurements in this age group, reasons underlying the variability of 
measurements should be further investigated. 
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INTRODUCTION 
Prospective studies have demonstrated that reduced lung function after birth is associated with 
increased respiratory morbidity during infancy 
1
, throughout childhood, and even into adulthood 
2
. Prematurely born infants are at increased risk for later respiratory morbidity 
3
 and reduced lung 
function compared to term infants that can be detected shortly after birth 
4,5
. Therefore, early 
identification of infants at risk is crucial to implement preventive strategies to reduce long-term 
morbidity.  
Airway obstruction in infants can be measured using the interrupter technique (Rint). Neergard 
and Wirz described this method almost a century ago 
6
, but Rint was not routinely used in 
pediatric studies before measurements were standardized 
7,8
 and ATS/ERS recommendations for 
pre-school children were published 
9
. Rint was measured in few studies during infancy 
10-13
, but 
studies comparing Rint between term and preterm infants are lacking despite the fact that 
measurements can be done during tidal breathing.  
Studies systematically assessing Rint in infants and children reported poor repeatability 
12,14
 and 
high variability of measurements 
10,11,15
. This indicates that Rint measurements require further 
quality assessment, which is important since Rint was previously used to assess bronchodilator 
response in asthmatic 
16,17
 and prematurely born children 
18
.  
Based on studies reporting increased airway resistance in former preterm born children in early 
childhood 
4
, and the high variability of Rint measurements reported from pre-school children 
15
, 
we hypothesized that: i) preterm infants have increased airway resistance compared to term 
infants in infancy and ii) measurements have high variability in both study groups. The aim of 
this study was to compare Rint measurements between term and preterm infants. In addition, we 
aimed to assess variability of Rint in both study groups. 
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METHODS 
Study design and subjects 
This prospective, nested, case-control study included term (≥37 weeks) and preterm (<37 weeks) 
infants from the Basel-Bern infant lung development (BILD) birth cohort 
19
. Rint was measured 
at two centers in Switzerland (Basel and Bern) at 42–50 weeks postmenstrual age. Inclusion 
criteria were ≥5 interruptions during one measurement 9, Rint ≥1 kPa·s·L⁻ ¹ and occlusion time 
<200 ms. In Basel, all infants from 2011–2015 were included. In Bern from 2003-2007, 
unequally more term than preterm infants were measured. Therefore, to obtain equal group sizes 
in Bern, all preterm infants were included and matched to term infants according to study year 
and number of interruptions. The Ethics Committees of Basel and Bern approved the study and 
parents provided written consent. 
Rint measurements  
Rint was measured according to ATS/ERS guidelines for preschool children 
9
 and 
recommendations for infants 
8,20
 during behaviorally defined, unsedated non-REM sleep in 
supine position using a rigid face mask (Teleflex medical AG, Ruesch, Silicone, size 2, Belp 
Switzerland) lined with putty to ensure a leak-free seal and to reduce dead space. Interruptions 
were manually triggered (Exhalyzer D, Eco Medics AG, Duernten Switzerland) every 3-6 
breaths. Rint was calculated using the linear back-extrapolation method, applied to the trace of 
pressure at airway opening between 30 and 70 ms post-interruption 
10
.  
Data recording and processing 
Rint was recorded and processed 
10,21
 using WBreath (Version 3.28.0.0, ndd Medizintechnik AG, 
Zurich, Switzerland). Before data analysis, values were corrected to body temperature pressure 
saturation (BTPS) and zero-offset of flow baseline was performed, as described previously 
22
. 
Breath detection was manually adapted to manufacturer’s recommendations to increase analysis 
sensitivity. The first measurement was designated Rint1, containing all interruptions of the first 
measurement. After a 2-minute break, a second measurement was completed in a subgroup 
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designated Rint2, containing all interruptions of the second measurement. Rint1 was divided into 
groups of 5 successive interruptions named in alphabetical order. Therefore, Rint_a represents 
the first 5 interruptions of Rint1 and Rint_b represents the following 5 interruptions of Rint1 and 
so forth. The last subgroup (Rint_i) contained interruption numbers 40–45. Rint2 was not divided 
into subgroups (Supplementary E-Figure 1). 
Rint variability 
Intra-measurement and inter-measurement variability (coefficient of variation (CV) (%) = 
standard deviation (SD)/mean×100), were used to evaluate variability of Rint within one 
measurement and between measurements.   
Outcome parameters 
Outcomes are visualized in Supplementary E-Figure 1. 
Rint and CV 
Main outcomes were mean Rint1 and mean CV1. The number of interruptions of Rint1 varied 
between term and preterm infants. Therefore, Rint and CV from the first group of interruptions 
of Rint1 (Rint_a) were analyzed to control for different interruption numbers. Further, the 9
th
 
group (Rint_i) was analyzed to assess potential differences between groups at different time 
points.  
Trends of Rint during one measurement 
Trends of Rint over time during one measurement were assessed using visual inspection and 
detrended analysis.  
Comparison of Rint and CV between successive measurements 
To assess differences between two subsequent measurements, Rint1 and Rint2 were compared in 
those infants that completed two measurements. 
Statistics  
After inspection of data for normal distribution, paired t-tests were used to compare Rint and CV 
between measurements in one infant and unpaired t-tests to compare Rint and CV between term 
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and preterm infants. For analysis of trends during repeated measurements, Kernel density 
estimations 
23
 were applied to compare original Rint to linear-detrended-Rint 
24
 by ANOVA test. 
To control for center differences and confounders, linear regression analysis was done to study 
the association between prematurity separately with Rint and CV, adjusted for study center, sex, 
and weight at study date. The association between clinical parameters (e.g. oxygen therapy, 
mechanical ventilation) with Rint and CV in preterm infants was analyzed using linear 
regression. P<0.05 defined statistical significance. Data was analyzed using Stata
®
 (Stata 
Statistical Software: release 11. STATA Cooperation; College Station, TX) and Matlab R2015ab 
(The MathWorks, Inc., Natick, MA, USA). 
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RESULTS 
In Basel, 16 (16%) of 100 term infants, and 14 (14.7%) of 95 preterm infants fulfilled the 
inclusion criteria. In Bern, 49 (26.3%) of 186 term infants, and 34 (15.1%) of 225 preterm 
infants fulfilled inclusion criteria. To obtain equal group sizes in Bern, 34 of the 49 term infants 
were matched to 34 preterm infants. For final analysis, 50 term, and 48 preterm, infants from 
both centers were included (Figure 1). Mean postmenstrual age at study was 44 weeks (range 42-
47) for term, and 45 weeks (range 40-50) for preterm, infants (Table 1). Mean number of 
occlusion during Rint measurements was 38 in term (range 5-252), and 44 in preterm, infants 
(range 6-230). The distribution of sex and gestational age was similar at both centers, but 
differences in weight and length were noted (Supplementary E-Table 1). There was no difference 
in success rate of measurements between centers for term (P=0.635) and preterm infants 
(P=0.865). Anthropometrics, Rint, and CV between included and excluded term infants from 
Bern did not differ (Supplementary E-Figure 2, Supplementary E-Table 2).  
Comparison of Rint and CV in term and preterm infants 
In general, Rint was lower and CV higher in term compared to preterm infants. Mean Rint1 in 
term infants was 4.2 ± (SD; 1.9) kPa·s·L⁻ ¹ and in preterm infants 5.6 ± (2.8) kPa·s·L⁻ ¹, 
resulting in a mean difference of -1.35 (95% CI -2.31 to -0.38) kPa·s·L⁻ ¹. The corresponding 
mean CV in term infants was 29.6 ± (SD; 14.9) % and in preterm infants 20.2 ± (8.4) %, 
resulting in a mean difference of 9.41 (95% CI 4.53 to 14.3) % (Table 2 and Figure 2). For both 
Rint and CV, associations with prematurity were similar after adjustment. In preterm infants, 
Rint was 1.2 (95% CI 0.3 to 2.2) kPa·s·L⁻ ¹ higher and CV was -9.8 (95% CI -14.8 to   -4.7) % 
lower compared to term infants (Supplementary E-Table 3). Very similar results were obtained 
when stratifying the analysis by center and at different time points during one measurement 
(Supplementary E-Table 3, Table 2, Supplementary E-Figure 3, Supplementary E-Results). In 
preterm infants, oxygen therapy was associated with an increased Rint. Adjusted coefficient was 
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0.31 (95% CI 0.03 to 0.56) kPa·s·L⁻ ¹ per ten day increase in oxygen therapy (Supplementary E-
Table 4). 
Trends of Rint during one measurement 
Trends of Rint were assessed in 13 term, and 14 preterm, infants completing 45 interruptions. 
Comparison of original Rint versus linear-detrended Rint revealed no differences in term 
(P=0.939) and preterm infants (P=0.932) (Supplementary E-Figure 4).  
Comparison of Rint and CV between successive measurements 
There was no difference in Rint and CV between two successive measurements in term (n=24) 
and preterm (n=22) infants. Difference in mean Rint1 compared to mean Rint2 in term infants 
was 0.05 (95% CI -1.25 to 1.35) kPa·s·L⁻ ¹ and in preterm infants -0.13 (95% CI -1.67 to 1.4) 
kPa·s·L⁻ ¹. Difference in mean CV1 compared to mean CV2 in term infants was -1.57 (95% CI -
9.92 to 6.78) % and in preterm infants 0.003 (95% CI -5.75 to 5.76) %. A high intra-subject 
variability of Rint and CV between two successive measurements was observed. Intra-subject 
variability of Rint and CV in term infants ranged from -86.5% to 90.6% and from -101.5% to 
77.5%, respectively. Intra-subject variability of Rint and CV in preterm infants ranged from -
47.1 to 56.3% and from -87.2% to 105.7%, respectively (Figure 3). 
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DISCUSSION 
This study of healthy term and preterm infants found that Rint measured during natural sleep was 
increased in preterm compared to term infants, even over subsequent measurements. A high CV 
was observed in both groups with preterm infants having a lower CV compared to term infants.  
Few studies measured Rint in healthy newborns without sedation 
10-12
. Using the same occlusion 
time, Rint values reported by Fuchs et al. (3.64 kPa·s·L⁻ ¹) 11 were comparable to the current 
study (4.2 kPa·s·L⁻ ¹). This was not unexpected since the previously studied subjects 11 were a 
subset of this study. Adams et al. found a higher Rint measured between days 1-4 after birth 
12
. 
Diverging results might be due to differences in study age, data acquisition and analysis 
software, occlusion time, and quality control. In another study, Rint measured in preterm infants 
during sedation at one year 
18
 was lower than in our study. This difference might be explained by 
the older age of study participants, since Rint decreases with increasing age 
25
. Airway resistance 
in infants can be assessed with other methods, e.g. the single occlusion technique (SOT) 
9
, but 
methodological differences limit comparison. Van Putte-Katier et al. measured airway resistance 
with SOT in term infants 
26
 reporting a higher Rint compared to this study, possibly explained by 
methodological differences 
26
.  
Rint values did not change significantly over subsequent measurements. Furthermore, raw Rint, 
versus linear-detrended Rint, did not differ, indicating no significant impact of trends during 
measurements. In children, Rint was stable over time 
15,27
 and results of this study suggest that 
longitudinal Rint measurements in infants might be feasible. 
A relatively high CV in term, and preterm infants, during and between measurements was 
observed. Previous studies in preschool children reported a CV between 8% and 23% 
14,28,29
, and 
it was shown that age is inversely associated with CV of Rint 
14,28
. The high CV could therefore 
be due to young age during measurements, but also due to methodological reasons. For example, 
during measurements in school-aged children the investigator supports the cheeks and throat to 
decrease upper airway compliance 
30
, while measurements in newborns are performed without 
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manual support. The use of a facemask did not result in more variability than a mouthpiece, but 
this was shown only for pre-school children 
31
, not for infants. Maturation processes of motor 
activity during infancy might further explain differences in CV: a study in healthy infants 
reported that variability of spontaneous movements decreased with increasing age 
32
. We 
speculate that an age-dependent variability of spontaneous motor activity similarly applies for 
breathing parameters, which may further explain a higher CV in infants compared to children 
14,15
.  
Reduced airway function at school age in former preterm infants is well-documented 
33-35
. 
Increased specific respiratory resistance 
33
 and decreased expiratory flows were reported in 
former preterm infants assessed at 11 years 
33
 and 6 years of age 
35
. However, it was recently 
reported that Rint measured at 6 years was not associated with prematurity 
36
. The latter 
contradicts previous studies 
33,35
, and the authors speculated that the small number of preterm 
infants in their study might have resulted in insufficient power to detect differences in Rint 
36
. 
Despite methodological differences in assessing airway obstruction in this study compared to 
studies in former preterm children 
33,35
, the higher Rint of our preterm infants indicate that 
airway obstruction reported in former preterm children at school-age can be observed at early at 
infancy.  
Variability of measurements could be considered noise, but could also be regarded as a 
biological signal per se. We observed a lower CV of Rint in preterm compared to term born 
infants, and a similarly, lower short-term variation in preterm infants was reported 
37
. Thus, less 
variability during tidal breathing in preterm infants suggests an association between immaturity 
and breathing control. It is unclear whether this finding is due to residual lung disease, 
differences in central regulation, or both. In biological systems in general, variability of 
physiological parameters are considered a healthy state 
38
. Studies comparing other physiological 
parameters (tidal breathing 
37
, heart rate 
39
) between term and preterm infants reported less 
variability in preterm infants. The question whether or not lower Rint variability in preterm 
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infants could have prognostic relevance for subsequent respiratory morbidity can only be 
addressed in longitudinal studies.   
Strengths and limitations 
Strengths of this study are that measurements were performed according to current ATS/ERS 
standards 
8
 using the same equipment throughout the study. Data quality was further improved 
by manual inspection and rigorous assessment. Only high quality measurements were included, 
diminishing the influence of technical issues, which could have influenced e.g. intra-test 
variability. Measurements were performed during unsedated sleep, reflecting a more natural state 
of breathing, which is relevant to reliably study breathing mechanics 
40
. 
A limitation is that no quality criteria were applied during measurement recording. With the only 
available software, however, data analysis can only be performed after measurements. Success 
rate in this study (14% to 26%) was low, but a similar rate was previously reported in infants 
(12%) 
7
. The low success rate is not unsurprising, since measurements were performed during 
natural sleep without sedation. Rint in term and preterm infants was higher in Basel compared to 
Bern. This may be partly explained by differences in postmenstrual age and weight at study 
between centers. However, these inter-center differences are unlikely to bias our results since 
associations with prematurity were similar after adjustment and stratification by center. Since 
this matched case-control study was embedded within a prospective cohort, 15 term infants from 
Bern were excluded to obtain similar group sizes. However, a selection bias is unlikely, since 
Rint, CV and anthropometrics of included versus excluded subjects did not differ. Mean number 
of interruptions in preterm infants were higher compared to term infants. One could speculate 
that this resulted in a lower CV in preterm infants. We feel that this is unlikely, since CV during 
the first 5 interruptions was also higher in preterm infants, and a similar trend was observed in a 
subgroup of infants at interruptions 40-45. We further acknowledge the relatively low sample 
size which limits our conclusions, particularly in regards to inter-measurement variability.  
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Conclusion 
In conclusion, this study provides first evidence of higher airway resistance and lower variability 
during interrupter measurements in unsedated preterm compared to term infants, suggesting 
differences in breathing mechanics during early infancy. Measurements were performed during 
natural sleep, which is more representative of normal breathing in these infants, but is consistent 
with findings of increased Rint in sedated pre-school children. Future studies need to assess 
whether Rint can be used as a prognostic marker for subsequent respiratory morbidity taking into 
consideration the high variability of measurements per se which require further interpretation. 
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Table 1 Population characteristics 
 Term (n=50) Preterm (n=48) P-value 
Anthropometrics    
Male sex 21 (42) 29 (60.4) 0.068 
Postmenstrual age at birth, weeks 
39.7 ± 1.2  
(37–41.9) 
30.1 ± 3.0 
 (24.6–35.4) 
<0.001 
Postmenstrual age at study date, 
weeks 
44. ± 1.2 
 (41.8–47.0) 
44.6 ± 1.6  
(39.6–50.6) 
0.319 
Length at birth, cm 49.5 ± 2.6 (42–57) 39.2 ± 4.7 (31–50) <0.001 
Length at study date, cm 55 ± 2.3 (50 –59) 53.4 ± 2.8 (47–60) 0.002 
Weight at birth, kg 3.4 ± 0.5 (2.1–4.3) 1.4 ± 0.6 (0.6–2.8) <0.001 
Weight at study date, kg 4.4 ± 0.6 (3.1–5.7) 4.3 ± 0.7 (3.0–5.4) 0.123 
Clinical parameters    
Mechanical ventilation, days n/a 1.9 ± 4.2 (0–27)  
Oxygen therapy, days n/a 32.4 ± 34 (0–133)  
CRIB score n/a 2.5 ± 2.9 (0–9)*  
Apgar score at 5 min 9.2 ± 0.9 (5–10) 7.6 ± 1.4 (5–9) <0.001 
Chorioamnionitis 1 (2) 20 (41.7) <0.001 
Patent ductus arteriosus 0 (0) 3 (3.1) 0.073 
Atrial septal defect 0 (0) 2 (4.2) 0.145 
Values are means ± SD (range) or number (percentage) of infants. 
*
Data available on n=45 
infants, missing data on n=3. Differences between term and preterm infants were tested with t-
test and χ2-test. 
CV, coefficient of variation; CRIB, clinical risk index for babies; n/a, not applicable; Rint, 
airway resistance; SD, standard deviation. 
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Values are means ± SD (range). Rint values are given in kPa·s·L⁻¹ and CV in %. Rint1 and CV1 
contain all data from the first measurement. Rint_a and CV_a contain data from the first 5 
interruptions, whereas Rint_i and CV_i contain data from the 9
th
 group of interruptions. Rint2 and 
CV2 contain all data from the second measurement (described in Methods and Supplemental 
Figure S1). 
‡
Data available on n=13 infants, missing data on n=37. 
‡‡
Data available on n=14 
infants, missing data on n=34. 
*
Data available on n=24 infants, missing data on n=26. 
**
Data 
available on n=22 infants, missing data on n=26. Differences between term and preterm infants 
were tested with t-test.  
CV, coefficient of variation; Rint, airway resistance; SD, standard deviation. 
  
Table 2 Rint and coefficient of variation of measurements 
 Term (n=50) Preterm (n=48) Mean difference (95% CI) P-value 
Rint1 
4.2 ± 1.9  
(1.8–11.4) 
5.6 ± 2.8 
 (2.0–15) 
-1.35 ± 0.49 
 (-2.3 to -0.38) 
0.007 
CV1 
29.6 ± 14.9  
(7.2–70.4) 
20.2 ± 8.4  
(6.5–39.6) 
9.41 ± 2.46  
(4.53 to 14.30) 
<0.001 
     
Rint_a 
3.9 ± 1.7  
(1.8–8.8) 
5.2 ± 2.7  
(1.7–14.9) 
-1.35 ± 0.46 
 (-2.26 to -0.45) 
0.004 
CV_a 
24.6 ± 16.4  
(4.2–82.3) 
17.8 ± 8.3 
 (4.8–43.8) 
6.83 ± 2.64  
(1.59 to 12.07) 
0.011 
     
Rint_i 
4.6 ± 2.1 
 (3.0–8.9)‡ 
6.6 ± 3.7 
 (2.2–14.3)‡‡ 
-1.94 ± 1.17 
 (-4.36 to 0.47) 
0.11 
CV_i 
16.7 ± 7.6 
 (3.3–29.1)‡ 
12.2 ± 7.7 
 (1.7–31.4)‡‡ 
4.47 ± 2.95  
(-1.62 to 10.55) 
0.143 
     
Rint2 
4.2 ± 2.2 
 (1.8–11.8)* 
5.3 ± 2.7 
 (1.7–11.1)** 
-1.02 ± 0.72  
(-2.47 to 0.44) 
0.167 
CV2 
28.3 ± 11.4  
(7.3–55.4)* 
20.9 ± 9.3  
(8.9–42.3)** 
7.36 ± 3.08 
 (1.16 to 13.56) 
0.021 
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Figure 1 Flow chart of the study population. Numbers represent valid lung function tests and 
Rint measurements and datasets excluded from analysis. To obtain equal group sizes from term 
and preterm infants enrolled in Bern, 34 out of 49 term infants were matched to 34 preterm 
infants according to study year and number of interruptions.  
MBW, multiple breath washout; REM, rapid eye movement; TBFVL, tidal breathing flow–
volume loop; Rint, airway resistance. 
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Figure 2 Comparison of Rint and CV between term and preterm infants. (a) Mean Rint1 from all 
interruptions in term infants was 4.2 ± (SD; 1.9) kPa·s·L⁻¹ and in preterm infants was 5.6 ± (2.8) 
kPa·s·L⁻¹. (b) Mean CV1 from all interruptions in term infants was 29.6 ± (14.9) % and preterm 
infants was 20.2 ± (8.4) %. Horizontal line represents mean ± SD values; P-values refer to t-test 
comparing term versus preterm infants.  
CV, coefficient of variation; Rint, airway resistance; SD, standard deviation. 
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Figure 3 Inter-measurement and intra-subject variability of Rint and CV in term and preterm 
infants. Left panel (a) Mean Rint of the first measurement (Rint1) in term infants (n=24) was 4.3 
± (SD; 2.3) kPa·s·L⁻¹ and of the second measurement (Rint2) was 4.2 ± (2.2) kPa·s·L⁻¹. Right 
panel (a) Mean Rint of the first measurement in preterm infants (n=22) was 5.1 ± (2.3) kPa·s·L⁻¹ 
and of the second measurement was 5.3 ± (2.7) kPa·s·L⁻¹. Left panel (b) Mean CV of the first 
measurement (CV1) in term infants was 26.7 ± (16.9) % and of the second measurement (CV2) 
was 28.3 ± (11.4) %. Right panel (b) Mean CV of the first measurement in preterm infants was 
20.9 ± (9.6) % and of the second measurement was 20.9 ± (9.3) %. Variability between two 
successive measurements for Rint ranged in term infants from -86.5% to 90.6% and in preterm 
infants from -47.1 to 56.3%. Variability between two successive measurements for CV ranged in 
term infants from -101.5% to 77.5% and in preterm infants from -87.2% to 105.7%. P-values 
refer to t-test comparing the first and the second measurement.  
CV, coefficient of variation; Rint, airway resistance; SD, standard deviation.  
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Supporting results  
Rint and CV at different time points of one measurement 
We first compared the first group of interruptions of one measurement between term and preterm 
infants: Mean Rint_a in term infants was 3.9 ± (SD; 1.7) kPa·s·L⁻¹ and in preterm infants was 5.2 
± (2.7) kPa·s·L⁻¹. Mean Rint_a was significantly lower in term compared to preterm infants with 
a mean difference of -1.35 (95% CI -2.26 to -0.45) kPa·s·L⁻¹. The corresponding mean CV_a in 
term infants was 24.6 ± (16.4) % and in preterm infants was 17.8 ± (8.3) %. Mean CV_a was 
significantly higher in term compared to preterm infants with a mean difference of 6.83 (95% CI 
1.59 to 12.07) %. Secondly, we compared the 9
th
 group of interruptions of one measurement 
obtained in a subgroup of 13 term and 14 preterm infants. Mean Rint_i was lower in term 
compared to preterm infants: Rint_i mean difference was -1.94 (95% CI -4.36 to 0.47) kPa·s·L⁻¹. 
Mean CV_i was higher in term compared to preterm infants: CV_i difference was 4.47 (95% CI -
1.62 to 10.55) % (Table 2). 
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E-Table 1 Characteristics of study participants in children’s hospitals from Basel and Bern 
 Basel 
 
Bern 
 
Term 
n=16 
Preterm 
n=14 
 Term 
n=34 
Preterm 
n=34 
Male sex  5 (31.3) 8 (57.1) 
 
16 (47.1) 21 (61.8) 
Postmenstrual age at birth, wks 39.4 (1.2)  31.7 (1.7)  
 
39.9 (1.2) 29.4 (3.2) 
Postmenstrual age at study date, wks 44.7 (1.2)
 
 44.6 (1.9) 
 
45 (1.2) 44.6 (1.6) 
Length at birth, cm 47.9 (2.8)
*
 42.4 (4.1) 
 
50.2 (2.2)
*
 37.9 (4.4)
§
 
Length at study date, cm 54.2 (2.7) 54.6 (3.4)
*
 
 
55.4 (2.0) 52.8 (2.3)
*
 
Weight at birth, kg 3.2 (0.5) 1.7 (0.5)
*
 
 
3.4 (0.4) 1.3 (0.6)
*
 
Weight at study date, kg 4.3 (0.6) 4.5 (0.6) 
 
4.5 (0.5) 4.2 (0.7) 
Rint1,  kPa·s·L⁻¹ 3.7 (1.7) 4.3 (1.5)* 
 
4.5 (2.0) 6.1 (3.1)
*
 
CV1, % 33.0 (14.4) 22.9 (9.2) 
 
28.1 (15.1) 19.1 (8.0) 
Values are numbers (percentage) or means ± (SD). 
§
 Data available for n=33 infants, missing data on n=1. Rint_1st _round and CV_1st _round were 
calculated from all data from the first round of measurements. Differences between centers for 
term and preterm infants were tested with t-test and χ2-test; *P-values <0.05. 
Rint, airway resistance; CV, coefficient of variation; SD, standard deviation; wks, weeks. 
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E-Table 2 Comparison of characteristics between all and selected Bernese term infants 
 All subjects 
n=49 
Selected subjects 
n=34 
P-value 
 
Male sex  26 (53.1) 16 (47.1) 0.289 
Postmenstrual age at birth, wks 35.0 (4.4) 35.8 (4.8) 0.477 
Postmenstrual age at study date, wks 39.9 (1.1) 39.9 (1.2) 0.995 
Length at birth, cm
§
 50.1 (2.2) 50.2 (2.2) 0.774 
Length at study date, cm 55.3 (2.1) 55.4 (2.0) 0.840 
Weight at birth, kg 3.5 (0.5) 3.4 (0.4) 0.649 
Weight at study date, kg 4.5 (0.5) 4.5 (0.5) 0.878 
Rint1,  kPa·s·L⁻¹ 4.4 (1.9) 4.5 (2.0) 0.773 
CV1, % 27.7 (13.7) 28.1 (15.1) 0.906 
Values are numbers (percentage) or means ± (SD). 
§
Missing data on n=1 infant. Rint1 and CV1 were calculated from all data from the first round of 
measurements. Differences between centers for all subjects and selected subjects were tested 
with t-test and χ2-test. 
Rint, airway resistance; CV, coefficient of variation; SD, standard deviation; wks, weeks. 
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E-Table 3 Association of prematurity with Rint and CV by study center 
 Unadjusted model  Adjusted model
+
 
 Coefficient 95% CI P-value  Coefficient 95% CI P-value 
 All infants
*
 
Rint1 1.3 0.4 to 2.2 0.007  1.2 0.3 to 2.2 0.012 
CV1 -9.3 -14.1 to -4.4 <0.001  -9.8 -14.8 to -4.7 <0.001 
        
 Infants from Bern 
 
Rint1 1.6 0.4 to 2.9 0.011  1.5 0.3 to 2.2 0.032 
CV1 -8.9 -14.8 to -3.1 0.003  -9.0 14.8 to -4.7 0.006 
        
 Infants from Basel  
Rint1 0.6 -0.7 to 1.8 0.356  0.9 -0.3 to 2.1 0.139 
CV1 -10.1 -19.3 to -0.9 0.032  -10.7 -20.4 to -0.9 0.003 
Coefficient and 95% CI for the association of prematurity with Rint (kPa·s·L⁻ ¹) and CV (%) 
derived from linear regression analysis. 
+ 
This model was adjusted for sex and weight at study 
date. 
*
For analysis of all infants, the adjusted model was additionally adjusted for study center. 
Mean Rint1 and mean CV1 contain all data from the first measurements. 
Rint, airway resistance; CV, coefficient of variation. 
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E-Table 4 Association of clinical parameters with Rint and CV in preterm infants 
 Unadjusted model  Adjusted model
+
 
 Coeff, 95% CI P-value  Coeff. 95% CI P-value 
 Outcome Rint1 
Mechanical ventilation 0.32 0.11 to 0.54 0.570  0.24 -0.17 to 0.22 0.804 
Oxygen therapy therapy, 
days 
0.32 0.19 to 0.54 0.004  0.31 0.03 to 0.56 0.029 
CRIB score 0.09 -0.19 to 0.39 0.503  -0.04 -0.37 to 0.28 0.503 
        
 Outcome CV1 
Mechanical ventilation -4.33 -10.1 to 1.35 0.132  -3.93 -9.81 to 1.95 0.185 
Oxygen therapy therapy, 
days 
-0.43 -1.12 to 0.28 0.234  -0.19 -1.05 to 0.66 0.651 
CRIB score -0.21 -1.07 to 1.13 0.503  -0.21 -1.14 to 0.73 0.665 
Coefficient and 95% CI for Rint (kPa·s·L⁻ ¹) and CV (%) per ten day increase in mechanical 
ventilation/oxygen therapy or for one score in increase in CRIB derived from linear regression 
analysis. 
+ 
This model was adjusted for sex and weight at study date. Mean Rint1 and mean CV1 
contain all data from the first measurements. 
Rint, airway resistance; Coeff, coefficient; CV, coefficient of variation; CRIB: clinical risk index 
for babies. 
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E-Figure 1 Classification of Rint measurements and outcomes assessed. First measurement was 
designated Rint1, containing all interruptions of the first measurement. The second measurement 
was designated Rint2, contained all interruptions of the second measurement. Rint1 was further 
divided into groups of 5 interruptions named in alphabetical order (Rint_a to Rint_i). Thus, Rint_a 
to Rint_i contained 9×5=45 interruptions.  
The following outcomes were compared between term and preterm infants: i) Rint and 
corresponding CV at different time points during measurements (Rint1/CV1, Rint_a/CV_a 
Rint_i/CV_i and Rint2/CV2) ii) trends of Rint during one measurement iii) and intra-subject 
variability in term and preterm infants between two subsequent measurements.   
Rint, airway resistance. 
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E-Figure 2 Comparison of Rint between all and selected Bernese term infants. (a) Mean Rint of 
all term infants (n=49) was 4.4 ± (SD 1.9) kPa·s·L⁻¹ and of selected term infants (n=34) 4.5 ± (2) 
kPa·s·L⁻¹ (P=0.773). (b) Mean CV of all term infants was 27.7 ± (13.7) % and of selected term 
infants was 28.1 ± (15.1) % (P=0.905). Horizontal line represents mean ± SD values. P-values 
refer to t-test comparing all infants versus selected term infants.   
CV, coefficient of variation; Rint, airway resistance; SD, standard deviation. 
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E-Figure 3 Robustness of differences in Rint and CV between term and preterm infants. (a) 
Mean Rint of the first five interruptions (Rint_a) in term infants (n=50) was 3.9 ± (SD; 1.7) 
kPa·s·L⁻¹ and in preterm infants (n=48) was 5.2 ± (2.7) kPa·s·L⁻¹. (b) In these infants, mean CV 
(CV_a) in term infants was 24.6 ± (16.4) % and in preterm infants was 17.8 ± (8.3) %. (c) Mean 
Rint of interruptions 40-45 (Rint_i) in term infants (n=13) was 4.6 ± (2.1) kPa·s·L⁻¹ and in 
preterm infants (n=14) was 6.6 ± (3.7) kPa·s·L⁻¹. (d) In these infants, mean CV (CV_i) in term 
infants was 16.7 ± (7.6) % and in preterm infants was 12.2 ± (7.7) %. Horizontal line represents 
mean ± SD values; P-values refer to t-test comparing term versus preterm infants.  
CV, coefficient of variation; Rint, airway resistance; SD, standard deviation. 
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E-Figure 4 Trends of Rint during one measurement in term and preterm infants. (a-b) Trends of 
Rint were assessed using 9 groups of Rint measurements (Rint_a to Rint_i, resulting in 45 
interruptions) in 13 term and 14 preterm infants. (c-d) The probabilities between raw Rint values 
and linear-detrended-Rint values were compared in term and preterm infants using the Kernel 
smoothing density function. Open circle line represents original values and crossed line 
represents linear-detrended-Rint values. There was no difference between original Rint and 
linear-detrended-Rint for (c) term (P=0.939) and (d) preterm infants (P=0.932). P-values refer to 
ANOVA-test comparing original versus linear-detrended values in term and preterm infants. 
CV, coefficient of variation; Rint, airway resistance. 
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3.3 Methodological challenges to assess airway inflammation 
3.3.1 Exhaled nitric oxide and asthma development 
 
Predictive value of exhaled nitric oxide in healthy infants for asthma at school age  
Usemann J, Fuchs O, Anagnostopoulou P, Korten I, Gorlanova O, Röösli M, Latzin P,  
Frey U 
Published in Eur Respir J. 2016 Sep;48(3):925-8. doi: 10.1183/13993003.00439-2016 
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3.3.2 Exhaled nitric oxide and Cystic Fibrosis 
 
Lower exhaled nitric oxide in infants with Cystic Fibrosis compared to healthy 
controls  
Korten I, Liechti M, Hafen G, Rochat I, Usemann J, Singer F, Moeller A, Frey , Latzin 
P, Casaulta C for the BILD and SCILD study group 
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Abstract   
Exhaled nitric oxide (FENO) is a well-known marker for airway inflammation. However, despite 
chronic airway inflammation, in patients with Cystic Fibrosis (CF) FENO is decreased. To 
understand if reduced FENO is primary related to Cystic Fibrosis Transmembrane Regulator 
(CFTR) dysfunction or an epiphenomenon of chronic inflammation, we measured FENO in 
infants with CF prior to clinical symptoms. FENO was lower in CF infants compared to healthy 
controls (p=0.0006) and the effect was more pronounced in CF infants without residual CFTR 
function (p<0.0001). This suggests that FENO is reduced in CF a priori, possibly associated with 
underlying CFTR dysfunction.  
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Introduction 
The fractional concentration of exhaled nitric oxide (FENO) is a well-known biomarker for 
airway inflammation and elevated in a number of inflammatory disorders of the lung (1). 
However, despite chronic severe airway inflammation, in patients with Cystic Fibrosis (CF) 
FENO is decreased (2-4). The following underlying causes have been discussed: (i) reduced NO 
synthase isoenzyme (NOS) expression (ii) lack of NOS substrates, (iii) NO decomposition by 
bacterial reductases or (iv) impaired NO diffusion through viscous mucus (1, 5, 6). Reduced 
levels of NO or NOS have been related to a number of adverse effects, such as increased airway 
narrowing, reduced ciliary motility and susceptibility to infections (2, 7).   
Absent or residual function of the Cystic Fibrosis Transmembrane Conductance Regulator 
(CFTR) protein in CF patients results in insufficient NOS induction, which however appears 
reversible (8). Reduced FENO normalizes in patients with CF after treatment with Ivacaftor, one 
of the first approved CFTR-targeting drugs for certain gating mutations (9). This suggests that 
decreased FENO in CF is not an epiphenomenon of chronic inflammation or infection, but might 
be reduced in CF airways a priori, associated with the defect in CFTR.  
In order to understand whether reduced FENO in CF airways is primary related to CFTR mutation 
independent of secondary inflammation, FENO measurements in early life before the onset of first 
infections need to be explored. We thus measured FENO in infants with CF and healthy controls 
at five to twelve weeks of age.  
Methods 
We enrolled infants with CF diagnosed by newborn screening and contemporary healthy infants 
aged five to twelve weeks, matched 1:2 based on season of birth and sex, from two ongoing birth 
cohort studies, the Swiss Cystic Fibrosis Infant Lung Development (SCILD) cohort (10)) and  
the Basel Bern Infant Lung development cohort (11) born between 2011 and 2015.  
Exclusion criteria was a history of respiratory symptoms suggesting upper- or lower respiratory 
tract infection prior to the study. Clinical examination was normal in all infants. Infants with 
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asymptomatic bacterial colonization were not excluded (n=5). Lung function measurements were 
performed five and twelve weeks of age in regular, quiet sleep as previously described (12). In 
brief, FENO measurements were obtained online using a tight fitting mask, with a rapid response 
chemiluminescence analyser  (CLD 77; Eco Medics AG, Duernten, Switzerland; analysis 
software: WBreath 3.28, ndd, Zurich, Switzerland). To avoid contamination by ambient nitric 
oxide (NO), we used NO-free air for inspiration.  FENO was measured during multiple breaths in 
quiet sleep, during the third quartile of expiration. Mean FENO was then calculated over 100 
breaths. As FENO is flow dependent, results are presented for both FENO and V’NO (FENO 
multiplied with corresponding expiratory flow), which were the primary outcomes. Additionally, 
flow and respiratory rate are displayed as secondary outcomes. Details have been previously 
described (12-15). We compared NO levels between healthy controls and infants with CF. 
Subsequently, patients were stratified into CFTR groups with (i) no residual function (two copies 
of class I and/or class II mutations), (ii) residual function (infants with at least one copy of a 
class III-VI mutation, and (iii) unclassified mutations. As FENO data were not perfectly normally 
distributed in visual inspection, we illustrate average estimates in both mean and median. We 
thus performed both Wilcoxon-Man-Whitney test and linear regression after log transformation 
of variables and adjusted for possible confounders (age, sex, maternal atopy and smoking during 
pregnancy). The study was performed in Bern and approved by the Ethics committee Bern, 
Switzerland. Informed consent was obtained from the parents.  
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Results 
We analysed 102 measurements in 34 infants with CF and 68 healthy controls. For 
anthropometric data and results of measurements, see Table 1.  
Table 1: study population and FENO measurements 
 
healthy infants (n = 68) infants with CF (n = 34) 
Gender, female 33 (48.5)  12 (35.29)  
Age at study date, wk 5 (1.2)  8 (2.5)  
Gestational age, wk 39.5 (1.4)  38.7(1.7)  
Length at birth, cm 50 (2.3)  50 (2.8)  
Weight at birth, g 3400 (567)  3310 (569)  
Weight at study date, g 4430 (485)  4970 (1413)  
CF mutation*:  
 
 No residual CFTR 
function 
(class I and/or  II) 19 (56) 
Residual CFTR function 
(class I/II and III-VI) 7 (21) 
Unknown CFTR function  8 (23) 
FENO ppb 17.0 (5.0) 13.7 (5.3) 
FENO ppb median (IQR) 16.4 (13.8  – 18.7) 12.2 (10.2 – 16.3) 
V’NO nl/min 46.3 (11.5)  38.5 (15.7) 
Flow exp. ml/s 47.8 (11.0) 48.2 (11.1) 
Respiratory Rate (1/min) 43.1 (8.5) 43.0 (8.5) 
results are displayed in number (%) and mean (+/- SD) if not stated otherwise 
*CF infants were grouped in 1: two known copies of class I and/or II mutations 2: 
one class I or II mutation plus one other mutation 3. >=1 mutation not classified or 
unknown mutation. All children in group #3 however had two copies of disease 
causing mutations. 
wk= weeks 
 
Significantly lower FENO and V’NO values were found in infants with CF compared to healthy 
controls (median difference for FENO 4.25 ppb, p=0.0006 and for V’NO 12.15 nl/min, p=0.002). 
Flow and respiratory rate were comparable between groups, thus lower FENO values were not 
due to differences in breathing patterns, confirmed by significant differences for V’NO. The 
stratified analysis based on CFTR function revealed that in infants without residual CFTR 
Results - Exhaled nitric oxide and Cystic Fibrosis 
158 
function,  FENO levels were even lower compared to healthy controls (median difference 4.4 ppb, 
p<0.0001; V’NO 13.25 nl/min, p=0.0001), see Figure 1.  
 
Figure 1: (A) FENO and (B) V’NO measurements in healthy infants (n = 68) and infant with CF 
with (I) no CFTR residual function (n=19), (II) with CFTR residual function (n=7) and (III) 
unknown CFTR function (n=8). Each dot symbolizes one infant. Lines indicate mean +/-SD. 
 
FENO levels between infants with and without residual CFTR function also differed significantly 
(p=0.005), however numbers for analysis were low. All findings were confirmed when analysed 
in linear regression and after adjustment for confounders, assuring robustness of our results (see 
Table 2A and 2B). 
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Table 2A : Comparison of lung function measurements between healthy infants and CF 
infants  
 
unadjusted model adjusted model   
 Coef 95% CI p-value Coef 95% CI p-value 
FeNo (log) -0.24 [-0.37,-0.11] <0.0001 -0.32 [-0.50,-0.15] <0.0001 
V'No (log) -0.23 [-0.35,-0.10] 0.001 -0.27 [-0.44,-0.11] 0.002 
Flow (log) 0.01 [-0.09,0.11] 0.85  0.05 [-0.09,0.18] 0.5  
respiratory rate (log) 0 [-0.08,0.08] 0.97 0.03 [-0.07,0.14] 0.53 
linear regression model comparing measurements between healthy infants (n = 58) and infants 
with CF (n= 34), after log transformation of variables to obtain normal distributuion. baseline are 
healthy infants,  adjusted model : adjusted for gender, age at measurement, maternal atopy and 
smoking in pregnancy, Coef = beta Coefficient; 95% CI = 95% Confidence interval 
 
 
Five infants received antibiotic therapy prior or during measurements, indication was 
asymptomatic bacterial colonization (throat swab), but there was no association between therapy 
and FENO levels (results not shown).  
 
Discussion  
We show that exhaled FENO is reduced in young infants with CF and that this effect is more 
pronounced in infants without residual CFTR function. Importantly, FENO measurements were 
performed prior to first respiratory symptoms, suggesting absence of significant lower airway 
disease in the majority of children. Data were also robust after adjusting for other known 
Table 2B : Comparison of lung function measurements between healthy infants and CF 
infants with class I/II mutation   
 
unadjusted model adjusted model   
 Coef 95% CI p-value Coef 95% CI p-value 
FeNo (log) -0.37 [-0.52,-0.22] <0.0001 -0.35 [-0.54,-0.16] <0.0001 
V'No (log) -0.34 [-0.48,-0.20] <0.0001 -0.2 [-0.37,-0.03] 0.03 
Flow (log) 0.02 [-0.10,0.15] 0.73 0.15 [-0.02,0.31] 0.08 
respiratory rate (log) 0.02 [-0.07,0.12] 0.63 0.09 [-0.04,0.22] 0.12 
linear regression model comparing measurements between healthy infants (n = 58) and infants 
with CF and class I/II mutations  (n= 19) , after log transformation of variables to obtain normal 
distributuion. baseline are healthy infants,  adjusted model : adjusted for gender, age at 
measurement, maternal atopy and smoking in pregnancy,  Coef = beta Coefficient; 95% CI = 95% 
Confidence interval 
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confounders such as atopy. Our results are in line with a previous preliminary study (five infants 
with CF) (16) and support our hypothesis that FENO is reduced in CF a priori. Low NOS 
expression seems related to CFTR mutation and residual function. Increase in FENO values 
following treatment with Ivacaftor in patients with a class IV mutation (9, 17) further supports 
the hypothesis that FENO is a proxy of CFTR function. It may be an important player in 
progression of CF lung disease, as reduced FENO is associated with reduced neutrophil 
sequestration, bacteriostatic properties, and mucociliary transport (2).  
Thus, FENO levels in early life might be of prognostic value for disease development. 
Furthermore, treatment response in FENO after CFTR modifier therapy (9, 18) might be a 
promising biomarker as the measurement is fast and easy.   
Although this clearly has to be confirmed in larger prospective studies, our results of lower FENO 
in CF airways early after birth, likely associated with underlying CFTR dysfunction, might open 
up a new chapter in the field of early FENO measurements in patients with CF.  
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3.4 Translational research: assessing complexity of airway disease 
3.4.1 Multivariable approach: immune function and genetics 
 
CHI3L1 polymorphisms, cord blood YKL-40 levels and later asthma development 
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Online supplement 
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S1 Methods 
Study design and subjects 
In this prospective cohort study, healthy term neonates were recruited antenatally from April 
1999 to January 2007 in the region of Bern, Switzerland, described in detail elsewhere [1]. 
Exclusion criteria for the study were pre-term delivery (<37 weeks), major birth defects, 
respiratory distress after birth, other significant perinatal disease or later diagnosis of airway 
malformation or specific chronic respiratory disease [1-3]. The Ethics Committee of the region 
of Bern approved the study and written consent from all parents was acquired at enrolment.  
Genotyping and quality control  
DNA was extracted from umbilical cord blood. Genome-wide SNP genotyping was performed 
by Illumina HumanOmniExpress Bead Chips (Illumina Inc., San Diego, USA). Individuals with 
low genotype rate (<97%), unusual high or low heterozygosity (±3 SD beyond the mean) and 
discordance between reported and observed sex were excluded (see Figure 1). In total, 142 
unrelated individuals of European ancestry with measured YKL-40 levels were considered for 
the analysis. SNPs were excluded if they had a call rate less than 98%, minor allele frequency 
(MAF) more than >5%, and Hardy-Weinberg equilibrium p-value less than 10
-6
. Quality control 
statistics was calculated using PLINK [4] version 1.07 and R version 3.0.2 [5] (www.r-
project.org) using the GenABEL package.  
YKL-40 measurement 
Cord blood was acquired from the umbilical cord and stored immediately at –80°C. Serum was 
diluted 1:20 before YKL-40 was measured in duplicates by a sandwich enzyme-linked 
immunosorbent assay (ELISA) kit (R&D Systems, USA) according to the manufacturer´s 
instructions. The mean of the 2 duplicates was used in the statistical analysis. Minimum 
detection limit of the assay is 3.55 pg/ml, inter-assay variability is 5.3%, and intra-assay 
variability is 14%. Data are presented as ng/ml. 
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Outcomes during the first year  
The outcome respiratory symptoms during the first year were assessed by weekly telephone 
interviews done by research nurses using a standardised symptom score that groups symptoms 
into four levels according to severity, with a high sensitivity for lower respiratory tract symptoms 
[3, 6]. The outcomes ‘weeks with respiratory symptoms’ were defined as total number of weeks 
a child had any respiratory symptom, independent of type or severity; ‘weeks with severe 
respiratory symptoms’ were defined as a symptom score ≥3 e.g repeated sleep disturbances 
during the night, or general practitioner consultation, as described previously [3]. Lung function 
was performed according to ERS/ATS standards [7] during unsedated sleep in supine position 
with the head midline, as previously reported [8]. For infant lung function at 5 weeks, we used 
the first 100 regular breaths of tidal breathing during non-rapid eye movement (non-REM) sleep 
from the total recording over 10 min. We calculated mean tidal breathing parameters of flow, 
volume, and flow-volume loop. Outcome parameters were tidal volume (VT), mean tidal 
expiratory flow, time to peak tidal expiratory flow (TPTEF)/expiratory time (TE) ratio and minute 
ventilation (V'E). Tidal breathing measurements were done using an ultrasonic flow meter device 
(Exhalyzer D; Eco Medics AG, Dürnten, Switzerland). 
Outcomes at 6 years 
At follow-up with 6 years, respiratory health was assessed with questions adapted from the 
International Study of Asthma and Allergies in Childhood (ISAAC) [9]. The questionnaires have 
been validated and used in our study since 1999 [1]. Asthma was diagnosed if one on the 
following was present in the previous year: (1) physician diagnosis of asthma or (2) episodic 
wheeze. Atopy was defined by allergic rhinitis, allergic asthma or atopic dermatitis. A skin-prick 
test was done for eight allergens (Dog dander, cat dander, Dermatophagoides pteronyssinus, 
mixed tree pollens, mixed grass pollens, Alternaria tenuis, positive control (histamine), negative 
control (NaCl), Allergomed, Switzerland) positive in case of hives bigger than histamine in any 
of the tested allergens. Spirometry was performed to measure forced expiratory volume in 1 
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second (FEV1), forced vital capacity (FVC), and forced expiratory flow at 25-75% of FVC 
(FEF25-75%), according to ATS standards [10]. Data are expressed as z-scores using normative 
data from the Global Lung Function Initiative [11]. Spirometry was done using the JAEGER
®
 
Master-Screen Body (CareFusion, Würzburg, Germany).  
Risk factors 
A standardised questionnaire was employed to assess pre- and post-natal exposure to putative 
risk factors [3, 8, 9] (e.g. siblings, tobacco smoke exposure, and maternal atopy) on the outcomes 
respiratory symptoms during the first year, at the 5-week lung function, and at 6 years (asthma, 
atopy, positive prick test and spirometry) (Table S1). We validated maternal smoking by cotinine 
levels in the first urine of the newborn (gas-liquid chromatography, IST, Lausanne, Switzerland). 
Maternal asthma (self-reported or doctor-diagnosed asthma) and maternal atopic disease (history 
of allergic rhinitis, allergic asthma or atopic dermatitis) was assessed. Parental education was 
categorised into low (<4 years of apprenticeship) and high (≥4 years of apprenticeship). 
Statistical analysis  
Anthropometric and clinical outcomes were compared by sex using t-test and Mann-Whitney U-
test. We performed regression analysis with cord blood YKL-40 levels as outcome and SNPs as 
exposures. Because 44 (21%) of cord blood YKL-40 levels were below detection limit, we used 
a Tobit regression model with a detection limit of 1 (concentration ng/ml). To minimise the 
effect of outliers, and to differentiate between different exposure levels, we categorised YKL-40 
(ng/ml) into quintiles: YKL-40 non-detects, YKL-40 (7–37.9), YKL-40 (38–49.9), YKL-40 (50–
65.9) and YKL-40 (66–98). The YKL-40 non-detects served as reference level. The overall 
association of different YKL-40 levels with the outcomes was calculated with the Cochran-
Armitage trend test, shown as Ptrend. A trend of association was defined for Ptrend <0.2. 
We examined the association of SNPs and cord blood YKL-40 levels with respiratory symptoms 
during the first year. The outcome ‘weeks with respiratory symptoms’ showed an over-
dispersion, and data was analysed using Poisson regression based on robust variance estimates 
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[12]. First, univariable regression analysis was performed, and secondly, a multivariable model 
with adjustment for other exposures associated with respiratory symptoms (2) such as sex, 
gestational weight, and maternal smoking during pregnancy was used. Then, we analysed with 
univariable linear regression models the associations of SNPs and YKL-40 levels with natural-
log-transformed lung function measures at 5 weeks. In a multivariable model we adjusted for 
anthropometric data (sex, birth length, age and weight at study) and for sensitivity analysis 
additionally for potential confounders (e.g. maternal asthma, delivery type).  
We assessed the associations of SNPs and cord blood YKL-40 levels with the outcomes (asthma, 
atopy, prick test results) at 6 years with logistic regression. First, univariable analysis was 
performed for each outcome variable, and secondly, a multivariable model with adjustment for 
e.g sex and parental smoking was used. Lung function measures at 6 years were analysed with 
linear regression analysis. First, univariable analysis was performed and secondly with 
adjustment for presence or absence of siblings, daycare attendance and asthma of the child. For 
sensitivity analysis we additionally adjusted for potential confounders (e.g. maternal asthma, 
delivery type).  
The selection of variables for the adjusted models was based on physiological plausibility, 
potential effects of genetic variation on the outcomes and the best fit based on the Akaike 
information criterion [13]. An additive genetic model was used with P-values adjusted for 
multiple testing for 7 tests (since 7 SNPs were used in this study) with the Benjamini-Hochberg 
procedure (false discovery rate <0.1) [14] to balance power and the potential for false-positive 
results. A P–value < 0.05 was considered to be significant. Power was calculated with Quanto 
[15]. Data was analysed with STATA
®
 (Stata Statistical Software: release 13. STATA
®
 
Cooperation, College Station, TX, USA), R version 3.0.2 (www.r-project.org) [5] using the 
GenABEL package and PLINK [4] version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/). 
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Figure S1 Flow chart of the study population 
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Table S1 Potential risk factors of the study subjects 
Prenatal risk factors n (%) 
Male sex 76 (53.5) 
Siblings
*
 73 (51.5) 
Caesarean section 17 (11.9) 
Maternal asthma
$
 17 (11.9) 
Maternal atopy
#
 61 (42.9) 
Positive maternal skin prick test
+
 55 (38.7) 
Maternal smoking in pregnancy
§
 12 (8.5) 
High maternal education
¶
 94 (67.2) 
Low maternal education
¶
 46 (32.9) 
High paternal education
¶
 112 (80) 
Low paternal education
¶
 28 (20) 
*
Defined as presence or absence of siblings; 
$
defined as self-reported or doctor-diagnosed asthma; 
#
defined if one of 
the following was present: allergic asthma, allergic rhinitis, atopic dermatitis; 
+
positive in case of hives bigger than 
positive control histamine in any of the tested allergens; 
§
maternal active smoking during pregnancy;
 ¶
parental 
education was categorised into low (<4 years of apprenticeship) and high (≥4 years of apprenticeship). Data are 
derived from n=142 subjects. 
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Table S2 Characteristics and prevalence of the SNPs employed in this study 
SNP Location Allele MAF HW P-value Genotype distribution 
  (major/minor) (%)  all prevalence n (%) 
rs880633 missense G/A 46.2 0.564 GG 44 (30.9) 
     GA 71 (50) 
     AA 27 (19.1) 
rs10399931 upstream G/A 23.3 0.688 GG 85 (59.9) 
     GA 52 (36.6) 
     AA 5 (3.5) 
rs10399805 upstream C/T 10.5 1 CC 113 (79.6) 
     CT 28 (19.7) 
     TT 2 (1)  
rs1538372 intron G/A 33.8 1 GG 65 (45.8) 
     GA 62 (43.7) 
     AA 15 (10.6) 
rs10920579
§
 intergenic C/T 18.2 0.336 CC 92 (64.8) 
     CT 49 (34.5) 
     TT 1 (1) 
rs7542294 intron C/T 13.5 0.760 CC 108 (76.1) 
     CT 31 (21.8) 
     TT 3 (2.1) 
rs2486064 intergenic C/T 40.1 0.236 CC 50 (35.2) 
     CT 64 (45.1) 
     TT 28 (19.7) 
HW: Hardy-Weinberg; MAF: minor allele frequency; SNP: single nucleotide polymorphism. 
§
Proxy for rs4950928: 
rs10920579 (r
2=1, D’=1, calculated with HapMap). SNPs were genotyped with Illumina HumanOmniExpress Bead 
Chips. Data are derived from n=142 subjects.  
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Table S3 Associations between SNPs and cord blood YKL-40 levels 
 Univariable model  Adjusted
#
 model  
 Coef 95% CI P-value  Coef 95% CI P-value 
$
SNP        
rs10920579 5.40 -5.07–15.87 0.976  5.91 -4.75–16.57 0.936 
rs880633 3.57 -4.13–11.27 0.976  3.64 -4.11–11.38 0.936 
rs10399931 7.42 -1.96–16.82 0.839  7.86 -1.61–17.32 0.721 
rs10399805 -0.18 -13.05–15.5 0.976  -0.53 -13.56–12.51 0.936 
rs1538372 3.38 -4.78–11.57 0.976  3.63 -4.55–11.82 0.936 
rs7542294 3.26 -8.01–14.55 0.976  3.02 -8.37–14.21 0.936 
rs2486064 3.63 -3.78–11.05 0.976  3.50 -3.51–11.11 0.936 
Data is given as the probability of cord blood YKL-40 levels (ng/ml) being above detection per each SNP. Coef: 
Coefficient; CI: confidence interval; SNP: single nucleotide polymorphism. 
#
This model was adjusted for sex, 
presence or absence of siblings, type of delivery, maternal atopy and parental education. 
$
P-values for SNPs are 
shown after correction for multiple testing according to Benjamini-Hochberg. Data are derived from n=142 subjects. 
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Table S4 Associations between SNPs and cord blood YKL-40 levels with weeks with any respiratory symptoms and weeks with severe 
respiratory symptoms during the first year of life 
 Univariable model  Multivariable$ model  Full Multivariable* model 
 IRR¶ 95% CI P-value  IRR¶ 95% CI P-value  IRR¶ 95% CI P-value 
Exposure Outcome weeks with any respiratory symptoms# 
SNP#            
rs10920579 0.97 0.73–1.23 0.731  0.96 0.76–1.19 0.963  0.98 0.79–1.19 0.994 
rs880633 1.12 0.92–1.35 0.731  1.09 0.91–1.29 0.963  1.09 0.92–1.29 0.994 
rs10399931 1.00 0.82–1.30 0.731  1.01 0.83–1.22 0.963  1.03 0.86–1.23 0.994 
rs10399805 1.34 0.97–1.75 0.512  1.25 0.96–1.62 0.592  1.25 0.99–1.58 0.364 
rs1538372 1.01 0.85–1.25 0.731  1.00 0.84–1.18 0.963  1.00 0.85–1.16 0.994 
rs7542294 1.21 0.92–1.53 0.731  1.17 0.92–1.47 0.963  1.21 0.97–1.49 0.428 
rs2486064 0.89 0.74–1.02 0.512  0.84 0.84–0.98 0.232  0.85 0.73–0.99 0.267 
YKL-40 (ng/ml)            
YKL-40 non-detects 1 reference Ptrend  1 reference Ptrend  1 reference Ptrend 
YKL-40 (7–37.9) 1.05 0.5–2.1   1.22 0.6–2.4   1.16 0.5–2.3  
YKL-40 (38–49.9) 1.25 0.5–2.8   1.43 0.6–3.2   1.39 0.6–3.1  
YKL-40 (50–65.9) 1.13 0.6–2.3   1.31 0.6–2.6   1.48 0.7–2.9  
YKL-40 (66–98) 1.42 0.7–2.7 0.131£  1.38 0.7–2.5 0.127£  1.40 0.7–2.6 0.237£ 
            
Exposure Outcome weeks with severe respiratory symptoms§ 
SNP#            
rs10920579 1.23 0.79–1.91 0.571  1.20 0.81–1.77 0.969  1.20 0.82–1.75 0.820 
rs880633 1.16 0.76–1.74 0.571  1.07 0.72–1.57 0.969  1.09 0.74–1.59 0.820 
rs10399931 1.20 0.81–1.74 0.571  1.16 0.82–1.63 0.969  1.22 0.86–1.71 0.820 
rs10399805 1.44 0.89–2.29 0.571  1.31 0.73–2.03 0.969  1.27 0.82–1.93 0.820 
rs1538372 1.06 0.74–1.51 0.571  1.01 0.84–1.38 0.969  1.04 0.77–1.38 0.820 
rs7542294 1.23 0.76–1.98 0.571  1.19 0.73–1.94 0.969  1.21 0.73–1.96 0.820 
rs2486064 0.93 0.65–1.30 0.571  0.88 0.63–1.21 0.969  0.90 0.67–1.21 0.820 
YKL-40 (ng/ml)            
YKL-40 non-detects 1 reference Ptrend  1 reference Ptrend  1 reference Ptrend 
YKL-40 (7–37.9) 0.93 0.47–1.83   1.13 0.59–2.18   1.06 0.54–2.06  
YKL-40 (38–49.9) 1.13 0.49–2.56   1.36 0.63–2.95   1.28 0.61–2.74  
YKL-40 (50–65.9) 1.08 0.55–2.09   1.25 0.66–2.39   1.41 0.73–2.71  
YKL-40 (66–98) 1.27 0.67–2.41 0.372£  1.29 0.67–2.46 0.234£  1.32 0.71–2.51 0.190£ 
CI: confidence interval; IRR: incidence risk ratio; SNP: single nucleotide polymorphism. $Adjusted for sex, gestational weight, maternal smoking 
during pregnancy and maternal atopic disease. *Adjusted for sex, gestational weight, maternal smoking during pregnancy, maternal atopic 
disease, presence or absence of siblings, nursery, parental smoking during the first year, parental education. #Defined as any (day or night) 
respiratory symptoms independent of severity. §Defined as any (day or night) respiratory symptoms with a symptom score  3 [3]. #P-values for 
SNPs are shown after correction for multiple testing according to Benjamini-Hochberg. £Ptrend -values were calculated with the Cochran-Armitage 
trend test. Data are derived from n=142 subjects. 
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Table S5 Associations between SNPs and cord blood YKL-40 levels with lung function at 5 weeks 
 Univariable association  Adjusted* association 
 Coef 95% CI P-value  Coef 95% CI P-value 
Exposure  Outcome tidal volume (ml) $ 
SNP#   
rs10920579 0.96 0.91–1.01 0.793  0.96 0.91–1.01 0.541 
rs880633 0.99 0.94–1.03 0.793  0.98 0.94–1.03 0.920 
rs10399931 0.96 0.91–1.01 0.793  0.96 0.91–1.01 0.449 
rs10399805 1.01 0.94–1.08 0.793  1.00 0.94–1.08 0.920 
rs1538372 0.97 0.93–1.01 0.793  0.98 0.93–1.01 0.920 
rs7542294 1.01 0.95–1.07 0.793  1.01 0.95–1.07 0.920 
rs2486064 0.99 0.95–1.03 0.793  0.98 0.95–1.03 0.920 
YKL-40 (ng/ml)        
YKL-40 non-detects 1 reference Ptrend  1 reference Ptrend 
YKL-40 (7–37.9) 1.05 0.97–1.14   1.02 0.87–1.18  
YKL-40 (38–49.9) 0.95 0.89–1.03   0.98 0.85–-1.13  
YKL-40 (50–65.9) 1.00 0.99–1.08   1.05 0.91–1.21  
YKL-40 (66–98) 1.00 0.92–1.08 0.930£  0.98 0.85–1.13 0.841£ 
        
Exposure  Outcome mean tidal expiratory flow$ 
SNP#   
rs10920579 1.05 0.97–1.13 0.41  1.05 0.98–1.13 0.478 
rs880633 1.03 0.98–1.08 0.41  1.03 0.98–1.08 0.478 
rs10399931 0.94 1.01–1.14 0.178  1.07 1.07–1.14 0.233 
rs10399805 1.06 0.86–1.03 0.41  0.94 0.86–1.03 0.478 
rs1538372 1.07 1.01–1.12 0.112  1.06 1.01–1.12 0.227 
rs7542294 0.93 0.86–1.01 0.41  0.93 0.86–1.01 0.431 
rs2486064 1.02 0.97–1.07 0.41  1.02 0.97–1.07 0.478 
YKL-40 (ng/ml        
YKL-40 non-detects 1 reference Ptrend  1 reference Ptrend 
YKL-40 (7–37.9) 0.99 0.88–1.11   0.983 0.88–1.09  
YKL-40 (38–49.9) 1.05 0.94–1.17   1.06 0.95–1.17  
YKL-40 (50–65.9) 1.05 0.94–1.17   1.06 0.95–1.17  
YKL-40 (66–98) 1.03 0.93–1.15 0.152£  1.03 0.93–1.14 0.194£ 
        
Exposure  Outcome ratio TPTEF/TE%
$ 
SNP#   
rs10920579 1.10 0.98–1.21 0.549  1.08 0.97–1.19 0.959 
rs880633 0.96 0.89–1.03 0.999  0.96 0.89–1.04 0.971 
rs10399931 1.04 0.94–1.14 0.999  1.03 0.93–1.13 0.971 
rs10399805 0.98 0.86–1.11 0.999  0.99 0.86–1.12 0.971 
rs1538372 1.00 0.91–1.07 0.999  0.99 0.91–1.06 0.971 
rs7542294 0.93 0.83–1.04 0.999  0.94 0.94–1.05 0.971 
rs2486064 1.00 0.93–1.07 0.999  1.00 0.99–1.07 0.971 
YKL-40 (ng/ml)        
YKL-40 non-detects 1 reference Ptrend  1 reference Ptrend 
YKL-40 (7–37.9) 1.04 0.89–1.21   1.02 0.89–1.21  
YKL-40 (38–49.9) 1.00 0.86–1.15   0.98 0.86–1.15  
YKL-40 (50–65.9) 1.06 0.91–1.12   1.05 0.91–1.12  
YKL-40 (66–98) 0.99 0.85–1.14 0.866£  0.98 0.85–1.14 0.818£ 
        
Exposure  Outcome minute ventilation (ml · min-1) $ 
SNP#   
rs10920579 1.03 0.97–1.09 0.409  1.02 0.96–1.08 0.507 
rs880633 1.04 0.99–1.08 0.409  1.03 0.98–1.07 0.507 
rs10399931 1.05 0.99–1.11 0.395  1.04 0.99–1.09 0.507 
rs10399805 0.96 0.89–1.03 0.409  0.96 0.90–1.02 0.507 
rs1538372 1.06 1.01–1.11 0.053  1.05 1.01–1.09 0.114 
rs7542294 0.95 0.89–1.01 0.409  0.96 0.91–1.01 0.507 
rs2486064 1.03 0.96–1.05 0.409  1.01 0.97–1.05 0.507 
YKL-40 (ng/ml)        
YKL-40 non-detects 1 reference Ptrend  1 reference Ptrend 
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YKL-40 (7–37.9) 1.01 0.93–1.11   1.00 0.92–1.09  
YKL-40 (38–49.9) 1.03 0.95–1.12   1.03 0.94–1.11  
YKL-40 (50–65.9) 1.04 0.96–1.14   1.05 0.96–1.13  
YKL-40 (66–98) 1.05 0.96–1.14 0.174£  1.04 0.95–1.12 0.230£ 
Coef: coefficient; CI: confidence interval; TPTEF/TE ratio of time to reach peak tidal expiratory flow to total expiratory time. All lung function 
parameters were log converted for analysis and results shown as exponentiated coefficients. *Adjusted for the following additional risk factors: 
sex, gestational length, postnatal age at lung function, weight at lung function. $Missing data on n=20; data available for n=122.  
#P-values for SNPs are shown after correction for multiple testing according to Benjamini-Hochberg. £Ptrend -values were calculated with the 
Cochran-Armitage trend test. 
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Table S6 Associations between SNPs and cord blood YKL-40 levels with positive prick test at school age 
 Univariable association  Multivariable
*
 association 
 OR 95% CI P-value  OR 95% CI P-value 
Exposure Outcome positive prick test
+
 
SNP
#
  
rs10920579 0.78 0.27–2.19 0.921  0.65 0.22–1.90 0.983 
rs880633 0.96 0.46–1.99 0.921  0.87 0.39–1.88 0.983 
rs10399931 0.56 0.21–1.14 0.921  0.46 0.17–1.12 0.945 
rs10399805 0.89 0.24–3.19 0.921  0.99 0.26–3.36 0.983 
rs1538372 1.06 0.49–2.23 0.921  0.93 0.42–2.01 0.983 
rs7542294 0.91 0.31–2.64 0.921  0.92 0.32–2.69 0.983 
rs2486064 0.93 0.45–1.91 0.921  0.78 0.36–1.63 0.983 
        
YKL-40 (ng/ml)        
YKL-40 non-detects 1 reference Ptrend  1 reference Ptrend 
YKL-40 (7–37.9) 1.01 0.24–4.24   0.95 0.22–4.14  
YKL-40 (38–49.9) 1.24 0.29–5.26   1.05 0.23–4.73  
YKL-40 (50–65.9) 1.17 0.27–4.96   1.07 0.25–4.64  
YKL-40 (66–98) 2.8 0.75–10.42 0.128£  2.56 0.66–9.88 0.169£ 
CI: confidence interval; OR: odds ratio; SNP: single nucleotide polymorphism. 
*
Adjusted for the following 
additional risk factors: sex, parental smoking during childhood, maternal atopy, parental education. 
+
Positive in 
case of hives bigger than positive control histamine in any of the tested allergens. Missing data on n=38; data 
available for n=104. 
#
P-values for SNPs are shown after correction for multiple testing according to Benjamini-
Hochberg. 
£
Ptrend-values were calculated with the Cochran-Armitage trend test. 
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Table S7 Associations between SNPs and cord blood YKL-40 levels with lung function at 6 years 
 Univariable association  §Adjusted association 
 Coef 95% CI p-value  Coef 95% CI p-value 
Exposure Outcome FVC (z-score)$ 
SNP#        
rs10920579 0.27 -0.29–0.47 0.803  0.10 -0.31–0.51 0.968 
rs880633 0.18 -0.07–0.44 0.609  0.17 -0.10–0.44 0.968 
rs10399931 0.05 -0.29–0.38 0.803  0.05 -0.29–0.49 0.968 
rs10399805 0.44 -0.06–0.95 0.526  0.44 -0.11–1.02 0.714 
rs1538372 0.01 -0.26 –0.29 0.803  -0.01 -0.30–0.29 0.968 
rs7542294 0.43 0.01–0.85 0.332  0.43 -0.01–0.84 0.336 
rs2486064 -0.14 -0.44–0.15 0.803  -0.15 -0.44–0.13 0.968 
YKL-40 (ng/ml)        
YKL-40 non-detects 1 reference Ptrend  1 reference Ptrend 
YKL-40 (7–37.9) 0.14 -0.44–0.72   0.20 -0.40–0.81  
YKL-40 (38–49.9) 0.16 -0.43–0.74   0.21 -0.41–0.82  
YKL-40 (50–65.9) 0.10 -0.45–0.65   0.16 -0.43–0.75  
YKL-40 (66–98) 0.34 -0.22–0.91 0.280£  0.39 -0.21–0.99 0.326£ 
        
Exposure Outcome FEV1 
 (z-score) # 
SNP#   
rs10920579 -0.07 -0.47–0.33 0.743  -0.09 -0.52–0.33 0.863 
rs880633 0.05 -0.24–0.33 0.743  0.03 -0.22–0.25 0.863 
rs10399931 -0.08 -0.44–0.28 0.743  -0.09 -0.61–0.25 0.863 
rs10399805 0.36 -0.15–0.29 0.743  0.36 -0.14–0.22 0.863 
rs1538372 -0.14 0.45–0.86 0.743  -0.17 0.44–0.19 0.863 
rs7542294 0.26 -0.41–0.17 0.743  0.27 -0.15–0.67 0.863 
rs2486064 -0.23 -0.52–0.67 0.743  -0.26 -0.53–0.07 0.721 
YKL-40 (ng/ml)        
YKL-40 non-detects 1 reference Ptrend  1 reference Ptrend 
YKL-40 (7–37.9) 0.01 -0.59–0.61   0.09 -0.53–0.71  
YKL-40 (38–49.9) -0.14 -0.73–0.45   -0.04 -0.67–0.61  
YKL-40 (50–65.9) 0.03 -0.54–0.61   0.11 -0.51–0.73  
YKL-40 (66–98) 0.28 -0.31–0.88 0.428£  0.43 -0.21–1.11 0.239£ 
        
Exposure Outcome FEF25-75% 
 (z-score)& 
SNP#   
rs10920579 -0.10 -0.51–0.31 0.963  -0.18 -0.61–0.23 0.709 
rs 880633 -0.30 -0.58–0.27 0.834  -0.30 -0.57–0.01 0.276 
rs10399931 -0.17 -0.52–0.19 0.963  -0.22 -0.59–0.13 0.709 
rs10399805 -0.18 -0.72–0.36 0.963  -0.11 -0.66–0.43 0.709 
rs1538372 -0.29 -0.58–0.01 0.963  -0.31 -0.58–0.01 0.332 
rs7542294 -0.16 -0.61–0.29 0.963  -0.15 -0.62–0.28 0.709 
rs2486064 -0.13 -0.44–0.18 0.963  -0.14 -0.46–0.17 0.709 
YKL-40 (ng/ml)        
YKL-40 non-detects 1 reference Ptrend  1 reference Ptrend 
YKL-40 (7–37.9) 0.25 -0.31–0.81   0.27 -0.31–0.84  
YKL-40 (38–49.9) -0.26 -0.83–0.31   -0.17 -0.77–0.43  
YKL-40 (50–65.9) -0.08 -0.61–0.45   -0.05 -0.61–0.52  
YKL-40 (66–98) -0.07 -0.61–0.47 0.610£  0.01 -0.56–0.59 0.836£ 
Coef: Coefficient; CI: confidence interval; SNP: single nucleotide polymorphism; FVC: forced vital capacity; FEV1: forced expiratory 
volume in one second; FEF: forced expiratory flow from 25-75% of exhalation. $Missing data on n=51; data available for n=91. #Missing 
data on n=66; data available for n=76. &Missing data on n=62; data available for n=80. §Adjusted for presence or absence of siblings, daycare 
attendance and asthma of the child. #P-values for SNPs are shown after correction for multiple testing according to Benjamini-Hochberg.  
£ Ptrend -values were calculated with the Cochran-Armitage trend test. 
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3.4.2 Time series approach: characterization of respiratory symptoms 
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Key messages 
 In this study, we developed a method to objectively characterize the dynamic symptom 
pattern of prospectively assessed respiratory symptoms during infancy.  
 Utilizing this method, we identified a group of infants exposed to host factors and 
environmental exposures, which were also at increased risk for wheezing and atopy at 
school age.   
 This suggests that the assessment of dynamic symptom patterns may help to better 
characterize subjects susceptible for later disease. 
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Abstract 
Background: Children with frequent respiratory symptoms in infancy have an increased risk for 
later asthma, but the association with the dynamic symptom pattern is unknown. We developed 
an observer-independent method to characterize the dynamics of symptoms and tested its 
association with respiratory morbidly at school age.  
Methods: In this birth-cohort of healthy neonates, we prospectively assessed weekly respiratory 
symptoms during infancy, resulting in a time series of 52 symptom scores. For each infant, we 
calculated the probability of transition between two consecutive symptom scores. These 
transition probabilities were used to construct a Markov matrix, which characterized the dynamic 
symptom pattern quantitatively using a single entropy parameter. Based on this parameter we 
determined 4 phenotypes. Using logistic regression, we then determined the association with 
wheezing and atopy at school age. 
Results: From 369 eligible neonates, 322 (87%) attended follow-up at 6 years and had complete 
data for >48 weeks of respiratory symptom scores during infancy (16864 observations). 
Compared to the healthy reference phenotype, the high-risk phenotype, defined by the highest 
irregularity (and thus entropy parameter) of the Markov matrix, had an (adjusted odds ratio; 95% 
CI) for wheezing of (OR 3.85; 1.11–13.43), and for atopy of (OR 3.45; 1.09–10.87) at school 
age. The high-risk phenotype was predominantly male (82%), and contained more infants 
exposed to maternal asthma (23%), and environmental tobacco smoke (41%). 
Conclusion: Our study describes a novel method to characterize dynamics of respiratory 
symptoms at infancy, which may reflect susceptibility and recovery patterns of the airways.  
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Introduction  
Wheezing disorders in early childhood have a high prevalence [1], with a major health issue [2], 
and methods to identify infants at risk for subsequent asthma are needed. Exposure to host 
factors (e.g. sex, maternal atopy), and environmental risk factors (e.g. childcare, siblings, 
environmental tobacco smoke (ETS) exposure, air pollution) influence the incidence and 
duration of respiratory symptoms during infancy [3, 4], and are associated with wheezing 
episodes during childhood [5]. In clinical practice, assessing risk factors, estimating the 
frequency of respiratory symptoms, and also the symptom pattern (e.g. episodic versus persistent 
symptoms) [6], may help to identify infants at risk for later asthma.  
Especially the pattern of symptom deterioration and recovery (i.e. progression from a given 
symptoms state to another) may be informative, as it is determined by the dynamic symptom 
pattern that a subject undergoes during a given time window. While it is known that persistent 
wheeze in infants is more closely associated with later asthma and reduced lung function than 
episodic wheeze [6, 7], it is difficult to characterize the dynamic symptom pattern observer-
independently, and to estimate its predictive value for persistence of respiratory symptoms 
during preschool age. 
We hypothesize that the dynamic symptom pattern may not only be determined by exposure to 
infectious risk factors (siblings, childcare), but also by host factors and exposure to ETS or air 
pollution. The dynamic symptom pattern may thus contain information on susceptibility of the 
airways to infectious triggers. This hypothesis was supported by our previous study (Stern et al. 
[8]), in which infants exposed to higher air pollution levels recovered more slowly from viral 
infections than those with lower exposure levels. Similarly, infants of allergic mothers [9], or 
those exposed to ETS [9], are more likely to suffer from persistent wheeze during childhood.  
Previous studies used a Markov model the trajectory of asthma severity [10], and to model 
asthma control [11]. The dynamic pattern of subsequently assessed respiratory symptoms could 
be mathematically represented using this Markov model (also known as Markov matrix) [12]. 
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Each row of this matrix encodes a conditional probability distribution, which can be measured 
using the Shannon entropy [13]. Consequently, by calculating entropy of the probability 
distributions encoded in the Markov matrix, we could objectively characterize the pattern of 
symptom deterioration and recovery.  
The aim was to develop a method to characterize the dynamic pattern of weekly assessed 
respiratory symptom scores during infancy with a Markov matrix for each infant. First, we tested 
if we could identify specific dynamic phenotypes using these Markov matrices. Next, we tested 
whether these dynamic phenotypes predicted wheezing and atopy at school age. Lastly, we 
determined if environmental risk factors were more common in specific dynamic phenotypes, to 
explore if specific dynamic symptom patterns are influenced by host factors and environmental 
exposures. 
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Methods  
Details are outlined in the appendix.  
Study design  
In the Basel-Bern infant lung development (BILD) birth-cohort study, we prospectively assessed 
weekly respiratory symptom scores (states 0 to 4) [14] during infancy, resulting in 52 
consecutive observations. We used these symptom scores to develop a method which 
summarizes the dynamic symptom pattern with a Markov matrix for each infant. These Markov 
matrices were characterized using one single quantitative measure, namely entropy. First, we 
tested if we could identify specific dynamic phenotypes based on this entropy parameter. Next, 
we tested the association between dynamic phenotypes with wheezing and atopy at school age 
(primary outcomes). Allergic sensitization, upper respiratory tract infection (URTI), lung 
function and FeNO measurements at school age were secondary outcomes. Lastly, we compared 
the distribution of risk factors across dynamic phenotypes.  
Study participants  
This study comprised a group of unselected, healthy term born neonates recruited antenatally in 
two centers (Bern and Basel) in Switzerland [15]. From 1999 to 2015, 369 children from Bern 
were invited for a follow up at 6 years. The Ethics Committees of Bern and Basel, Switzerland 
approved the study. Written informed consent was obtained from parents before enrolment.  
Exposures: respiratory symptoms during infancy 
During the first year of life, research nurses called the parents weekly to assess the child’s health 
and respiratory symptoms using a standardized symptom score that groups symptoms into 4 
levels according to severity [4, 14]. Weeks with respiratory symptoms were defined as the total 
number of weeks a child had any respiratory symptom, independent of type or severity; weeks 
with severe respiratory symptoms were defined as a symptom score of ≥3 (e.g repeated sleep 
disturbances during the night, or general practitioner consultation), as described previously [4, 
14] (Table S1). 
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Markov matrix to assess dynamics of respiratory symptoms  
We used a Markov model approach to examine trajectories between subsequently assessed 
symptom scores. We assessed transitions between different levels of the symptom scores: state 
zero: healthy, symptom score 0; states 1-4: symptomatic states, symptom scores 1-4. For each 
symptom state, we counted how often a transition to any other state, assessed in the subsequent 
week occurred. For each child, this count information can be displayed in a 5×5 matrix (vertical 
axis initial state, horizontal-axis target state). These counts are absolute frequencies, which were 
used to calculate relative frequencies for each transition (Figure 1 A-C). This matrix is called 
Markov matrix [12], which was then graphically represented using a three-dimensional 
landscape. Finally, the landscape’s irregularity was quantified using a single entropy value [16] 
(Figure 2, supplementary methods). 
Risk factors   
At baseline, we used a standardized questionnaire to assess pre-and postnatal exposure to risk 
factors for respiratory symptoms during infancy [4] or asthma development (e.g. number of 
siblings, maternal asthma). Parental atopic disease was defined as self-reported, doctor-
diagnosed asthma, hay fever, or eczema. Maternal education was categorized as low (3 years of 
secondary education) and high (≥4 years of secondary education). Duration of breastfeeding 
(exclusive or non-exclusive) was weekly assessed and binary coded (as <26 and ≥26 weeks). All 
risk factors were categorized as binary variables in order to compare under-or overrepresentation 
across phenotypes. 
Outcomes: respiratory outcomes and atopic sensitization at school age 
At 6 years, asthma and allergy were assessed by an adapted International Study of Asthma and 
Allergies in Childhood (ISAAC) questionnaire [17].  We choose the following outcomes: “any 
wheezing between 1-6 years”; “current wheezing”, defined by wheezing over the past 12 
months; upper respiratory tract infection (URTI), defined by ear infection, throat infection, or 
serious cold (defined by symptoms ≥2 weeks) over the past 12 months. Atopy was defined as 
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allergic rhinitis, allergic asthma, or atopic dermatitis. A skin-prick test (SPT) was determined 
positive if a wheal diameter of any of the seven tested aeroallergens was greater than positive 
control [15].  
Spirometry was performed using the MasterLab setup (Jaeger, Wuerzburg, Germany) according 
to standard guidelines [18]. Forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), 
FEV1/FVC ratio, and forced expiratory flow at 25-75% of FVC (FEF25-75%) were expressed as z-
scores [19]. We measured the fraction of exhaled nitric oxide (FeNO) using a commercially 
available analyzer (CLD 77 AM; Eco Medics AG, Duernten, Switzerland) according to current 
guidelines [20].  
Statistical analysis  
Entropy is a measure for disorder within a dynamic system, and higher entropy values 
correspond to more irregularity [13]. For each infant, we calculated entropy [21] of the Markov 
matrix, which provides a quantitative measure of the irregularity patterns of symptom 
deterioration and recovery. The frequency distribution of entropy visually appeared multimodal, 
with 4 modi (Figure 3A). Therefore, we defined 4 dynamic phenotypes based on the slope of the 
cumulative distribution function curve, and a slope of zero was used for cutoff. We defined 4 
similarly sized reference phenotypes by the frequency distribution of total number of weeks with 
respiratory symptoms during infancy (Figure 3B). 
Using logistic regression, we studied the association of the 4 dynamic phenotypes, the 4 
reference phenotypes, and asthma risk factors, with the child’s outcomes. For “any wheezing”, 
“current wheezing”, atopy and positive prick test of the child, analyses were adjusted for sex, 
maternal education and asthma, ETS exposure, childcare, and siblings. For FeNO, we 
additionally adjusted for asthma of the child and inhaled corticosteroid use. For lung function, 
we adjusted for maternal education, maternal asthma, ETS exposure, childcare, and siblings. 
Chi
2
 and Kruskal–Wallis tests were used to compare characteristics across phenotypes. A 
Bonferroni-corrected significance level was used to account for multiple pair-wise testing. We 
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used the weighted kappa-statistic [22] to compare agreement between dynamic and reference 
phenotypes.  
For sensitivity analyses, we repeated the analysis in infants having ≥1 episode of symptom score 
≥3, and within an additional, independent sample from our cohort of 242 infants. To explore that 
the entropy distribution was not an artifact of our analysis, we re-categorized the symptom states 
(0, 1, 2, (3+4)→3), we simulated data, and perturbed the existing data. Furthermore, we 
corrected our findings for potentially unobserved events.   
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Results  
From 369 eligible subjects, 322 (87%) were studied (Figure S1), having >48 weeks of symptom 
series during infancy and complete data on risk factors and outcomes (Table 1). Demographic 
data and distribution of respiratory symptoms did not differ between infants followed-up and 
those lost to follow-up, but exposure to risk factors did (Table S2).  
Distribution of respiratory symptoms 
In infants followed-up, we had information for 16864 person–weeks. On average, the number of 
weeks with any respiratory symptom was (median; range) (4; 0-23 weeks). In contrast, severe 
symptoms were rare (0; range 0-6 weeks). Figure 1D shows the distribution of all symptom 
states. 
Dynamics of respiratory symptoms assessed by the Markov matrix 
Figure 2 shows the dynamic pattern of respiratory symptoms for 2 infants. Both had the same 
number of symptom weeks, but different patterns of the Markov matrix landscape. The shape of 
the matrix landscape, characterized by a single entropy parameter differed as well. 
Outcomes at school age 
From 322 children at follow-up, 105 (32.9%) had any wheezing, and 38 (11.7%) had current 
wheezing. There were 120 (37.5%) children with allergic diseases, and a subgroup of 270 
completed a SPT, 37 (13.6%) of which were positive. Lung function was completed in 222 
(68.7%) children, and 231 (71.7%) had FeNO measurements. 
Associations of dynamic phenotypes, reference phenotypes and risk factors with outcomes 
at school age 
We defined 4 dynamic phenotypes using the Markov matrix and 4 corresponding reference 
phenotypes by the distribution of respiratory symptom weeks (Figure 3). Compared to baseline 
phenotpye one, in the adjusted logistic regression model, male gender, maternal asthma, dynamic 
phenotype 4 and reference phenotypes 2 and 3 were associated with any wheezing during 
childhood (Table 2). Dynamic phenotype 4 and male gender were also associated with current 
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wheezing and atopy (Table 2). Similar associations were obtained for the outcome positive SPT, 
but only reference phenotype 3 was associated with URTI (Table S3). Compared to the baseline 
phenotype, lung function and FeNO measurements did not differ between phenotypes 2-4 (Table 
S4). We obtained similar results in infants with ≥1 episode of symptom score ≥3 (data not 
shown). 
Over-and underrepresentation of risk factors across phenotypes   
Dynamic phenotypes  
These 4 phenotypes included 141, 102, 62 and 17 infants (Table 3, Figure 3). These differed with 
regards to the number of weeks with any and severe symptoms: phenotype 1 had severe 
symptoms for 0.21 weeks, phenotype 2 for 0.57 weeks, phenotype 3 for 1.53 weeks, and 
phenotype 4 for 3.06 weeks. Also, entropy differed across phenotypes: phenotype 1 had entropy 
of 0.012, phenotype 2 of 0.15, phenotype 3 of 0.29, and phenotype 4 of 0.44. 
Furthermore, risk factors differed across phenotypes: phenotype 1 had an underrepresentation of 
children with siblings, or attended childcare and were more likely born via Cesarean section. 
Phenotype 2 had an underrepresentation of males, and more infants had siblings. Phenotype 3 
had more males, and infants were less likely born via Cesarean section. Phenotype 4, the 
smallest group, had an overrepresentation of males, and infants attending childcare. In this 
phenotype, more infants were born to asthmatic mothers, or to mothers who smoked during 
pregnancy, and were also more likely exposed to tobacco during infancy. We considered this as 
high-risk dynamic phenotype, since associations with later wheezing and atopy were strongest. 
Reference phenotypes  
Phenotypes included 147, 98, 57, and 20 infants (Table 3), respectively. Phenotypes 1, 2, 3, and 
4 had 0.14, 0.70, 1.81, and 2.05 weeks with severe symptoms; entropy was 0.05, 0.16, 0.29, and 
0.32, respectively. Risk factors differed across phenotypes. Phenotype 1 had an 
underrepresentation of males; fewer infants had siblings and were more likely born via Cesarean 
section. In phenotype 2, infants were less likely born via Cesarean section. Phenotype 3 had 
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more males, more infants with siblings and childcare attendance, and fewer infants born via 
Cesarean section. Phenotype 4 had an overrepresentation of males and more infants had siblings, 
and were more likely born to asthmatic mothers. 
Comparison between temporal and reference phenotypes 
There was high overlap between the dynamic and reference phenotypes. Overlap was strongest 
between phenotype 1, with a low number of symptoms and weakest between phenotype 4, with a 
high number of symptoms (Figure 4). This indicates that phenotyping based on dynamic 
symptom patterns identifies infants with different characteristics compared to the reference 
method based on number of symptom weeks. In the high-risk dynamic phenotype 4, we found an 
overrepresentation of infants from smoking and asthmatic mothers, whereas in the reference 
phenotype 4, e.g. presence of siblings was strongly overrepresented. Although symptoms were 
frequent in reference phenotype 4, a much small proportion compared to dynamic phenotype 4 
developed wheezing and atopy.    
Validation of the phenotypes, sensitivity analysis  
Within the validation dataset, there were differences in anthropometric data and risk factors 
between centers (Table S5), but not in the distribution of respiratory symptoms. Phenotypes 
characteristics were comparable to the main analysis (Table S6). Several sensitivity analyses 
ruled out that the multimodal distribution of entropy was an artifact due to our methodology. 
After correcting our findings for potentially unobserved events, we observed three dynamic 
phenotypes, as detailed in the online supplement, and Figure S2 and Figure S3. 
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Discussion 
Based on times series of weekly symptom scores during infancy from healthy infants, we 
developed a novel method, which characterizes the dynamic symptom pattern in an observer-
independent manner. With this method, we calculated the transition probability between two 
consecutive symptom scores. These transition probabilities were used to construct a Markov 
matrix which was characterized using a single entropy parameter for each infant. Based on 
entropy, we determined 4 phenotypes. The phenotype with the highest entropy value (high risk 
dynamic phenotype) had more infants attending childcare, and exposure to maternal asthma a 
prenatal ETS, and had the highest prevalence of wheezing (35%) and atopy (64%) at school age. 
Although defined by entropy, this phenotype had also the highest total number of severe 
respiratory symptom weeks. In comparison, in the reference phenotype defined by the total 
number of any respiratory symptom weeks, infants with a high number of symptom weeks had 
more likely siblings or asthmatic mothers. Only 20% had current wheezing and 35% atopy at 
school age. These findings are consistent with the hypothesis that host factors and exposure to 
ETS may play a role for the dynamic symptom pattern, and are likely relevant for future disease, 
although we observed on overlap of infectious risk factors between the dynamic and reference 
phenotypes. 
Comparison with literature 
Similarly to other studies [10, 23], we observed an association between male gender and 
childhood asthma. The association between low maternal education and the risk for atopy should 
be interpreted with caution since mothers in our study were all relatively well educated. The 
“low” maternal education in our study is therefore only partially comparable to previous studies.  
Phenotypes from the dynamic symptom pattern as well as total number of symptom weeks 
during infancy were not associated with lung function or FeNO at school age. These findings 
differ to results from a large European birth cohort (ALSPAC study) describing an association 
between different wheezing phenotypes (early transient, persistent wheeze, etc.) with lung 
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function at 8-9 years of age [7, 24]. Differences could be due to the small number of lung 
function measurements at school age in our study, and because only few children had a severely 
reduced lung function in this unselected study population. Also, while our method assessed any 
respiratory symptoms (mostly cough and rhinitis), ALSPAC measures ‘wheezing’ [7, 24], which 
may reflect other airway properties. Nevertheless, future studies may profit from the use of our 
observer-independent method for the analysis of wheezing symptoms.  
Potential mechanism, interplay between host and environmental risk factors     
Interplay between an exposure (e.g. virus) and host predisposition (e.g. infant exposed to 
maternal asthma) is thought to determine the response to a respiratory infection. Studies further 
suggest that the severity of respiratory infections in children does not only depend on the virus 
type [25], but is modified by microbial composition [26] and environmental factors [4, 9]. 
Interplay between viral stimuli, microbial composition and genetic predisposition are suggested 
to affect airway epithelial function [27, 28]. We speculate that infants with a higher fluctuation 
between respiratory symptom scores (and thus higher average entropy of the Markov matrix) are 
those having an epithelial dysfunction and are at increased risk for developing asthma and atopy. 
Markers associated with asthma exacerbations (e.g cytokine expression, impaired interferon 
response) were identified previously [27]. In order to test our hypothesis of an epithelial 
dysfunction during infancy relevant for future disease, prospective studies assessing these 
markers during respiratory infections are needed. 
Methodological aspects, limitations of the method 
While we did not define phenotypes based on “classical” data driven methods (e.g. Ward’s 
hierarchical clustering [29] or latent class analysis [7, 24, 30, 31]), our phenotype identification 
was still data driven, as they were exclusively defined by the data structure of transition patterns. 
Previous studies using unsupervised methods assessed symptoms at 2 [30] up to 14 times [32]. 
The resolution of the respiratory symptoms of this study is unique, since we had a minimum of 
49 observation time points. Comparison of phenotypes in this and previous studies is limited 
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since previous studies phenotyped based on wheeze during childhood [7, 29-31, 33], while this 
study focused on any respiratory symptom during infancy. Most previous studies investigated the 
association of phenotypes with the child’s risk factors, (e.g. allergic sensitization), while our 
study assessed prenatal (e.g. maternal smoking during pregnancy), and early postnatal (e.g. 
breastfeeding, childcare attendance) risk factors.  
It is striking that entropy of the Markov matrix in our study showed a multimodal distribution 
with 4 peaks, suggesting we can use entropy to define 4 phenotypes. Sensitivity analysis ruled 
out the possibility that this distribution is an artifact due to our methodology. For example, we 
tested if this distribution could be a mathematical phenomenon related to the scoring system (5 
states). However, re-categorization of the states (0, 1, 2 (3+4)→3), did not systematically change 
the identified phenotypes. We further challenged our method and corrected our analysis for 
potentially unobserved events, resulting in higher average entropy values of the Markov matrix. 
We defined 3 phenotypes, indicating that applying our method in other populations with 
different symptom patterns may result in different entropy distributions.   
Strengths and limitations  
We prospectively assessed respiratory symptoms weekly by telephone interviews, obtaining 
reliable data on respiratory morbidity [14] and reducing a potential recall bias compared to 
retrospectively reported symptoms. We had only a few missing data points; 2 infants out of the 
eligible participants had ≤48 weeks of observations and were excluded. We used the same 
questionnaire to assess risk factors and outcome data throughout the entire study period in both 
centers, reducing potential inter-center differences. Since this study was conducted in a healthy 
population, there were only 38 subjects with current wheezing (38) at school age. Furthermore, 
the high risk-phenotypes incorporated only small numbers and misclassification of just one 
subject could have a major influence on our findings. Very few cohort studies prospectively 
assessed respiratory symptoms during infancy (e.g. for high risk infants [34], overview for 
unselected infants [4]). Due to lack of data, we could not validate our method in any of those, but 
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we performed an external validation in 242 infants from our cohort not seen for follow-up. This 
was an unselected study population, and results are therefore not directly applicable to high-risk 
populations. Performing a similar study within a larger cohort at increased risk for asthma and 
allergic diseases could further validate the developed method, and may contribute to our 
understanding of the predictive value for future disease.   
Clinical relevance and research application 
Our results indicate that specific dynamic symptom patterns during infancy are associated with 
wheezing at school age. This may guide pediatricians to identify those at risk among the large 
number of symptomatic subjects. Our method could be used in ongoing research on asthma 
control, as it objectively quantifies symptom patterns, and could be considered complementary to 
routine asthma biomarkers (e.g. FeNO, peak expiratory flow). Furthermore, assessment of 
symptom patterns is non-invasive, does not require laboratory equipment, and thus could be used 
in telemonitoring [35].  
Conclusion 
In this study, we developed a method to characterize the transition probabilities between 
respiratory symptoms and found that they were associated with wheezing and atopy at school 
age. Furthermore, these transitions probabilities enabled us to identify four distinct phenotypes 
of which one consisted of predominantly male subjects of asthmatic mothers and ETS exposure. 
This indicates that symptom patterns contain relevant information on risk factors for asthma 
development. The developed method has potential in various research settings, since it is based 
only on respiratory symptom scores, which can be assessed without laboratory equipment or 
specially trained experts.  
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Table 1 Characteristics of the study population  
Anthropometric data at birth Mean (SD) Median (IQR) Range n (%) 
Gestational age, weeks 39.6 (1.2) 39.8 (38.8–40.5) 36.7–41.8  
Birth weight, kg 3.3 (0.4) 3.3 (3.0–3.6) 2.1–4.9  
Length, cm 49.5 (1.9) 50.0 (48–51) 44–57  
     
Respiratory  symptoms in the first year of life 
Weeks with symptoms 5.3 (4.6) 4 (0–20) 0–23  
Weeks with severe symptoms 0.71 (1.1) 0 (0–1) 0–6  
     
Risk factors     
Male sex    167 (51.8) 
Siblings    159 (49.4) 
Caesarean section    54 (16.7) 
Maternal asthma    34 (10.5) 
Maternal atopy    116 (36.1) 
Childcare    62 (19.5) 
Maternal smoking in pregnancy    27 (8.4) 
Parental smoking during infancy    70 (21.7) 
Breastfeeding >26 weeks    252 (78.3) 
Low maternal education     202 (62.7) 
     
Season of birth     
Spring    87 (27.4) 
Summer    83 (25.7) 
Autumn    80 (24.8) 
Winter    72 (22.6) 
     
Outcomes during childhood     
Any wheezing    105 (32.9) 
Current wheezing    38 (11.7) 
Atopy    120 (37.5) 
Skin prick test positive
*
    37 (13.6) 
URTI
+
     122 (37.9) 
Values are means (SD), median (IQR) or number (percentage). IQR: interquartile range; n: 
number; SD: standard deviation; URTI: Upper respiratory tract infection. Data are derived from 
322 infants with a total of 16864 observed symptom weeks. *A skin prick test was completed in 
a subset of 270 children. 
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Table 2  Association of symptom dynamic phenotypes, reference phenotypes, and risk factors with outcomes during 
childhood 
 Univariable association  Multivariable association# 
 OR 95% CI P-value  OR 95% CI P-value 
Exposure Outcome any wheezing between 1-6 years
+ 
 (105/322) 
Respiratory symptom, weeks (Reference Phenotypes)      
Phenotype 1 (baseline) (147) 1 reference   1 reference  
Phenotype 2 (98) 2.09 1.19 –3.67 0.010  1.88 1.04–3.40 0.036 
Phenotype 3 (57) 3.10 1.62–5.94 0.001  2.62 1.31–5.23 0.006 
Phenotype 4 (20) 2.82 1.07–7.39 0.034  1.99 0.70–5.61 0.192 
Transition states, entropy (Dynamic Phenotypes)      
Phenotype 1 (baseline) (141) 1 reference   1 reference  
Phenotype 2 (102) 1.02 0.57–1.81 0.931  1.05 0.57–1.93 0.855 
Phenotype 3 (62) 1.95 1.04–3.66 0.036  1.80 0.92–3.50 0.081 
Phenotype 4 (17) 12.64 3.44–46.47 <0.001  9.14 2.35–35.46 0.001 
Risk factors         
Male sex 3.05 1.86–5.01 <0.001  2.90 1.75–4.81 <0.001 
Siblings 1.22 0.77–1.95 0.386  1.27 0.78–2.09 0.328 
Maternal asthma 2.23 1.09–4.58 0.028  2.16 1.03–4.55 0.041 
Childcare 1.49 0.84–2.64 0.169  1.40 0.75–2.59 0.284 
Parental smoking during 
infancy 
1.08 0.61–1.89 0.783  0.99 0.55–1.81 0.995 
Low maternal education 1.23 0.76–2.01 0.391  1.13 0.66–1.93 0.644 
        
Exposure Outcome current wheezing at 6 years
¶ 
(38/322) 
Respiratory symptom, weeks (Reference Phenotypes)      
Phenotype 1 (baseline) (147) 1 reference   1 reference  
Phenotype 2 (98) 1.04 0.42–2.54 0.927  0.92 0.36–2.31 0.865 
Phenotype 3 (57) 2.74 1.16–6.45 0.020  2.41 0.97–5.98 0.056 
Phenotype 4 (20) 2.57 0.74–8.85 0.133  1.89 0.51–7.06 0.340 
Transition states, entropy (Dynamic Phenotypes)      
Phenotype 1 (baseline) (141) 1 reference   1 reference  
Phenotype 2 (102) 1.07 0.44–2.54 0.878  1.12 0.46–2.75 0.792 
Phenotype 3 (62) 1.67 0.67–4.14 0.267  1.61 0.62–4.11 0.327 
Phenotype 4 (17) 5.37 1.71–16.91 0.004  3.85 1.11–13.43 0.034 
Risk factors        
Male sex 2.52 1.21–5.28 0.014  2.26 1.06–4.81 0.033 
Siblings 1.15 0.58–2.28 0.670  1.19 0.61–2.42 0.616 
Maternal asthma 1.71 0.65– 4.45 0.141  1.66 0.62–4.41 0.306 
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Childcare 1.35 0.61–3.02 0.462  1.38 0.58–3.27 0.457 
Parental smoking during 
infancy 
1.33 0.61–2.89 0.468  1.15 0.51–2.59 0.723 
Low maternal education 1.77 0.82–3.78 0.141  1.63 0.73–3.66 0.229 
        
Exposure Outcome atopy at 6 years
*
 (120/320) 
Respiratory symptom, weeks (Reference Phenotypes)      
Phenotype 1 (baseline) (147) 1 reference   1 reference  
Phenotype 2 (98) 0.93 0.54–1.59 0.797  0.86 0.49–1.53 0.630 
Phenotype 3 (57) 1.52 0.81–2.83 0.188  1.51 0.77–2.96 0.228 
Phenotype 4 (20) 0.94 0.35–2.51 0.910  0.73 0.25–2.10 0.562 
Transition states, entropy (Dynamic Phenotypes)      
Phenotype 1 (baseline) (141) 1 reference   1 reference  
Phenotype 2 (102) 1.13 0.66–1.93 0.643  1.26 0.72–2.22 0.413 
Phenotype 3 (62) 1.16 0.62–2.16 0.641  1.20 0.62–2.34 0.573 
Phenotype 4 (17) 3.51 1.22–10.08 0.019  3.45 1.09–10.87 0.034 
Risk factors         
Male sex 2.15 1.35–3.42 0.001  2.10 1.29 –3.40 0.003 
Siblings 1.09 0.69–1.72 0.686  1.01 0.63–1.63 0.944 
Maternal asthma 1.55 0.76–3.18 0.226  1.51 0.72–3.17 0.274 
Childcare 0.62 0.34–1.14 0.127  0.63 0.33–1.21 0.168 
Parental smoking during 
infancy 
1.09 0.63–1.88 0.752  0.92 0.5–1.64 0.786 
Low maternal education 2.30 1.40–3.77 0.001  2.03 1.20–3.41 0.008 
CI: confidence interval; OR: odds ratio. Logistic regression for the outcomes any wheezing, current wheezing and 
atopic disease. Symptom dynamic phenotypes were defined by entropy of transition states, reference phenotypes by 
weeks with any respiratory symptom. When considering phenotypes as exposure, phenotype one from the reference 
phenotype, or symptom dynamic phenotype served as baseline, respectively. Numbers in brackets indicate group 
sizes. 
#
Adjusted for the following binary variables: male gender, low maternal education, maternal asthma, maternal 
smoking during pregnancy, childcare attendance during infancy, and presence of siblings. 
+
Defined as any wheezing 
episode between one and six years of age.
 ¶
Defined by wheezing over the past 12 months before follow-up. 
*
Atopic 
disease was defined as allergic rhinitis, allergic asthma, or atopic dermatitis. 
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Table 3 Characteristics of symptom dynamic phenotypes and reference phenotypes 
 Phenotype 1 Phenotype 2 Phenotype 3 Phenotype 4 P-value 
 Dyn. Ref. Dyn. Ref. Dyn. Ref. Dyn. Ref. Dyn. Ref. 
 141 147 102 98 62 57 17 20   
Respiratory 
symptoms            
Weeks with severe 
symptoms 
0.21 
(0.41) 
0.14 
(0.37) 
0.57 
(0.78) 
0.70 
(0.75) 
1.53 
(1.40) 
1.81 
(1.42) 
3.06 
(1.20) 
2.05 
(1.79) <0.001 <0.001 
Weeks with 
symptoms 
1.74  
(1.52) 
1.56 
(1.09) 
6.07  
(3.32) 
5.70 
(1.44) 
10.13 
(3.56) 
10.51 
(1.54) 
13.18 
(3.94) 
16.50 
(2.93) <0.001 <0.001 
           
Respiratory 
symptoms  
transition states           
Entropy of 
transition states 
0.012 
(0.01) 
0.05 
(0.03) 
0.15 
(0.02) 
0.16 
(0.09) 
0.29 
(0.03) 
0.29 
(0.09) 
0.44 
(0.03) 
0.32 
(0.09) <0.001 <0.001 
           
Risk factors           
Male sex 49.6 43.5 45.1 54.0 59.6 63.1 82.3 70.0 0.076 0.08 
Siblings 36.8 38.1 57.8 53.0 59.6 63.1 64.7 75.0 0.004 0.004 
Caesarean section 24.1 23.8 13.7 10.2 4.4 10.5 17.6 5.0 0.024 0.08 
Maternal asthma 9.9 8.8 9.8 11.2 9.6 10.5 23.5 20.0 1 1 
Maternal atopy 37.5 33.3 30.3 37.7 41.9 38.6 35.2 40.0 1 1 
Childcare 13.4 11.5 19.6 23.4 24.1 28.0 47.0 30.0 0.024 0.044 
Maternal smoking  
during pregnancy 
 
7.8 
 
6.8 
 
7.8 
 
8.1 
 
6.4 
 
12.2 
 
23.5 
 
10.0 0.56 1 
Parental smoking 
during infancy 
 
24.1 
 
23.1 
 
17.6 
 
19.3 17.7 
 
22.8 
 
41.1 
 
20.0 0.48 1 
Breastfeeding ≤26 
weeks 21.3 
 
20.5 
 
20.6 
 
24.5 20.9 
 
24.6 
 
29.5 
 
5.0 1 1 
Low maternal 
education 
 
64.5 
 
61.9 
 
59..8 
 
65.3 
 
59.7.3 
 
57.9 
 
76.4 
 
70.0 1 1 
           
Seasons at birth           
Spring 24.8 26.5 33.3 28.5 28.5 24.5 24.8 30.0 1 1 
Summer 22.7 18.3 24.5 37.7 37.7 26.3 22.7 20.0 1 0.032 
Autumn 36.1 35.3 19.6 17.3 17.3 12.2 36.1 20.0 <0.001 0.004 
Winter 16.1 19.7 22.5 16.3 16.3 36.8 16.3 30.0 0.112 0.068 
           
Outcomes during  
childhood    
 
      
Any wheezing
+
 26.8 22.2 27.7 37.7 41.9 47.3 82.3 45.0 <0.001 0.008 
Current wheezing
$
 9.2 8.8 9.8 9.2 14.5 21.1 35.3 20.0 0.112 0.196 
Atopy 34.3 36.3 37.3 34.7 37.7 46.4 64.7 35.0 <0.001 1 
Skin prick test 
positive
#
 12.8 14.5 13.7 12.2 12.3 12.3 25.0 21.4 0.052 1 
URTI
¶
 36.8 34.1 41.2 37.7 35.5 50.9 35.3 30.0 0.448 0.54 
Values are percent or mean (SD). Symptom dynamic phenotypes (Dyn.) are shown on white background, and 
reference phenotypes (Ref.) are shown on grey shading background· Symptom dynamic phenotypes were 
defined by average entropy of transition states, reference phenotypes by weeks with any respiratory symptom. 
Differences in the distribution of characteristics across phenotypes were assessed using Chi-squared tests for 
categorical variables, and Kruskal–Wallis for continuous variables. P-values are Bonferroni corrected, 
accounting for multiple testing. 
+
Defined as any wheezing episode between one and six years of age.
 $
Defined by 
wheezing over the past 12 months before follow-up.
 *
Atopic disease was defined as allergic rhinitis, allergic 
asthma, or atopic dermatitis.
 #
A skin prick test was completed in a subset of 270 children. 
¶
Upper respiratory 
tract infection (URTI) was defined by ear infection, throat infection, or serious cold (defined by symptoms ≥two 
weeks) over the past 12 months before follow-up. 
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Figures 
  
Figure 1 Representative Markov matrix of one infant and distribution of respiratory symptoms 
states during infancy among all study participants. A) Temporal pattern of respiratory symptoms 
scores during the first year of life for one infant. We assessed transitions between different levels 
of the symptom scores: state zero: healthy, symptom score 0; states 1-4: symptomatic states, 
symptom scores 1-4. For each symptom state (i.e. initial state, 1st time point), we counted how 
often a transition to any other state (i.e. target state, 2nd time point), as assessed during the 
subsequent week, occurred. B) This count information is displayed in a 5×5 matrix. C) These 
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counts are absolute frequencies, which were used to calculate relative frequencies. D) 
Transitions of all study participants. Vertical-axis represents the total number of weeks of each 
transition state. Horizontal-axis represents all possible transitions. Type1: healthy state; Type 2: 
increasing symptoms; Type 3: stable symptoms; Type 4: decreasing symptoms. Data are shown 
as box plots. Numbers in brackets indicate initial symptom score (initial state) and target 
symptom score (target state) assessed in the subsequent week. 
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Figure 2 Representative Markov matrix patterns for two infants. Figure 1A (infant 1) and 2A 
(infant 2) show the respiratory symptoms states (scores 0-4) over the first year of life for each 
week. The total number of “weeks with respiratory symptoms” during the first year for both 
infants was the same (44 weeks symptom score 0, 4 weeks symptom score 1, 2 weeks symptom 
score 2 and 2 weeks symptom score 3). The Markov matrices in figure 1B and 2B show the 
empirical probability of each transition (described in the methods and Figure 1). 1C, 2C: Colors 
of the peaks’ heights correspond to the empirical probability of each transition. The pattern of 
the Markov matrix landscape was expressed using a single average entropy parameter16 
(described in online supplement methods), which was 0.2 for infant 1, and 0.47 for infant 2.  
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Figure 3 Frequency distribution of entropy of the Markov matrices and “weeks with any 
respiratory symptom” among the 322 study participants. Left side scaling axis indicate number 
of infants. Continuous line indicates cumulative probability of infants (right side scaling axis) 
dotted lines indicate cut-off between phenotypes. A) We used the frequency distribution of 
average entropy from the Markov matrices to define 4 phenotypes including 141, 102, 62 and 17 
infants. B) We used the frequency distribution of the total number of weeks with any respiratory 
symptom to define phenotypes with sizes similar to those defined in panel A), including 147, 98, 
57 and 20 infants. C) Three-dimensional representation of the average transition patterns from all 
infants within one phenotype, as defined in panel A). Colors correspond to the empirical 
probability of each transition. Numbers 0-4 represent the respiratory symptom scores. 
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Figure 4 Overlap of infants allocated to the same phenotype compared between the two 
phenotyping methods. Individual circle size is proportional to the number of infants in each 
phenotype. Green indicates dynamic phenotypes and red reference phenotypes. The overlap of 
infants allocated to phenotype 1 was 122 (70%), to phenotype 2 was 57 (40%), to phenotype 3 
was 32 (37%) and to phenotype 4 was 6 (19%). There was high overall agreement between the 
two clustering methods, indicated by a weighted kappa-statistic value of 0.64 (range 0-1).  
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Supplementary Information  
Additional methods for study participants 
This ongoing prospective birth cohort study comprised a group of unselected, healthy term-born 
neonates recruited antenatally [1]. Infants were enrolled in two centers in Switzerland (in Bern 
between 1999 and 2015, and Basel between 2011 and 2015). Exclusion criteria for the study 
were preterm delivery (< 37 week gestational age), major birth defects, respiratory distress after 
birth, other significant perinatal disease or a later diagnosis of airway malformation, or specific 
chronic respiratory disease.  
 
Additional methods on skin prick testing 
Skin prick testing was performed in a subgroup of 270 children to the following allergens: dog 
and cat dander, two tree mixtures, grass mixture, Alternaria alternate, Dermatophagoides 
pteronyssinus, and Dermatophagoides farinae (Allergomed AG, Therwil, Switzerland). Positive 
control was histamine; negative control was the solution in which allergens were dissolved. The 
reaction was assessed 15 minutes after skin prick testing. Response was determined positive if a 
wheal diameter of any of the tested allergen was greater than the positive control.  
 
Additional methods on lung function and fractional exhaled nitric oxide measurement 
Spirometry was performed with the child in a seated position with the nose clipped using the 
MasterLab setup (Jaeger, Wuerzburg, Germany) according to standard guidelines. The best of at 
least three repeatable forced expiratory maneuvers (within 100 ml) was recorded [2]. Forced 
expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/FVC ratio and forced 
expiratory flow at 25-75% of FVC (FEF25-75%) were expressed as sex- and height-standardized z-
scores [3]. We measured the fraction of exhaled nitric oxide (FeNO) by the single-breath method 
with a rapid-response chemoluminescence analyzer (CLD 88 sp; EcoMedics, Duernten, 
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Switzerland). Flow was recorded using an ultrasonic flow meter (Spiroson; EcoMedics) 
according to current guidelines [4].  
 
Additional methods for the Markov matrix 
Respiratory tract infections during infancy were prospectively assessed using the following 
scores: Score zero for the healthy state and scores 1-4 (in ascending order of severity) for the 
symptomatic states (Table S1). For each possible symptom state x out of the five states 0,1,2,3,4, 
we counted how often, during the time window of 52 weeks observation, a transition to any other 
state y (in symbols xy) took place within one week’s time. For example, an infant is healthy 
(symptom score=0) for three consecutive weeks (transition: 0→0→0); develops a severe 
infection during the fourth week with symptom score 3 (transitions: 0→0→0→3); this infection 
(symptom score=3) lasts another week (transitions: 0→0→0→3→3); and finally, the infant fully 
recovers during the subsequent week (symptom score=0) (transitions: 0→0→0→3→3→0). 
Hence, this 6 weeks observation period can be described by the following transitions 
(momentary state → target state): 0→0, 0→0, 0→3, 3→3, 3→0. Therefore, during the time 
window of observation, the transition 0→0 was observed two times, and the transitions 0→3, 
3→3, 3→0 once, respectively. All the other remaining possible transitions (there is a total of 
5×5=25 possible transitions among the five states 0, 1, 2, 3, and 4), were not observed during this 
6 weeks observation period. All these counts, or absolute frequencies, can be displayed in a 5×5- 
table in which the rows and columns are labeled using the symptom states (0, 1, 2, 3, and 4). 
Such a table is displayed in Figure 1B for one patient of the cohort. 
The absolute frequencies from this table were then replaced by the corresponding relative 
frequencies (empirical probabilities). Thereby, the entries in the table can be interpreted as 
conditional probabilities. For example, a given patient is currently displaying symptoms 
corresponding to state x, and the probability that the symptoms will progress to symptom state y 
can be calculated (Figure 1C). Such a table of conditional probabilities is referred to in 
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mathematicians as a Markov matrix [5]. Each row in this matrix encodes a discrete probability 
distribution, namely the probability to progress from a given state to any other of the possible 
five states. We calculated the average estimated entropy [6] of all the conditional probability 
distributions defined by the rows of the participant’s Markov matrix. This average estimated 
entropy gives a quantitative measure for the irregularity of the patterns of symptom deterioration 
and recovery of a given patient. 
The entropy was estimated using the maximum likelihood estimator, which results from the 
substitution of the empirical probabilities (i.e., the entries in a given row of a Markov matrix) 
into the Shannon entropy formula: 
         ∑  
 
   
        
Pi,j denotes the probability coefficient of each states transition at ith row and jth column of the 
Markov matrix. 
 
When a row in a given Markov matrix only contained zeros, the value of the entropy was not 
calculated. Such rows did not contribute to the calculation of the average entropy over all rows 
of the Markov matrix. A row containing only zeros corresponds to a lack of empirical knowledge 
about those symptom transitions that were not reported. For the sake of consistency, this 
“policy” was also applied when we estimated the entropy using an estimator that addresses the 
issue of potentially unobserved events within the framework of our sensitivity analysis (see next 
subsection below). 
 
Additional methods for statistical analysis  
The Shannon entropy is defined as the average amount of information needed to specify the state 
of a random variable governed by a given probability distribution. In the context of statistical 
physics in can be interpreted as measure of disorder within a system; higher entropy values 
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correspond to more irregularity [7]. For each infant, we calculated the average estimated entropy 
[6] of all the conditional probability distributions defined by the rows of the participant’s 
Markov matrix. This average estimated entropy gives a quantitative measure of the irregularity 
in the patterns of symptom deterioration and recovery of a given patient. The frequency 
distribution of entropy visually appeared multimodal, with 4 clearly distinguishable modi (Figure 
3a). Therefore, we defined 4 dynamic phenotypes based on the slope of the cumulative 
distribution function curve, and a slope of zero was used for cutoff. We defined 4 similarly sized 
reference phenotypes by the frequency distribution of total number of weeks with respiratory 
symptoms during infancy (Figure 3b). 
Using logistic regression analysis, we studied the association of the 4 dynamic phenotypes, the 4 
reference phenotypes, and known asthma risk factors (e.g. sex, maternal asthma), with the 
child’s outcomes at 6 years. For “any wheezing”, “current wheezing”, atopy and positive prick 
test of the child, we adjusted the analyses for sex, maternal education, maternal asthma, ETS 
exposure, childcare, and presence of siblings. For the outcome FeNO, we additionally adjusted 
for asthma of the child and inhaled corticosteroid use. For lung function, analyses were adjusted 
for maternal education, maternal asthma, ETS exposure, childcare, and presence of siblings. 
Differences in the distribution of characteristics across phenotypes were assessed using Chi
2
 tests 
for categorical variables, and Kruskal–Wallis for continuous variables. A Bonferroni-corrected 
significance level was used to account for multiple pair-wise testing. We used the weighted 
kappa-statistic [8] to compare agreement between the dynamic and reference phenotypes. 
Analyses were done using Stata 11.2 software (StataCorp, College Station, Tex), Matlab R2015b 
(The MathWorks, Inc., Natick, MA, USA) and R, Version 3.0.2 [9]. 
 
Additional methods for sensitivity analysis  
We performed several sensitivity analyses:  
1) We repeated the analysis in infants having ≥1 episode of symptom score ≥3.  
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2) Robustness of the identified phenotypes was investigated within an additional, independent 
sample from our cohort. That sample, included infants not seen for follow up, and hence, these 
infants were not included in the main analysis. This sample served as an independent data set for 
an external validation of the method.  
3) To explore that the distribution of entropy was not a statistical artifact of our analysis 
approach, we re-categorized the symptom states (0, 1, 2, (3+4)→3), we simulated different data 
sets and perturbed the existing data sets.  
4) As revealed by our data, within this healthy cohort some symptoms transitions were hardly 
ever reported, especially transitions between severe respiratory symptoms. Many participants did 
not report certain transitions at all during the time window of observation. Assigning probability 
zero to a transition just because it was not reported during the time window of observation may 
be a precipitate conclusion. Bayesian inference provides a rigorous mathematical framework for 
dealing with unobserved events [10]. Therefore, we estimated the entropy using an estimator that 
takes into account the issue of unobserved events (Schuerman and Grassberger [11]) and 
thereby, using a Bayesian approach, compensating for the underestimation of the entropy that 
may arise from the use of the maximum likelihood estimator in the presence of unobserved 
events.  
We applied the suggested approach by Schuerman and Grassberger [11], and conducted also a 
simulation- and perturbation-based sensitivity analysis to rule out a potential artifact behind the 
observed multimodal distribution of the average estimated entropy. 
 
Additional results for sensitivity analysis  
1) We obtained similar results in infants with ≥1 episode of symptom score ≥3 (data not shown). 
2) In the validation dataset of 242 infants, dynamic phenotypes included 83, 101, 46 and 12 
infants. Phenotypes 1, 2, 3 and 4 had 0.23, 0.65, 1.41, and 2.92 weeks with severe symptoms, 
respectively. Risk factors differed across phenotypes Risk factors differed across phenotypes: 
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phenotype 1 had an underrepresentation of children attended childcare. Phenotype 2 had an 
underrepresentation of males. Phenotype 3 had more males, and more infants had siblings. 
Phenotype 4, the smallest group, had an overrepresentation infants attended childcare, and were 
more breastfed. Reference phenotypes included 83, 131, 41 and 15 infants, respectively. 
Phenotypes 1, 2, 3 and 4 had 0.16, 0.66, 1.34, and 3.2 weeks with severe symptoms, respectively. 
Phenotype 1 had an underrepresentation of males; fewer infants had siblings and attended less 
childcare. In phenotype 2, infants were more likely born via Cesarean section. Phenotype 3 had 
more males, more infants with siblings and childcare attendance, and fewer infants born via 
Cesarean section. Phenotype 4 had an overrepresentation of males, and more infants had 
siblings, and were more likely born to atopic mothers (Table S6). 
3) The outcomes of the following sensitivity analysis ruled out the possibility of an artifact in our 
methodology. Re-categorization of the states (0, 1, 2 (3+4)→3), did not systematically change 
the entropy distribution and the identified phenotypes (data not shown). The striking observed 
multimodality of the distribution of the average estimated entropy (4 dominant peaks) did not 
show up in a simulated dataset in which all possible symptom transitions were assumed to be 
equally likely (Figure S2B). We perturbed the existing data by shuffling and thereby randomly 
altering the chronological order of each patient’s reported symptoms. The resulting distribution 
of the average entropy remained qualitatively very similar to the one observed in the unperturbed 
data (Figure S2C). A multimodal distribution was observed when the data was simulated in such 
a way, that the probability of any given symptom transition was determined by the pooled, 
existing data of the cohort. However, the shape of the distribution changed considerably in this 
simulated dataset (Figure S2D). This is not surprising, as our method captures the patterns of 
symptom deterioration and recovery, and not necessarily the temporal symptom pattern.  
4) We repeated the whole analysis to define dynamic phenotypes, taking into account the issue 
of potentially unobserved events [11]. Based on this method, we defined three phenotypes. These 
phenotypes included 122, 117, and 12 infants, respectively. Phenotypes 1, 2, 3 and 4 had 0.23, 
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0.03, 1 and 2.0 weeks with severe symptoms, respectively. Risk factors differed across 
phenotypes: phenotype 1 had an overrepresentation of children attended childcare and less 
infants were exposed to tobacco smoke during pregnancy or during the first year of life. 
Phenotype 2 had an underrepresentation of males and more infants were born via Cesarean 
section. Phenotype 3 had more males, and more infants had siblings. More mothers had asthma 
and infants were more exposed to tobacco smoke during pregnancy and thereafter. Dynamic 
phenotype 3 had the highest prevalence of current wheezing (20.5%) and atopy (49.4%) at 
school age. 
Analogously, we performed the simulation- and perturbation-based sensitivity analysis, which 
ruled out an artifact behind the observed multimodal distribution of the average estimated 
entropy (Figure S3).  
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Results 
Table S1 Respiratory symptom score
*
 
Symptom  
score 
Daytime symptoms  
(cough, wheeze, or breathing 
difficulties) 
Night-time symptoms  
(cough, wheeze, or breathing 
difficulties) 
0 None None 
1 Slight; no treatment given Slight; sleep not disturbed 
2 Required treatment but no outside help Sleep disturbed once; no help required 
3 Severe; required help from GP Sleep disturbed more than once  
or child needed help 
4 Very severe; admitted to hospital Sleep very disturbed or GP called 
*
Published with permission from the BMJ publishing group. GP: general practitioner.  
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Table S2 Characteristics of the cohort  
  Follow-up study 322 Lost to follow-up 47 
 
P-value 
Anthropometrics at birth      
Gestational age, weeks  39.6 ± 1.2 39.8 ± 1.2  0.139 
Birth weight, kg  3.3 ± 0.4 3.3 ± 0.4  0.622 
Length, cm  49.5 ± 1.9 49.4 ± 2.2  0.821 
      
Respiratory symptoms in the first year of life 
weeks with severe symptoms  0.72 ± 1.1 1.0 ± 2.04  0.169 
weeks with symptoms  5.33 ± 4.61 5.74 ± 4.23  0.568 
      
Risk factors      
Male sex  167 (51.8) 29 (61.7)  0.207 
Siblings  159 (49.4) 28 (59.5)  0.192 
Caesarean section  54 (16.7) 4 (14.8)  0.146 
Maternal asthma  34 (10.5) 9 (19.2)  0.086 
Maternal atopy  116 (36.1) 17 (36.2)  0.985 
Childcare  62 (19.2) 7 (13.5)  0.474 
Maternal smoking during pregnancy  27 (8.4) 9 (19.2)  0.020 
Parental smoking during infancy  70 (21.7) 16 (34.1)  0.062 
Breastfeeding  >26 weeks  252 (78.3) 23 (65.2)  <0.001 
Low maternal education  202 (62.7) 30 (65.2)  0.744 
      
Season of birth      
Spring  87 (27.1) 10 (21.3)  0.404 
Summer  83 (25.7) 27 (27.6)  0.783 
Autumn  80 (24.8) 14 (29.8)  0.468 
Winter  72 (22.4) 10 (21.3)  0.867 
Data are given as mean ± standard deviation or absolute numbers (percent). Children younger than 5 
years were not enrolled for pre-school follow-up. P-values are for comparison between subjects lost-to 
follow-up, and those who were followed up. We used the Chi-squared tests for categorical variables, and 
Kruskal–Wallis for continuous variables. 
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Table S3  Associations between phenotypes defined by different dimension of respiratory symptoms during infancy 
and current wheezing and positive prick test   
 Univariable association  Multivariable association
*
 
 OR 95% CI P-value  OR 95% CI P-value 
Exposure Outcome upper respiratory tract infection¶ 
 
 (122/322) 
Respiratory symptom, weeks (Reference Phenotypes)      
Phenotype 1 (baseline) (147) 1 reference   1 reference  
Phenotype 2 (98) 1.17 0.69 – 2.01 0.549  1.22 0.71 – 2.12 0.466 
Phenotype 3 (57) 2.01 1.07 – 3.74 0.028  2.16 1.12 – 4.15 0.021 
Phenotype 4 (20) 0.89 0.31 – 2.29 0.722  0.92 0.32 – 2.64 0.882 
Transitions, entropy (Dynamic Phenotypes)      
Phenotype 1 (baseline) (141) 1 reference   1 reference  
Phenotype 2 (102) 1.19 0.71 – 2.02 0.497  1.25 0.73 – 2.14 0.411 
Phenotype 3 (62) 0.94 0.51 – 1.75 0.849  0.97 0.51 – 1.84 0.929 
Phenotype 4 (17) 0.93 0.32 – 2.67 0.898  0.91 0.31 – 2.74 0.865 
Risk factors         
Male sex 1.03 0.66 – 1.63 0.867  1.02 0.64 – 1.63 0.901 
Siblings 0.79 0.51 – 1.25 0.330  0.81 0.51 – 1.27 0.367 
Maternal asthma 1.01 0.48 – 2.21 0.965  1.01 0.48 – 2.09 0.996 
Childcare 1.23 0.71 – 2.16 0.465  1.18 0.66 – 2.13 0.556 
Parental smoking during 
infancy 
1.03 0.61 – 1.78 0.894  1.04 0.59 – 1.81 0.886 
Low maternal education 0.97 0.61 – 1.54 0.899  0.99 0.61 – 1.61 0.970 
        
Exposure Outcome positive prick test
 
(37/270) 
Respiratory symptom, weeks (Reference Phenotypes)      
Phenotype 1 (baseline) (147) 1 reference   1 reference  
Phenotype 2 (98) 0.81 0.36 – 1.84 0.631  0.79 0.33 – 1.85 0.591 
Phenotype 3 (57) 0.82 0.30 – 2.22 0.698  0.82 0.28 – 2.35 0.714 
Phenotype 4 (20) 1.60 0.40 – 6.35 0.501  1.88 0.41 – 8.60 0.412 
Transitions, entropy (Dynamic Phenotypes)      
Phenotype 1 (baseline) (141) 1 reference   1 reference  
Phenotype 2 (102) 1.07 0.47 – 2.42 0.864  1.22 0.52 – 2.88 0.638 
Phenotype 3 (62) 0.94 0.34 – 2.60 0.919  0.98 0.34 – 2.83 0.977 
Phenotype 4 (17) 2.26 0.64 – 7.94 0.201  2.63 0.64 – 10.67 0.175 
Risk factors         
Male sex 2.63 1.21 – 5.68 0.014  2.57 1.16 – 5.67 0.019 
Siblings 0.99 0.49 – 1.98 0.986  0.92 0.44 – 1.92 0.841 
Maternal asthma 0.43 0.99 – 1.91 0.272  0.41 
0.09 – 1.86 
 
0.252 
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Childcare 0.76 0.30 – 1.94 0.575  0.78 0.29 – 2.11 0.634 
Parental smoking during 
infancy 
0.96 0.41 – 2.22 0.925  0.77 0.322 – 1.87 0.577 
Low maternal education 2.16 0.94 – 4.93 0.068  1.95 0.82 – 4.64 0.131 
CI: confidence interval; OR: odds ratio. Logistic regression for the outcomes any wheezing, current wheezing and 
atopic disease. Symptom dynamic phenotypes were defined by entropy of transition states, reference phenotypes by 
weeks with any respiratory symptom. When considering phenotypes as exposure, phenotype one from the reference 
phenotype, or dynamic phenotype served as baseline, respectively. Numbers in brackets indicates group sizes. 
*Adjusted for the following variables: male gender, low maternal education, maternal asthma, maternal smoking 
during pregnancy, childcare attendance during infancy and presence of siblings• ¶Upper respiratory tract infection 
(URTI) was defined by ear infection, throat infection, or serious cold (defined by symptoms ≥two weeks) over the 
past 12 months before follow-up. 
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Table S4  Associations between phenotypes defined by different dimension of respiratory symptoms during infancy 
and lung function at school age  
 Univariable association  Multivariable association
*
 
 OR 95% CI P-value  OR 95% CI P-value 
Exposure Outcome zFEV1 
Respiratory symptom, weeks (Reference Phenotypes)      
Phenotype 1 (baseline) (105) 1 reference   1 reference  
Phenotype 2 (61) 0.09 -0.19 – 0.38 0.516  0.7 -0.22 – 0.36 0.645 
Phenotype 3 (42) -0.10 -0.42 – 0.21 0.524  -0.10 -0.45 – 0.24 0.546 
Phenotype 4 (14) -0.11 -0.62 – 0.38 0.649  -0.07 -0.60 – 0.45 0.772 
Transitions, entropy (Dynamic Phenotypes)      
Phenotype 1 (baseline) (100) 1 reference   1 reference  
Phenotype 2 (68) 0.04 -0.23 – 0.32 0.731  0.06 -0.22 – 0.35 0.662 
Phenotype 3 (45) 0.15 - 0.16 – 0.47 0.332  0.18 -0.14 – 0.51 0.265 
Phenotype 4 (9) 0.05 -0.56 – 0.67 0.867  0.06 -0.59 – 0.71 0.853 
        
Exposure Outcome zFVC 
Respiratory symptom, weeks (Reference Phenotypes)      
Phenotype 1 (baseline) (105) 1 reference   1 reference  
Phenotype 2 (61) 0.01 -0.05 – 0.08 0.676  0.00 -0.06 – 0.07 0.859 
Phenotype 3 (42) 0.02 -0.05 – 0.11 0.490  0.01 -0.07 – 0.09 0.744 
Phenotype 4 (14) 0.01 -0.11 – 0.14 0.819  0.00 -0.12 – 0.13 0.952 
Transitions, entropy (Dynamic Phenotypes)      
Phenotype 1 (baseline) (100) 1 reference   1 reference  
Phenotype 2 (68) 0.01 -0.05 – 0.08 0.618  0.02 -0.04 – 0.09 0.525 
Phenotype 3 (45) 0.01 -0.06 – 0.09 0.764  0.00 -0.07 – 0.88 0.873 
Phenotype 4 (9) -0.03 -0.17 – 0.11 0.665  -0.05 -0.20 – 0.08 0.434 
        
Exposure Outcome zFEV1/FVC 
Respiratory symptom, weeks (Reference Phenotypes)      
Phenotype 1 (baseline) (105) 1 reference   1 reference  
Phenotype 2 (61) 0.01 -0.29 – 0.31 0.944  0.05 -0.25 – 0.36 0.718 
Phenotype 3 (42) -0.06 -0.40 – 0.28 0.723  0.02 -0.33 – 0.37 0.907 
Phenotype 4 (14) -0.15 -0.69 – 0.37 0.558  -0.11 -0.66 – 0.43 0.679 
Transitions, entropy (Dynamic Phenotypes)      
Phenotype 1 (baseline) (100) 1 reference   1 reference  
Phenotype 2 (68) -0.01 -0.31 – 0.27 0.904  0.06 -0.24 – 0.36 0.696 
Phenotype 3 (45) -0.01 -0.35 – 0.32 0.924  0.05 -0.28 – 0.39 0.758 
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Phenotype 4 (9) -0.19 -0.85 – 0.45 0.549  -0.15 -0.83 – 0.52 0.656 
        
Exposure Outcome zFEF25-75% 
Respiratory symptom, weeks (Reference Phenotypes)      
Phenotype 1 (baseline) (105)        
Phenotype 2 (61) 0.06 -0.20 – 0.33 0.641  0.10 -0.18 – 0.39 0.468 
Phenotype 3 (42) 0.01 -0.30 – 0.33 0.916  0.08 -0.24 – 0.41 0.616 
Phenotype 4 (14) -0.23 -0.72 – 0.25 0.346  -0.13 -0.64 – 0.37 0.611 
Transitions, entropy (Dynamic Phenotypes)      
Phenotype 1 (baseline) (100)        
Phenotype 2 (68) -0.03 -0.30 – 0.23 0.781  0.01 -0.25 – 0.29 
 
0.889 
Phenotype 3 (45) 0.21 -0.09 – 0.52 
- 
0.171  0.29 -0.03 – 0.61 0.076 
Phenotype 4 (9) -0.10 -0.64 – 0.43 
 
0.697  0.01 -0.54 – 0.58 
 
0.948 
        
Exposure 
+
Outcome FeNO ppb 
Respiratory symptom, weeks (Reference Phenotypes)      
Phenotype 1 (baseline) (101)        
Phenotype 2 (74) 0.96 0.80 – 1.16 
 
0.715  0.98 0.81 – 1.18 
 
0.860 
Phenotype 3 (40) 0.90 0.72 – 1.13 0.386  0.88 0.69 – 1.11 0.301 
Phenotype 4 (16) 1.15 0.83 – 1.59 
 
0.390  1.20 0.86 – 1.69 
 
0.270 
Transitions, entropy (Dynamic Phenotypes)      
Phenotype 1 (baseline) (99)        
Phenotype 2 (77) 1.05 0.87 – 1.26 
 
0.595  1.03 0.85 – 1.24 0.751 
Phenotype 3 (46) 0.97 0.78 – 1.20 0.804  0.96 0.76 – 1.20 
 
0.740 
Phenotype 4 (9) 0.75 0.49 – 1.14 0.184  0.69 0.44 – 1.07 0.102 
Coef: coefficient CI: confidence interval; FeNO: fractional exhaled nitric oxide; FVC: forced vital capacity; FEV1: 
forced expiratory volume in one second; FEF: forced expiratory flow from 25-75% of exhalation. Lung function 
parameters are expressed as z-scores according to Qanjer et al.[33], FeNO was log-transformed before analyses and 
results are shown for exponentiated coefficients. Symptom dynamic phenotypes were defined by entropy of 
transition states, reference phenotypes by weeks with any respiratory symptom. Phenotype one from the reference 
phenotype, or symptom dynamic phenotype served as baseline, respectively. Numbers in brackets indicates group 
sizes. 
*
Adjusted for the following binary variables: maternal education, maternal asthma, maternal smoking during 
pregnancy, childcare attendance during infancy and presence of siblings. 
+
Additionally adjusted for the following 
binary variables: sex, hay fever of the child, inhaled corticosteroid use. 
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Table S5 Comparison of characteristics between the 242 infants enrolled in the two study 
centers not seen for follow up  
 Basel 
75 
Bern 
167 
P-value 
 
Anthropometric data at birth 
Gestational age, wks 39.31 ± 1.32 39.75 ± 1.11 0.007 
Birth weight, kg 3.2 ± 0.55 3.4 ± 0.44 0.016 
Length, cm 49.14 ± 2.51 49.61 ± 2.09 0.139 
    
Respiratory symptoms in the first year of life 
weeks with severe symptoms 0.77 ± 1.19 0.76 ± 1.19 0.861 
weeks with symptoms 6.14 ± 4.54 6.43 ± 4.72 0.753 
    
Risk factors 
Male sex 36 (48.0) 92 (54.9) 0.307 
Siblings 30 (40.0) 117 (70.1) <0.001 
Caesarean section 31 (41.3) 30 (17.9) <0.001 
Maternal asthma 12 (9.0) 15 (8.9) 0.468 
Maternal atopy 36 (48.0) 52 (31.1) 0.012 
Childcare 46 (61.3) 109 (22.3) 0.001 
Maternal smoking in pregnancy 3 (4.0) 16 (9.6) 0.146 
Parental smoking during infancy 15 (20.0) 38 (22.7) 0.632 
Breastfeeding  26 weeks 27 (36.0) 108 (22.7) 0.920 
Low maternal education 21 (28.0) 82 (50.3) 0.229 
    
Seasons at birth 
Spring 22 (29.3) 37 (22.6) 0.464 
Summer 15 (20.0) 46 (27.5) 0.238 
Autumn 21 (28.0) 51 (30.5) 0.826 
Winter 17 (22.6) 33 (19.7) 0.606 
Values are means ± standard deviation or number (percentage). Differences in the distribution of 
characteristics between centers were assessed using Chi
2
 tests for categorical variables, and 
Kruskal–Wallis for continuous variables. 
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Table S6 Characteristics of phenotypes defined by transition probabilities among respiratory symptoms states 
and by respiratory symptoms weeks during infancy from the 242 study participants not seen for follow-up 
 Phenotype 1 Phenotype 2 Phenotype 3 Phenotype 4 P-value 
 Dyn. Ref. Dyn. Ref. Dyn. Ref. Dyn. Ref. Dyn. Ref. 
 83 83 101 103 46 41 12 15   
Respiratory 
symptoms            
Weeks with severe 
symptoms 
0.23 
(0.45) 
0.16 
(0.41) 
0.65 
(0.96) 
0.66 
(0.85) 
1.41 
(2.02) 
1.34 
(1.35) 
2.92 
(1.56) 
3.2 
(2.98) <0.001 <0.001 
Weeks with 
symptoms 
1.74  
(1.52) 
1.56 
(1.09) 
6.65  
(3.05) 
5.70 
(1.44) 
10.46 
(3.33) 
10.51 
(1.54) 
16.42 
(2.84) 
16.50 
(2.93) <0.001 <0.001 
           
Respiratory 
symptoms  
transition states           
Entropy of 
transition states 
0.02 
(0.02) 
0.03  
(0.04) 
0.16 
(0.02) 
0.16 
(0.07) 
0.29 
(0.03) 
0.26 
(0.08) 
0.4 
(0.04) 
0.4 
(0.09) <0.001 <0.001 
           
Risk factors           
Male sex 55.4 53.1 45.5 50.1 67.4 63.4 41.6 40.0 0.304 1 
Siblings 53.1 53.1 63.4 65.1 73.9 63.4 41.6 66.6 0.224 1 
Caesarean section 20.5 18.1 26.7 32.1 28.2 2.9 33.3 26.6 1 0.676 
Maternal asthma 12.1 13.3 7.8 7.8 8.7 9.8 16.7 6.7 1 1 
Maternal atopy 42.2 38.5 31.7 38.8 36.9 24.4 33.3 40.0 1 1 
Childcare 25.3 21.7 46.5 47.6 34.8 41.4 75 60.0 0.004 0.004 
Maternal smoking  
during pregnancy 
 
8.4 
 
8.4 
 
8.9 
 
8.7 
 
4.4 
 
4.8 
 
8.3 
 
6.7 1 1 
Parental smoking 
during infancy 
 
21.7 
 
20.5 
 
24.2 
 
21.4 17.4 
 
24.4 
 
16.7 
 
26.7 1 1 
Breastfeeding ≤26 
weeks 62.6 
 
59.1 
 
67.3 
 
70.8 54.4 
 
58.5 
 
91.7 
 
66.6 0.372 1 
Low maternal 
education 
 
41.8 
 
46.2 
 
47.5 
 
41.2 
 
41.3 
 
46.3 
 
25.0 
 
33.3 1 1 
           
Seasons at birth           
Spring 15.6 14.4 22.8 28.2 45.6 36.6 16.7 20.0 0.008 0.136 
Summer 20.5 24.1 32.7 25.2 17.4 21.9 25.0 40.0 0.564 1 
Autumn 40.9 39.7 26.7 27.2 17.4 19.5 25.0 20.0 0.12 0.284 
Winter 22.9 21.7 17.8 19.4 19.6 21.9 33.3 20.0 1 1 
Values are percent or means (SD). Symptom dynamic phenotypes (Dyn.) are shown on white background and 
reference phenotypes (Ref.) are shown on grey shading background. Symptom dynamic phenotypes were 
defined by average entropy of transition states, reference phenotypes by weeks with any respiratory symptom. 
Differences in the distribution of characteristics across phenotypes were assessed using Chi-squared tests for 
categorical variables, and Kruskal–Wallis for continuous variables. P-values are Bonferroni corrected, 
accounting for multiple testing. 
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Figures 
 
 
 
Figure S1 Flow Chart of the study population.   
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Figure S2 Histograms of estimated entropy in the cohort and in simulated and perturbed data 
sets. A) Histogram of average estimated entropy of the rows of the Markov matrix of each 
participant in the cohort. B) Histogram of average estimated entropy of the rows of the Markov 
matrix in a simulated data set in which all symptom transitions are assumed to be equally 
probable. C) Histogram of average estimated entropy of the rows of the Markov matrix of each 
participant after each participant’s chronological order of reported symptoms was randomly 
permuted. D) Histogram of average estimated entropy of the rows of the Markov matrix in a 
simulated data set in which the probabilities of symptom transitions were determined by the 
pooled cohort data. The entropy in all four panels was estimated using the maximum likelihood 
estimator of the entropy.  
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Figure S3 Histograms of estimated entropy in the cohort and in simulated and perturbed data 
sets when controlling for unobserved events. A) Histogram of average estimated entropy of the 
rows of the Markov matrix of each participant in the cohort. B) Histogram of average estimated 
entropy of the rows of the Markov matrix in a simulated data set in which all symptom 
transitions are assumed to be equally probable. C) Histogram of average estimated entropy of the 
rows of the Markov matrix of each participant after each participant’s chronological order of 
reported symptoms was randomly permuted. D) Histogram of average estimated entropy of the 
rows of the Markov matrix in a simulated data set in which the probabilities of symptom 
transitions were determined by the pooled cohort data. The entropy in all figures was estimated 
using an estimator that corrects for unobserved events (Schuerman and Grassberger algorithm 
(SG Alg.) [11]). Compared to Figure S2A, a shift towards higher entropy values can be 
observed. 
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3.4.3 Analytical approach: in vitro air pollution exposure  
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Highlights (in a separate file, 3-5 bullet points, <80 characters or 20 words each) 
 The use of ethanol-gasoline blends may reduce dependency on fossil fuels 
 Toxicity of exhaust from modern gasoline cars has not yet been thoroughly investigated 
 Toxic effects of ethanol-gasoline blend exhaust are unknown 
 We exposed human bronchial epithelial cells for 6hrs to fresh car exhaust 
 Exposure to exhaust from pure gasoline or ethanol-gasoline blend had only minor toxic 
effects  
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Abstract 
Air pollution exposure, including passenger car emissions, may cause substantial respiratory 
health effects and cancer death. In western countries, the majority of passenger cars are driven 
by gasoline fuel. Recently, new motor technologies and ethanol fuels have been introduced to 
the market, but potential health effects have not been thoroughly investigated.  
We developed a coculture model composed of bronchial epithelial cells (ECs) and natural killer 
cells (NKs) mimicking the human airways to compare toxic effects between pure gasoline (E0) 
and ethanol-gasoline-blend (E85, 85% ethanol, 15% gasoline) exhaust emitted from a flexfuel 
gasoline car. We drove a steady state cycle, exposed ECs for 6hrs and added NKs. We assessed 
exhaust effects in ECs alone and in cocultures by RT-PCR, flow cytometry, and oxidative stress 
assay. 
We found no toxic effects after exposure to E0 or E85 compared to air controls. Comparison 
between E0 and E85 exposure showed a weak association for less oxidative DNA damage after 
E85 exposure compared to E0. Our results indicate that short-term exposure to gasoline 
exhaust may have no major toxic effects in ECs and NKs and that ethanol as part of fuel for 
gasoline cars may be favorable. 
 
Keywords 
Airways; Gasoline exhaust; ethanol-gasoline blend; diesel exhaust particles; Cocultures; DNA 
damage; flexfuel  
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1. Introduction 
Air pollution is an important cause of cardiopulmonary and cancer mortality (Kurt et al. 2016). 
In Europe, about half a million premature deaths per year are attributed to exposure to 
ambient air pollution (WHO 2014), and road traffic is a major source of particulate air pollution. 
Most cars in western countries are driven by gasoline fuel, and the World Health Organization 
recognizes potential adverse health effects by classifying gasoline exhaust as “possibly 
carcinogenic to humans” (IARC 2014). There are currently ongoing initiatives to promote the 
use of ethanol-gasoline blends to potentially reduce emissions of harmful air pollutants, and 
lower dependency on fossil fuels (Guarieiro 2013). 
Few studies have investigated the adverse effects of gasoline exhaust (Lund et al. 2007, 
Mauderly et al. 2014, Reed et al. 2008), summarized in (Claxton 2015). However, these studies 
mostly used older gasoline technologies, and toxicological studies on emissions from modern 
gasoline engine technologies (e.g. gasoline direct injection (GDI)) and gasoline-ethanol blends 
are rare (McDonald et al. 2007). A recent study reported that exposure of murine lung slices to 
GDI engine exhaust upregulated genes related to the metabolism of polycyclic aromatic 
hydrocarbons and oxidative stress (Maikawa et al. 2016). Slightly increased cytotoxicity was 
reported in primary airway epithelial cells (ECs) upon exposure to aged gasoline particles (Kunzi 
et al. 2015), whereas acute exhaust exposure of a GDI flex-fuel vehicle using pure gasoline and 
ethanol-gasoline blends to an airway coculture model (consisting of ECs, macrophages and 
dendritic cells) showed no toxic effects (Bisig et al. 2016). Importantly, the latter study did not 
include primary natural killer cells (NKs) in their coculture model. However, NKs have central 
immune regulatory functions. They are involved in the control of lung cancers and the defense 
against viral pathogens in the lung (Vivier et al. 2008). Furthermore, cell-cell interactions 
between ECs and NKs are important to regulate the activation status of NKs (Vivier et al. 2008, 
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Whitsett and Alenghat 2015). Therefore, it may be important to study toxic effects of gasoline 
exhaust on both ECs and NKs. 
ECs are the predominant cell type in the respiratory tract (Ochs and Weibel 2008) and are 
vulnerable to inflammation, viral infections and malignant degeneration. They serve as a 
physical barrier for pathogens, are important regulators of airway immune responses (Müller 
and Jaspers 2012, Swamy et al. 2010), and communicate with other cells via soluble factors and 
cell-cell interactions (Whitsett and Alenghat 2015). ECs recruit and activate immune cells, 
including NKs, via cytokine release (Vivier et al. 2008), and regulate NKs’ activation status via 
expression of surface receptors, including UL16-binding proteins (ULBPs) and MHC class I 
polypeptide-related sequence (MIC) A/B (Obeidy and Sharland 2009). Expression of EC stress 
receptors, including ULBPs and MICA/B, can be upregulated by exposure to oxidative stressors, 
e.g. hydrogen peroxide (Borchers et al. 2006), or air pollutants (Müller et al. 2013). 
NKs are classified as innate lymphoid cells (Spits et al. 2013) and their activity is regulated via 
expression of inhibitory (e.g. CD158b and CD159a), and activating (e.g. CD314 and CD335), 
receptors on their surface. HLA or MHC class I molecules binding of inhibitory receptors reduces 
NKs’ activation, ensuring the recognition of “self”, and avoiding the killing of healthy, 
autologous cells. ULBPs or MICA/B from ECs can bind to CD314 (also called NKG2D), and viral 
hemagglutinins can bind to CD335 (also called NKp46), both resulting in increased cytokine 
release and killing potential of NKs. NKs’ killing potential and cytokine release (e.g. interleukin 
(IL) 4 and interferon (IFN) γ) is crucial for early pathogen defense, especially against viruses, and 
the immuno-surveillance of tumor development (Campbell and Hasegawa 2013). A potential 
reduction of the cytotoxic activity and/or a change of the cytokine release due to car exhaust 
exposure may hence increase the susceptibility to viral infections and tumor development 
(Guillerey and Smyth 2016). 
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A central feature of the human airway’s complexity are cell-cell interactions, and coculture 
models are suggested as more favorable models than monocultures to study the effects of 
exhaust emission (Alfaro-Moreno et al. 2008, Müller et al. 2010, Rothen-Rutishauser et al. 
2008). Therefore, we developed a novel coculture model with a human bronchial EC line and 
primary human NKs to study toxic effects of gasoline and ethanol-gasoline blend exhaust. We 
used freshly generated exhaust from a modern car engine (containing both particles and 
gaseous compounds) to best mimic exhaust exposure to human lungs. 
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2. Material and Methods 
2.1 Study design 
This experimental in vitro study describes the effects of pure conventional lead free gasoline 
(E0) and conventional lead free gasoline with 85% ethanol (E85) exhaust compared to air 
control exposures in two cell culture models (monocultures of ECs, cocultures of ECs and NKs) 
(Figure 1). 
 
Figure 1. Schematic overview of the study design. CO = carbon monoxide, CO2 = carbon dioxide, 
T.HC = total hydrocarbons, NOx = nitrogen oxides, EC = epithelial cell, NKs = natural killer cells. 
2.2 Cell cultures 
2.2.1 Bronchial epithelial cells 
We maintained the human bronchial EC line 16HBE14o- (kindly provided by Dr. Gruenert, 
University of California, San Francisco) as previously described (Bauer et al. 2015). Briefly, we 
kept the cells at 37°C and 5% carbon dioxide (CO2) in collagen and fibronectin (BD Bioscience, 
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Allschwil, Switzerland) coated tissue culture flasks in minimum essential medium (MEM) with 
1% L-glutamine, 1% penicillin/streptomycin (both Sigma-Aldrich, Buchs, Switzerland), and 10% 
heat inactivated fetal bovine serum (FBS; BioConcept, Allschwil, Switzerland), and split them 
three times per week. For experimental cultures, we seeded 5x104 cells in 500µl medium in the 
apical, and 1ml medium in the basolateral chamber into transwells (Corning 12-well transwell 
polyester membrane Insert, pore size 0.4µm; Sigma-Aldrich), grew them for 6 days until the 
monolayer was confluent and exposed them for 20hrs at the air-liquid interface (ALI) before 
using them for experiments. 
2.2.2 Natural killer cells (NKs) 
We enriched primary NKs from the peripheral blood of ten healthy non-smoking volunteers 
[age mean (standard deviation) 36.6 (12.4) years, BMI 22.9 (4.2), female/male ratio 7:3]. The 
study was approved by the Ethics Committee Nordwest- und Zentralschweiz, Switzerland. 
Written informed consent of the donors was obtained. NKs from six donors were used to 
establish the coculture model and the validation experiments. NKs from four donors were used 
for the two exposure series (E0 and E85, with air controls each, Figure 1). We performed the 
isolation of peripheral blood mononuclear cells using a density gradient of Lymphoprep in 
SepMate tubes (both StemCell Technologies, Grenoble, France), and enriched NKs using the 
EasySep Human NK cell Enrichment Kit (StemCell Technologies), both according to 
manufacturer’s instructions. NKs were re-suspended in RPMI 1640 media with L-glutamine 
completed with 10% FBS and 1% penicillin/streptomycin. 
2.2.3 Coculture model of bronchial ECs and NKs 
We added 2.5x105 NKs in 100µl media to the confluent bronchial EC monolayer at the ALI for 
incubation of 20hrs at 37°C, 5% CO2 and 80% humidity. We compared endpoints of ECs and NKs 
in cocultures to ECs and NKs in monocultures to assess potential coculturing effects. In order to 
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study the effects of car exhaust emissions, we exposed the ECs for 6hrs to the exhaust in the 
Laboratory for Exhaust Emission Control, transported them to the cell culture lab of the 
University Children’s Hospital Basel, and added the NKs approximately 2hrs after the end of the 
6hr exposure period. 
2.3 Microscopic characterization of the coculture model 
We fixed the cells in 4% paraformaldehyde (PFA; Electron Microscopy Sciences, Lucerna-Chem, 
Lucerne, Switzerland) and stained them with hematoxylin-eosin for histological analysis. 
For analysis with laser scanning microscopy (LSM), NKs were stained with DiO (Vybrant Cell-
Labeling Solution; Molecular Probes, Thermo Fisher Scientific, Reinach, Switzerland), according 
to manufacturer’s instructions, and added to the confluent ECs at ALI. After 20hrs, cocultures 
were fixed with 4% PFA and washed with PBS (with Ca2+, Mg2+; Sigma-Aldrich). Cocultures were 
stained with rhodamine phalloidin (Molecular Probes, Thermo Fisher Scientific) for the f-actin 
cytoskeleton, according to manufacturer’s instructions, and mounted in a Vectashield mounting 
medium (Vector Laboratories, Reactolab, Servion, Switzerland). Samples were analyzed with a 
Zeiss LSM 510 Meta and images were processed with the IMARIS Software from Bitplane. 
2.4 Validation of the coculture model with diesel particulate matter exposure and unspecific 
stimulation 
We weighed 300μg of diesel particulate matter (DPM) (1650b, National Institute of Standards 
and Technology, USA) in a 0.5ml low retention Eppendorf tube and transferred the DPM into 
the loading chamber of a Dry Powder Insufflator™ (PennCentury, USA). One puff (200μl, 
corresponding to about 150μg DPM) was sprayed on one insert with confluent ECs. 4hrs later 
NKs or media (as a control) were added to the cells. 20hrs later the cells were fixed using Trizol 
(Lubioscience, Lucerne, Switzerland) and stored at -80°C until analysis of gene expression (RT-
PCR) was performed. 
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For validation of the coculture model, cells were stimulated with the unspecific stimuli phorbol 
12-myristate 13-acetate (PMA; Acros Organics, Thermo Fisher Scientific; 50ng/ml) and 
ionomycin (MP Biomedicals, Lucerna-Chem; 1µg/ml) for 4hrs and subsequently analyzed with 
flow cytometry. 
2.5 Exposure to gasoline and ethanol-gasoline exhaust emissions 
2.5.1 Exposure system and protocol 
We utilized a previously established and described exhaust exposure system (Müller et al. 
2010) and exposure protocol (Bisig et al. 2016). Briefly, a GDI flex-fuel gasoline passenger car 
(Volvo V60 T4F, with 3-way catalyst, Euro 5 standard) was driven at a steady state cycle with 
stepwise decreasing velocity from 95km/h, 61km/h, 45km/h to 26km/h, and idling for 20min 
each. Freshly produced exhaust was diluted 10x with filtered ambient air using a Minidiluter 
(MD19-2E, Matter Engineering) and transferred to the exposure chamber with a constant flow 
of 2l/min. ECs as monocultures at ALI were exposed to freshly produced car exhaust (E0 or E85) 
or filtered ambient air (as control) under controlled conditions (37°C, 5% CO2, ~80% humidity). 
The exposures were performed for 2hrs and 6hrs, for a better overview only the data points 
after 6hrs are shown, the 2hr exposures showed very similar trends as the 6hr exposures. 
Feasibility of the exposure conditions has been previously shown (Müller et al. 2012, Steiner et 
al. 2013a, Steiner et al. 2013b). Thereafter, half of the ECs were cultured as monocultures and 
NKs were added to the other half of the ECs to obtain cocultures. No washing was performed to 
remove potentially deposited exhaust particles. 20hrs later the samples were harvested for 
analysis. We repeated exposure to E0 and E85 each on four different days, resulting in a 
repetition number (n) of 4. 
  
Results - Analytical approach: in vitro air pollution exposure 
250 
2.5.2 Fuel and exhaust characterization 
We used pure conventional lead free gasoline (E0) and conventional lead free gasoline with 
85% ethanol (E85). The Laboratory for IC-Engines and Exhaust Emission Control of the Bern 
University of Applied Sciences analyzed the particle number (PN) concentration; using a 
condensation particle counter (TSI 3790), and the concentrations of carbon monoxide (CO), 
CO2, nitrogen oxides (NOx), and total hydrocarbon (T.HC) using an automotive emission 
analyzer (Horiba MEXA-9400H). Exhaust characterization was performed as previously 
described (Bisig et al. 2016). 
2.6 Endpoints 
2.6.1 Quantitative real-time RT-PCR 
mRNA was isolated using the RNA Clean&Concentrator (Zymo Research). cDNA was prepared 
using the GoScript Reverse Transcription System (Promega). Quantitative real-time RT-PCR was 
done with GoTaq qPCR Master Mix (Promega) in 15µl reaction volume. β-actin was used as 
housekeeping gene. We used the following primer: β-actin - forward (FW) 
CCTCGCCTTTGCCGATCC and reverse (RV) CTCGTCGCCCACATAGGAAT, ULBP2 – FW 
GGCAACAAGACAGTCACACCT and RV GTACTGGGTTCTGTGCTTTCCA, MICA – FW 
AAGACAACAGCACCAGGAGC and RV TCCATTCCTCAGTCTCCAGGT, IL-8 – FW 
CTGATTTCTGCAGCTCTGTG and RV ATTTCTGTGTTGGCGCAGTG, and IP-10 – FW 
CTAGAACTGTACGCTGTACC and RV CTTGATGGCCTTCGATTCTG. Thermal cycles for all genes 
were carried out using the CFX Connect Real-time System from Bio-Rad at 95°C for 1min, 
followed by 45 cycles of 95°C for 5sec, and 60°C for 30sec, followed by the melt curve (increase 
from 65°C to 95°C with 1°C each 5sec). 
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2.6.2 Flow cytometry analysis 
Brefeldin A (eBioscience, Vienna, Austria) was added for the last 4hrs of the post-exposure 
incubation to block the Golgi apparatus and accumulate cytokines in the cytosol. We lifted the 
cells of the transwells by accutase treatment (Sigma-Aldrich; 30min at 37°C), divided the 
samples into various tubes for different antibody (AB) panels (Table 1), and stained the cells 
with viability dye (Fixable Viability Dye eFluor 450, eBioscience) following the supplier’s 
instructions. For the staining of surface markers, cells were re-suspended in flow staining buffer 
(PBS without Ca2+, Mg2+ (Sigma-Aldrich), 1% FBS, 0.9% sodium azide (Sigma-Aldrich)) and 
incubated with ABs for 20min at room temperature, and subsequently fixed with 2% PFA for 
10min. After surface marker staining, intracellular staining of NKs was done with the 
Intracellular Fixation & Permeabilization Buffer Set (eBioscience) according to the 
manufacturer’s protocol (30min incubation at room temperature with ABs). All samples were 
re-suspended in flow staining buffer for acquisition with a BD LRS Fortessa flow cytometer (BD 
Bioscience). Data was analyzed using FlowJo software version 10. 
 
Table 1. Flow cytometry antibody cocktails used for different endpoints. 
 
AF488 AF700 APC APC-Cy7 BV605 FITC PE PE-Cy7 PE-TR 
Isotype control 
EC SM 
IgG2a1 
 
IgG23 CD456 IgG11 
 
IgG23 
  
EC SM 
MICA/
B1  
ULBP2/5
/63 
CD456 
CD1831 
(CXCR3)  
ULBP33 
  
Isotype control 
NK cell SM  
IgG2a3 IgG11 CD456 IgG11 IgG11 IgG24 IgG11 IgG25 
NK cell SM 
 
CD159a3 
(NKG2A) 
CD3141 
(NKG2D) 
CD456 
CD1831 
(CXCR3) 
CD3351 
(NKp46) 
CD158b4 CD161 CD565 
NK cell ICS 
  
IFN-γ2 CD456 
 
grzB4 IL-42 
  
CD45 was used for differentiation between ECs and NKs. Abbreviations: SM, surface marker; ICS, 
intracellular staining; AF, AlexaFluor; APC, allophycocyanin; APC-Cy7, allophycocyanin-cyanine 
7; BV605, brilliant violet 605; FITC, fluorescein isothiocyanate; PE, phytoerythrin; PE-Cy7, 
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phytoerythrin-cyanine 7; PE-TR, phytoerythrin-texas red. The antibodies were purchased from 
the following companies: 1BioLegend (Lucerna-Chem), 2eBioscience, 3R&D Systems (Bio-Techne, 
Zug, Switzerland); 4BD Bioscience; 5Molecular Probes; 6Tonbo (LuBio Science, Lucerne, 
Switzerland) 
2.6.3 NKs’ killing potential 
We assessed NKs’ killing potential with the 7-AAD/CFSE Cell-mediated Cytotoxicity Assay Kit 
(Cayman Chemical, Biozol, Eiching, Germany) according to the manufacturer’s instructions. 
Briefly, we added 5x104  pre-stained human chronic myelogenous leukemia cells (K562 cell line, 
Sigma-Aldrich), serving as target cells, to the 2.5x105  NKs in the coculture transwells, ending up 
with a target:NKs ratio of 1:5, and incubated them for the last 4hrs of the post-exposure 
incubation. Samples were measured by flow cytometry. Data are presented as a percentage of 
dead target cells minus background cytotoxicity (percentage of dead target cells incubated with 
assay kit dyes only). For positive controls, NKs only and NKs in cocultures were stimulated with 
human recombinant IL-12 (BioLegend, 10ng/ml) for 20hrs. Stimulated NKs alone showed a 30% 
increase, and cocultured NKs an 8% increase in killing potential compared to unstimulated cells 
(data not shown). 
2.6.4 Oxidative DNA damage 
DNA was analyzed using the OxyDNA Assay Kit (Calbiochem, MERCK Millipore, Schaffhausen, 
Switzerland). Cells were detached from the transwell membranes using accutase (15min, 37°C), 
fixed with 2% PFA, and permeabilized with 70% ethanol (BioUltra 99.8%, Sigma-Aldrich). After 
re-suspension in PBS (without Ca2+, Mg2+), cells were washed with wash solution and 5µl FITC 
conjugate was added. After 1h incubation, cells were washed twice and DNA damage indicated 
by the bound FITC-labelled dye was measured using flow cytometry (BD LSR Fortessa). As 
positive controls, cells were incubated with methylene-blue (Sigma-Aldrich; 3mM) for 1h at 
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37°C, and after removal of the methylene-blue, exposed for 30min to light at room 
temperature, resulting in a 44% increase of oxidative DNA damage (data not shown). 
2.6.5 Cellular oxidative stress 
We assessed glutathione (GSH) using the Glutathione Assay Kit (Cayman Chemical, Biozol) 
following the supplier’s protocol. The basolateral medium was removed to avoid measurement 
interferences with FBS, and the cells were collected using the lysis buffer of the kit. 
Deproteination of samples with metaphosphoric acid (Sigma-Aldrich) was done before 
performing the assay. We normalized the measured levels of GSH to the levels of total protein 
in the samples, which were assessed using the Pierce BCA Protein Assay Kit (Thermo Scientific, 
Thermo Fisher Scientific), according to manufacturer`s instructions for the assay kit’s 
microplate procedure. Microplates were analyzed with the Synergy H4 Hybrid Microplate 
Reader (BioTek, Lucerne, Switzerland). Cells exposed to tert-butylhydroperoxid (Sigma-Aldrich; 
10mM) for 2.5hrs served as positive controls, resulting in lower GSH levels (11.5 % on average, 
data not shown) and thus increased oxidative stress. 
2.6.6 Data analysis and statistics 
For statistical analysis, we used Prism GraphPad (Version 6.05, La Jolla, USA). Data are shown as 
median [range]. Comparisons of monocultures with cocultures were analyzed with Wilcoxon 
signed-rank test. For comparison between E0 and E85 exhaust, samples were normalized to 
corresponding air controls, and compared using Mann-Whitney test (for EC monocultures), or 
Wilcoxon signed-rank test (for cocultures). P<0.05 was considered statistically significant. 
Results shown are representative of 4 independent experiments, unless otherwise stated. 
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3. Results 
3.1 Characterization of the novel EC-NKs coculture model 
To study interactions of bronchial ECs and NKs, we developed a novel coculture model by 
adding primary peripheral blood NKs to the apical side of a confluent monolayer of the human 
bronchial 16HBE14o- EC line cultured at the ALI. Histological analysis using light microscopy and 
LSM images showed the presence of NKs on the apical side of ECs (white arrow heads, Figure 
2), indicating direct cell-cell contact between cocultured ECs and NKs. To ensure viability of ECs 
and NKs in cocultures, we analyzed the percentage of dead ECs and NKs via flow cytometry. No 
effect on the viability of ECs or NKs after coculturing was found (Table 2, Table 3). 
 
Figure 2. (A) Histological image of the haemotoxylin-eosin stained coculture model consisting 
of 16HBE14o- bronchial ECs and primary NKs (white arrow heads). (B) Laser scanning 
microscope (LSM) image of a coculture. 3D projection showing live stained NKs (green) and the 
f-actin cytoskeleton (red, transparent rendering). 
 
EC surface receptor expression of ULBP2/5/6, MICA/B and CD183 were unchanged in cocultures 
compared to ECs in monocultures. However, the expression of the EC stress receptor ULBP3 
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significantly decreased after coculturing (Table 2). Cocultured NKs showed significantly higher 
expression of CD16, CD56, CD158b, CD159a and CD183; whereas CD314 and CD335 expression 
was lower compared to NKs only (Table 3). Intracellular IFN-γ production was not affected by 
coculturing, while granzyme B and IL-4 production were significantly decreased (Table 3). NKs’ 
killing potential was significantly reduced in cocultures compared to NKs alone (Table 3), while 
ECs alone did not affect the viability of the target cells (data not shown). 
 
Table 2. Comparison of ECs in monoculture and ECs in coculture with NKs.  
 
EC monoculture EC coculture p-value 
Cytotoxicity (% of dead ECs) 60.3 [41.1-82.6] 58.8 [32.3-75.0] 0.106 
EC surface 
markers (MFI) 
MICA/B 81.2 [16.8-275] 70.7 [4.80-268] 0.963 
ULBP1 14.9 [0.19-55.1] 14.5 [-0.6-38.9] 0.946 
ULBP2/5/6 405 [119-1011] 336 [107-804] 0.130 
ULBP3 305 [82.8-852] 268 [60.7-736] *0.024 
CD183 2645 [996-7011] 2756 [1647-7493] 0.995 
DNA damage (MFI) 7885 [70-15492] 6466 [32-14333] 0.426 
Values are presented as median [range] of percentage of dead cells or MFI. Data were analyzed 
by Wilcoxon signed-rank test, n=13-18, *p<0.05. Abbreviations: MFI, mean fluorescence 
intensity. 
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Table 3. Comparison of NKs only and NKs in coculture with ECs. 
 
NKs only NKs in coculture p-value 
Cytotoxicity (% of dead NKs) 6.60 [3.12-13.2] 3.80 [1.7-20.5] 0.051 
NK cell surface 
markers (MFI) 
CD16 36992 [-328-59782] 48941 [21086-71514] *<0.001 
CD56 421 [-6.15-894] 769 [611-1594] *<0.001 
CD158b 942 [399-4320] 1388 [633-4590] *0.003 
CD159a 218 [-311-268] 274 [-343-423] *0.029 
CD183 681 [-198-1432] 1112 [-314-3949] *0.011 
CD314 437 [-21.5-701] 393 [-52.4-639] *0.034 
CD335 596 [-2.9-769] 529 [-299-625] *<0.001 
NK cell 
intracellular 
markers (MFI) 
grzB 431 [204-900] 394 [180-851] *0.016 
IFN-γ 143 [-121-322] 128 [-68.6-249] 0.520 
IL-4 367 [251-1217] 283 [98.2-477] *0.003 
NKsʼ killing potential (% of dead 
target cells) 
70.2 [28.7-8.5] 25.6 [4.8-73.1] *<0.001 
DNA damage (MFI) 3828 [8.8-6688] 1852 [6.8-6405] *0.003 
Values are presented as median [range] of percentage of dead cells or MFI. Data were analyzed 
by Wilcoxon signed-rank test, n=13-18, *p<0.05. Abbreviations: MFI, mean fluorescence 
intensity. 
3.2 Validation of the coculture model 
In order to validate that our novel coculture model is feasible to assess exhaust related cell 
damage, we studied the response to DPM exposure, known to have toxic effects on ECs and 
NKs (Boland et al. 1999, Muller et al. 2013, Takizawa et al. 1999). DPM exposure was weakly 
associated with increased mRNA expression of stress receptors ULBP2 and MICA, and of the 
pro- inflammatory cytokine IL-8 in mono- as well as in cocultures (p=0.125 and p=0.06, 
respectively). There was weak evidence of reduced IP-10 expression following DPM exposure 
(p=0.06) (Figure 3). 
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Figure 3. Effect of DPM on ECs. Data are normalized to the housekeeping gene β-actin and to 
the negative control, shown as median with interquartile range and single values as diamonds. 
Tested with Mann-Whitney Test for monocultures, and Wilcoxon singed-rank test for cocultures. 
Abbreviations: CC, coculture; MC, monoculture. 
As an additional validation, we exposed cocultures to PMA/ionomycin, which was weakly 
associated with decreased surface expression of MICA/B, ULBP2/5/6, and ULBP3 and increased 
expression of CD183 in cocultured ECs compared to unstimulated controls (p=0.125, Figure 4). 
 
Figure 4. Effect of PMA/ionomycin stimulation on EC surface receptor expression of 
cocultures. Data are normalized to the negative controls and are shown as median with 
interquartile range and single values as diamonds, tested with Wilcoxon singed-rank test. 
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PMA/ionomycin resulted in a weak evidence for decreased expression of CD16, CD56, CD158a, 
CD183, CD335 in NKs in cocultures and NKs only, and increased the CD159a expression in 
cocultures (Figure 5A-G). Increased intracellular production of IFN-γ in cocultures, as well as in 
monocultures, and decreased granzyme B production in cocultures was weakly associated with 
PMA/ionomycin stimulation, while IL-4 production was not changed (Figure 5H-J). 
 
Figure 5. Effect of PMA/ionomycin stimulation on immunophenotype and intracellular 
markers of NKs. Data are normalized to the unstimulated controls and shown as median with 
interquartile range and single values as diamonds, tested with Wilcoxon singed-rank test. 
Abbreviations: CC, coculture; NKs, natural killer cells. 
 
3.3 Exhaust characterization  
We measured volatile exhaust components (CO, T.HC, and NOx) and the PN concentration 
(Figure 6). No differences between E0 and E85 exhaust emissions were found for CO, NOx, and 
PN concentration, while T.HC was significantly lower in E85 compared to E0 exhaust. 
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Figure 6. Exhaust characterization. (A-C) Volatile Fraction and (D) Particle Number 
Concentration. Data are shown as Box- and whisker-plots. *p<0.05 tested with Mann-Whitney 
Test. Abbreviations: CO, carbon monoxide; T.HC, total hydrocarbons; NOx, nitrogen oxides; PN, 
particle number. 
 
3.4 Comparison of E0 and E85 effects on ECs and NKs in monocultures and cocultures 
We normalized all values to the corresponding air controls to determine whether E0 and E85 
exhaust induced different effects in our cell cultures (Table 4 for EC endpoints,   
Table 5 for NKs endpoints). 
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Table 4. Comparison of effects of exposure to E0 or E85 exhaust in ECs of monocultures or 
cocultures. 
 
E0 E85 p-value 
Flow cytometry measurement 
Cytotoxicity (% dead EC) 
MC 0.87 [0.69- 0.99] 1.03 [0.93- 1.32] 0.06 
CC 0.84 [0.74- 0.94] 0.98 [0.83- 1.30] 0.25 
EC surface 
markers 
(MFI) 
MICA/B 
MC 1.75 [1.07- 2.44] 1.05 [0.83- 1.20] 0.11 
CC 1.53 [1.01- 3.02] 1.07 [0.30- 1.35] 0.25 
ULBP2/5/6 
MC 1.38 [1.17- 1.73] 1.23 [0.90- 1.48] 0.49 
CC 1.30 [1.15- 1.92] 1.13 [0.28- 1.61] 0.38 
CD183 
MC 1.12 [0.77- 1.87] 0.86 [0.64- 1.60] 0.49 
CC 1.09 [0.93- 1.27] 1.00 [0.85- 1.07] 0.38 
DNA damage (MFI) 
MC 1.62 [0.89- 10.7] 0.82 [0.41- 1.07] 0.06 
CC 1.25 [0.94-2.43] 0.97 [0.79- 0.99] 0.20 
Quantitative real-time RT-PCR 
ULBP2 
MC 0.88 [0.44-2.77] 0.70 [0.06-0.79] 0.57 
CC 1.05 [0.49-4.68] 1.23 [0.28-3.95] >0.99 
MICA 
MC 0.83 [0.59-3.44] 1.22 [0.05-33.69] 0.83 
CC 1.10 [0.94-4.89] 1.55 [0.46-7.11] >0.99 
IL-8 
MC 0.49 [0.28-0.91] 0.71 [0.06-20.48] 0.57 
CC 0.80 [0.60-4.11] 1.33 [0.22-14.88] 0.25 
IP-10 
MC 0.71 [0.16-0.81] 18.78 [0.69-33.06] 0.23 
CC 1.30 [0.96-1.72] 2.02 [0.05-4.7] >0.99 
Colorimetric assay 
Oxidative Stress 
(GSH/total protein) 
MC 1.06 [1.02- 1.08] 1.19 [0.92- 1.20] 0.34 
#CC 0.99 [0.78- 1.31] 0.99 [0.96- 1.00] >0.99 
 
Data are normalized to corresponding air controls (resulting in 1 = no effect). Values are 
presented as median [range] of percentage of dead cells, MFI, relative gene expression or ratio 
of GSH relative to total protein. #includes ECs and NKs, since the cells cannot be separated for 
this assay. Data of EC monocultures were analyzed by Mann-Whitney test and those of 
cocultures by Wilcoxon signed-rank test. Abbreviations: CC, coculture; GSH, glutathione; MC, 
monoculture, MFI, mean fluorescence intensity.  
Results - Analytical approach: in vitro air pollution exposure 
261 
Table 5. Comparison of effects of exposure to E0 and E85 in NKs cocultured with ECs.  
 
E0 E85 p-value 
Cytotoxicity (% dead NKs) 0.76 [0.52-1.67] 1.05[ 1.01-1.39] 0.38 
NK cell surface markers 
(MFI) 
CD16 1.02 [0.98-1.04] 0.97 [0.96-1.02] 0.25 
CD56 1.01 [0.91-1.08] 0.99 [0.92-1.09] >0.99 
CD158b 1.01 [0.95-1.15] 1.02 [0.90-1.13] 0.63 
CD159a 0.99 [0.81-1.07] 1.15 [1.03-1.92] 0.13 
CD183 1.39 [0.86-1.48] 1.27 [0.97-1.29] 0.50 
CD314 1.97 [0.10-6.70] 1.20 [0.90-1.34] 0.50 
CD335 1.22 [0.92-1.48] 1.28 [1.10-1.41] 0.63 
NK cell intracellular 
markers (MFI) 
grzB 1.00 [0.92-1.13] 1.05 [0.88-1.12] >0.99 
IFN-γ 0.96 [0.88-1.00] 1.08 [0.85-1.79] 0.38 
IL-4 1.00 [0.88-1.60] 0.92 [0.86-1.03] 0.38 
Killing potential (% dead target cells) 0.92 [0.77-1.14] 0.92 [0.86-1.09] 0.88 
DNA damage (MFI) 1.13 [0.87-1.84] 0.71 [0.59-1.04] 0.13 
Data are normalized to corresponding air controls (resulting in 1 = no effect, negative values 
were adjusted to positive values by adding the same fixed value to all data points of the same 
endpoints). Values are presented as median [range] of percentage of dead cells, or MFI. Data 
were analyzed by Wilcoxon signed-rank test. Abbreviations: grzB, granzyme B; MFI, mean 
fluorescence intensity. 
The exposure upon E85 exhaust was weakly associated with slightly more killed cells in 
monocultures compared to the exposure to E0 exhaust (p=0.06, Table 4). There was no 
difference in cytotoxicity between E85 and E0 exhaust upon cocultures or NKs (Table 4, Table 
5). The expression of EC surface receptors did not differ between E0 and E85 exhaust exposed 
ECs in mono- or cocultures (Table 4). Expression of NK cell surface receptors and the production 
of intracellular mediators did not differ between cells exposed to E0 or E85 exhaust (Table 5). 
NKs’ killing potential was not different between both exposure conditions (Table 5). We 
observed a weak association of increased oxidative DNA damage (p=0.06) after exposure to E0 
exhaust compared to E85 in ECs of monocultures, but not in ECs of cocultures or NKs (Table 4, 
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Table 5). Gene expression of ULBP2, MICA, IL-8 or IP-10 was not different between E0 and E85 
exposure (Table 4). The level of oxidative stress was not different between exposure to E0 or 
E85 exhaust (Table 4).  
4. Discussion 
We developed a novel coculture model of bronchial ECs and NKs mimicking the human airways 
to study effects of exposure to E0 and E85 exhaust in vitro. Coculturing reduced the ULBP3 
expression of ECs, altered the receptor expression of NKs, and reduced their killing potential. 
We validated the novel coculture model showing that DPM exposure changed gene expression 
of ECs, and unspecific stimulation with PMA/ionomycin altered surface receptor expression of 
ECs and NKs. The exposure to E0 and E85 exhaust had only minor toxic effects on ECs and NK 
cells compared to air. Looking at the results more closely, we found a weak association for 
higher cytotoxicity, but lower oxidative DNA damage in ECs after exposure to E85 exhaust 
compared to E0 (Table 4). The increase for cytotoxicity was only about 18% in ECs exposed to 
E85 compared to E0, and therefore the biological relevance may be questionable. However, the 
level of oxidative damage in ECs exposed to E0 reached twice the level of ECs exposed to E85. 
While the death of ECs leads to the replacement of the cells, oxidative DNA damage may be a 
starting event for cancer development (Clift and Rothen-Rutishauser 2013), and thus may be 
more relevant for long term effects. 
One strength of the study is the exposure model (Müller et al. 2010), using whole fresh gasoline 
exhaust which enabled us to expose cells to complete gasoline exhaust mixtures, including 
gaseous and particulate components. This exposure setup represents more closely real-life 
exposure conditions. Given that (pro-) inflammatory effects have also been attributed to non-
particulate matter components of exhaust emissions (Holder et al. 2007, Lund et al. 2007, Reed 
et al. 2008), the use of whole exhaust exposure to assess the toxicity of exhaust emissions is 
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crucial. Our exposure system was controlled for temperature, humidity, and CO2 concentration. 
Furthermore, the setup includes exposure of cells to filtered ambient air, which serve as a 
corresponding control and to which effects of exhaust exposure can be normalized. This 
allowed for a comprehensive evaluation of the toxic effects of exhaust emissions in a 
biologically relevant in vitro airway exposure model. 
In this study, we used human cells to avoid potential translation difficulties from animal data. 
We used the human bronchial EC line 16HBE14o-, which has already been used in several in 
vitro air pollution studies (Bauer et al. 2015, Baulig et al. 2003, Müller et al. 2012, Steiner et al. 
2013b), and represents a good model of the bronchial part of the human airways. As for NKs, 
we used primary cells from healthy human donors, representing an important cell type in the 
respiratory system. Combining ECs and NKs in cocultures allowed us to take into account that 
the human airways consist of numerous different cell types, which interact with each other 
(Ochs and Weibel 2008). The characterization of our coculture model showed changes in almost 
all studied markers of NKs upon coculturing with ECs. This illustrates the ability of NKs to adapt 
to their microenvironment and thus to adjust their function to varying conditions. The 
coordinated responses in cocultures represent a more realistic model of the physiological 
setting in the body than single cell types (Alfaro-Moreno et al. 2008, Bauer et al. 2015, Müller et 
al. 2010), and therefore, our results mimic more closely in vivo conditions. We used a cell 
culture model specifically developed to study respiratory physiology. This model is exposed to 
air (by air-liquid interface) and mimics the human airways more closely than submerged 
conditions (Ghio et al. 2013), and therefore is a favorable setting to study air pollutant 
exposure. 
Our study is limited by the in vitro study design, focusing on two cell types only. Therefore, with 
our model, we only represent part of the complexity of the airways and cannot conclude on 
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exhaust effects on other cells types of the lung. We could only repeat the experiments four 
times. This is due to restriction of financial and human resources and the limited time the 
Laboratory for Exhaust Emission Control was available for our project. 
Another study used the exact same exposure system and set-up to investigate the effects of 
gasoline exhaust emissions in a triple cell coculture model of 16HBE14o- ECs, human monocyte-
derived macrophages and human monocyte-derived dendritic cells (Bisig et al. 2016). They 
found no effects of gasoline exhaust emissions in the cell model and no differences between 
the exposure to pure gasoline and ethanol-gasoline blend (E85 or gasoline with 10% ethanol) 
exhaust emissions. Their findings, along with our results, therefore, suggest only minor toxic 
effects of gasoline exhaust. However, these findings stand in contrast to older studies 
investigating toxic effects of gasoline exhaust. These older studies found lung cytotoxicity, 
suppression of macrophages and oxidant stress in rodents (Mauderly et al. 2014), upregulated 
factors of vascular remodeling and increase in vascular oxidative stress in mice (Lund et al. 
2007) and mild lung irritation and decrease oxidant production by alveolar macrophages in a 
sub-chronic setting with rodents (Reed et al. 2008). However, it has to be considered that all of 
those studies used older engine technologies, and not the newer GDI technology that was used 
in our study. Thus, the differences in findings may reflect technological progress. Two other 
studies investigated the effects of methanol, another gasoline fuel blend, and found less 
adverse effects in several cell lines for exposure to organic extracts of methanol exhaust 
compared to organic extracts of gasoline exhaust (Che et al. 2010, Zhang et al. 2007). These 
findings, and our results of reduced oxidative DNA damage after E85 exposure compared to E0, 
are further supported by Muñoz et al., reporting reduced genotoxic potential of PAHs (Munoz 
et al. 2016) due to blending of gasoline with ethanol. 
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Other studies have associated the exposure to diesel exhaust particles or fine particulate 
matter to stress or inflammatory signals in ECs (Auger et al. 2006, Holder et al. 2007). ULBPs 
and MICA/B are known to be highly expressed on stressed ECs after infections, mutations and 
oxidative stress (Borchers et al. 2006), and are ligands for the activating receptor CD314 on the 
surface of NKs (Obeidy and Sharland 2009). We found, however, no increased expression of 
ULBPs, MICA/B or CD314 and no signs for a changed function of NKs cocultured with ECs 
exposed to E0 exhaust. We found that neither exposure to E0 nor to E85 exhaust - both 
conditions with low particle numbers - affected NKs. However, when directly comparing the 
oxidative DNA damage induced by E0 and E85, exposure to E0 exhaust resulted in increased 
DNA damage compared to E85. We speculate that the higher hydrocarbon concentration in the 
E0 exhaust, known to cause DNA damage (Toraason et al. 2001), may explain this finding. 
With regards to the increasing number of passenger cars worldwide, the predominance of 
gasoline-driven cars in western countries, and the increasing popularity of ethanol-gasoline 
blends, it is of high importance to gain more insight into the potential health effects of those 
fuel blends. We found no major toxic effects of pure gasoline or ethanol-gasoline exhaust 
emissions from a modern flex-fuel car in EC monocultures or cocultures of ECs and NKs. 
Therefore, based on our findings, we speculate, that the augmented use of ethanol as part of 
fuel for gasoline cars does not seem to be harmful. As our study investigated only acute effects 
in two cell types, additional in vitro studies with other cells types, and animal and human in vivo 
studies examining chronic exposure scenarios, are needed to further support our findings. 
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4 General discussion  
In summary, this PhD thesis adds further information on early lung development from infancy 
until school age. Following our aim to improve our understanding of infant lung function, we 
studied the methodological challenges of two different infant lung function tests. First, we 
studied MBW measurements, which provide information on lung volumes and ventilation 
homogeneity. We investigated the magnitude of MBW measurement errors from the lung 
function of healthy infants, and were able to outline recommendations that greatly improve the 
quality of the outcomes. Second, we studied Rint measurements that provide information on 
airway obstruction. We demonstrated that Rint measurements in unsedated infants shortly after 
birth are feasible despite their time-consuming nature. This technique allows for the 
determination of airway obstruction during the vulnerable phase of lung development.  
We studied airway inflammation shortly after birth using FeNO levels, in order to further 
understand early disease pathologies in asthma and CF. In regards to asthma development, we 
found that FeNO measured in the naïve airways of newborns was not associated with asthma at 
school age. Thus, FeNO measurements in infancy were not helpful to predict the risk for asthma 
development. We also compared FeNO levels between healthy newborns and infants with CF. 
Our finding of reduced FeNO levels in infants with CF compared to healthy controls contributed 
to our understanding of early airway pathology in CF disease.  
In order to address the complexity of airway disease, we applied three different approaches to 
studying the pathophysiology:  i) we assessed different risk factors (genetic, immunological) and 
used epidemiological models to study their association with asthma development. We found that 
a key immune regulator YKL-40, and polymorphisms from the gene encoding this protein, may 
be associated with asthma at school age; ii) We applied a time-series approach and used 
prospectively assessed respiratory symptom scores during infancy to develop a novel method to 
characterize these symptoms. Utilizing this method, we were able to observer-independently 
assess dynamic patterns of symptoms. This method could be useful in prospective cohort studies, 
Discussion 
274 
and could be applied to predict asthma development; iii) we took an analytical approach, to study 
the in vitro effect of air pollution within a newly developed cell-culture model. We exposed 
different human respiratory cells to gasoline and ethanol-gasoline exhaust. Comparison between 
gasoline and ethanol-gasoline exposure showed a weak association for less oxidative DNA 
damage after ethanol-gasoline exposure.  
The relevant conclusions drawn from each project, including future directions, are described 
below. 
 
4.1 Recommendations to improve infant lung function tests  
In this study of healthy infants, we quantified the magnitude of MBW measurement errors. We 
demonstrated that non-systematic, inter-center differences in MBW outcomes in infants can be 
greatly reduced by including correctly recorded environmental conditions in the software 
analysis algorithms and by making minimal alterations in these algorithms. We provided several 
simple recommendations for the user. This included, e.g. to examine the recorded temperature 
during measurements in the software, and make any necessary adjustments. Along with the 
increasing need to include infant lung function tests in multicenter studies for patients with CF 
[95, 96], arises the need to obtain higher quality measurements, and this should be the focus of 
both clinical scientists and equipment manufacturers. We hope the recommendations outlined 
here will help improve the quality and reliability of MBW measurements in specialized and non-
specialized settings. 
The quality of Rint measurements has never been systematically studied in infants. We 
demonstrated the feasibility of Rint measurements in unsedated infants shortly after birth. We 
further provided first evidence of higher airway resistance in preterm compared to term-born 
infants. Variability of measurements was high in both groups, but higher in term compared to 
preterm infants. Variability of measurements could be considered noise, but could also be 
regarded as a biological signal per se. The less variability of Rint in preterm infants may also 
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suggest an association between immaturity and breath control. The clinical relevance of our 
findings needs to be evaluated. Future studies will need to assess whether Rint could be used as a 
prognostic marker for subsequent respiratory morbidity, taking into consideration the high 
variability of measurements per se, requiring further interpretation. 
 
4.2 New insights on nitric oxide metabolism  
We measured postnatal airway FeNO in unselected healthy newborns during natural sleep and 
found no association with asthma at school age. This finding contradicted studies measuring 
FeNO at later time points during childhood, describing an association with subsequent 
respiratory disease [36, 37]. This caused us to speculate that nitric oxide metabolism may play a 
role in the pathophysiology of childhood asthma only after exposure to environmental factors.  
Using the same methodology, we compared postnatal FeNO between healthy infants and infants 
with CF disease. We demonstrated that FeNO is lower in CF patients compared to controls. 
Further, we found that this effect is even more pronounced in infants homozygous for class I 
and/or class II mutations without residual function in the Cystic Fibrosis Transmembrane 
Regulator (CFTR). This finding indicates that FeNO is reduced in CF a priori, and may be 
considered a proxy of CFTR function. It was previously shown that FeNO is associated with 
reduced neutrophil sequestration, bacteriostatic properties, and mucociliary transport [97], and 
therefore may be an important player in the progression of CF lung disease.   
 
4.3 Effects of polymorphisms in CHI3L1 and YKL-40 levels with asthma development  
We studied the association of a key immune regulator YKL-40, and genetic polymorphism from 
the gene encoding this protein, with asthma at school age. We found no robust association 
between genetic variation in CHI3L1 and asthma development, but found some indication that 
the SNP rs10399805 might be related to asthma diagnosis at 6 years of age. In order to test the 
robustness of our findings, large replication studies within a prospective study design in an 
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unselected population are warranted. In previous studies, the biomarker YKL-40 was shown to 
be elevated in children and adults with severe asthma [59, 61, 98]. In our healthy study 
population, we found a trend of association between elevated cord blood YKL-40 levels and 
asthma. This finding requires further validation before YKL-40 may be considered an early 
biomarker for asthma development in unselected infants.  
 
4.4 A novel method to characterize respiratory symptoms 
We developed a novel method to characterize the transition probabilities between respiratory 
symptoms. We found that different symptom dynamic patterns were associated with wheezing 
and atopy at school age. Furthermore, these symptom dynamics enabled us to identify four 
distinct phenotypes, of which one consisted of predominantly male subjects of asthmatic 
mothers, exposed to environmental tobacco smoke (ETS) exposure. These findings indicate that 
symptom dynamics contain relevant information on risk factors for asthma development. The 
developed method could potentially be applied in various research settings, since it is based only 
on respiratory symptom scores, which can be assessed without laboratory equipment or specially 
trained experts. 
 
4.5 A novel cell model to study air pollution exposure 
We developed a novel coculture model consisting of human bronchial epithelial and natural 
killer cells, to study toxic effects of air pollution. In our in vitro study, we demonstrated that pure 
gasoline or ethanol-gasoline exhaust exposure emissions of a modern car had no major toxic 
effects on these cells. Comparison between gasoline and ethanol-gasoline exposure showed a 
weak association for less oxidative DNA damage after ethanol-gasoline exposure. In our study, 
only acute effects in two cell types were investigated, and additional in vitro studies with other 
cells types could help elucidate the effects of gasoline in other cell types of the lung.  
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4.6 Physiological mechanisms 
The pathophysiological mechanisms of airway disease during childhood are complex, and many 
factors contribute to disease severity. Findings from this study may further contribute to our 
understanding of the mechanisms relevant in early life.  
We provided further insights into FeNO metabolism during early childhood, and speculated on 
the basis of our findings that environmental factors modify FeNO levels. While FeNO levels 
may be modified by the environment, there was also indication that the genetic background 
partly predetermines FeNO levels. FeNO levels in newborns were decreased in infants with CF, 
and this effect was even more pronounced in those infants with no residual CFTR function. This 
indicates that FeNO levels are reduced a priori due to the genetic profile. Studies support the 
idea that the genetic background influences FeNO levels. Our study group has previously 
reported several genetic determinants located in the 6q12 gene locus which modify FeNO levels 
in healthy newborns [99]. Another study in adult asthmatics reported an association between 
polymorphisms in the inducible nitric oxide synthase (iNOS) and FeNO levels [100].   
Applying our novel method, which captures symptom dynamic patterns, we were able to identify 
a group of infants at high risk for the development of wheezing symptoms during childhood. 
Interestingly, a large proportion of infants in this group were exposed to ETS, which underlies 
the impact of this exposure on airway disease development. While ETS exposure is clearly a 
relevant risk factor for respiratory symptoms, there are several other factors that determine a 
child’s response to respiratory infections. Studies suggest that the severity of respiratory 
infections in children depends not only on the virus type [101], but also its modification by 
microbial composition [102] and environmental factors [8, 87]. Interplay between viral stimuli, 
the microbial composition and the genetic predisposition are suggested to affect airway epithelial 
function [103, 104]. We speculate that infants with more fluctuations during symptom 
deterioration and recovery are those infants with an epithelial dysfunction, and are thus at an 
increased risk for developing persistent wheezing. Markers associated with asthma exacerbations 
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(e.g. cytokine expression, impaired interferon response) were identified previously [103]. In 
order to test our hypothesis of an epithelial dysfunction during infancy relevant for future 
disease, prospective studies assessing these markers during respiratory infections are needed. 
 
4.7 Relevance 
Results from this PhD thesis provide new insights on early lung development, and may 
contribute to a better assessment of airway pathologies. Especially in infants with CF, 
maintenance of normal lung function is crucial, since reduced lung function is associated with 
increased morbidity and mortality [105]. Infant lung function can assess lung pathologies at an 
early stage, which can then lead to the application of therapies before airway damage is 
permanent. This can ultimately improve long term outcome. We addressed relevant 
methodological issues in infant lung function testing and provided recommendations on how to 
improve the quality of outcomes. These results could lead to an improved assessment of early 
airway damage, and may improve the clinical management of CF patients. 
It is advantageous to assess airway function using objective lung function tests. In young 
children, these tests are time-consuming and expensive, and therefore only applied in specialized 
centers. Simpler, but still objective methods to assess airway function are therefore needed. We 
were able to develop a method that can observer-independently characterize respiratory 
symptoms, and provides relevant information on airway mechanics. This method can broadly be 
applied, since no technical equipment is needed, only the simple assessment of respiratory 
symptoms.  
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4.8 Conclusions and outlook  
For the different projects in this PhD, different scientific recommendations for next steps could 
be described. In order to understand the relevance of our recommendations to improve outcomes 
from infant lung function measurements, application in larger study populations would be 
necessary. Applying our recommendations in multicenter trials could also improve comparability 
and reduce inter-center differences.  
We provided new insights on FeNO metabolism and speculated that environmental exposures 
modify nitric oxide synthase (NOS). In order to confirm that environmental exposures indeed 
modify NOS expression during infancy, frequent longitudinal assessment of FeNO levels and 
NOS expression would be necessary. Our findings should encourage further research on factors 
impacting NO metabolism during infancy. In particular, modifying environmental factors, e.g. 
air pollution and aeroallergens, should be in focus, since exposure to these can be actively 
reduced. These risk factors may therefore serve as targets for new preventive strategies in 
childhood asthma development. In regards to FeNO assessed in patients with CF, a further 
scientific step would be to continue follow-up of the patients during childhood in order to see if 
FeNO levels in infancy may be of prognostic value for later disease severity.  
Our novel method to characterize respiratory symptoms was useful to predict later asthma 
development in an unselected population. We would suggest that further research seek to 
validate the developed method in high-risk populations, as well, in which clinical application 
may be of even greater interest. It is advantageous that our method is based only on respiratory 
symptom scores, which can be assessed without laboratory equipment or specially trained 
experts. This opens up the possibility for application in telemonitoring-settings, in which the 
assessment of symptoms is crucial [106].  
We also highlighted the toxic effects of car exhaust exposure within an in vitro setting. From a 
public health perspective, it is imperative that we apply methods which further decrease the toxic 
effects of air pollution. For example, our cell culture model could be used to investigate whether 
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newly available particle filters for gasoline cars are useful to reduce the toxic effects of car 
exhaust.  
Some of these steps are currently being undertaken in ongoing projects within our group, with 
which I am also involved. Some specific questions can, however only be answered in different 
specific populations, e.g. in high-risk populations for asthma development. Results from these 
studies will hopefully increase our knowledge of potentially harmful exposures and may improve 
clinical management.  
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6 Appendix of additional manuscripts 
During my PhD studies, I was also involved in several projects which did not directly relate to 
the hypotheses of my thesis. These projects extended my knowledge and broadend my scientific 
experience. 
1) A long-standing and close collaboration between the BILD cohort study and the Swiss 
Tropical and Public Health Institute Basel (Swiss TPH) enabled me to be involved in a 
collaboration work between the institutions. Working together with Dr. Danielle Vienneau
 
(Swiss Tropical and Public Health Institute, Basel, Switzerland) and Mrs. Manuella Lech 
Cantuaria (The Mærsk Mc-Kinney Møller Institute, Faculty of Engineering, University of 
Southern Denmark, Odense, Denmark) we investigated the association between residential 
exposure to road traffic noise during pregnancy and postnatal stress, as assessed by the 
concentration of glucocorticoid metabolites at 5 weeks of age.  
2) I also had the opportunity to take part in a project which investigated the relevance of viral 
and bacterial pathogens for subsequent respiratory diseases during infancy. Together with Dr. 
Roland Neumann (University Children’s hospital Basel, Switzerland) and PD Dr. Markus Hilty 
(Institute for Infectious Diseases, University of Bern, Bern), we investigated the hypothesis that 
a distinct microbial composition during the first symptomatic viral infection is associated with 
subsequent respiratory symptoms. 
3) I was involved in a study designed to explore factors influencing aerobic exercise capacity, 
expressed as peak oxygen consumption (VO2peak) with a specific focus on transmembrane 
conductance regulator (CFTR) genotype in children and adults with CF. This project was done 
under under the lead of Dr. Thomas Radtke and Prof. Susi Kriemler (both Epidemiology, 
Biostatistics and Prevention Institute, University of Zurich, Switzerland). 
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ABSTRACT 
Background: Traffic noise has been associated with an increased risk for several non-auditory 
health effects, which may be explained by a noise-induced release of stress hormones (e.g. 
glucocorticoids). Although several studies in children and adults have shown an increased 
secretion of glucocorticoids after exposure to noise, information regarding newborns is scarce. 
Objectives: To investigate the association between residential exposure to road traffic noise and 
postnatal stress, as assessed by the concentration of glucocorticoid metabolites at five weeks of 
age. 
Methods: Residential noise exposure was estimated for each infant based on spatially detailed 
modeled data for all buildings. Adjusted multivariable linear regression models were used to 
estimate the association between noise exposure and the concentration of nine glucocorticoid 
metabolites measured in urine of 165 infants from a prospective birth cohort in Bern, 
Switzerland. Noise exposure was assessed by three different metrics (i.e. Lden, LeqD or LeqN) 
and categorized into tertiles: low (reference), medium and high categories. 
Results: Borderline positive associations were found between high road traffic noise and 
cortisone (% change: 22.57% [95% confidence interval: -1.8, 53.0%]) and β-cortolone (51.5% [-
0.9, 131.5%]), in comparison to infants exposed to low noise levels. On the contrary, newborns 
exposed to higher noise levels showed a borderline significant reduction of tetrahydrocortisol (-
23.7% [-42.8, 1.9%]) and α-cortolone (-18.3% [-33.6, 0.6%]) concentrations. 
Conclusions: Our findings suggest a potential effect of noise on glucocorticoid metabolism in 
early postnatal life. A possible physiological relevance and association with short- and long-term 
adverse health effects needs to be further investigated. 
 
Keywords: Road traffic; Noise; Glucocorticoids; Cortisol; Postnatal stress; Environmental 
stressors  
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1. Introduction  
In the past few decades, there has been a growing concern about health impacts triggered by 
environmental noise from different sources, such as industry, neighbors and transportation. As 
one of the most widespread sources of environmental stress, noise from transportation is 
considered a major threat for public health. Transportation noise has been identified as a major 
contributor to the environmental burden of disease in Europe (Hänninen et al. 2014; WHO 
2011), and a recent evaluation in Switzerland found that the burden of transportation noise was 
equal to that of air pollution in terms of total external costs (Vienneau et al. 2015b).  
Studies have demonstrated an association between exposure to transportation noise and an 
increased risk for several non-auditory health effects in adults, including reduced quality of life 
(Dratva et al. 2010; Héritier et al. 2014), hypertension (Haralabidis et al. 2008; Paunović et al. 
2014; van Kempen and Babisch 2012), ischemic heart disease (Babisch 2014; Héritier et al. 
2017; Seidler et al. 2016; Sørensen et al. 2012; Vienneau et al. 2015a), respiratory health (Recio 
et al. 2016b), and diabetes (Eze et al. 2017; Sørensen et al. 2013). In relation to studies in 
children, most are focused on blood pressure (Babisch et al. 2009; Belojevic et al. 2008), 
cognitive function (Haines et al. 2001; Stansfeld et al. 2017) and respiratory outcomes (Ising et 
al. 2003, 2004a, 2004b).  
Noise induced health effects are postulated to occur through the activation of either a direct or 
indirect pathway (Münzel et al. 2016). In the direct pathway, noise directly triggers an 
instantaneous activation of the central nervous system; in the indirect pathway stress markers are 
activated through annoyance (Babisch 2002). Regardless of the pathway, noise exposure results 
in stress responses, characterized by activation of the neuroendocrine system (i.e. hypothalamus-
pituitary-adrenal (HPA) axis and sympathetic-adrenal-medulla axis), and a subsequent release of 
stress hormones, e.g. glucocorticoids.  
The stimulation of glucocorticoid production results in several regulatory effects on 
physiological functions in the human body. The secretion of glucocorticoids induces immune 
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responses, and might act on both the production of cytokines and lymphocyte proliferation 
(Dobbs et al. 1996). Overproduction of glucocorticoids also affects blood glucose levels by 
inhibiting insulin secretion and increases the concentration of lipids and lipoproteins (e.g. 
cholesterol and triglycerides) (Aich et al. 2009; Qureshi et al. 2009; Recio et al. 2016a).  
A number of studies have empirically demonstrated that exposure to transportation noise indeed 
increase stress-induced secretion of glucocorticoids, mostly cortisol. For instance, Ising et al. 
(2004b) and Wagner et al. (2010) showed an association between elevated salivary cortisol 
levels and traffic noise in children and adults, respectively. Furthermore, a substantial increase in 
morning saliva cortisol levels in women exposed to aircraft noise higher than 60 dB was reported 
by Selander et al. (2009). While the association is well reported in children and adults, this has 
never been investigated in newborn infants who are particularly vulnerable to environmental 
exposures and likely to experience long term effects.  
We aimed to investigate the association between residential exposure to road traffic noise 
(during and shortly after pregnancy) and postnatal stress, as assessed by the concentration of 
glucocorticoid metabolites measured in urine from infants at five weeks of age.  
2. Materials and Methods 
2.1 Study design and subjects 
This study included a subgroup of 205 healthy infants from the prospective Basel-Bern Infant 
Lung Development (BILD) birth cohort, recruited antenatally between 2005 and 2011 in the 
region of Bern, Switzerland. We determined the residential history during pregnancy and after 
birth, and assessed pre- and early postnatal risk factors (e.g. tobacco smoke exposure, socio-
economic status, delivery mode) (Bradley and Corwyn 2002; Floyd et al. 1993; Latimer et al. 
2012; Rice et al. 2007) via standardized questionnaires (Fuchs et al. 2012). Addresses were 
geocoded using a reference file from the Swiss Federal Statistical Office (Neuchâtel). Exclusion 
criteria for the study were delivery <35 weeks gestational age and problems during the extraction 
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of urine samples and/or analysis. The study was approved by the Ethics Committee of Bern, 
Switzerland. Written informed consent was obtained from parents before enrollment. 
2.2 Exposure assessment 
Noise exposure assessment was based on detailed noise modeling for the year of 2011 from the 
SiRENE (Short and Long Term Effects of Traffic Noise Exposure) study (Karipidis et al. 2014). 
The SiRENE database included road traffic noise estimates (dB) for façade points for each 
dwelling in every building in Switzerland. Data (VECTOR25) from the Swiss Federal Office of 
Topography (Swisstopo 2007) was used to characterize the buildings and dwelling units from the 
period of 1998 to 2006, with height and number of floors for each building estimated by a digital 
surface model combined with a digital terrain model for Switzerland. Road traffic noise was 
calculated at a maximum of 3 façade points per building façade and floor, with a minimum 
spacing distance of 5 meters. 
The noise exposure metrics used in our study included: Lden, average sound level over all 24h 
periods of a year, with an additional 5dB for the evening (19:00 – 23:00) and an additional 10dB 
for the night (23:00 – 07:00) hours; and LeqD and LeqN, which respectively represent the 
average sound level over all day (07:00 – 23:00) and night (23:00 – 07:00) periods of a year. 
Since no residential floor information was available for the BILD study participants, we used 
noise estimates from the middle floor of the relevant residential building. Noise levels from the 
façade point with the maximum Lden for each participant were assigned, i.e. selected the most 
exposed façade point for the residential unit based on the Lden. Exposure variables were 
censored at 35 dB (Lden, LeqD) or 25 dB (LeqN).  
Since traffic-related air pollution was shown to affect glucocorticoids metabolism (Rüedi et al. 
2013), we also assessed residential nitrogen dioxide (NO2) exposure averaged for the in-utero 
period of each infant. We estimated NO2 exposure using a validated time-space hybrid model for 
our study area (Proietti et al. 2016).  
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2.3 Outcome assessment 
To assess urinary glucocorticoid levels, parents provided diapers with clean urine from infants at 
five weeks of age (hereby referred as “newborns” throughout the paper). Within 24 hours, the 
urine was centrifuged out from the diapers at 4378 rpm for 8 minutes at room temperature 
(Multifuge 3SR+, Thermo Fisher Scientific) and immediately stored at −20 °C. After sample 
processing (i.e. pre-extraction, enzymatic hydrolysis, extraction from the hydrolysis mixture, 
derivatization, gel filtration), gas chromatography-mass spectrometry was carried out to 
quantitate the different stress hormones as previously described (Dhayat et al. 2015; Garde et al. 
2004; Shackleton 1986). This work was conducted at the Department of Nephrology, 
Hypertension and Clinical Pharmacology, University Hospital of Bern, Switzerland, using a gas 
chromatograph 7890A from Agilent Technologies (La Jolla, California, USA) coupled to a mass 
selective detector (Hewlett-Packard 5975C). Measured steroids were then standardized to urinary 
creatinine concentration (QuantiChrom Creatinine Assay, DICT-500; BioAssay Systems, 
Hayward, CA, USA) and expressed in μg/mmol creatinine (Garde et al. 2004; Dhayat et al. 
2015).  
2.4 Statistical analysis 
Multivariable linear regression models were used to evaluate the association between road traffic 
noise (i.e. as determined separately by Lden, LeqD or LeqN) and the concentration of each 
glucocorticoid metabolite. The noise exposure variables were categorized into tertiles 
(subsequently referred to as “low”, “medium” and “high” categories). 
We restricted our analysis to the nine glucocorticoid metabolites: eight of which were detectable 
in the urine of all the study participants (cortisol, 5α-tetrahydrocortisol (α-THF), 
tetrahydrocortisol (THF), α-cortol, cortisone, tetrahydrocortisone (THE), α-cortolone, β-
cortolone) and the ninth had negligible missing data (β-cortol, for which only two of 165 
observations were missing). Since the distribution of concentrations for many of the 
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glucocorticoid metabolites was strongly right-skewed, data were normalized by natural 
logarithmic transformation.  
All models were calculated unadjusted (i.e. crude), adjusted for anthropogenic factors including 
sex, gestational age and weight at the time of urine sample (i.e. basic) and further adjusted for 
potential confounders (i.e. full) identified in previous studies as relevant risk factors (Dhayat et 
al. 2015; Rüedi et al. 2013): delivery mode; pathological cardiotocogram (CTG); maternal 
smoking during pregnancy; educational status of the mother; season at birth; vaginal infection; 
maternal atopy; and existence of older siblings. We used backwards step selection, retaining all 
statistically significant variables (p < 0.1) or variables that, when removed, changed the risk 
estimate by at least 10% of the previous value. 
All statistical analyses were performed in R software (version 3.1.2). 
3. Results 
3. 1 Summary statistics 
From the 205 enrolled newborns, we excluded those with low gestational age (n=2), jellified 
urine samples (n=35) and unreadable chromatogram (n=3), giving a total sample of 165 (80.5%) 
newborns. Of those, 88 (53%) were male, the mean (SD) gestational age was 39.5 (1.3) weeks 
and weight at the time of the urine sample was 4.3 (0.6) kg. 21% of the newborns were delivered 
by Cesarean section and 5% of the mothers smoked during pregnancy (Table 1). The medians for 
long-term exposure to road traffic noise were 52.4 dB(A) for LeqD, 45.6 dB(A) for LeqN and 
54.4 dB for Lden (Table 2). The cortisol and cortisone concentration (in μg/mmol creatinine) 
measured from urine were 109.5 (72.4) and 352.8 (205.8), respectively. Details on the 9 
glucocorticoid metabolites are provided in Table 3. 
All noise exposure metrics were highly correlated with each other (Pearson’s correlation (r) 
ranged between 0.99 and 1.00). Noise and NO2 exposure during pregnancy showed low 
correlation coefficients (r = 0.33 for all exposure metrics). 
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3.2 Association between noise and glucocorticoid metabolite concentration 
As depicted in Figure 1, traffic noise exposure was found to be borderline associated with 
change in concentrations of four glucocorticoid metabolites in the urine of newborns, with 
indications of a dose-response (DR): cortisone (+ DR), β-cortolone (+ DR), THF (- DR) and α-
cortolone (- DR).  
Borderline positive associations (defined as p-value<0.1) were found between road traffic noise 
and cortisone for newborns in our high exposure category (%change = 22.6%; 95%CI: -1.8, 
53.0%, p-value = 0.074) (Figure 1) compared to newborns in our low exposure category. We saw 
an increase in β-cortolone concentration for newborns in the high category (%change = 51.5%; 
95%CI: -0.9, 131.5%, p-value = 0.057), whereas the borderline significant association for α-
cortolone concentration in the high exposed category was in the opposite direction (%change = -
18.3%; 95%CI: -33.6, 0.6%, p-value = 0.059). Newborns exposed to higher noise also showed a 
borderline significant reduction in THF concentration (%change = -23.7%; 95%CI: -42.8, 1.9%, 
p-value = 0.069).  
Similar results were obtained for the crude and basic models for Lden (Table S1), and likewise 
results for models based on the alternative noise metrics LeqD and LeqN and different exposure 
classifications were comparable (Figures 2 and S3, and Tables S2 and S3). 
4. Discussion  
In this study of unselected newborns, we found borderline significant associations between high 
traffic noise exposure and the concentration of several steroid metabolites measured in urine 
(Figure 1).  
Glucocorticoids metabolites, a subset of steroid hormones, can be further divided into branch E, 
with glucocorticoid progenitor cortisone, and branch F, with glucocorticoid progenitor cortisol. 
The enzyme 11-hydroxysteroid dehydrogenase (HSD) type 1 converts cortisone to cortisol, 
whereas 11-HSD type 2 does the opposite. Both enzymes regulate the amount of available 
progenitor glucocorticoids in each branch. Glucocorticoid metabolites downstream from the 
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progenitor are then generated by different enzymes. We found exposure to higher noise levels 
increased the concentration of cortisol and decreased the concentration of downstream 
metabolites (-THF, THF, -cortol) in the F branch. In the E branch, cortisone was increased 
while the downstream metabolite -cortolone was decreased and -cortolone was increased.  
There are several influencing factors through which noise exposure could modify the metabolite 
concentrations. This includes the availability of co-factors (i.e. associated enzymes that catalyze 
the metabolite synthesis), negative feedback mechanisms which reduce the metabolite synthesis, 
or the activity of enzymes involved in the glucocorticoid pathway (Miller and Auchus 2011). It 
is possible that noise exposure modifies the amount of glucocorticoid metabolites by changing 
the activity of the enzymes 11-HSD type I and 11-HSD type 2. However, since we measured 
the glucocorticoid metabolome rather than enzyme activity directly, our hypothesis needs 
confirmation by mechanistic studies. Interestingly, previous studies in rats suggested that the 
enzyme activity of 11-HSD type 2 is modified by prenatal (Peña et al. 2012) and social stress 
(Vodička et al. 2014). 
The most plausible mechanism to explain noise-induced health effects is related to changes in 
the HPA axis activity that, in turn, increases levels of secreted glucocorticoids. Several studies 
have indicated the activation of the HPA axis due to exposure to noise from transportation (Ising 
et al. 2004b; Selander et al. 2009). With respect to noise exposure during pregnancy, a study 
performed in pregnant monkeys revealed higher levels of cortisol in the offspring of mothers 
exposed to noise during gestation than mothers unexposed  (Clarke et al. 1994).   
It has been previously suggested that both fetal and early postnatal life environment are 
important determinants of the risk of metabolic and cardiovascular diseases in later life (Barker 
1995; Barker et al. 1989). It has also been suggested that stress after birth is associated with 
reduced neurodevelopment (reviewed in Flacking et al. 2012). A number of studies, when 
seeking to explain the association between low birth weight and a range of health diseases in 
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adulthood, have pointed to excess of glucocorticoids as a key factor for long-term effects in the 
offspring (Edwards et al. 1993; Edwards et al. 1996; Gohlke et al. 2015).   
Although exposure to higher levels of glucocorticoid may result in beneficial short-term 
metabolic consequences, excess is related to increased blood pressure and alterations of the 
glucose metabolism in the long term (Edwards et al. 1996). These effects can persist and increase 
the risk of cardiovascular, metabolic, neuroendocrine and behavioral disorders later in life (Seckl 
2001). Studies in rats have suggested that increased fetal exposure to glucocorticoids may 
explain higher risks of hypertension (Benediktsson et al. 1993), diabetes (Nyirenda et al. 1998) 
and endocrine system alterations (Barbazanges et al. 1996) in adulthood. Furthermore, the 
glucocorticoid receptor has several interactions with the epigenome, which may explain the 
aforementioned long term effects (Hunter et al. 2015).  
The precise exposure window related to the changes in glucocorticoids concentration observed in 
our study is still unclear, i.e. whether the change in concentrations was due to maternal stress 
during pregnancy or stress in early infancy. Regardless of the uncertainty about the relevant 
exposure time, we have demonstrated that individuals exposed to higher levels of noise had 
higher changes in glucocorticoid concentrations, indicating traffic noise exposure as a potential 
stressor shortly after birth. Whether these changes lead to adverse health effects, and whether 
those effects persist later in life, still needs to be determined. 
Strengths and limitations 
One of the main strengths of our study is the standardized assessment of detailed prenatal risk 
factors, enabling us to control for potential confounders. Glucocorticoid measurements were all 
performed at the same time point (5 weeks of age), eliminating a known age-dependent impact 
on measurements (Dhayat et al. 2015). Since the samples were collected at different time points 
over the day, however, possible effects due to the diurnal rhythm of metabolites could not be 
ruled out.   
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Our models were adjusted for air pollution which, while not highly correlated in our study, can 
be correlated with traffic noise due to the common source. We also used spatially detailed noise 
and air pollution models in assigning individual level exposures at the home address and 
investigated the effects of day and night noise separately. Due to the high correlation among the 
noise metrics (Pearson’s correlation > 0.99 for all combinations), we obviously observed very 
similar associations regardless of the metric and, therefore, cannot assess if day or night 
exposure is more influential on change in glucocorticoid concentrations. The noise metrics 
further represent the longer-term average rather than noise specifically for pregnancy and 5-
weeks after birth. This is considered adequate given that daily fluctuations in noise levels are 
similar day-to-day, and noise is less influenced by meteorology than air pollution. Further, it was 
not feasible to employ spot noise measurements for this study.  
Detailed information on the floor where the residence was located was not available, reducing 
precise assessment of the noise exposure. However only 13.3% participants resided in buildings 
taller than three floors, thus our assumption of the middle building floor is reasonable for most 
participants. As in most studies, noise exposure was only assessed at home and we further did 
not have information on window opening behavior, placement of the infant’s sleeping room, or 
amount of time spent outside the home. This last point is less relevant for the newborns included 
in this study since healthy babies in Switzerland are typically cared for by mothers at home after 
a brief hospital stay. Mothers and infants may of course enjoy some daytime hours outdoors, but 
we also adjusted for season of birth to account for potential differences in exposure due to 
outdoor activity and window opening behavior.  
It may also be viewed as a limitation that glucocorticoid metabolites were assessed at one time 
point, and are therefore just snap-shot. This should be considered in the interpretation of our 
results, given the possible short-term physiologic alterations during the first year of life (Dhayat 
et al. 2015). Only by longitudinal assessment of noise exposure based on measurements, in line 
with repeated measurements of cortisol metabolites, conclusions on a sustained and 
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physiologically relevant effect of noise exposure upon cortisol metabolites is possible. Finally, 
we recognize our small sample size to the large confidence intervals and borderline associations. 
Thus, future research on traffic noise exposure and the release of stress hormones in a larger 
sample is recommended to confirm our findings. 
5. Conclusions 
To the extent of our knowledge, this is the first study to suggest a potential effect of traffic noise 
exposure on glucocorticoid metabolism in early postnatal life. Further prospective studies are 
needed to better understand the clinical relevance of our findings, especially in subjects exposed 
to high noise levels where potential adverse effects may be more relevant. 
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Table 1: Demographic data for the 165 newborns. 
 
Notes: 
a
 Result is given in mean ± standard deviation  
b
 Result is given in number (%) 
 
 
 
 
 
 
 
 
Table 2: Noise exposure data for the 165 newborns. 
 Median IQR 
Range for tertiles 
T1 T2 T3 
 LeqD (day) road noise exposure 
(dB(A)) 
52.4  45.4 – 57.9 
35.0 – 
46.8 
46.8 – 
56.2 
56.2 – 
69.5 
 LeqN (night) road noise exposure 
(dB(A)) 
45.6  38.2 – 50.7 
25.0 – 
39.5 
39.5 – 
49.0 
49.0 – 
62.4 
 Lden road noise exposure (dB) 54.4 47.0 – 59.6 
35.0 – 
48.4 
48.4 – 
57.9 
57.9 – 
71.2 
  
 Summary statistics 
Anthropometric data  
    Gestational age at birth (weeks) 
a
 39.5 ± 1.3 
    Weight at the time of urine collection (kg) 
a
 4.3  ± 0.6 
    Length at the time of urine collection (cm) 
a
 54.2 ± 2.0 
    Sex (male) 
b
 88 (53) 
Family history  
    Maternal education (low) 
b
 30 (18) 
    Maternal education (medium) 
b
 56 (34) 
    Maternal education (high) 
b
 79 (48) 
    Older siblings 
b
 97 (59) 
Pregnancy history - 
    Caesarean section 
b
 34 (21) 
    Vaginal infection during pregnancy 
b
 42 (25) 
    Maternal smoking during pregnancy 
b
  8 (5) 
    Pathological cardiotocogram 
b
 18 (11) 
    NO2 exposure during pregnancy (µg/m
3
) 
a
 17.1 ± 5.3 
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Table 3: Glucocorticoid metabolite concentrations (in μg/mmol creatinine) in newborns. 
Metabolite 
a
 Mean ± SD IQR 
Cortisol 109.5 ± 72.4 63.2 – 122.6 
5α-Tetrahydrocortisol (α-THF) 55.8 ± 53.6 23.0 – 75.2 
Tetrahydrocortisol (THF) 31.1 ± 63.1 12.7 – 28.2 
α-Cortol 181.3 ± 178.8 64.6 – 233.6 
β-Cortol 72.3 ± 109.3 33.4 – 70.4 
Cortisone 352.8 ± 205.8 196.4 – 461.0 
Tetrahydrocortisone (THE) 1632.0 ± 844.4 986 - 2053 
α-Cortolone 227.8 ± 125.0 139.2 – 298.6 
β-Cortolone 691.6 ± 395.1 413.8 – 917.4 
Notes: 
a. Glucocorticoid metabolite concentrations were measured for all newborns (n=165), except for 
β-cortol (n=163) 
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Figures 
Figure 1. Association between road traffic noise (determined by Lden) and the concentration of 
glucocorticoid metabolites in newborn’s urine. Points represent the percent change in 
concentration derived from full adjusted models in comparison to newborns in the low exposure 
(i.e. reference) category; error bars show 95% CI. Glucocorticoids metabolites can be divided 
into branch E, with glucocorticoid progenitor cortisone, and branch F, with glucocorticoid 
progenitor cortisol.  
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Figure 2. Comparison of the associations for high exposure categories based on different traffic 
noise exposure metrics (i.e. Lden, LeqD and LeqN) and the concentration of glucocorticoid 
metabolites in newborn’s urine. Points represent the percent change in concentration derived 
from full adjusted models in comparison to newborns in the low exposure (i.e. reference) 
category; error bars show 95% CI. Glucocorticoids metabolites can be divided into branch E, 
with glucocorticoid progenitor cortisone, and branch F, with glucocorticoid progenitor cortisol. 
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Table S1. Association between road traffic noise (determined by Lden) and concentreation of 
glucocorticoid metabolites 
a
 
Cortisol 
metabolite 
 Crude model Basic model b Adjusted model c 
 Noise exposure (Lden) level 
d 
Noise exposure (Lden) level 
d 
Noise exposure (Lden) level 
d 
 Medium High Medium High Medium High 
Cortisol %change 2.8 (-16.2, 
26.1) 
15.9 (-5.7, 
42.5) 
3.8 (-15.1, 
26.9) 
15.2 (-6.5, 
41.9) 
0.1 (-19.2, 
24.0) 
12.1 (-10.3, 
40.1) 
p-value 0.795 0.162 0.717 0.185 0.991 0.316 
5α-
Tetrahydrocortisol 
(α-THF) 
%change -6.47 (-31.4, 
27.5) 
-2.7 (-28.8, 
33.0) 
-6.7 (-31.8, 
27.5) 
-4.4 (-30.8, 
32.2) 
-5.9 (-32.0, 
30.1) 
-13.8 (-38.5, 
20.8) 
p-value 0.673 0.864 0.662 0.786 0.712 0.39 
Tetrahydrocortisol 
(THF) 
%change -8.23 (-30.3, 
20.8) 
-16.9 (-37.1, 
9.7) 
-7.2 (-29.2, 
21.8) 
-19.8 (-39.5, 
6.2) 
-0.2 (-24.4, 
31.7) 
-23.7 (-42.8, 
1.9) 
p-value 0.542 0.192 0.592 0.125 0.989 0.069 
α-Cortol %change 4.7 (-25.0, 
46.1) 
9.6 (-21.7, 
53.3) 
7.3 (-21.2, 
46.1) 
7.3 (-22.1, 
47.7) 
2.3 (-26.3, 
42.0) 
2.2 (-27.3, 
43.7) 
p-value 0.789 0.596 0.655 0.667 0.892 0.901 
β-Cortol %change -13.7 (-32.9, 
10.9) 
-5.1 (-26.3, 
22.2) 
-12.9 (-32.2, 
11.9) 
-8.0 (-29.0, 
19.0) 
-13.0 (-33.2, 
13.2) 
-15.3 (-35.5, 
11.3) 
p-value 0.251 0.685 0.282 0.525 0.301 0.236 
Cortisone %change 4.6 (-14.7,  
28.1) 
22.4 (-0.3, 
50.2) 
5.5 (-13.8, 
29.1) 
22.8 (-0.4, 
51.3) 
2.8 (-16.9, 
27.2) 
22.6 (-1.8, 
53.0) 
p-value 0.666 0.055 0.604 0.056 0.797 0.074 
Tetrahydrocortisone 
(THE) 
%change 4.1 (-13.9, 
25.8) 
1.9 (-15.9, 
23.4) 
4.8 (-13.4, 
26.6) 
3.0 (-15.4, 
25.3) 
3.5 (-14.8, 
25.6) 
-5.9 (-23.1, 
15.2) 
p-value 0.681 0.848 0.632 0.772 0.732 0.557 
α-Cortolone %change -1.0 (-18.4, 
20.1) 
-7.1 (-23.6, 
13.0) 
-0.9 (-18.3, 
20.3) 
-10.5 (-26.7, 
9.4) 
-3.5 (-21.0, 
17.9) 
-18.3 (-33.6, 
0.6) 
p-value 0.918 0.462 0.931 0.281 0.729 0.059 
β-Cortolone %change 25.8 (-13.4, 
82.7) 
51.5 (3.9, 
120.8) 
26.3 (-13.4, 8) 
53.4 (3.9, 
126.6) 
27.6 (-15.1, 
91.8) 
51.5 (-0.9, 
131.5) 
p-value 0.231 0.032 0.227 0.033 0.243 0.057 
Notes: 
a. Results are shown in percent change in concentration (95%CI) in comparison with newborns in the low exposure category (i.e. reference 
category); p-values < 0.1 are indicated in bold print. 
b. The Basic model was adjusted for sex, gestational age at birth and weight at the time of urine collection. 
c. The Adjusted model was further adjusted for maternal smoking during pregnancy, delivery mode, occurrence of vaginal infection, maternal 
education, existence of older siblings, season at birth and NO2 exposure during pregnancy. 
d. Categorized into tertiles (i.e. <48.4: low; 48.4-57.9: medium; >57.9: high). 
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Table S2. Association between road traffic noise (determined by Leq during the day) and concentrations 
of glucocorticoid metabolites 
a
 
Cortisol 
metabolites 
 Crude model Basic model b Adjusted model c 
 Noise exposure (LeqD) level 
d 
Noise exposure (LeqD) level 
d 
Noise exposure (LeqD) level 
d 
 Medium High Medium High Medium High 
Cortisol %change 2.1 (-16.9, 
25.3) 
16.4 (-5.2, 
42.9) 
4.2 (-14.9, 
27.6) 
14.3 (-7.0, 
40.5) 
1.1 (-18.4, 
25.3) 
10.6 (-11.3, 
37.9) 
p-value 0.844 0.148 0.692 0.206 0.92 0.374 
5α-
Tetrahydrocortisol 
(α-THF) 
%change -4.6 (-30.1, 
30.3) 
-4.7 (-30.2, 
30.1) 
-5.3 (-30.9, 
29.8) 
-6.1 (-31.8, 
29.4) 
-6.1 (-32.1, 
30.0) 
-13.5 (-38.1, 
20.8) 
p-value 0.768 0.763 0.736 0.703 0.707 0.396 
Tetrahydrocortisol 
(THF) 
%change -9.3 (-31.2, 
19.7) 
-15.9 (-36.2, 
11.0) 
-7.3 (-29.5, 
21.9) 
-19.3 (-38.9, 
6.6) 
-3.1 (-26.7, 
28.2) 
-20.6 (-40.4, 
5.9) 
p-value 0.493 0.223 0.587 0.133 0.827 0.118 
α-Cortol %change 1.2 (-27.6, 
41.3) 
13.3 (-18.9, 
58.3) 
7.1 (-21.6, 
46.1) 
7.6 (-21.6, 
47.6) 
2.3 (-26.3, 
42.0) 
2.2 (-27.0, 
43.3) 
p-value 0.948 0.465 0.668 0.652 0.894 0.898 
β-Cortol %change -14.4 (-33.5, 
10.2) 
-4.6 (-25.8, 
22.7) 
-13.7 (-33.0, 
11.0) 
-7.3 (-28.2, 
19.7) 
-14.2 (-34.1, 
11.7) 
-13.9 (-34.3, 
12.8) 
p-value 0.229 0.716 0.253 0.561 0.257 0.28 
Cortisone %change 5.7 (-13.9, 
29.7) 
20.7 (-1.6, 
48.1) 
7.5 (-12.3, 
31.8) 
19.6 (-2.8, 
47.2) 
5.5 (-14.8, 
30.7) 
18.6 (-4.9, 
47.8) 
p-value 0.597 0.073 0.487 0.092 0.624 0.132 
Tetrahydrocortisone 
(THE) 
%change 1.8 (-15.9, 
23.2) 
4.2 (-13.9, 
26.1) 
3.2 (-14.7, 
25.0) 
4.6 (-13.9, 
27.1) 
1.3 (-16.6, 
23.0) 
-3.4 (-20.9, 
18.1) 
p-value 0.854 0.672 0.744 0.648 0.898 0.738 
α-Cortolone %change -1.4 (-18.8, 
19.8) 
-6.6 (-23.1, 
13.4) 
-1.2 (-18.7, 
20.0) 
-9.8 (-26.0, 
10.0) 
-4.3 (-21.7, 
16.9) 
-17.1 (-32.6, 
1.9) 
p-value 0.89 0.49 0.901 0.311 0.666 0.076 
β-Cortolone %change 23.9 (-14.8, 
80.3) 
53.2 (5.3, 
122.8) 
25.0 (-14.5, 
82.6) 
54.1 (4.8, 
126.6) 
26.7 (-15.8, 
90.5) 
52.2 (0.0, 
131.5) 
p-value 0.263 0.027 0.251 0.029 0.258 0.052 
Notes: 
a. Results are shown in percent change in concentration (95%CI) in comparison with newborns in the low exposure category (i.e. reference 
category); p-values < 0.1 are indicated in bold print. 
b. The Basic model was adjusted for sex, gestational age at birth and weight at the time of urine collection. 
c. The Adjusted model was further adjusted for maternal smoking during pregnancy, delivery mode, occurrence of vaginal infection, maternal 
education, existence of older siblings, season at birth and NO2 exposure during pregnancy. 
d. Categorized into tertiles (i.e. <46.8: low; 46.8-56.2: medium; >56.2: high). 
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Figure S1. Association between daytime road traffic noise and the concentration of 
glucocorticoid metabolites in newborn’s urine. Points represent the percent change in 
concentration derived from full adjusted models in comparison to newborns in the low exposure 
(i.e. reference) category; error bars show 95% CI. Glucocorticoids metabolites can be divided 
into branch E, with glucocorticoid progenitor cortisone, and branch F, with glucocorticoid 
progenitor cortisol. 
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Table S3. Association between road traffic noise (determined by Leq during the night) and concentrations 
of glucocorticoid metabolites 
a 
Cortisol 
metabolites 
 Crude model Basic model b Adjusted model c 
 Noise exposure (LeqN) level 
d 
Noise exposure (LeqN) level 
d 
Noise exposure (LeqN) level 
d 
 Medium High Medium High Medium High 
Cortisol %change 3.6 (-15.5, 
27.1) 
16.4 (-5.2, 
42.9) 
4.6 (-14.4, 
27.9) 
15.6 (-6.0, 
42.2) 
0.3 (-19.1, 
24.4) 
12.2 (-10.1, 
40.1) 
p-value 0.734 0.15 0.66 0.172 0.977 0.31 
5α-
Tetrahydrocortisol 
(α-THF) 
%change -2.0 (-28.1, 
33.7) 
-0.3 (-27.0, 
36.1) 
-2.2 (-28.5, 
33.7) 
-2.0 (-29.0, 
35.2) 
-2.8 (-29.8, 
34.7) 
-12.2 (-37.3, 
23.0) 
p-value 0.901 0.983 0.889 0.901 0.866 0.45 
Tetrahydrocortisol 
(THF) 
%change -6.4 (-28.9, 
23.3) 
-16.1 (-36.3, 
10.7) 
-5.2 (-27.7, 
24.5) 
-18.9 (-38.7, 
7.3) 
1.1 (-23.5, 
33.6) 
-23.2 (-42.4, 
2.5) 
p-value 0.638 0.217 0.703 0.144 0.941 0.075 
α-Cortol %change 5.7 (-24.2, 
47.5) 
10.1 (-21.2, 
53.8) 
7.9 (-20.7 – 
47.0) 
7.5 (-21.8, 
47.8) 
1.1 (-27.3, 
40.5) 
1.5 (-27.8, 
42.6) 
p-value 0.743 0.575 0.628 0.656 0.949 0.931 
β-Cortol %change -12.5 (-32.0, 
12.5) 
-4.3 (-25.6, 
23.0) 
-11.4 (-31.0, 
14.0) 
-7.1 (-28.2, 
20.1) 
-12.5 (-32.9, 
14.1) 
-14.9 (-35.2, 
11.7) 
p-value 0.298 0.732 0.349 0.575 0.325 0.248 
Cortisone %change 6.8 (-12.8, 
30.9) 23.6 (0.8, 51.6) 
7.8 (-11.9, 
31.8) 24.0 (0.7, 52.6) 
4.9 (-15.3, 
29.8) 
23.8 (-0.7, 
54.4) 
p-value 0.525 0.043 0.468 0.044 0.665 0.06 
Tetrahydrocortisone 
(THE) 
%change 5.7 (-12.6, 
27.8) 
2.7 (-15.2, 
24.2) 
6.4 (-12.0, 
28.7) 
3.7 (-14.7, 
26.1) 
4.0 (-14.4, 
26.4) 
-5.7 (-22.9, 
15.4) 
p-value 0.567 0.788 0.521 0.715 0.695 0.572 
α-Cortolone %change -0.6 (-18.1, 
20.6) 
-6.9 (-23.3, 
13.1) 
-0.4 (-17.9, 
20.9) 
-10.2 (-26.4, 
9.6) 
-4.2 (-21.6, 
17.2) 
-18.6 (-33.8, 
0.2) 
p-value 0.953 0.474 0.971 0.291 0.68 0.054 
β-Cortolone %change 25.6 (-13.5, 
82.4) 
51.1 (3.8, 
119.8) 
26.0 (-13.5, 
83.7) 
52.9 (3.7, 
125.5) 
26.2 (-16.3, 
90.1) 
50.3 (-1.6, 
129.5) 
p-value 0.233 0.033 0.231 0.033 0.268 0.061 
Notes: 
a. Results are shown in percent change in concentration (95%CI) in comparison with newborns in the low exposure category (i.e. reference 
category); p-values < 0.1 are indicated in bold print. 
b. The Basic model was adjusted for sex, gestational age at birth and weight at the time of urine collection. 
c. The Adjusted model was further adjusted for maternal smoking during pregnancy, delivery mode, occurrence of vaginal infection, maternal 
education, existence of older siblings, season at birth and NO2 exposure during pregnancy. 
d. Categorized into tertiles (i.e. <39.5: low; 39.5-49.0: medium; >49.0: high). 
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Figure S2. Association between night time road traffic noise and the concentration of glucocorticoid 
metabolites in newborn’s urine. Error bars show 95% CI. Points represent the percent change in 
concentration derived from full adjusted models in comparison to newborns in the low exposure (i.e. 
reference) category; error bars show 95% CI. Glucocorticoids metabolites can be divided into branch E, 
with glucocorticoid progenitor cortisone, and branch F, with glucocorticoid progenitor cortisol. 
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Figure S3. Comparison of the associations for the different traffic noise exposure metrics (i.e. Lden, LeqD 
and LeqN) and the concentration of each glucocorticoid metabolite: a) cortisol; b) 5α-tetrahydrocortisol 
(α-THF); c) tetrahydrocortisol (THF); d) α-cortol; e) β-cortol, f) cortisone, g) tetrahydrocortisone (THE); 
h) α-cortolone; i) β-cortolone. Points represent the percent change in concentration; error bars show 95% 
CI. Reference category: low noise exposure. Full adjusted models.  
 
 
a) b) c) 
d) e) 
g) h) i) 
f) 
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Running title: Nasal microbiota in infants at first ARI 
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Descriptor number: 10.11 Pediatrics: Respiratory Infections. 
Word count main text: 3550/3500 words.  
AT A GLANCE COMMENTARY 
Scientific Knowledge on the Subject: Acute respiratory tract infections (ARI) with viral and 
bacterial pathogens in the first year of life have been implicated in the development of chronic 
respiratory disease. The impact of viral infections on the upper airway microbiota remains 
largely unknown. 
What This Study Adds to the Field: Five infant clusters were identified based on their distinct 
nasal microbiota at the onset of first ARI in infancy. Three weeks after the onset of the first ARI, 
these clusters reduced from five to three; whereby distinct microbial composition was 
associated with symptom persistence. The type of respiratory virus was not predictive of 
symptom persistence.  
This article has an online data supplement, which is accessible from this issue's table of 
contents online at www.atsjournals.org. 
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ABSTRACT 
Rationale: Infections with viral and bacterial pathogens in the first year of life have been 
implicated in the development of chronic respiratory disease, but the interplay between 
viruses, bacteria and host is complex, and underlying mechanisms remain largely unknown. 
Objectives: To prospectively determine whether the nasal microbiota changes between the 
onset of the first symptomatic acute respiratory tract infection (ARI) in the first year of life and 
three weeks later, and to explore possible associations of the nasal microbiota with host, 
environmental and viral factors, as well as with duration of respiratory symptoms. 
Methods: Nasal microbiota profiles of 167 infants in their first year of life were determined at 
the onset of the first ARI, and three weeks later, by 16S ribosomal ribonucleic acid PCR 
amplification and subsequent pyrosequencing. Infants were clustered based on their nasal 
microbiota using hierarchical clustering methods at both time points. 
Measurements and Main Results: We identified five dominant infant clusters with distinct 
microbiota at the onset of ARI in symptomatic formerly infection-naïve infants; these five 
clusters reduced to only three clusters after three weeks. In these three clusters, symptom 
persistence was overrepresented in the Streptococcaceae-dominated cluster and 
underrepresented in the cluster dominated by “Others” (P < 0.001). Duration of symptoms was 
not associated with type of respiratory virus. 
Conclusions: Infants with prolonged respiratory symptoms after their first ARI tend to exhibit 
distinct microbial compositions three weeks after the ARI onset, indicating close microbiota-
host interactions which seem to be important for symptom persistence and recovery. 
Word count abstract: 247/250 words. 
Keywords: microbiota; infant; infection, respiratory tract; symptoms, respiratory.  
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INTRODUCTION 
The increasing prevalence of wheezing disorders in infants and preschool children has become 
a major health issue and its complex causes remain largely unknown (1). Viral infections are 
well known triggers for episodic wheeze, as well as for multiple trigger wheeze, and represent a 
risk factor for the subsequent development of asthma (2-4). In addition to viral infections, 
bacterial colonization of the airways in neonates with certain species of bacteria, particularly 
Moraxella catarrhalis, Haemophilus influenzae and Streptococcus pneumoniae, has been shown 
to be associated with the development of childhood asthma (5, 6). It has been hypothesized 
that viral infections may sustainably alter epithelial function, increasing the risk for chronic 
airway disease (7), and that changes in microbial diversity may play a role; particularly in 
symptomatic infants (8-10). It has also been recognized that airway microbiota in patients with 
asthma exhibit distinct differences in airway microbiota compared to healthy subjects (11-13). 
Bacterial airway colonization seems to influence and modulate respiratory morbidity in various 
conditions such as asthma, cystic fibrosis and chronic obstructive pulmonary disease (14-16). 
Composition of airway microbiota is highly dynamic and various environmental factors have 
been shown to influence colonization patterns. Antimicrobial exposure and vaccinations, as 
well as tobacco smoke exposure, can lead to changes of the airway microbiota (17, 18). In a 
prospective cohort study, Mika et al. (19) investigated the nasal microbiota longitudinally in 
infants during the first year of life, in the absence of acute respiratory tract infections. They 
showed that the composition of nasal microbiota in infants is highly dynamic and seems to be 
predominantly influenced by age and season. However, little is known about how and to what 
degree acute respiratory tract infections (ARI), which are often caused by viruses, influence the 
dynamically changing microbiota. In particular, this influence on the prevalence of certain 
commensal bacteria, shown to be associated with asthma development (5). Interactions 
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between viruses and bacteria are well known (20), but their relation to respiratory symptoms in 
the first year of life has not been studied. Recently, Korten et al. (8) demonstrated for human 
rhinovirus (HRV) that the microbiota primarily changes in cases of symptomatic ARI, but not in 
cases of asymptomatic HRV colonization. Thus, we hypothesize that the first symptomatic viral 
infection in infection-naïve infants may induce distinct changes of microbiota following all 
commonly observed respiratory viruses. We also hypothesize that distinct clusters of infants 
with specific microbial response patterns can be identified, which could be associated with 
severity of clinical symptom response and host risk factors, such as atopy, as suggested by Teo 
et al (6). 
In a prospective birth cohort of infection-naïve healthy infants, we aimed 1) To determine 
whether clusters based on the composition and diversity of the upper respiratory tract 
microbiota changed between the onset of the first symptomatic ARI, caused by common 
respiratory viruses, and three weeks later; and 2) To investigate the association of host factors, 
environmental factors and respiratory viruses with infant clusters based on bacterial 
composition; 3) To explore the duration of respiratory symptoms in relation to microbiota or 
virus type, after the onset of symptoms. 
 
METHODS 
Study design 
This study was performed as part of the Basel Bern Infant Lung Development (BILD) cohort 
study (21). The study was approved by the local ethics committees (Ethics Committee of the 
Canton of Bern; Ethics Committee of Basel (EKBB)). Informed written parental consent was 
obtained prior to enrolment in the study. Infants from this prospective birth cohort were 
followed by weekly standardized telephone interviews, as previously described (22). Parents 
Appendix 
328 
were advised to call the study team as soon as their child presented with symptoms of an acute 
respiratory tract infection (ARI) which was defined as more than 2 consecutive days of cough 
and/or wheeze accompanied by fever (>38°C), rhinitis, otitis media or pharyngitis (21). Nasal 
swabs were taken at the onset of ARI (swab A), and three weeks later (swab B), as described in 
the Supplementary methods E1. Nasal swabs were analyzed by real-time polymerase chain 
reaction (PCR) assays targeting five different respiratory viruses (human rhinovirus/enterovirus 
(HRV/EV), respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human 
coronavirus (HCoV), human parainfluenzavirus (HPIV)), which have been shown to be the most 
common viruses in our population (3). Details on the methods of viral analyses are provided in 
an online data supplement (Supplementary methods E1). The results of viral studies of a subset 
of infants, also reported in this study, have been reported previously (3). Extensive data on 
several host factors were collected using questionnaires (14). Microbiota analysis 
Nasal swabs were prospectively taken at the onset of the first ARI and three weeks later. Nasal 
swabs were further analyzed by amplification of bacterial 16S ribosomal ribonucleic acid (rRNA) 
by PCR and 454 Titanium FLX sequencing, as described previously (17). Details on the 
microbiota analysis can be found in an online supplement (Supplementary methods E1).  
Estimation of relative bacterial abundances and microbiota clustering 
Sequencing products were analyzed using Pyrotagger, with the definition of operational 
taxonomic units (OTUs) based on 97% similarity, estimation of chimeras, and taxonomic 
assignments (23). Bacterial abundances were calculated using Pyrotagger, as described 
elsewhere (17, 23). Resulting OTUs were assigned to the five most abundant families with the 
remaining families grouped together as “Others”. These families were used as input variables 
for hierarchical clustering at the onset of ARI (swab A) and three weeks later (swab B). Details 
on the clustering method are provided in an online supplement (Supplementary methods E1). 
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Calculation of α and β diversity was performed, as described previously (19); details can be 
found in an online data supplement (Supplementary methods E1). 
Statistical analyses 
Descriptive statistics were used for exploration and analysis of the association between host 
and environmental factors and viruses with nasal microbiota. Assuming non-normal 
distribution, Kruskal-Wallis and Wilcoxon signed rank sum tests were used. Fisher’s exact tests, 
Chi-square tests and enrichment analyses (24) were employed where appropriate. A P value of 
< 0.05 was considered statistically significant. Season and age dependency (19) of the clusters 
was evaluated in a sensitivity analysis using logistic regression analyses. Statistical analyses 
were performed using Stata 11 software (StataCorp. 2009. Stata Statistical Software: Release 
11. College Station, Texas, United States) and Matlab 2015b (Mathworks, Natick, 
Massachusetts, United States). 
 
RESULTS 
Study population 
A total of 252 infants met the criteria for an ARI in the study period. Nasal swabs were available 
from 200 infants. After exclusion of low-quality samples, nasal swabs of 197 infants were 
analyzed, including 183 complete nasal swab pairs, i.e. available data from the onset of ARI 
(swab A) and three weeks later (swab B). Prior to final analysis, an additional 16 study 
participants were excluded due to antibiotic exposure within 4 weeks prior to either swabbing, 
resulting in 167 nasal swab pairs (Figure 1). Table 1 summarises sociodemographic and clinical 
characteristics of the study population. 
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Results of viral analysis 
Real-time PCR detected viruses in swab A and swab B in 108 study participants (64.7 %). The 
most abundant viruses in swab A were RSV (17.8 %), followed by HRV/EV (13.8 %), HPIV (11.4 
%), HMPV (6.0 %) and HCoV (5.4 %). Three weeks after the onset of ARI (swab B) the number of 
detected viruses was lower (except for HCoV), the most frequently detected viruses were RSV 
(11.4 %), followed by HRV/EV (10.8 %), HCoV (6.0 %), HPIV (3.0 %), and HMPV (3.0 %). In 59 
subjects (35.3 %) none of the targeted viruses could be detected. Positive virus detection at 
swab B, different to the result at the onset of infection (swab A), could be found in 42 subjects 
(25.1 %).  
Description of bacterial composition and diversity  
Composition of the microbial communities consisted of five most abundant families 
(Moraxellaceae, Streptococcaceae, Corynebacteriaceae, Pasteurellaceae, and 
Staphylococcaceae); remaining families were grouped together as “Others” (Table 2). Among 
“Others”, the most prevalent families included Neisseriaceae, Prevotellaceae, 
Acidaminococcaceae and Flavobacteriaceae. Median (IQR) bacterial density was not 
significantly different between swabs at both time points (swab A: 41.5 (37.8) vs swab B: 32.4 
(43.1) ng/µL). Moraxellaceae and Streptococcaceae represented the two most abundant 
bacterial families, together accounting for more than 50 % of bacterial abundance in either 
swab. Bacterial abundances of Corynebacteriaceae and “Others” at the onset of ARI were 
significantly lower than three weeks later (median (IQR) swab A: 0.1 % (0.7) vs swab B: 0.2 % 
(1.1), P = 0.002 and median (IQR) swab A: 6.6 % (14.7) vs swab B: 9.4 % (27.3), P = 0.004 
respectively). Abundances of the remaining bacterial families (Moraxellaceae, 
Streptococcaceae, Pasteurellaceae and Staphylococcaceae) were not significantly different 
between onset of ARI and three weeks later (Table 2). Shannon Diversity Index (SDI) and 
Appendix 
331 
bacterial richness of all samples were lower at the onset of ARI (SDI median (IQR) swab A: 1.0 
(0.8), bacterial richness median (IQR) 33 (35)) compared to three weeks later (SDI median (IQR) 
swab B: 1.1 (1.2), bacterial richness median (IQR) 38 (36); P = 0.013 and 0.052 respectively) 
(Table 2). 
Infant cluster analysis based on bacterial families 
Five main clusters could be identified in swab A (n = 165), whereas only three main clusters 
could be identified in swab B (n = 155) (Figure 2). The five most prevalent clusters at swab A 
were cluster A1 (Moraxellaceae-dominated, 33.9 %), cluster A2 (Moraxellaceae & 
Streptococcaeae-dominated, 30.9 %), cluster A3 (Streptococcaceae-dominated, 18.8 %), cluster 
A4 (“Others”-dominated, 8.5 %) and cluster A5 (Pasteurellaceae-dominated, 7.9 %). The three 
clusters based on bacterial abundances in swab B were cluster B1 (Moraxellaceae-dominated, 
61.9 %, cluster B2 (“Others”-dominated, 21.9 %) and cluster B3 (Streptococcaceae-dominated, 
16.1 %) (Figure 2). The most abundant cluster in both swabs was dominated by Moraxellaceae, 
which showed the lowest bacterial diversity (SDI median (IQR) A1: 0.67 (0.63); B1: 0.88 (0.76)). 
The number of infants in this cluster increased in size between the onset of ARI and three 
weeks later from 33.9 % to 61.9 % (Figure 3). Cluster A4 (“Others”-dominated) at the onset of 
ARI resembles in its composition cluster B2 three weeks later and more than doubles in size 
(from 8.5 % to 21.9 %) (Figures 2 and 3). In infants of these two clusters, the bacterial diversity 
was highest (SDI median (IQR) A4: 2.54 (1.52); B2: (2.40 (0.56)). Differences in the SDI and 
Jaccard dissimilarity indices between infant clusters were significant (P < 0.001) (Supplementary 
table E1). 
Influence of host and environmental factors on infant clusters 
Infant clusters were tested for differences based on the following factors: age, season at first 
ARI, sex, cohabitating siblings, cesarean section, atopy, childcare attendance, breastfeeding 
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status and environmental tobacco smoke exposure. Statistically significant differences between 
clusters at the onset of infection could be seen in infants with atopy risk, with higher 
proportions in cluster A2 and A5 (76.5 % and 84.6 % respectively) compared to cluster A3 (38.7 
%) (P = 0.008) (Supplementary table E2). In swab B, childcare attendance was significantly 
different between clusters with an overrepresentation of childcare attendance in the 
Moraxellaceae-dominated cluster B1 (P = 0.030) (Supplementary table E3). For all the other 
aforementioned host and environmental factors no significant differences could be observed 
(Supplementary tables E2 and E3). 
Respiratory viruses and infant clusters 
At the onset of infection (swab A), HMPV occurrence was significantly different between 
clusters, with the highest detection rate in the Streptococcaceae-dominated cluster A3 (16.1 %) 
(P = 0.030). For all other tested respiratory viruses (HRV/EV, RSV, HCoV, HPIV) no significant 
difference in occurrence between clusters could be found (Supplementary table E4). Three 
weeks after the onset of infection (swab B), presence of HRV/EV, as well as of HCoV, was 
significantly different among clusters (P = 0.030 and P = 0.007 respectively). HRV/EV was 
overrepresented in the Moraxellaceae-dominated cluster B1 (14.6 %) vs B2 (2.9 %) and B3 (0.0 
%). HCoV was highest in cluster B3 (20.0 %) vs B1 (4.2 %) and B2 (0.0 %). HRV and HCoV were 
both underrepresented in the “Others”-dominated cluster B2 (P = 0.020 and P < 0.001 
respectively) (Supplementary table E5). 
Occurrence of any new virus in swab B compared to viral detection in swab A was significantly 
different among clusters (P = 0.042), with an overrepresentation in cluster B1 (29.2 %) and an 
underrepresentation in cluster B2 (8.8 %). New detection of HRV/EV and HCoV in swab B, 
compared to the onset of infection, was also significantly different among clusters (P = 0.017 
and P = 0.021 respectively) (Supplementary table E5). 
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Duration of respiratory symptoms and infant clusters  
Weekly recorded symptom persistence after the onset of infection showed a mean (SD, range) 
duration of 2.3 (1.5, 1-11) weeks. Presence of symptoms two weeks after the onset of ARI 
showed a borderline significant difference between clusters determined at swab A (P = 0.061): 
symptomatic infants were more common in cluster A2 (37.3 %, P = 0.025) and 
underrepresented in clusters A3 (12.9 %, P < 0.01) and A4 (7.1 %, P < 0.01) (Table 3).  
Presence of symptoms three weeks after the onset of ARI was different between clusters in 
swab B (P < 0.001). There were less symptomatic infants in cluster B2 (5.9 %, odds ratio (95 % 
CI) 0.2 (0.0-0.7)) and more symptomatic infants in clusters B1 (29.2 %) and B3 (56.0 %, odds 
ratio (95 % CI) 3.3 (1.3-8.0)) (Figure 3, Table 4, Supplementary table E6). Adjusting for age and 
season did not change these associations (Supplementary table E7). Interestingly, SDI in swab B 
was much higher in cluster B2 (SDI median (IQR): 2.40 (0.56)) compared to B1 (0.88 (0.76)) and 
B3 (1.06 (0.69)) (P < 0.001) (Supplementary table E1). 
Overall, mainly in clusters with lower diversity and overrepresentation of Moraxellaceae or 
Streptococcaceae (A1, B1, B3), the proportion of persistently symptomatic patients was higher, 
whereas infants in clusters characterized by high diversity and overrepresentation of “Others” 
(A4, B2), showed more rapid symptom recovery following ARI. (Figure 3, Table 4). 
Duration of respiratory symptoms and respiratory viruses 
Enrichment analysis revealed an overrepresentation of HCoV in cluster B3, in which the 
presence of symptoms at swab B, as well as being continuously symptomatic for ≥ three weeks, 
is overrepresented (Supplementary table E5). Despite this finding, type of virus at swab A and 
swab B was not associated with duration of respiratory symptoms (Supplementary tables E8 - 
E10). 
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DISCUSSION 
Using an unsupervised approach in a representative prospective central European white 
healthy birth cohort (21), we could show that the nasal microbiota of infection-naïve infants 
exhibited five distinct major microbial patterns at the onset of the first acute respiratory tract 
infection, largely independent of the type of common respiratory virus. Three weeks after the 
onset of the ARI, these five distinct clusters became three dominant clusters. The duration of 
respiratory symptoms was associated with clusters based on microbiota three weeks after the 
onset of infection, but not with commonly observed respiratory viruses, indicating close 
microbiota-host interactions.  
Bacterial composition of nasal swabs in our study consisted primarily of five families 
(Moraxellaceae, Streptococcaceae, Corynebacteriaceae, Pasteurellaceae, and 
Staphylococcaceae) which is comparable to previous studies on microbiota in infants and young 
children (6, 8, 17, 19, 25). 
With the exception of childcare and atopy, we did not observe any other host or environmental 
effects on microbiota cluster composition. Childcare attendance was higher in infants of the 
Moraxellaceae-dominated cluster B1. The association of increased abundance of Moraxella in 
infants attending childcare has been similarly observed by Teo et al. (6). 
At the onset of infection (swab A), higher rates of HMPV in the Streptococcaceae-dominated 
cluster A3 could be found. A similar observation has been described previously by Verkaik et al. 
Frequent nasopharyngeal carriage of Streptococcus pneumoniae in children seemed to increase 
susceptibility to HMPV (26). Three weeks after the onset of infection there was a higher 
proportion of HCoV detection in the Streptococcaceae-dominated cluster B3, compared to the 
other clusters. However, the rate of HCoV detection was too low to allow meaningful statistical 
analyses. In the literature, no specific effect of HCoV on Streptococcaceae could be found. 
Appendix 
335 
HRV/EV detection was higher in the Moraxellaceae-dominated cluster B1. This is consistent 
with published observations. Korten et al. reported an increase of Moraxellaceae in infants with 
symptomatic HRV/EV infections (8). Kloepfer et al. found similarly increased detection rates of 
Moraxella catarrhalis and Streptococcus pneumoniae associated with HRV/EV (27). 
We observed less symptomatic infants in the ”Others”-dominated cluster B2 three weeks after 
the onset of infection. Bacterial abundances of Staphylococcaceae and Corynebacteriaceae 
were significantly higher in cluster B2 than in clusters B1 or B3 (Figure 2). Similarly, Teo et al. 
recognized Staphylococcus and Corynebacterium as commensals, which seem to be associated 
with respiratory health (19). Three weeks after the onset of ARI, we found most symptomatic 
infants in the Streptococcaceae-dominated cluster B3. Similarly, Kloepfer et al. identified 
detection of Streptococcus pneumoniae as a relevant co-factor associated with increased 
respiratory symptoms with concurrent HRV infection (27). 
In our study, duration of symptoms was not associated with type of virus which is consistent 
with observations by Carlsson et al (28). He described the duration of wheezy episodes in high-
risk infants and young children as independent of the microbial trigger. However, numbers of 
detected viruses in our study might have been too low to detect associations between virus-
type and symptom duration. 
Strength of the study is the relatively high number of studied infants from a prospective birth 
cohort with comprehensive information on antenatal and postnatal history, including weekly 
telephone interviews (21). However, due to the high variability of the microbiota, it is possible 
that significant differences in the bacterial composition associated with certain viruses and host 
factors could only become obvious with an even higher number of infants. A limitation of our 
study is that the age at onset of ARI naturally varied, since the focus of this prospective study 
was to catch the very first symptomatic ARI in infants. Our study design precludes information 
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on the nasal microbiota in an asymptomatic period immediately prior to the first ARI. 
Additional information on this could help recognize changes in the bacterial composition which 
might have preceded symptoms of the ARI, and could have contributed to an understanding of 
the cause-effect relationships between microbiota, viruses and respiratory symptoms. We 
analyzed only five different viruses in our samples and, therefore, might have missed the 
presence of other viruses. However, we deliberately focused on the five targeted viruses that 
have previously been shown to be the most common viruses in our population (3). 
Respiratory tract microbiota seems to affect susceptibility to viral infections, which has been 
shown in animal, in-vitro and clinical studies (as reviewed by (20, 29)). Viral-bacterial 
interactions are complex and certain combinations of viruses and bacteria can exert either 
synergistic or inhibitory effects. It seems that certain bacteria can lead to an enhanced or 
reduced inflammatory response, and thereby modulate the burden of respiratory symptoms 
(10). The clusters three weeks after the onset of infection that were associated with increased 
symptoms were dominated by Moraxellaceae and Streptococcaceae, two potentially 
pathogenic bacterial families, which might result in a sustained ARI with symptoms. In a recent 
study, young children showed an exaggerated inflammatory response to RSV in the presence of 
nasopharyngeal microbiota clusters enriched with Haemophilus influenzae and Streptococcus 
pneumoniae (10). In contrast, cluster B2, which exhibited fewer symptoms, contained higher 
abundances of Corynebacteriaceae and Staphylococcaceae. These organisms have similarly 
been recognized by Teo et al. to be associated with respiratory health (6). Nasopharyngeal 
Staphylococcus aureus was found to be associated with lower disease severity in RSV infections 
(10). Biesbroek et al. reported less ARI in infants with nasopharyngeal microbiota dominated by 
Corynebacterium and Dolosigranulum (25). Whether these organisms are simply biomarkers 
indicating respiratory health, or whether they have immediate protective effects on the 
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respiratory tract, remains unclear. Cluster B2 identified three weeks after the onset of ARI was 
also characterized by higher bacterial diversity compared to the other clusters. Lower diversity 
in infants with longer persistence of symptoms could reflect an outgrowth of certain potentially 
pathogenic bacterial families e.g. Moraxellaceae, or potentially a lack of beneficial microbiota. 
It has been shown that the production of pro-inflammatory cytokines by dendritic cells is higher 
after stimulation by Moraxella catarrhalis and Haemophilus influenzae compared to Prevotella 
strains, common commensals of the respiratory tract microbiota. Co-stimulation with 
Prevotella reduces the Haemophilus influenzae-induced production of pro-inflammatory 
cytokines (30). This could indicate that commensals, such as Prevotella and others, are not only 
filling a niche, but are also functionally important for the maintenance of “healthy” equilibrium. 
Overall, our data show that high diversity of upper respiratory tract microbiota at the very first 
ARI and three weeks later seems to be beneficial for health. Treatment with antibiotics seems 
attractive, but data on antibiotic effects in the manipulation of airway microbiota in infants and 
children is scarce. A prerequisite would be to know the “ideal” microbial composition 
associated with respiratory health and the highest resilience in order to optimize antimicrobial 
treatment. Immunomodulatory substances, such as OM-85, a bacterial lysate, could be another 
potential modifier of the airway microbiota (31). 
In conclusion, nasal microbiota at the onset of the first ARI in infants is different compared to 
three weeks later. The fact that infants with prolonged respiratory symptoms after ARI, 
compared to infants with quicker recovery, tend to exhibit distinct microbial compositions 
indicates the presence of close microbiota-host interactions. Future studies will need to reveal 
how the microbial composition influences the dynamic equilibrium of viruses and bacteria, and 
how this is related to inflammation, mucosal function, immune development and subsequent 
chronic lung disease. 
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Table 1. Baseline characteristics of study population 
Variable  
Total participants, n (% male) 167 (57) 
Gestational age, weeks; mean (SD*) 39.3 (2.0) 
Birth weight, kg; mean (SD) 3.3 (0.55) 
Season at birth Spring 62 (37) 
 Summer 44 (26) 
 Autumn 32 (19) 
 Winter 29 (17) 
Age at ARI†, weeks; mean (SD; range) 29.9 (12.5; 2-52) 
Season at ARI Spring 40 (24) 
 Summer 14 (8) 
 Autumn 38 (23) 
 
Winter 75 (45) 
Atopy 109 (65) 
Childcare attendance 32 (19) 
Breastfeeding at time of ARI 99 (60) 
Environmental tobacco smoke exposure 24 (14) 
Other siblings (living in the same household) 106 (63) 
One sibling 75 (45) 
≥ two siblings 31 (19) 
Data are presented as n (%) unless otherwise noted. *SD, standard deviation; †ARI, acute respiratory 
tract infection. ‡Swab A taken at the onset of ARI, swab B taken three weeks later. 
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Table 2. Abundances of bacterial families and Shannon Diversity Indices (SDI) 
Bacterial family At onset of ARI* 
(swab A) 
Three weeks after onset of ARI* 
(swab B) 
Moraxellaceae 52.4 (66.5) 49.5 (66.2) 
Streptococcaceae 19.2 (41.03) 16.31 (33.9) 
Corynebacteriaceae 0.1 (0.7) 0.2 (1.1)† 
Pasteurellaceae 0.4 (1.9) 0.3 (1.5) 
Staphylococcaceae 0.1 (0.6) 0.1 (0.6) 
“Others” 6.6 (14.7) 9.4 (27.3)† 
SDI, median (IQR) 1.0 (0.8) 1.1 (1.2)‡ 
Richness, median (IQR) 33 (35) 38 (36) ‡ 
*ARI, acute respiratory tract infection. †Abundance of Corynebacteriaceae and “Others” 
significantly different between swab A and swab B (P = 0.002 and 0.004 respectively, Wilcoxon 
signed rank sum test); ‡Shannon Diversity Indices (SDI) and bacterial richness are lower at time 
point A compared to time point B (P = 0.013 and 0.052 respectively, Wilcoxon signed rank sum 
test). Data are presented as median % (IQR) for bacterial families and as median (IQR) for SDI 
and bacterial richness. 
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Table 3. Infant clusters at the onset of ARI* (swab A) and presence of symptoms 
Cluster 
(n= 165) 
A1 
(n= 56) 
A2 
(n = 51) 
A3 
(n= 31) 
A4 
(n = 14) 
A5 
(n = 13) 
P value 
Symptomatic 
after 1 week 
38 (67.8) 43 (84.3)  19 (61.3) 8 (53.3) 9 (69.2) 0.121
† 
Symptomatic 
after 2 
weeks 
17 (30.4) 19 (37.3)  4 (12.9)  1 (7.1)  4 (30.8) 0.061
‡ 
Symptomatic 
after 3 
weeks 
19 (33.9) 12 (23.5) 8 (25.8) 4 (28.6) 5 (38.5) 0.754‡ 
Continuously 
symptomatic 
for ≥ 3weeks 
13 (23.3) 9 (17.6) 2 (6.5)  1 (7.1) 3 (23.1) 0.329
‡ 
*ARI, acute respiratory tract infection. Data are presented as n (%). Statistical analyses were 
performed using a Chi-square† or Fisher’s exact test‡. Significant overrepresentation (bold 
letters, ) and significant underrepresentation (bold/italic letters, ) of presence of symptoms 
in the clusters was assessed by enrichment analysis. 
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Table 4. Infant clusters three weeks after onset of ARI* (swab B) and presence of symptoms 
Cluster 
(n = 155) 
B1 
(n = 96) 
B2 
(n = 34) 
B3 
(n = 25) 
P value 
Symptomatic 
after 1 week 
70 (72.9) 22 (64.7) 16 (64.0) 0.135† 
Symptomatic 
after 2 
weeks 
28 (30.2) 5 (14.7)  9 (36.0) 0.454
† 
Symptomatic 
after 3 
weeks 
27 (29.2) 2 (5.9)  14 (56.0)  < 
0.001‡ 
Continuously 
symptomatic 
for ≥ 3weeks 
16 (16.7) 1 (2.9)  9 (36.0)  0.010
‡ 
*ARI, acute respiratory tract infection. Data are presented as n (%). Statistical analyses were 
performed using a Chi-square† or Fisher’s exact test‡. Significant overrepresentation (bold 
letters, ) and significant underrepresentation (bold/italic letters, ) of presence of symptoms 
in the clusters was assessed by enrichment analysis. 
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FIGURES 
 
Figure 1. Flow chart of the study population 
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Figure 2. Composition of the most common clusters at the onset of the first ARI (swab A) and 
three weeks later (swab B) illustrated as bacterial abundances of the 5 most common bacterial 
families with the remaining grouped as “others”. Clusters with sizes of < 5 % are not depicted. 
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Figure 3. Results of hierarchical clustering based on the microbial composition at the onset of 
the first ARI (swab A) and three weeks later (swab B). The size of the circles and the numbers 
inside indicate the number of individuals assigned to each cluster. The connecting bars indicate 
the transition from one particular cluster to another between swabs A and B; the size of the 
bars corresponds to the number of transitioning individuals.  
Areas in the circles of darker green on the left side of the panel indicate the proportion of 
infants at swab A in each cluster who were asymptomatic at swab B compared to the 
proportion of symptomatic infants at swab B (lighter green). 
Areas in the circles of darker orange on the right side of the panel indicate the proportion of 
asymptomatic infants at swab B compared to the proportion of symptomatic infants (lighter 
orange). SDI, Shannon Diversity Index. 
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Supplementary methods E1 
Viral analysis 
Nasal swabs were analyzed by real-time polymerase chain reaction (PCR) assays targeting five 
different respiratory viruses (human rhinovirus/enterovirus (HRV/EV), respiratory syncytial 
virus (RSV), human metapneumovirus (HMPV), human coronavirus (HCoV), human 
parainfluenzavirus (HPIV)), which have been shown previously to be the most common viruses 
in our population (1). One part of the samples has been analysed previously as described by 
Regamey et al. (1). The other part was studied using commercially available real-time PCR kits 
(HCoV/HPIV r-gene®, Rhino/EV/Cc r-gene®, RSV/hMPV r-gene®, Argene, bioMérieux, Marcy-
l’Etoile, France); the analysis was performed according to the manufacturer’s recommendation. 
Definition of acute respiratory tract infection and symptom score 
An acute respiratory tract infection (ARI) was defined as more than two consecutive days of 
cough and/or wheeze accompanied with fever (>38°C), rhinitis, otitis media or pharyngitis (1). 
Wheeze was defined as a squeaky noise or whistling from the chest audible to parents. 
Respiratory symptoms were assessed using a standardized scoring system (2). Throughout the 
first year of life i.e. also during the time of the ARI any use of antibiotics was recorded (3).  
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Nasal swab collection 
Nasal swabs were collected at the onset of the first ARI (swab A) and three weeks later (swab B) 
at the homes of the infants by a research nurse using Neonatal Flocked Swabs (UTM, Copan, 
Italy) and transport tubes (UTM, Copan, Italy). The samples were immediately snap-frozen and 
then stored at minus 80°C in phosphate-buffered saline containing 40 U/mL RNase-inhibitor 
(Roche, Basel, Switzerland). 
Definition of host factors 
A detailed pre- and postnatal questionnaire allowed collecting extensive data on several host 
factors which were of interest in our study. Atopy was defined as positive if the infants’ mother, 
father or siblings were suffering from eczema, allergic rhinitis or asthma. Siblings were counted 
when living in the same household as the study participant. Environmental tobacco smoke (ETS) 
exposure was defined as positive if there was at least one parent smoking tobacco in the same 
household. Data on nutrition including breastfeeding were collected throughout the first year 
of life in weekly telephone interviews. 
Microbiota analysis 
Bacterial 16S ribosomal ribonucleic acid PCR amplification and 454 Titanium FLX sequencing 
Amplification of bacterial 16S ribosomal ribonucleic acid (rRNA) by PCR and 454 Titanium FLX 
sequencing has been described previously (4, 5). In summary, after DNA extraction the variable 
regions V3 to V5 of bacterial 16S rRNA were amplified by using the multiplex identifier tagged 
primer pair 341F/907R. After elution of the PCR reactions by 40 µL of double-distilled water, 
the concentration was measured with the Agilent 2100 Bioanalyzer (Agilent Technologies, 
Basel, Switzerland). Amplification products with a concentration of less than 1.0 ng/ µL which 
corresponds to less than 1 pg/ µL bacterial DNA were excluded from this study according to 
recent recommendations (6). Samples were pooled using 40 ng/ µL of purified PCR product, 
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resulting in 8 amplicon pools labelled with unique multiplex identifiers. The reads from 454 
Titanium amplicon sequencing were submitted to the National Center for Biotechnology 
Information Sequence Read Archive. Bacterial density was described as the concentration of 
PCR product within a sample. 
Calculation of α and β diversity 
Alpha diversity analysis was performed using the “diversity” function of the “vegan” software 
package of R, version 3.02 (http://www.R-project.org) calculating the Shannon Diversity Index 
(SDI) to describe within-community diversity. For community comparisons between swab A and 
swab B the β diversity was calculated using the “vegdist” function of the “vegan” software 
package of R. We chose the Manhattan-type Jaccard dissimilarity index as weighted 
(abundance-based) β diversity. 
Clustering of microbiota 
The hierarchical clustering was performed using Matlab 2015b (Mathworks, Natick 
Massachusetts, United States). The five most frequent bacterial families with the remaining 
families grouped together as “Others” were used as input variables for clustering of both 
swabs. The optimal number of clusters was determined by Silhouette index (7) and KL index (8) 
for both swabs. Both indices suggested 6 clusters for swab A. Since the sixth cluster was too 
small for phenotyping purposes (n = 2 infants), it was thus excluded from the study, resulting in 
five clusters, including 165 infants. For swab B, KL index suggested five clusters and Silhouette 
index suggested seven clusters. Also taking into account the clusters’ sizes, the optimal cluster 
number for swab B was six. However, as the last three clusters were too small for phenotyping 
purposes (n ≤ 6 infants), they were not considered for the current study, resulting in three 
clusters, including 155 infants. The clustering was also validated with the K-means clustering 
method, which resulted in similar cluster numbers and classes for both swabs.   
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Supplementary table E1. Shannon Diversity Indices (SDI) and Jaccard dissimilarity indices in 
infant clusters 
Swab A. At the onset of ARI* 
 
Swab B. Three weeks after the onset of ARI* 
 Cluster B1 Cluster B2 Cluster B3 P value§ 
Index        
SDI† 0.88 (0.76) 2.40 (0.56) 1.06 (0.69) < 0.001 
Jaccard‡ 0.46 (0.34) 0.74 (0.21) 0.52 (0.49) < 0.001 
*ARI, acute respiratory infection. †SDI, Shannon diversity index. ‡Jaccard dissimilarity index. 
§Kruskal-Wallis test. Data are presented as median, (IQR). 
  
 Cluster A1 Cluster A2 Cluster A3 Cluster A4 Cluster A5 P value§ 
Index       
SDI† 0.67 (0.63) 1.18 (0.68) 1.02 (0.94) 2.54 (1.52) 0.87 (0.76) < 0.001 
Jaccard‡  0.35 (0.43) 0.56 (0.35) 0.73 (0.37) 0.83 (0.28) 0.81 (0.26) < 0.001 
Appendix 
354 
Supplementary table E2. Host and environmental characteristics in infant clusters present at 
the onset of ARI* (swab A) 
Cluster 
(n = 165) 
A1 
(n = 56) 
A2 
(n = 51) 
A3 
(n = 31) 
A4 
(n = 14) 
A5 
(n = 13) 
P value 
Age, months 7.2 [3.8-
8.8] 
7.4 [5.3-
8.8] 
7.3 [3.7-
9.0] 
7.2 [4.8-
9.4] 
5.7 [4.3-
8.2] 
0.920 
Seasons       
Spring 13 (23.2) 12 (23.5) 7 (22.6) 3 (21.4) 5 (38.5) 0.807† 
Summer 4 (7.1) 2 (3.9)  5 (16.1)  1 (7.1) 1 (7.7) 0.364
† 
Autumn 12 (21.4) 11 (21.6) 8 (25.8) 2 (14.3) 5 (38.5)  0.650
† 
Winter 27 (48.2) 26 (51.0) 11 (35.5) 8 (57.1) 2 (15.4)  0.105
† 
Sex, male 33 (58.9) 26 (51.0) 18 (58.1) 11 (78.6)  7 (53.9) 0.609
‡ 
Siblings 35 (62.5) 31 (60.8) 20 (64.5) 8 (57.1) 10 (76.9) 0.761‡ 
Cesarean 
section 
6 (10.7) 8 (15.7) 6 (19.4) 3 (21.4) 2 (15.4) 0.835† 
Atopy 36 (64.3) 39 (76.5)  12 (38.7)  9 (64.3) 11 (84.6)  0.008
‡ 
Childcare 13 (23.2) 9 (17.7) 7 (22.6) 3 (21.4) 0 (0.0)  0.479
† 
Breastfeeding 31 (55.4) 33 (64.7) 17 (54.8) 8 (57.1) 10 (76.9) 0.768‡ 
ETS§ 6 (10.7) 5 (9.8) 6 (19.4) 4 (28.6)  3 (23.1) 0.355
† 
*ARI, acute respiratory tract infection. Data are presented as median [interquartile range] or n 
(%). Statistical analyses were performed using a Kruskal Wallis test for age and Fisher’s exact 
test† or Chi-square test‡ for categorical variables. Significant overrepresentation (bold letters, 
) and significant underrepresentation (bold/italic letters, ) of presence of symptoms in the 
clusters was assessed by enrichment analysis. §ETS, environmental tobacco smoke exposure.  
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Supplementary table E3. Host and environmental characteristics in infant clusters three weeks 
after the onset of ARI* (swab B) 
Cluster 
(n = 155) 
B1 
(n = 96) 
B2 
(n = 34) 
B3 
(n = 25) 
P value 
Age, months 7.1 [4.9-8.7] 8.0 [4.9-9.3] 6.0 [3.8-8.5] 0.142 
Seasons     
Spring 24 (25.0) 7 (20.6) 5 (20.0) 0.892† 
Summer 9 (9.4) 4 (11.8) 0 (0.0)  0.216
† 
Autumn 22 (22.9) 6 (17.6) 6 (24.0) 0.852† 
Winter 41 (42.7) 17 (50.0) 14 (56.0) 0.438† 
Sex, male 54 (56.3) 17 (50.0) 18 (72.0)  0.471
‡ 
Siblings 65 (67.7) 15 (44.1) 18 (72.0) 0.095‡ 
Cesarean section 12 (12.5) 9 (26.5)  1 (4.0)  0.085
† 
Atopy 67 (69.8) 20 (58.8) 15 (60.0) 0.699‡ 
Childcare 24 (25.0)  3 (8.8)  2 (8.0)  0.030
† 
Breastfeeding 55 (57.3) 19 (55.9) 20 (80.0)  0.199
‡ 
ETS§ 12 (12.5) 6 (17.7) 5 (20.0) 0.814† 
*ARI, acute respiratory tract infection. Data are presented as median [interquartile range] or n 
(%). Statistical analyses were performed using a Kruskal Wallis test for age and Fisher’s exact 
test† or Chi-square test‡ for categorical variables. Significant overrepresentation (bold letters, 
) and significant underrepresentation (bold/italic letters, ) of presence of symptoms in the 
clusters was assessed by enrichment analysis. §ETS, environmental tobacco smoke exposure. 
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Supplementary table E4. Infant clusters and detected viruses at the onset of ARI* (swab A) 
 
Cluster 
(n = 165) 
A1 
(n = 56) 
A2 
(n = 51) 
A3 
(n = 31) 
A4 
(n = 14) 
A5 
(n = 13) 
P value 
Any virus  26 (46.4) 20 (39.2)  20 (64.5)  7 (50.0) 7 (53.8) 0.267† 
HRV/EV 8 (14.3) 5 (9.8) 6 (19.4) 2 (14.3) 2 (15.4) 0.773‡ 
RSV 8 (14.3) 11 (21.6) 5 (16.1) 3 (21.4) 3 (23.1) 0.808‡ 
HMPV 3 (5.4) 0 (0.0)  5 (16.1)  1 (7.1) 1 (7.7) 0.030
‡ 
HCoV 4 (7.1) 4(7.8) 1 (3.2) 0 (0.0)  0 (0.0)  0.836
‡ 
HPIV 7 (7.1) 2 (3.9)  5 (16.1) 2 (14.3) 1 (7.7) 0.293
‡ 
> 1 virus 3 (5.4) 2 (3.9) 2 (6.5) 1 (7.1) 0 (0.0) 0.914‡ 
*ARI, acute respiratory tract infection. Data are presented as n (%). Statistical analyses were 
performed using a Chi-square† or Fisher’s exact test‡. Significant overrepresentation (bold 
letters, ) and significant underrepresentation (bold/italic letters, ) of virus detection in the 
clusters was assessed by enrichment analysis. 
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Supplementary table E5. Infant clusters and detected viruses three weeks after the onset of 
ARI* (swab B) 
Cluster 
(n = 155) 
B1 
(n = 96) 
B2 
(n = 34) 
B3 
(n = 25) 
P value 
Any virus 33 (34.4) 6 (17.7) 9 (36.0) 0.162† 
HRV/EV 14 (14.6)  1 (2.9)  0 (0.0)  0.030
‡ 
RSV 11 (11.5) 2 (5.9)  5 (20.0)  0.256
‡ 
HMPV 3 (3.1) 1 (2.9) 1 (4.0) 1.000‡ 
HCoV 4 (4.2) 0 (0.0)  5 (20.0)  0.007
‡ 
HPIV 4 (4.2) 1 (2.9) 0 (0.0)  0.826
‡ 
> 1 virus 3 (8.3) 0 (0.0) 2 (8.0) 0.185‡ 
New virus§ 28 (29.2)  3 (8.8)  7 (28.0) 0.042
‡ 
 Type of new 
virus 
    
 HRV/EV 12 (12.5)  0 (0.0) 0 (0.0) 0.017
‡ 
 RSV 9 (9.4) 1 (2.9)  3 (12.0) 0.447
‡ 
 HMPV 3 (3.1) 1 (2.9) 1 (4.0) 1.000‡ 
 HCoV 3 (3.1) 0 (0.0) 4 (16.0)  0.021
‡ 
 HPIV 4 (4.2) 1 (2.9) 0 (0.0) 0.826‡ 
*ARI, acute respiratory tract infection. Data are presented as n (%). Statistical analyses were 
performed using a †Chi-square or ‡Fisher’s exact test. §Positive virus detection in swab B 
different to result of swab A (either no or different virus detected in swab A). 
Significant overrepresentation (bold letters, ) and significant underrepresentation (bold/italic 
letters, ) of virus detection in the clusters was assessed by enrichment analysis. 
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Supplementary table E6. Risk of symptom persistence by microbiota clusters three weeks after 
onset of ARI* (swab B) 
 
Cluster 
(n= 155) 
B1† 
(n= 96) 
B2 
(n = 34) 
B3 
(n= 25) 
Symptomatic after 1 week  0.7 (0.3-1.6); 
0.367 
0.7 (0.3-1.7); 
0.383 
Symptomatic after 2 weeks  0.4 (0.1-1.9); 
0.103 
1.4 (0.5-3.5); 
0.510 
Symptomatic after 3 weeks  0.2 (0.0-0.7); 
0.016 
3.3 (1.3-8.0); 
0.011 
Continously symptomatic for ≥ 
3 weeks 
 0.2 (0.0-1.2); 
0.073 
2.8 (1.0-7.5); 
0.038 
*ARI, acute respiratory tract infection. Data are presented as odds ratio (95 % confidence 
interval); P value. Associations were estimated using logistic regression. †Reference level is 
cluster 1. 
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Supplementary table E7. Association between clusters 3 weeks after the onset of infection 
(swab B) and presence of symptoms 3 weeks after onset of ARI* and continuous presence of 
symptoms for ≥ 3 weeks after onset of ARI 
*ARI, acute respiratory tract infection. †Adjusted for age and season. ‡B1 is reference cluster.  
 
  
 Unadjusted Model Adjusted model† 
Outcome: Presence of symptoms 3 weeks after onset of ARI 
 Coeff 95 % CI P value Coeff 95 % CI P value 
Cluster B1‡ . . . . . . 
Cluster B2 -1.83 -3.33, -
0.34 
0.016 -1.91 -3.42, -
0.39 
0.014 
Cluster B3 1.18 0.27, 2.09 0.011 1.33 0.36, 2.31 0.007 
Outcome: Continuous presence of symptoms for ≥3 weeks after onset of ARI 
Cluster B1‡ . . . . . . 
Cluster B2 -1.89 -3.94, 0.17 0.073 -1.90 -3.98, 0.17 0.072 
Cluster B3 1.03 0.06, 2.01 0.038 1.07 0.04, 2.10 0.041 
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Supplementary Table E8. Associations of detected viruses at swab A with symptom persistence 
 
 No virus 
(n= 85) 
HRV/EV 
(n = 21) 
RSV 
(n = 25) 
HMPV 
(n = 9) 
HCoV 
(n = 8) 
HPIV 
(n = 19) 
P value 
Symptomatic 
after 1 week 
57 (67.1) 17 (81.0) 19 (76.0) 8 (88.9) 6 (75.0) 12 (63.2) 0.550* 
Symptomatic 
after 2 
weeks 
21 (24.7) 7 (33.3) 5 (20.0) 3 (33.3) 5 (62.5) 5 (26.3) 0.283† 
Symptomatic 
after 3 
weeks 
24 (28.2) 6 (28.6) 7 (28.0) 1 (11.1) 4 (50.0) 6 (31.6) 0.687† 
Continously 
symptomatic 
for ≥ 3 
weeks 
13 (15.3) 5 (23.8) 3 (12.0) 0 (0.0) 4 (50.0) 3 (15.8) 0.132† 
Data are presented as n (%). Statistical analyses were performed using a Chi-square* or Fisher’s 
exact test†. 
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Supplementary Table E9. Associations of detected viruses at swab B with symptom persistence 
 
 No virus 
(n = 115) 
HRV/EV 
(n = 16) 
RSV 
(n = 17) 
HMPV 
(n = 4) 
HCoV 
(n = 10) 
HPIV 
(n = 5) 
P value 
Symptomatic 
after 1 week 
78 (67.8) 13 (81.3) 13 (76.5) 4 (100.0) 7 (70.0) 4 (80.0) 0.760 
Symptomatic 
after 2 
weeks 
28 (24.3) 3 (18.8) 6 (35.3) 2 (50.0) 5 (50.0) 2 (40.0) 0.268 
Symptomatic 
after 3 
weeks 
30 (14.0) 5 (31.3) 2 (11.8) 1 (25.0) 6 (60.0) 1 (20.0) 0.367 
Continously 
symptomatic 
for ≥ 3 
weeks 
16 (13.9) 2 (12.5) 4 (23.5) 1 (25.0) 4 (40.0) 1 (20.0) 0.236 
Data are presented as n (%). Statistical analyses were performed using a Fisher’s exact test. 
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Supplementary Table E10. Associations of new viruses* at swab B with symptom persistence 
 
 No virus 
(n = 124) 
HRV/EV 
(n = 16) 
RSV 
(n = 17) 
HMPV 
(n = 4) 
HCoV 
(n = 10) 
HPIV 
(n = 5) 
P value 
Symptomatic 
after 1 week 
85 (68.5) 10 (62.5) 10 (58.8) 4 (100.0) 6 (60.0) 4 (80.0) 0.871 
Symptomatic 
after 2 
weeks 
30 (24.2) 3 (18.8) 5 (29.4) 2 (50.0) 4 (40.0) 2 (40.0) 0.308 
Symptomatic 
after 3 
weeks 
31 (25.0) 5 (31.3) 5 (29.4) 1 (25.0) 5 (50.0) 1 (20.0) 0.214 
Continously 
symptomatic 
for ≥ 3 
weeks 
17 (13.7) 2 (12.5) 4 (23.5) 1 (25.0) 3 (30.0) 1 (20.0) 0.209 
Data are presented as n (%). Statistical analyses were performed using a Fisher’s exact test. 
*Viruses defined as new if different to result of swab A (either no or different virus present at 
swab A) 
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6.3 Aerobic exercise capacity in cystic fibrosis – does CFTR genotype matter? 
Radtke T, Hebestreit H, Gallati S, Schneiderman JE, Stevens D, Hulzebos EHJ, Takken T, 
Boas SR, Urquhart DS, Lands LC, Tejero S, Sovtic A, Dwyer T, Petrovic M, Harris RA, 
Karila C, Savi D, Usemann J, Mei-Zahav M, Ratjen F, Kriemler S, for the CFTR-Exercise 
study group.  
Submitted to Am J Respir Crit Care Med 
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Running title: CFTR genotype and aerobic fitness in cystic fibrosis 
 
Take home message  
In CF, lung function and nutritional status but not CFTR genotype is associated with exercise 
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Abstract 
Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) is expressed in human 
skeletal muscle cells and CFTR dysfunction may present an important determinant of aerobic 
exercise capacity in CF. Previous studies on the relationship between CFTR genotype and 
aerobic exercise capacity are scarce and contradictory.  
This study was designed to explore factors influencing aerobic exercise capacity, expressed as 
peak oxygen consumption (VO2peak) with a specific focus on CFTR genotype in children and 
adults with CF.  
In an international, multicentre cross-sectional study we collected data on CFTR genotype and 
cardiopulmonary exercise tests (CPET) in patients with CF age 8 years and older. CFTR 
mutations were classified into functional classes I-V.  
726 patients from 17 CF centres in North America, Europe and Asia had both valid maximal 
CPET and complete CFTR genotype data and were included in the analysis. Overall, patients 
had reduced VO2peak (mean±SD, 77.3 ± 19.1% predicted), but values were comparable among 
different CFTR classes. Using linear regression analysis adjusted for relevant confounders, 
lung function and body mass index, but not CFTR genotype were the main predictors of 
VO2peak, 
Lung disease severity and reduced nutritional status rather than CFTR genotype are the major 
determinants of aerobic exercise capacity in CF patients.  
 
Abstract Word Count: 200  
Total Word Count: 2951  
 
Keywords: cystic fibrosis transmembrane conductance regulator, peak oxygen consumption, 
lung disease, fitness. 
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Introduction 
Cystic fibrosis (CF) is a disorder with autosomal recessive inheritance that ultimately leads to 
respiratory failure and premature death. The disease is caused by mutations in the Cystic 
Fibrosis Transmembrane Conductance Regulator (CFTR) gene coding for the CFTR protein 
that functions as a channel, mainly for chloride and bicarbonate [1]. CFTR mutations are 
grouped into different classes based on their effect on CFTR protein production, trafficking, 
function and stability [1]. CFTR is expressed in cell membranes of epithelial cells. It can also 
be found at the level of the sarcoplasmic reticulum in airway smooth muscle [2] and human 
skeletal muscle cells [3, 4] and myocardium [5], but the precise physiological role of CFTR in 
these tissues is not fully understood [6]. Previous studies suggest intrinsic functional 
abnormalities in muscles lacking functional CFTR [3, 4], possibly based on a disturbed 
calcium homeostasis in the muscle and increased systemic inflammation [3]. It is therefore 
plausible, that dysfunctional CFTR in human skeletal muscle could be a contributing factor to 
peripheral muscle weakness [7, 8] and reduced exercise capacity (e.g., peak oxygen uptake, 
VO2peak) in CF [8, 9].   
As VO2peak is one of the best predictors for mortality in CF [10], the knowledge of 
important correlates of aerobic performance may help to guide patients’ care. Few 
predominantly small studies have previously investigated relationships between CFTR 
genotype and VO2peak in patients with CF [11-14]. These studies show controversial findings. 
In only one prominent study, Selvadurai and colleagues [12] found that children with CF 
carrying a F508del gene mutation on one allele and a class I or class II CFTR mutation on the 
second allele had strikingly lower VO2peak (by about 30-45%) and peak anaerobic exercise 
capacity (by about 10-17%) compared to patients with a class III, IV or V mutation on the 
second CFTR allele. However, Selvadurai et al. [12] applied univariate analysis and, thus, did 
not control for relevant determinants of exercise capacity such as nutritional status and 
chronic infection with Pseudomonas aeruginosa [8, 15, 16] that could have influenced their 
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study findings and interpretation.  
The current study was designed to investigate factors predicting VO2peak (primary 
endpoint) and maximum work rate (Wattmax, secondary endpoint) with a specific focus on 
CFTR genotype in a large international cohort of children and adults with CF. We aimed to 
compare aerobic exercise capacity among patients with CFTR mutations resulting in severely 
reduced function (combinations of class I-III mutations) to patients with combinations of class 
IV-V mutations characterised by some residual CFTR function at the cell surface [17].  
 
Methods 
Study design and patients 
We invited researchers from of the Exercise Working Group of the European Cystic Fibrosis 
Society to participate in the study. We also searched for publications in PubMed on exercise 
testing in CF to identify centres conducting clinical studies including cardiopulmonary 
exercise testing (CPET). Inclusion and exclusion criteria can be found in the online 
supplemental material as well as detailed information on CPET.  
The classification of CFTR genotype [18, 19] was performed by a geneticist (SG) who 
was blinded for exercise testing data. Details about the functional classification of CFTR 
alleles are shown in Table S1 of the online supplements. We investigated effects of CFTR 
genotype on maximal exercise capacity (% predicted) in patients with both CFTR alleles in 
either class I, II or III (corresponding to severely reduced CFTR function) compared to 
patients with at least one mutant allele in class IV or class V (corresponding to some residual 
CFTR function) [17]. In an exploratory analysis, we compared maximal exercise capacity 
between patients with at least one copy of the F508del mutation and categorised them into 
five groups based on their second CFTR mutation class [12, 18].  
We collected data on anthropometric characteristics, CF-related comorbidities (e.g., 
exocrine pancreatic insufficiency, CF-related diabetes (CFRD), colonisation with 
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Pseudomonas aeruginosa), pulmonary function, CPET related data and genetic data. Chronic 
Pseudomonas aeruginosa infection was considered to be present when >50% of at least 4 
sputum samples collected in the previous year were positive [20]. We calculated % predicted 
values for spirometry [21], VO2peak [22], Wattmax [23] and peak heart rate [24] as well as z-
scores for body mass index (BMI) based on WHO criteria [25]. Percent body fat was 
calculated using sex and age-specific prediction equations [26] and lean body mass was 
derived from body fat and weight. The primary outcome measure was VO2peak, expressed as 
% predicted [22]. 
Ethical approval for this study was obtained from the cantonal ethical committee of 
Zurich, Switzerland (2015-0109). All centres obtained ethical approval (if required) for the 
use of their anonymized patient data according to national and local policies.     
 
Statistical analysis 
Data are presented as means±SD, median (inter-quartile range) or N (%). The 
Kolmogorov-Smirnov Test was used to verify normal distribution of data. The vast majority 
of data were not normally distributed. Descriptive analysis was performed using a non-
parametric Mann-Whitney U test. The χ2 test was used to compare categorical variables 
between groups. Statistical comparisons between the five groups based on CFTR classes were 
performed using the non-parametric Kruskal-Wallis test.  
Simple linear regression analysis with study center adjustment as random intercept 
was used to determine predictors of VO2peak and Wattmax (% predicted). Multilevel mixed-
effects models with a random intercept for each study centre were used to determine 
associations between CFTR genotype-based group and VO2peak (%predicted, primary 
endpoint) and Wattmax (%predicted, secondary endpoint) and adjusted for the following 
predictor variables: age, sex, BMI z-score, FEV1 (% predicted), CF-related diabetes (CFRD), 
exocrine pancreatic insufficiency and infection with Pseudomonas aeruginosa.  
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To crosscheck and confirm our approach to define the exercise capacity outcome 
variables as percent-predicted values, we additionally performed linear mixed-models using a 
multiplicative, allometric approach to account for potential effects of body size and 
pulmonary function on the relationship between CFTR genotype and VO2peak (see online data 
supplement). 
All statistical analyses were performed with the statistical software package SPSS 
version 23 (IBM Corp. Armont, NY, USA) and Stata statistical software version 12 
(StataCorp. 2012, College Station, Texas, USA). The significance level was set at P<0.05. 
 
Results 
We contacted 32 centres in North America, Europe and Asia by email of which 17 provided 
data for this study. Included centres were from Canada (N=3, 293 patients), US (N=2, 110 
patients) and one centre each from Australia (N=30), France (N=59), Germany (N=69), 
Greece (N=39), Israel (N=37), Italy (N=34), Netherlands (N=93), Spain (N=51), Serbia 
(N=64), Switzerland (N=42), UK (N=39), and Vienna (N=30). A flow chart of included 
patients is shown in Figure 1 and patient characteristics are shown in Table 1. Patients that did 
not perform maximally during the CPET (N=112) were on average older, had lower FEV1, 
lower exercise capacity and more CF-related comorbidities (Table 1). The lower exercise 
capacity in patients not performing maximally was not explained by a pulmonary function 
limitation (i.e., a lower breathing reserve at end-exercise (VEpeak/MVVpred)) compared to the 
group demonstrating maximal effort (Table 1). Table 2 shows data for maximal exercise 
capacity, lung function, nutritional status and CPET-related variables grouped by CFTR class.  
 
Predictors of aerobic exercise capacity in patients with CF 
In univariate analyses with study center adjustment, age, FEV1 % predicted, forced vital 
capacity (FVC, % predicted), BMI z-score, CFRD and chronic Pseudomonas aeruginosa 
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infection were associated with VO2peak and Wattmax (expressed as % predicted). Exocrine 
pancreatic insufficiency was only associated with Wattmax (% predicted). FVC was not 
included in the final multilevel model due to a high collinearity with FEV1 (R=0.89, 
P=0.001). The CFTR functional class (I-V) was not associated with either VO2peak or Wattmax 
(% predicted). We noticed differences in VO2peak and Wattmax between the study centres. 
Consequently, the centre was included as random intercept in the multilevel mixed-effects 
models. In fully adjusted models, FEV1 % predicted (Beta-coefficient (95% CI)) 0.413 (0.356 
to 0.471), P<0.001 and BMI z-score 1.724 (0.727 to 2.771), P=0.001 were significantly 
associated with VO2peak (% predicted). In the model for Wattmax (% predicted), FEV1 % 
predicted 0.459 (0.395 to 0.524), P<0.001 and BMI z-score 1.241 (0.122 to 2.361), P=0.030 
remained the only significant predictors.  
 
Exercise capacity between patients with severely reduced CFTR function versus patients 
with residual CFTR function  
The prevalence of CF-related comorbidities was higher for patients with only class I-III CFTR 
mutations compared to patients with at least one CFTR allele associated with residual 
function (class IV or class V) (Table 3). Univariate analysis revealed no differences in aerobic 
exercise capacity (absolute and % predicted VO2peak and Wattmax) between the two groups. In 
mixed-effects models, lung function and nutritional status were the only predictors for VO2peak 
and Wattmax (% predicted) independent of CFTR function (Table 4). In accordance, the results 
were confirmed when allometric modelling was applied (see Table S2 in the online data 
supplement).  
 
Exercise capacity among patients with at least one copy of the F508del-CFTR mutation 
In 653 patients with at least one copy of the F508del-CFTR (class II) mutation, no differences 
between CFTR groups were found for either VO2peak or Wattmax (absolute values or % 
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predicted, see Table S3). In linear regression analyses, patients with one copy of a class V 
mutation had a significantly lower VO2peak compared to patients with two copies of a class II 
mutation (Beta-coefficient (95% CI)) -10.64 % (-17.03 to -4.24), P<0.001, see Table S4). 
Furthermore, Wattmax values were lower for the group with one copy of a class V mutation 
(Beta-coefficient (95% CI)) -9.95 % (-17.31 to -2.59) P=0.008). In addition, the same 
association was found for (ln) VO2peak (Beta-coefficient (95% CI)) -0.14 L (-0.22 to -0.06), 
P=0.001 and (ln) Wattmax (Beta-coefficient (95% CI)) -0.12 W (-0.21 to -0.04), P=0.005 in 
the allometric models (Table S5). 
 
Discussion 
This international multicentre study evaluated predictors of aerobic exercise capacity 
with particular focus on CFTR genotype in patients with CF. We found that severity of CFTR 
genotype using different CFTR categorisations, combinations and analytic approaches, was 
not predictive for aerobic exercise capacity. In the present study, pulmonary function and 
nutritional status were strongly associated with exercise capacity. Our data support previous 
studies showing that pulmonary function and nutritional status are (among others) strong 
predictors of aerobic exercise capacity in CF [9, 13, 27-30].  
Our main aim was to compare maximal exercise capacity between patients with CF 
carrying only minimal function CFTR mutations (classes I-III) and those with at least one 
residual function (class IV or V) CFTR mutation. In the primary analysis, our data showed no 
differences in aerobic exercise capacity between groups in both unadjusted and adjusted 
analyses. These results were confirmed by the use of allometric models that were computed to 
exclude potential limitations of the prediction equations for VO2peak and Wattmax [31]. 
Irrespective of what analytic approach was used – including the adjustments for important 
confounders, CFTR genotype was not related to aerobic exercise capacity in patients with CF.  
Appendix 
374 
In an exploratory analysis, we could not reproduce the findings of a study by 
Selvadurai et al. [12] that showed a strong relationship between the severity of CFTR 
functional impairment and reduced exercise capacity using univariate analysis in children 
with CF aged 8-17 years with at least one copy of the F508del-CFTR mutation. In univariate 
analysis, we noticed no between group differences in either absolute or % predicted values for 
VO2peak or Wattmax. In the adjusted analysis, patients with one copy of a class V mutation had 
significantly lower exercise capacity (about 10% predicted for both VO2peak and Wattmax) 
compared to patients homozygous for the F508del-CFTR mutation. Patients with one copy of 
a class V mutation had the same ethnical background and comparable lung function but better 
nutritional status and lower prevalence of exocrine pancreatic insufficiency compared to 
patients homozygous for the F508del-CFTR mutation. Moreover, there was no evidence for 
ventilatory limitation (i.e., lower breathing reserve) during exercise. Altogether, these factors 
do not explain the lower exercise capacity in these patients.  
Chronic systemic inflammation is known to be associated with reduced exercise 
capacity due to its deleterious effect on skeletal muscle function [32]. Unlikely, but one could 
argue that these patients have higher chronic systemic inflammation. Unfortunately, we do not 
have data on the level of inflammation on our patients, but chronic Pseudomonas aeruginosa 
infection is known to induce inflammatory processes in CF [33] that could negatively impact 
on exercise capacity. Van de Weert-van Leeuwen et al. [13] have previously been shown that 
presence of Pseudomonas aeruginosa in adolescents with CF is a predictor of a steeper 
decline in VO2peak over time, independent of age, nutritional status, pulmonary function and 
immunoglobulin G levels. However, relatively fewer patients with a group V mutation were 
colonized with Pseudomonas aeruginosa than patients with solely CFTR class II mutations 
(reference group) despite a lower VO2peak in the former compared to the latter group. 
Inflammation is, thus, unlikely causing the reduced VO2peak in the patients with group V-
mutations. Although, systemic inflammation has been shown to be associated with severity of 
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lung impairment [34, 35], lung function among groups was comparable. The differences 
between our study and the study by Selvadurai et al. [12] might be explained by the much 
better preserved lung function in all of our patients and our rigorous adjustment for important 
clinical confounders in the statistical models. Our data do not support a substantially higher 
exercise capacity in patients with mild CFTR mutations. Finally, we can only speculate that 
lower habitual physical activity, a determinant of VO2peak in CF [9] contributes to the reduced 
exercise capacity in patients with one copy of a class V mutation.  
Our data do not support a relevant role of CFTR genotype on aerobic exercise capacity 
in patients with CF. However, some theoretical considerations deserve further explanation to 
shed light on potential underlying molecular mechanisms of the CFTR defect and its potential 
consequences on peripheral muscle function and exercise capacity. Recently, the expression of 
functional CFTR channels in human skeletal muscle was demonstrated [3, 4]. Lamhonwah and 
colleagues [4] speculated that a dysfunction in sarcoplasmic reticulum CFTR channels might 
affect calcium release channels and thus ATP-mediated actin-myosin interaction that is 
essential for muscle contraction. Moreover, Divangahi et al. [3] suggested that excessive 
systemic inflammation initiates a process in which the abnormal vulnerability of CFTR-
deficient muscle to pro-inflammatory mediators could play a key role in the development of 
skeletal muscle weakness observed in individuals with CF [7]. Of note, these observations are 
based on animal experiments and have not yet been confirmed in humans. Based on the in vitro 
experiments, suggesting that systemic inflammation plus CFTR dysfunction may impair muscle 
function, one could speculate that potential detrimental effects of CFTR genotype on aerobic 
exercise capacity would only be detected with high levels of inflammation. Overall, our 
patients had moderately impaired pulmonary function (mean±SD FEV1 77.3 ± 23 % predicted) 
and a sub analysis including only patients with severe lung disease (FEV1<50% predicted) 
yielded similar results for the comparison between minimal-function and residual function 
mutations.  
Appendix 
376 
In the aggregate, in our study the severity of CFTR functional class had no negative 
influence on VO2peak, a strong and independent predictor of survival in CF [10, 36]. Previous 
work demonstrated differential effects of CFTR genotype and mortality [37], independent of 
lung function, nutritional status, pancreatic insufficiency or Pseudomonas aeruginosa 
colonization [17]. Whether the predictive value of VO2peak differs among groups with varying 
CFTR genotype remains to be investigated in longitudinal studies. Moreover, since regular 
exercise training has the potential to improve VO2peak in CF patients [38], future studies might 
explore whether there is a different responsiveness of VO2peak to exercise training according to 
CFTR genotype.  
In comparison to previous studies on the genetic contribution to aerobic exercise 
capacity in CF, our study with more than 700 patients provides by far the largest dataset on 
CPET-derived measures of aerobic exercise capacity in CF. We collected CPET data from 17 
specialised CF centers among Europe, North America and Asia including patients with a 
broad age range (8 to 61 years) and disease severity (FEV1 16 to 123 % predicted) providing a 
quite representative study sample for the overall CF population.  
This study has several limitations. Firstly, we collected data from different 
international study centres. Thus, we cannot rule out differences in treatment strategies and 
treatment quality possibly affecting the health status of the patients thereby introducing bias. 
Secondly, the groups classified according to CFTR classes were unevenly distributed with a 
high number of patients in the group with the most common F508del-CFTR mutation [39, 40] 
compared to patients carrying a CFTR class III, IV or V mutation. Despite the large sample 
size of 726 patients from 17 different CF centres worldwide, group sizes with CFTR class III-
V mutations were relatively small because of the generally low prevalence of these gene 
mutations [41]. For these reasons, the explanatory analysis should be interpreted with caution. 
Moreover, we were not able to consider all known confounders impacting exercise capacity 
such as physical activity [9] and inflammatory markers [13] that were either not routinely 
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assessed or not available for this retrospective analysis. Nevertheless, strong predictors of 
VO2peak such as pulmonary function [9, 13, 27-29] and nutritional status [30] as well as proxy 
measures of inflammation (i.e., Pseudomonas aeruginosa status), were included in our 
statistical analysis. Finally, we acknowledge the limitation of the retrospective study design 
and the collection of data over a large time period. However, it seems practically impossible 
to acquire such a large dataset on CPET variables in a prospective study that would overcome 
the limitations of the current study.  
In summary, in our large, international cohort of children, adolescents and adults with 
CF, we found that pulmonary function and nutritional status were strong predictors of 
exercise capacity without evidence of an association between the severity of CFTR genotype 
and reduced maximal exercise capacity. Future studies might explore whether there is a 
different responsiveness of VO2peak to exercise training according to CFTR genotype. 
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Figure 
Figure 1. Flow chart of included patients. CFTR, cystic fibrosis transmembrane conductance 
regulator; CPET, cardiopulmonary exercise test.  
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Table 1. Clinical characteristics and cardiopulmonary exercise testing data for patients with 
valid versus non-valid maximal exercise tests. 
Variable N Patients with valid 
maximal CPET 
N Patients with non-valid 
maximal CPET 
Age (years)
†
 726 16.4 (13.0, 22.1) 112 20.9 (13.9, 28.8) 
Sex (% females) 726 330 (45) 112 45 (40) 
BMI z-score
*
 726 -0.24 (-0.92, 0.47)  112 -0.01 (-0.74, 0.70) 
FEV1 (% predicted)
*
 724 79 (66, 91) 111 74.3 (56.9, 85.9) 
CFRD (N, %)
*
 723 79 (11) 109 20 (18) 
Pseudomonas 
aeruginosa (N, %)
†
 
716 371 (52) 105 83 (79) 
Pancreatic insufficiency 
(N, %) 
724 611 (84) 112 90 (80) 
VO2peak (% predicted)
†
 726 79 (66, 91) 112 68 (58, 76) 
Wattmax (%predicted)
†
 724 84 (70, 100) 112 74 (61, 90) 
HRpeak (% predicted)
†
 725 93 (88, 96) 112 87 (80, 92) 
RER
†
 639
‡
 1.16 (1.10, 1.23) 36
‡
 0.99 (0.96, 1.01) 
VEpeak (L.min
-1
)
†
 726 68.0 (53.3, 86.3) 112 56.9 (45.1, 75.6) 
VEpeak/MVVpred
†
 725 86 (70, 102) 111 76 (63, 87) 
Data are median (interquartile range) or N (%). BMI; body mass index; CFRD, Cystic 
Fibrosis Related Diabetes; CPET, cardiopulmonary exercise test; FEV1, forced expiratory 
volume in one second; RER, respiratory exchange ratio; VO2peak, peak oxygen consumption; 
Wattmax, maximum work rate; Statistical comparisons between groups were performed using 
the non-parametric Mann-Whitney U test or the χ2 test as appropriate. * P<0.05; † P<0.001; ‡ 
RER data were not available from two study centers. 
 
  
Table 2 Lung function, nutritional status and exercise capacity in 726 patients according to CFTR mutation (functional classes I-V) based on the functional defect of the milder of 
the two mutations. 
 CFTR class I/I CFTR class ≤ II/II CFTR class ≤ III/III CFTR class ≤ IV/IV CFTR class ≤ V/V 
N 32 550 39 63 42 
Age 14.6 (12.7, 18.3) 16.2 (12.9, 21.3) 16.7 (12.1, 25.0) 16.6 (12.1, 25.0) 19.0 (14.8, 26.5) 
Sex (% female) 14 (44) 244 (44) 16 (41) 34 (54) 21 (50) 
CFRD, (N, %)
*
 7 (22) 64 (12)  4 (10) 2 (3) 1 (2) 
Pancreatic insufficiency (N, %)
†
 35 (97)
 
 529 (93)
 
 34 (89)
 
 15 (24) 10 (24) 
Pseudomonas aeruginosa (N, %)
*
 32 (100) 519 (95) 21 (55) 23 (37) 15 (36) 
BMI (kg.m
-2
)
†
 18.8 (16.9, 20.1) 19.3 (17.3, 21.5) 20.4 (17.5, 24.2) 20.6 (18.8, 23.0) 22.3 (19.2, 25.0) 
BMI z-score
*
 -0.35 (-1.05, 0.39) -0.28 (-0.97, 0.35)  0.26 (-0.53, 1.04) -0.20 (-0.76, 0.63) 0.08 (-0.79, 1.14) 
Lean body mass (kg)
*
 38.2 (30.0, 46.4) 41.3 (32.9, 50.3) 43.5 (32.1, 55.2) 42.3 (36.7, 52.8) 47.0 (40.4, 61.1) 
Body fat (%)
†
 18.0 (15.5, 20.1) 18.0 (14.1, 22.1) 20.2 (16.9, 22.5) 21.0 (17.2, 25.2) 21.8 (18.7, 25.4) 
FEV1 (%pred) 80 (45, 93) 79 (60, 94) 78 (50, 90) 86 (72, 96) 80 (62, 94) 
VO2peak (L.min
-1
) 1.6 (1.3, 1.8) 1.7 (1.4, 2.3) 1.8 (1.3, 2.2) 1.8 (1.5, 2.3) 1.7 (1.3, 2.4) 
VO2peak (%pred) 77 (60, 86) 79 (65, 92) 77 (65, 96) 82 (70, 94) 74 (49, 94) 
VO2peak <82 %pred (N, %) 21 (66) 313 (57) 23 (59) 32 (51) 28 (67) 
Wattmax (W) 111 (83, 140) 127 (98, 170) 130 (95, 163) 124 (95, 170) 130 (85, 180) 
Wattmax (%pred) 77 (64, 88) 85 (70, 101) 83 (74, 102) 81 (69, 104) 80 (62, 102) 
Wattmax <93 %pred (N, %) 27 (84) 358 (65) 23 (59) 44 (70) 31 (74) 
HRmax (%pred) 92 (86, 96) 93 (88, 97) 91 (87, 97) 92 (87, 96) 92 (86, 96) 
RER 1.18 (1.12, 1.25) 1.16 (1.10, 1.23) 1.16 (1.11, 1.24) 1.14 (1.09, 1.20) 1.17 (1.08, 1.23) 
VEpeak (L.min
-1
) 62.3 (50.8, 81.7) 68.1 (53.9, 81.7) 68.0 (54.0, 85.0) 68.0 (51.7, 86.0) 68.0 (48.5, 82.7) 
VEpeak/MVVpred (%)
*
 81 (72, 106) 88 (71, 103) 95 (72, 118) 75 (64, 92) 80 (61, 101) 
Data are median (interquartile range) or N (%). BMI; body mass index; CFRD, Cystic Fibrosis related diabetes; FEV1, forced expiratory volume in one second; HRmax, maximum 
heart rate; MVVpred, predicted maximum voluntary ventilation (calculated as FEV1*35); RER, respiratory exchange ratio; VEpeak, peak minute ventilation; VO2peak, peak oxygen 
consumption; Wattmax, maximum work rate. Reduced exercise capacity (VO2peak <82%pred and Wattmax <93%pred) according to [10]. Statistical comparisons between different 
CFTR classes were performed using the non-parametric Kruskal-Wallis test or χ2 test for categorical variables. *P<0.05, †P<0.001 significantly different between CFTR classes.  
Appendix 
385 
Table 3 Clinical characteristics and cardiopulmonary exercise testing data between patients with two 
CFTR mutations in class I, II or III compared with patients with at least one mutation in class IV or V.  
Variable CFTR classes I-III CFTR classes IV-V 
N 621 105 
CFTR modulator therapy (N, %) 9 (1) 3 (3) 
Age 16.2 (12.9, 21.6) 18.0 (13.0, 25.5) 
Sex, (% female) 273 (44) 55 (52) 
CFRD, (N, %)
*
 75 (12) 3 (3) 
Pancreatic insufficiency, (N, %)
*
 585 (95) 25 (24) 
Pseudomonas aeruginosa, (N, %)
†
 332 (54) 38 (36) 
BMI z-score
*
  -0.25 (-0.95, 0.42) -0.11 (-0.77, 0.74) 
Body fat (%)
†
 18.1 (14.3, 22.2) 21.5 (17.4, 25.2) 
Lean body mass (kg) 41.1 (32.5, 50.3) 44.1 (36.4, 54.0) 
FEV1 (% predicted) 79 (59, 93) 84 (68, 96) 
VO2peak (L. min
-1
) 1.74 (1.4, 2.2) 1.78 (1.4, 2.4) 
VO2peak (% predicted) 79 (65, 91) 79 (67, 91) 
Wattmax (W) 125 (95, 168) 130 (94, 176) 
Wattmax (% predicted) 84 (70, 100) 82 (69, 96) 
HRmax (% predicted) 93 (88, 96) 92 (87, 96) 
RER 1.16 (1.10, 1.23) 1.15 (1.09, 1.23) 
VEpeak (L.min
-1
) 68.0 (53.9, 87.0) 68.0 (51.6, 85.0) 
VEpeak/MVVpred (%)
*
 88 (71, 104) 78 (63, 96) 
Data are median (interquartile range) or N (%). BMI; body mass index; CFRD, Cystic Fibrosis related diabetes; 
CFTR, cystic fibrosis transmembrane conductance regulator; FEV1, forced expiratory volume in one second; HRmax, 
maximum heart rate; MVVpred, predicted maximum voluntary ventilation (calculated as FEV1*35); RER, respiratory 
exchange ratio; VEpeak, peak minute ventilation; VO2peak, peak oxygen consumption; Wattmax, maximum work rate. 
Statistical comparisons between the two groups were performed using the non-parametric Mann-Whitney U test or 
the χ2 test, as appropriate. *P<0.05, †P<0.001 significantly different between CFTR classes. 
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Table 4. Linear regression models on the association between patients with two CFTR mutations 
in class I, II or III (group I-III) compared to patients with at least one mutation in class IV or V 
(group IV-V).  
VO2peak (%pred) B-coefficients (95% CI’s) SE P-value 
Age -0.14 (-0.32 to 0.04) 0.09 0.127 
Sex -1.32 (-3.49 to 0.85) 1.11 0.234 
CFRD  -1.29 (-4.88 to 2.30) 1.83 0.353 
Pseudomonas aeruginosa  -1.69 (-4.21 to 0.83) 1.28 0.189 
Pancreatic insufficiency -3.50 (-7.69 to 0.70) 2.14 0.130 
BMI z-score  1.78 (0.78 to 2.77) 0.51 <0.001 
FEV1 (% predicted) 0.41 (0.35 to 0.47) 0.03 <0.001 
CFTR group -3.51 (-7.86 to 0.83) 2.22 0.113 
    
Wattmax (%pred)    
Age 0.01 (-0.20 to 0.23) 0.11 0.898 
Sex 0.23 (-2.20 to 2.67) 1.24 0.852 
CFRD  -1.48 (-5.53 to 2.57) 2.06 0.473 
Pseudomonas aeruginosa  -2.52 (-5.36 to 0.32) 1.45 0.082 
Pancreatic insufficiency -4.47 (-9.20 to 0.26) 2.41 0.064 
BMI z-score  2.02 (0.55 to 3.50) 0.75 0.007 
FEV1 (% predicted) 0.48 (0.40 to 0.57) 0.04 <0.001 
CFTR group -4.65 (-9.56 to 0.25) 2.50 0.063 
BMI, body mass index; CFRD, Cystic Fibrosis related diabetes; FEV1, forced expiratory volume in one 
second; SE, standard error; VO2peak, peak oxygen consumption, Wattmax, maximum work load. The 
categorical variables CFRD, Pancreatic insufficiency, Pseudomonas aeruginosa are coded as ‘0’ = no; ‘1’ 
= yes. Sex is coded as ‘0’ for females and ‘1’ for males. CFTR groups are coded as ‘0’ (class I-III 
combined) and ‘1’ (class IV-IV combined). 
 
 
  
Appendix 
387 
ONLINE DATA SUPPLEMENT 
 
Aerobic exercise capacity in cystic fibrosis – does CFTR genotype matter? 
 
Thomas Radtke, Helge Hebestreit, Sabina Gallati, Jane E Schneiderman, Daniel Stevens, Erik HJ 
Hulzebos, Tim Takken, Steve Boas, Don S Urquhart, Larry C Lands, Sergio Tejero, Aleksandar 
Sovtic, Tiffany Dwyer, Milos Petrovic, Ryan A Harris, Chantal Karila, Daniela Savi, Jakob 
Usemann, Meir Mei-Zahav, Felix Ratjen and Susi Kriemler for the CFTR-Exercise study group  
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Methods 
 
Inclusion and exclusion criteria  
Study centres that could provide data on at least 20 patients, aged 8 years or older who completed a 
maximal cardiopulmonary exercise test (CPET) between January 1999 and December 2014 were eligible. 
We excluded patients with missing or incomplete information on cystic fibrosis transmembrane 
conductance regulator (CFTR) genotype and those who did not achieve the criteria for a maximal effort 
during CPET.  
 
Cardiopulmonary exercise test  
All patients performed a cycle ergometer test employing the Godfrey cycle protocol [1] or a modification 
thereof. Patients were tested during stable clinical conditions and exercise tests were performed as part of 
routine annual assessments and/or exercise studies. In case of exercise studies, baseline data were used. 
We excluded patients who did not achieve the criteria for a maximal effort during CPET: 1) a 
respiratory exchange ratio (RER) ≥1.05 for adults and ≥ 1.03 for children [2]; 2) peak heart rate that 
reached or exceeded predicted peak heart rate (for children ≥195 beats.min-1 [3]), for adults based on 
published equations in [4]); 3) ventilation at peak exercise (VEpeak) exceeding estimated maximal 
voluntary ventilation (MVV=forced expiratory volume in 1s (FEV1) x 35) [5]; 4) the patient achieved the 
predicted peak oxygen uptake (VO2peak); or 5) the patient achieved the predicted maximum work rate 
(Wattmax) [2]. At least one of five criteria had to be fulfilled for the test to be considered maximal. In case 
of missing data (e.g., RER or heart rate), the respective criterion was considered as not fulfilled.  
 
Body composition  
Body fat (BF, in %) was calculated using age and sex-specific prediction formulas ( 15 years; >15 years) 
by Deurenberg et. al.[6] Lean body mass (LBM) was calculated from body weight and body fat. We did a 
cross-validation between predicted values for BF (%) and LBM (kg) with dual-energy absorptiometry 
(DXA) measured BF (%) and LBM (kg) from the Swiss cohort (39 patients with CF; 20 females) aged 15 
to 39 years with a median (IQR) FEV1 of 62 (46, 75) % predicted)). The mean bias between predicted and 
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measured BF was 0.20% (95% CI, -1.39 to 1.43). The mean bias between predicted and measured LBM 
was -3.32 kg (95% CI, -4.30 to -2.50).  
 
Statistical analysis 
We performed regression analysis using a multiplicative, allometric approach [7, 8] to eliminate potential 
effects of body size and pulmonary function on the relationship between CFTR genotype and VO2peak. 
This approach is based on the assumption that VO2peak is not linearly related to measures of body size, e.g. 
body mass M, but is proportional to power functions of those measures, for example M to the power of an 
exponent x. This approach has been used previously to determine predictors of VO2peak in cystic fibrosis 
(CF) patients [8]. For the allometric model, we computed the natural logarithm (ln) of VO2peak (primary 
outcome measure) and Wattmax (secondary outcome measure), which entered the regression as dependent 
variable. We considered the following covariates in the model: age, ln(weight), ln(height), ln(FEV1), CF-
related diabetes, Pancreatic insufficiency, presence of Pseudomonas aeruginosa and CFTR genotype. We 
performed two separate analyses with ln(VO2peak) (in L) and ln(Wattmax) (in Watt) as dependent variables. 
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Supplementary Tables 
 
Table S1 Functional classification of CFTR alleles  
 
CFTR classes (I-V) 
 
CFTR nomenclature by legacy names 
 
Class I 
 
S4X, CFTRdele2,3, Q39X, E60X, 405+ 1G->A, 306delTAGA, 365-366insT, 
489delC, 547insGA, 557delT, 574delA, 621+1G->T, Y109X, 711+1G->T, 
Q220X, L218X, C276X, 1154insTC, 1461ins4, 1525-1G->A, S466X, S489X, 
Q493X, 1677delTA, E479X, Q525X, 1717-1G->A, G542X, G550X, R553X, 
E585X, 1898+1G->A, 1259insA, 2183AA->G, R709X, 2347delG, 2184insA, 
E822X, R785X, Q781X, 2896insAG, W882X, 2991del32, 3120+1G->A, 3121-
1G->A, V1108L, E1104X, R1070Q, Y1092X, E1104X, R1162X, 3791delC, 
3659delC, 3724delG, 3732delA, 3876delA, 3905insT, R1283M, W1274X, 
W1282X, 4040delA, 4021insT, CFTRdele10, CFTRdele19-21, CFTRdele16-18, 
CFTRdele14b-17b, c.3874-1G>A, 1154insTC  
 
Class II 
 
G85E, G178R, F508del, I507del, L1077P, M1101K, R1162X, N1303K 
 
 
Class III 
 
 
M1V, G551D, S549R, R560T, S549N, Y569D, H609R, H1085R, S1251N 
 
Class IV 
P5L, P67L, R74W, G126D, I148T, R117H, D192G, L206W, V232D, L320V, 
L365P, R334W, Q359K/T360K, R347P, T338I, N369Y, V562I, 1717- 8G->A, 
Y914C, L997F, D1152H, S1235R, S18I, S898R, A457P, G567A, V109C, 
G1244V 
 
 
Class V 
 
 
1249-30delAT, A455E, 1811+1.6kbA->G, 2789+5G>A, 2789+ 5G>A, 3272-
26A->G, 3849+10kbC->T, 5T, 5T-12TG, 5T-13TG  
 
CFTR, cystic fibrosis transmembrane conductance regulator.  
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Table S2 Linear regression models on the association between patients with two CFTR mutations in class 
I, II or III compared with patients with at least one mutation in class IV or V.  
ln(VO2peak) (L) B-coefficients (95% CI’s) SE P-value 
Age -0.00 (-0.00 to 0.00) 0.15 0.150 
Sex 0.16 (0.14 to 0.19) 0.01 <0.001 
ln(weight) (kg) 0.37 (0.25 to 0.48) 0.06 <0.001 
ln(height) (m) 0.51 (0.16 to 0.85) 0.17 0.004 
ln(FEV1) (L) 0.39 (0.34 to 0.43) 0.02 <0.001 
CFRD  -0.03 (-0.08 to 0.01) 0.02 0.169 
Pancreatic insufficiency  -0.03 (-0.09 to 0.02) 0.03 0.208 
Pseudomonas aeruginosa  -0.02 (-0.05 to 0.01) 0.02 0.224 
CFTR class  -0.42 (-0.96 to 0.01) 0.03 0.123 
    
ln(Wattmax) (W)    
Age -0.00 (-0.00 to 0.00) 0.00 0.199 
Sex 0.14 (0.11 to 0.17) 0.06 <0.001 
ln(weight) (kg) 0.29 (0.18 to 0.42) 0.06 <0.001 
ln(height) (m) 0.98 (0.61 to 1.35) 0.19 0.004 
ln(FEV1) (L) 0.39 (0.34 to 0.44) 0.03 <0.001 
CFRD  -0.01 (-0.06 to 0.03) 0.02 0.551 
Pancreatic insufficiency  -0.04 (-0.10 to 0.01) 0.03 0.119 
Pseudomonas aeruginosa  -0.03 (-0.06 to 0.00) 0.02 0.064 
CFTR class  -0.05 (-0.11 to 0.00) 0.03 0.063 
CFRD, Cystic Fibrosis related diabetes; CFTR, cystic fibrosis transmembrane conductance regulator; 
FEV1, forced expiratory volume in one second; ln, natural logarithm; SE, standard error; VO2peak, peak 
oxygen consumption, Wattmax, maximum work load. The categorical variables CFRD, exocrine Pancreatic 
insufficiency and Pseudomonas aeruginosa infection are coded as ‘0’ = no; ‘1’ = yes. Sex is coded as ‘0’ 
for females and ‘1’ for males.  CFTR groups are coded as ‘0’ for CFTR classes I-III and ‘1’ for CFTR 
classes IV-V. 
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Table S3 Clinical characteristics and cardiopulmonary exercise testing data according to the class of 
second CFTR mutation in patients with at least one copy of the F508del mutation.  
 CFTR class II/I CFTR class 
II/II 
CFTR class 
II/III 
CFTR class 
II/IV 
CFTR class 
II/V 
N 154 394 35 43 27 
Age 15.4 (12.7, 20.0) 16.4 (13.0, 
22.0) 
17.8 (13.2, 
25.6) 
16.9 (12.0, 
22.0) 
16.4 (13.7, 
24.0) 
Sex (% female) 81 (53) 161 (41) 15 (43) 20 (47) 9 (33) 
CFRD, (N, %) 14 (9) 50 (13)  3 (9) 1 (2) 0 (0) 
Pancreatic insufficiency 
(N, %)
†
 
147 (95)
 
 371 (95)
 
 30 (88)
 
 8 (22) 8 (30) 
Pseudomonas 
aeruginosa (N, %)
*
 
79 (52) 213 (55) 18 (53) 17 (39) 7 (26) 
BMI (kg.m
-2
)
*
 19.2 (17.2, 21.4) 19.3 (17.4, 
21.6) 
21.6 (17.5, 
24.7) 
20.6 (18.8, 
22.1) 
22.6 (19.2, 
25.1) 
BMI z-score -0.37 (-1.02, 
0.33) 
-0.25 (-0.94, 
0.41) 
0.35 (-0.49, 
1.04) 
-0.25 (-0.77, 
0.63) 
0.04 (-0.73, 
0.68) 
Body fat (%)
*
 18.6 (14.5, 22.4) 17.8 (14.0, 
22.0) 
21.2 (17.0, 
23.0) 
20.1 (14.9, 
24.1) 
21.2 (16.2, 
24.7) 
Lean body mass (kg)
 *
 41.0 (33.3, 49.4) 41.3 (32.7, 
50.7) 
45.2 (34.6, 
55.3) 
43.5 (35.9, 
52.8) 
48.7 (41.9, 
61.7) 
FEV1 (% predicted) 82 (64, 96) 78 (58, 93) 78 (49, 90) 85 (72, 96) 82 (63, 99) 
VO2peak (L.min
-1
) 1.75 (1.4, 2.2) 1.75 (1.4, 2.3) 1.85 (1.3, 2.2) 1.89 (1.5, 2.4) 1.96 (1.4, 2.5) 
VO2peak (% predicted) 78 (67, 91) 80 (65, 92) 77 (63, 93) 84 (70, 96) 75 (61, 87) 
Wattmax (W) 123 (92, 161) 129 (100, 175) 135 (97, 172) 117 (93, 175) 136 (112, 195) 
Wattmax (% predicted) 83 (68, 101) 86 (71, 101) 83 (72, 105) 81 (69, 95) 83 (74, 96) 
HRmax (% predicted) 93 (89, 96) 93 (88, 97) 93 (87, 98) 92 (86, 95) 92 (87, 96) 
RER 1.14 (1.11, 1.20) 1.16 (1.09, 
1.24) 
1.16 (1.09, 
1.24) 
1.14 (1.09, 
1.20) 
1.17 (1.08, 
1.23) 
VEpeak (L.min
-1
) 67.6 (54.1, 84.0) 68.7 (53.8, 
88.3) 
68.5 (55.9, 
87.1) 
68.2 (52.0, 
88.2) 
69.5 (53.5, 
86.0) 
VEpeak/MVVpred (%)
*
 83 (66, 100) 89 (73, 105) 95 (72, 118) 75 (65, 96) 78 (60, 89) 
Data are median (interquartile range) or N (%). BMI; body mass index; CFRD, Cystic Fibrosis related 
diabetes; FEV1, forced expiratory volume in one second; HRmax, maximum heart rate; MVVpred, predicted 
maximum voluntary ventilation (calculated as FEV1*35); RER, respiratory exchange ratio; VEpeak, peak 
minute ventilation; VO2peak, peak oxygen consumption; Wattmax, maximum work rate. Statistical 
comparisons between different CFTR classes were performed using the non-parametric Kruskal-Wallis 
test or χ2 test for categorical variables. *P<0.05; † P<0.001 significantly different between CFTR classes. 
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Table S4 Linear regression models on the association between class of second CFTR mutation and 
maximal exercise capacity in patients with at least one copy of the F508del mutation.  
 
VO2peak (%pred) B-coefficients (95% CI’s) SE P-value 
Age -0.12 (-0.31 to 0.08) 0.10 0.240 
Sex -1.17 (-3.47 to 1.12) 1.17 0.317 
BMI z-score  2.01 (1.02 to 3.14) 0.54 <0.001 
FEV1 (%predicted) 0.41 (0.35 to 0.47) 0.03 <0.001 
CFRD  -1.96 (-5.78 to 1.86) 1.95 0.315 
Pseudomonas aeruginosa  -2.52 (-5.16 to 0.12) 1.35 0.061 
Pancreatic insufficiency -2.64 (-7.26 to 1.97) 2.35 0.262 
CFTR class II/I -1.53 (-4.30 to 1.25) 1.41 0.280 
CFTR class II/II - - - 
CFTR class II/III -2.87 (-7.99 to 2.25) 2.61 0.272 
CFTR class II/IV 0.33 (-5.51 to 6.17) 2.99 0.912 
CFTR class II/V -10.64 (-17.03 to -4.24) 3.26 0.001 
    
Wattmax (%pred)    
Age 0.05 (-0.18 to 0.28) 0.12 0.673 
Sex 1.04 (-1.59 to 3.68) 1.34 0.437 
BMI z-score  1.33 (0.11 to 2.55) 0.62 0.033 
FEV1 (% predicted) 0.46 (0.40 to 0.53) 0.04 <0.001 
CFRD  -1.44 (-5.85 to 2.98) 2.25 0.523 
Pseudomonas aeruginosa  -2.80 (-5.84 to 0.25) 1.55 0.072 
Pancreatic insufficiency -3.62 (-8.94 to 1.71) 2.72 0.181 
CFTR class II/I -1.19 (-4.38 to 2.01) 1.63 0.466 
CFTR class II/II - - - 
CFTR class II/III -0.49 (-6.44 to 5.46) 3.03 0.872 
CFTR class II/IV -2.84 (-9.58 to 3.89) 3.44 0.408 
CFTR class II/V -9.95 (-17.31 to -2.59) 3.75 0.008 
CFRD, Cystic Fibrosis related diabetes; CFTR, cystic fibrosis transmembrane conductance regulator; FEV1, forced expiratory 
volume in one second; SE, standard error; VO2peak, peak oxygen consumption, Wattmax, maximum work load. The categorical 
variables CFRD, exocrine Pancreatic insufficiency and Pseudomonas aeruginosa infection are coded as ‘0’ = no; ‘1’ = yes. Sex 
is coded as ‘0’ for females and ‘1’ for males. CFTR classes were coded as class II/II = 1; class I/II = 2; class II/III = 3; class II/IV 
= 4 and class II/V =5. The CFTR class II/II was chosen as reference class.   
 
 
Appendix 
394 
Table S5 Linear regression models on the association between class of second CFTR mutation and 
maximal exercise capacity in patients with at least one copy of the F508del mutation.  
 
ln(VO2peak) (L) B-coefficients (95% CI’s) SE P-value 
Age -0.00 (-0.00 to 0.00) 0.00 0.188 
Sex 0.17 (0.14 to 0.20) 0.01 <0.001 
ln(weight) (kg) 0.38 (0.26 to 0.50) 0.06 <0.001 
ln(height) (m) 0.49 (0.12 to 0.85) 0.19 0.009 
ln(FEV1) (L) 0.40 (0.35 to 0.45) 0.03 <0.001 
CFRD  -0.04 (-0.08 to 0.01) 0.02 0.145 
Pancreatic insufficiency  -0.02 (-0.08 to 0.03) 0.03 0.431 
Pseudomonas aeruginosa  -0.03 (-0.06 to 0.01) 0.02 0.104 
CFTR class II/I -0.01 (-0.04 to 0.02) 0.02 0.568 
CFTR class II/II - - - 
CFTR class II/III -0.05 (-0.11 to 0.01) 0.03 0.111 
CFTR class II/IV 0.00 (-0.07 to 0.08) 0.04 0.858 
CFTR class II/V -0.14 (-0.22 to -0.06) 0.04 0.001 
    
ln(Wattmax) (W)    
Age -0.00 (-0.00 to 0.00) 0.00 0.423 
Sex 0.15 (0.12 to 0.18) 0.02 <0.001 
ln(weight) (kg) 0.30 (0.17 to 0.43) 0.07 <0.001 
ln(height) (m) 0.95 (0.55 to 1.34) 0.20 <0.001 
ln(FEV1) (L) 0.40 (0.34 to 0.45) 0.03 <0.001 
CFRD  -0.01 (-0.06 to 0.04) 0.03 0.657 
Pancreatic insufficiency  -0.04 (-0.10 to 0.02) 0.03 0.222 
Pseudomonas aeruginosa  -0.03 (-0.07 to 0.00) 0.02 0.076 
CFTR class II/I -0.02 (-0.05 to 0.02) 0.02 0.418 
CFTR class II/II - - - 
CFTR class II/III -0.04 (-0.11 to 0.03) 0.04 0.265 
CFTR class II/IV -0.04 (-0.12 to 0.04) 0.04 0.353 
CFTR class II/V -0.12 (-0.21 to -0.04) 0.04 0.005 
CFRD, Cystic Fibrosis related diabetes; CFTR, cystic fibrosis transmembrane conductance regulator; 
FEV1, forced expiratory volume in one second; ln, natural logarithm; SE, standard error; VO2peak, peak 
oxygen consumption, Wattmax, maximum work load. The categorical variables CFRD, exocrine Pancreatic 
insufficiency and Pseudomonas aeruginosa infection are coded as ‘0’ = no; ‘1’ = yes. Sex is coded as ‘0’ 
for females and ‘1’ for males. CFTR classes were coded as class II/II = 1; class I/II = 2; class II/III = 3; 
class II/IV = 4 and class II/V =5. The CFTR class II/II was chosen as reference class.   
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Curriculum vitae 
Personal data 
Date of birth: 25.01.1984 
Place of birth: Hamburg, Germany  
Nationality: German 
Marital status: unmarried, 2 daughters 
Languages: German, English, Italian, French, Spanish  
 
Positions 
08/14-07/17  PhD Student Pediatric Pneumology Research Group, UKBB, Basel 
07/11-08/14 Resident physician Pädiatrische Pneumologie m. S. Immunologie, Charité, 
Berlin 
MD-Thesis 
07/09-11/14 Max-Planck Institut Bad Nauheim, University Giessen, Germany. Research 
Group Structure und Development of the Alveolus, Prof. Seeger and Dr. 
R.E. Morty. “All–trans retinoic acid recruits Smad3 to drive TGF–β 
signaling in lung fibroblasts: implications for the management of 
bronchopulmonary dysplasia with retinoids”.  
 
Internships 
07/09-09/09 Internal Medicine, University Giessen 
09/09-11/09 Internal Medicine/Oncology, Memorial Sloan Kettering Center, New York, USA 
11/09-03/10 Surgery, Clinic Hirslanden, Zürich 
03/10-07/10 Pediatrics, L’Ospedale dei Bambini Meyer, Florence 
02/07-08/07 General clinical education University Padova, Italy  
 
Education 
03/04-04/10 Medical School, Justus-Liebig-Universität, Giessen 
07/01-05/03 High School, Albert Schweitzer Gymnasium, Hamburg  
06/00-06/01 Cranbrook-Kingswood Boarding School Detroit, Michigan, USA 
07/90-05/00 Elemantary School Albert Schweitzer Schule, Hamburg  
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Memberships 
  
 Gesellschaft für pädiatrische Pneumologie  
 Deutsche Gesellschaft für Kinder- und Jugendmedizin 
 Swiss School for Public Health (SSPH+) 
 PhD Program Health Sciences  
 
Scholarships and awards 
 German- Swiss and Austrian society for pediatric pneumology fellowship 
 Swiss School for Public Health (Switzerland) 
 University Children’s Hospital Basel Research Congress Fellowship (2016, 2017) 
 University Children’s Hospital Basel Research Award 
 
Reviews for Journals  
 European Respiratory Journal, PloS One, Pediatric Allergy and Immunology, British 
Medical Journal, Respiratory Medicine, Pediatric Research, International Journal of 
Public Health, Pediatric Pulmonology 
 
Master Thesis Supervision 
 Andrea Suter, MD Student University of Basel: “Can volumetric capnography predict 
respiratory morbidity during the first year of life in preterm infants?” 
 
Teaching activity 
 2 years of teaching students in anatomy during medical studies 
 2 semesters of weekly teaching “Problemorientiertes Lernen” at the “Modellstudiengang 
Charité-Universitätsmedizin, Berlin” 
 Supervision of medical master and doctorate students at the University of Basel 
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Publication list 
 
Submitted/completed original Articles: 
 
 Usemann J*, Xu B*,Delgado-Eckert E, Korten I, Anagnostopoulou P, Gorlanova O, 
Kuehni C, Röösli M, Latzin P, Frey U on behalf of the BILD study group. Dynamics of 
respiratory symptoms during infancy and associations with wheezing at school age. 
Under Review 
 
 Lech Cantuaria M*, Usemann J*, Proietti E, Blanes-Vidal V, Dick B, Frey C.E, Rüedi S, 
Héritier H, Wunderli J.M, Latzin P, Frey U, Röösli M, Vienneau D on behalf of the 
BILD study group. Glucocorticoid metabolites in newborns: a marker for traffic noise 
related stress? Manuscript ready for submission 
 
 Neumann R.P*, Hilty M*, Xu B, Usemann J, Korten I, Mika M, Müller L, Philipp, Frey 
U. Upper airway microbiota is associated with symptom persistence after the first acute 
symptomatic respiratory tract infection in infants. Under Review 
 
 Radtke T, Hebestreit H, Gallati S, Schneiderman JE, Stevens D, Hulzebos EHJ, Takken 
T, Boas SR, Urquhart DS, Lands LC, Tejero S, Sovtic A, Dwyer T, Petrovic M, Harris 
RA, Karila C, Savi D, Usemann J, Mei-Zahav M, Ratjen F, Kriemler S, for the CFTR-
Exercise study group. Aerobic exercise capacity in cystic fibrosis – does CFTR genotype 
matter. Under Review  
 
 Usemann  J, Roth M, Bisig C, Comte P, Czerwinski J, Mayer A.C.R., Latzin P, and 
Müller L. Gasoline particle filter reduces oxidative DNA damage in bronchial epithelial 
cells after whole gasoline exhaust exposure in vitro Under review Scientific Reports 
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Published original Articles: 
 Roth M*, Usemann J*, Bisig C, Comte P, Czerwinski J, Mayer A.C.R, Beier K, Rothen-
Rutishauser B, Latzin P, Müller L. Effects of gasoline and ethanol-gasoline exhaust 
exposure on human bronchial epithelial and natural killer cells in vitro. Accepted 
Toxicol. in vitro 
 
 Usemann J*, Demann D*, Anagnostopoulou A, Korten I, Gorlanova O, Schulzke S, Frey 
D, Latzin P. Interrupter technique in infancy: higher airway resistance and lower short-
term variability in preterm versus term infants. Accepted Ped Pulm 
 
 Korten I, Liechti M, Hafen G, Rochat I, Usemann J, Singer F, Moeller A, Frey, Latzin P, 
Casaulta C for the BILD and SCILD study group. Lower exhaled nitric oxide in infants 
with Cystic Fibrosis compared to healthy controls. Accepted J Cysti Fibr  
 
 Usemann J, Garten L, Bührer C, Dame C, Cremer M. Fresh-frozen plasma transfusion - 
a risk factor for pulmonary hemorrhage in extremely low birth weight infants? J Perinat 
Med. 2016 Dec 6  
 
 Usemann J, Fuchs O, Anagnostopoulou P, Korten I, Gorlanova O, Röösli M, Latzin P, 
Frey U. Predictive value of exhaled nitric oxide in healthy infants for asthma at school 
age. Eur Respir J 2016 Jul 7 
 
 Usemann J, Frey U, Mack I, Schmidt A, Gorlanova O, Röösli M, Hartl D, Latzin P. 
CHI3L1 polymorphisms, cord blood YKL-40 levels and later asthma development. BMC 
Pulm Med 2016 May 18 
  
 Anagnostopoulou P, Egger B, Lura M, Usemann J, Schmidt A, Gorlanova O, Korten I, 
Roos M, Frey U, Latzin P. Multiple breath washout analysis in infants: quality 
assessment and recommendations for improvement. Physiol Mes 2016 Feb 5 
 
 Usemann J, Ernst T, Schäfer V, Lehmberg K, Seeger K. EZH2 Mutation in an 
Adolescent with Weaver Syndrome developing Acute Myeloid Leukemia and Secondary 
Hemophagocytic Lymphohistiocytosis. Am J Med Gen Part A. 2016 Jan 14 
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 Fischer HS, Puder LC, Wilitzki S, Usemann J, Bührer C, Godfrey S, Schmalisch G. 
Relationship between computerized wheeze detection and lung function parameters in 
young infants. Pediatric Pulmonology 2015. Pediatr Pulmonol. 2015 Sep 11 
 
 Puder LC, Fischer HS, Wilitzki S, Usemann J, Godfrey S, Schmalisch G. Validation of 
computerized wheeze detection in young infants during the first months of life. BMC 
Pediatr. 2014 Oct 9; 14:257.  
 
 Schwartze JT, Becker S, Sakkas E, Wujak ŁA, Niess G, Usemann J, Reichenberger F, 
Herold S, Vadász I, Mayer K, Seeger W, Morty RE. Glucocorticoids recruit Tgfbr3 and 
Smad1 to shift transforming growth factor–b signaling from the Tgfbr1/Smad2/3 axis to 
the Acvrl1/Smad1 axis in lung fibroblasts. J Biol Chem. 2014 Feb 7;289(6):3262-75 
 
 Schwarz C, Usemann J, Stephan V, Kaiser D, Rothe K, Rückert JC, Neudecker J. 
Bilateral pneumothorax following a blunt trachea trauma. Respiratory Medicine Case 
Reports Volume 10, Pages 56-59, August 23, 2013 
 
*
 Equal contribution.  
 
Editorials: 
 Korten I, Usemann J, Latzin P. “Lung sparing growth”: Is the lung not affected by 
malnutrition? Eur Respir J. 2017 Apr 5;49(4).   
 
 Usemann J, Korten I, Latzin P. A big step forward in understanding global differences in 
respiratory health: first lung function data in African infants. Respirology. 2015 
Oct;20(7):1006-7 
 
Reviews: 
 Usemann J, Yammine S, Singer F, Latzin P. Inert gas washout: background and 
application in different lung diseases. Accepted Swiss Med Wkly 
 
 Frey U, Latzin P, Usemann J, Maccora J, Zumsteg U, Kriemler S. Asthma and obesity in 
children: current evidence and potential systems biology approaches. Allergy. 2015 
Jan;70(1):26-40. 
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Book Contribution: 
 
 Kompendium Pneumologie 2014 “State of the Art: Allergologie” Jakob Usemann, 
Philippe Stock. September 2014  
 
